malabar cancer centre, kannurpreface malabar cancer centre, kannur established in november 2001, is...
TRANSCRIPT
MALABAR CANCER CENTRE, KANNUR (an autonomous centre under Government of Kerala)
[Partially supported by the National Cancer Registry Programme,
Indian Council of Medical Research]
ANNUAL REPORT FOR THE YEAR 2011
FOREWORD
It is our pleasure to bring out the second report on hospital based cancer registry 2011, which can proudly be hailed as a tremendous team effort with limited staff strength under the able leadership of Dr.Saina Sunilkumar, a determined and steadfast officer. The success in this path gives us the confidence to proceed towards the bigger goal of population based cancer registry. We intend to establish a population based cancer registry encompassing two northern districts of Kerala‐ Kannur and Kasargod . The baseline work is initiated.
The assistance and the encouragement we enjoyed from Director of NCRP,Dr.Nandakumar is laudable. It is my duty to thank him and his team for all the support rendered to us.
The emergence of stomach as second most common cancer among men and decline in cervical cancer form the highlight of the report. The success of cancer awareness programmes , public awareness, improvement in living conditions and hygiene might have contributed significantly to the reduction in cervical cancer in this part of the country . The data on gastric cancer may require more refinement for better understanding and epidemiological and etiological study.
The number of cancer patients seeking treatment at the centre is increasing indicating the effectiveness of various developmental programmes and it may also be an indicator of increased awareness of cancer and effectiveness of early cancer detection programmes. The need of the hour is to declare cancer as a notifiable disease so that all cancers reported in the state can be brought under a common reporting platform for data analysis and strategy development.
I congratulate the entire team of cancer registry for their tremendous effort and hope this will be an impetus for the future development of the institution.
Dr.Satheesan Balasubramanian Director
PREFACE
Malabar Cancer Centre, Kannur established in November 2001, is a comprehensive cancer centre caters mainly from northern part of Kerala, also from other states like Karnataka, Tamilnadu & Pondicherry. Established hospital based cancer registry in 2011, partially supported by NCRP / ICMR. The first book of HBCR 2010 was brought out in 2012 and was informative for the fraternity in the field of oncology and health policy makers.
HBCR -2011 the second annual publication contains information on the cancer burden among the North Malabar region of Kerala, with a focus on cancer cases reported during 2011. Readers of the first book will recognize several topics and subjects that were covered in the first book, has been revisited with an intent to update, enhance and enrich the original pretext of those subjects, as new material has been discovered and technologies improved. Additionally a few new chapters have been added, introduced, addressing new critical sections and areas of responsibility for the Cancer Registry or Cancer program.
This data helps to effectively plan services, prioritize health resource allocation, develop and measure prevention & intervention strategies and identify high risk population within the region. The revision of new data items will help us achieve our mission to provide current high quality and useful data for the cancer surveillance, community cancer control researchers with the ultimate goal of reducing cancer morbidity and mortality. Similarly the apparent increase noticed in Breast and Lung Cancer needs prompt intervention strategies to curb the rising menace in the society.
The quality of this book is due to the skillful review of the manuscript for accuracy, consistency and competency of the entire team of Department of Cancer registry and Epidemiology. We sincerely thank our Director, for his support, guidance, advice and encouragement. I thank all my colleagues for their contribution. We believe that it has been well worth the effort
Dr. Saina Sunilkumar Head of the Cancer Registry & Epidemiology – In- charge Dept. of Cancer Registry
ACKNOWLEDGEMENT
The Hospital Based Cancer Registry of Malabar Cancer Centre, Kannur expresses its sincere thanks and gratitude to the following institutions/ Departments/ Individuals for supporting and promoting the activities of the Registry.
1. Dr. Satheeshan Balasubramanian, Director , MCC.
2. National Cancer Registry Programme, Indian Council of Medical Research, Banglore.
3. Medical Records Division, MCC Thalassery.
4. Department of Information & Technology.
5. Department of Pathology.
6. Department of Surgical Oncology.
7. Department of Radiation Oncology.
8. Department of Haemato Oncology.
CONTENTS
Sl No Title Page No.
I. INTRODUCTION .............................................................................. 11-36
1. Malabar Cancer Centre 11
2. Academic Departments and Faculty 14
3. Department of Cancer Registry 17
4. National Cancer Registry Programme 21
5. Hospital Based Cancer Registry 23
6. Patters of Patient Registration/District-wise 25
7. Summary of Results 27
8. Magnitude of Total Cancers 29
9. Tobacco Related Cancers 29
10. Leading Sites of Cancer 33
II. SUMMARY OF STATISTICS –NCRP-ICMR…………. …………… . 37-48 (Demographic, Diagnostic and Clinical Details)
1. Any specific treatment -Male/Female 39
2. Broad Age Group 40
3. Broad Groups of Treatment 41
4. Clinical Extent of Disease 42
5. Educational Status 43
6. Marital Status 43
7. Different Types of Microscopic Diagnosis 44
8. Different Methods of Diagnosis 45
9. Religion 46
10. Treatment only at RI 47
11. Type of Treatment Given 48
III. DESCRIPTIVE STATISTICS – NCRP-ICMR ............................... 49-138
12. Diagnostic Information 51
13. Clinical Information 63
14. Demographic Details 123
IV. DESCRIPTIVE STATISTICS – MCC………………………………… . 139-158
1. New/Old cases 141
2. Ten Leading Cancers – System Wise 142
3. Habits – Smoking, Alcohol & Panchewing 144
4. Family History/Heriditary Cancers 147
5. TNM Staging 148
6. Diagnostic Status 155
7. Comparison of Performance Status 156
8. Intention to Treat 157
9. Disease Status at First Follow-Up 158
V. TEN LEADING CANCERS –(DETAILED INFORMATION)…….. 159-254
(IRRESPECTIVE OF SEX)
1. Breast Cancer 161
2. Lung Cancer 172
3. Mouth Cancer 182
4. Stomach Cancer 192
5. Tongue Cancer 201
6. Cervix Cancer 210
7. Rectum Cancer 219
8. Ovary Cancer 228
9. Oesophagus Cancer 237
10. NHL 246
VI. CHILDHOOD CANCERS…………………………… ......................... 255
VII. SCHEDULED TRIBE PATIENTS………………………………. ........ 257
VIII. MULTIPLE CANCERS ..................................................................... 261
IX. NON MALIGNANT TUMORS .......................................................... 269
X. ABBREVIATIONS ......................................................................... 277
IX. REFERENCES ……………………………………………………....... 278
MCC Annual Report – HBCR 2011
11
MCC- A Comprehensive Cancer Centre in Northern Kerala
INTRODUCTION
Malabar Cancer Centre, situated in a beautiful hill top of Kodiyeri in Thalassery, is an
autonomous institution under Health and Family Welfare Department; Government of
Kerala, registered under Societies Registration Act XXI of 1860, and was started from
March 2001 onwards with an aim to establish a hospital, providing the much-required
oncology care to the population of North Kerala. The main objective being establishing
a modern Cancer Hospital and Research and Training Centre of international standard in
treatment and prevention of cancer. It is also the only comprehensive centre for cancer
prevention, control, treatment and research in the northern region of Kerala.
The institution is a tertiary cancer centre which renders its service to society with equal
thrust on clinical and translational research, Education and Clinical oncological
services. MCC is being developed as a postgraduate institute of oncology. The
institution is in the process of developing and establishing a unique Clinical Research
department to coordinate clinical research activities. It is our immense pleasure to
disclose the research association MCC has with School of Health Sciences, Kannur
University, Centre for Electronic Materials Technology, Thrissur and
P.S.Vaidhyarathnam Ayurveda College, Kottakkal which are expected to bring in
revolutionary changes in the management of cancer.
The control and management of the Society are vested in the Governing Body
consisting of 23 members with the Hon’ble Chief Minister of Kerala as the Chairman,
Hon’ble Minister for Health as Vice Chairman and Hon’ble Minister for Power as
Alternate Vice-Chairman. The routine activities and functions of the Centre are
supervised by the Executive Committee, with the Secretary, Department of Health and
Family Welfare, Government of Kerala, being the Chairman of the Committee. The
members in the Governing Body and Executive Committee are functioning by virtue of
their official positions.
MCC Annual Report – HBCR 2011
12
ORGANISATION Governing Body(GB):
The Governing Body of the Society consists of 23 members
1 Chairman Chief Minister of Kerala
2 Vice-Chairman Minister for Health & FW, Kerala
3 Alternate
Vice-Chairman
Minister for Electricity, Kerala
4 Member Secretary, Department of Finance, Kerala
5 Member Secretary, Department of Power, Kerala
6 Member District Medical Officer, Kannur
7 Member Secretary, Department of Health & FW, Kerala
8 Member An eminent Medical Scientist
9 Member Secretary, Department of Science, Technology & Environment
10 Member One nominee of the Ministry of Health, Government of India
11 Member Principal, Medical College, Kozhikode
12 Member Secretary- Planning & Economic Affairs Department, Kerala
13 Member Director- Rajiv Gandhi Centre for Bio technology, Trivandrum
14 Member Director of Medical Education, Directorate of Medical Education, Trivandrum
15 Member
& Secretary to GB
Director, Malabar Cancer Centre, Thalassery
16 Member M.L.A. of the Thalassery constituency
17 Member President, District Panchayat, Kannur District
18 Member Chairman, Thalassery Municipality, Thalassery
19 Member A public man from North Malabar region (to be nominated by Government of Kerala)
20 Member One Head of the department nominated from Malabar Cancer centre, Thalassery by the Government.
21 Member One nominee of the Charitable Society established for rehabilitation and financial assistance for poor cancer patients
22 Member Principal/Chief Executive Officer of Medical College, Pariyaram
23 Member Director, Regional Cancer Centre, Trivandrum
MCC Annual Report – HBCR 2011
13
EXECUTIVE COMMITTEE
The Executive Committee consists of
1 Secretary, Department of Health & Family Welfare, Government of Kerala
Chairman
2 Secretary, Department of Power ,Government of Kerala Member
3 Secretary, Department of Finance, Government of Kerala Member
4 Chairman, Thalassery Municipality Member
5 A public man from North Malabar to be nominated by Government of Kerala
Member
6 Secretary, Department of Planning, Government of Kerala Member
7 Director, Regional Cancer Centre, Trivandrum Member
8 The Director, Malabar Cancer Centre, Thalassery Member/Convener
MCC Annual Report – HBCR 2011
14
Departments
SlNo Department Sub Divisions
1 Department of Radiation Oncology Medical Physics Division
2 Department of Surgical Oncology
Surgical Oncology Division
Physiotherapy Division
Dietetics Division
Speech and Swallow Therapy Division
3 Department of Medical Oncology & Clinical Hematology
Pediatric Oncology Division
4 Department of Onco-Anesthesiology
5 Department of Clinical Laboratory Services and Translational Research
Onco Pathology Division
Molecular Oncology Division
Microbiology Division
Biochemistry Division
Transfusion Medicine Division
6 Department of Imageology
7 Department of Cancer Palliative Medicine
8 Department of Community Oncology Tobacco Cessation Clinic
9 Department of Cancer Registry and Epidemiology
Cancer Registry Division
Clinical Research and Biostatistics Division
Medical Records Division
Health Information Technology Division
10 Department of Oncology-Nursing
11
Department of Dental Medicine Rehabilitation
12 Department of Clinical Administration and Public Relations
13 Department of Engineering and Maintenance
14 General Administration Department
Administration Division
Accounts Division
Purchase Division
Store Division
MCC Annual Report – HBCR 2011
15
FACULTIES
SlNo Name Designation Qualification
1. Surgical Oncology
1 Dr. B Satheesan Director MBBS, MS, DNB Mch
2 Dr. Surij Salih Associate Professor
MBBS, MS (ENT), Mch (Head & Neck Oncology)
3 Dr.Sajith Babu T P Associate Professor
MBBS, MS (ENT), DNB (ENT)FHNS
4 Dr. Syam Vikram Assistant Professor MBBS, DNB
5 Dr. Nizamudheen.M.P Lecturer MBBS, MS (Gen.Surgery)
2. Medical Oncology, Clinical Hematologyology & Paediatric Oncology
1 Dr. Chandran K Nair Associate Professor MBBS,MD, DNB (Med),DM (Clinical Hematology), Fellowship in Hemato-oncology & Blood/Marrow Transplantation (University of British Columbia, Canada)
2 Dr. Vineetha Raghavan
Assistant Professor MBBS, MD Pediatrics
3. Radiation Oncology
1 Dr. Milind Kumar Associate Professor MBBS, MD Radiotherapy
2 Dr.M Geetha Assistant Professor MBBS, DMRT, MD Radiotherapy
3 Dr. Santam Chakaraborthy
Assistant Professor MBBS , MD Radiotherapy
4 Dr. Sujith Kumar M Assistant Professor MBBS , MD Radiotherapy
5 Dr. Sameer E P Lecturer MBBS, DMRT
6 Dr. Greeshma K E Lecturer MBBS, DMRT
4. Onco-Anesthesiology
1 Dr. Krishna Das Consultant Anaesthesiologist
MBBS,FICS in Anaesthesia
2 Dr.Krishnan Warrier Consultant Anaesthesiologist
MBBS, DA, MD Anaesthesiology
3 Dr. Roshan Milind Lecturer MD Physician(MBBS – MCI)
MCC Annual Report – HBCR 2011
16
5. Pathology &Transfusion Medicine
1 Dr. Sangeetha Nayanar Professor MBBS, MD , DNB Pathology
2 Dr. Kavitha K P Associate Professor MBBS, MD (Pathology)
3 Dr. Sithara Aravind Assistant Professor MBBS, MD (Pathology)
4 Dr. Aswathi Krishnan Assistant Professor MBBS, MD (Pathology)
6. Imageology
1 Dr. Satheesh babu TV Assistant Professor MBBS, MD
2 Dr. Sinewraz Visiting consultant MBBS , MD Radiology
3 Dr. Rethika Sreekuamr Visiting consultant MBBS, DMRD
7. Cancer Palliative Medicine
1 Dr. M.S Biji Assistant Professor MBBS, PG Diploma in pain & Palliative Medicine
8. Community Oncology
1 Dr. Neethu A P Lecturer MBBS
9. Cancer Registry and Epidemiology
1 Dr. Saina Sunil Kumar Lecturer MBBS
10. Dental Medicine and Rehabilitation
1 Dr. Phinse M Philip Lecturer BDS
MCC Annual Report – HBCR 2011
17
Department of Cancer Registry & Epidemiology
1. Cancer Registry Division Dr. Saina Sunilkumar, MBBS Lecturer, HOD in charge
Shamna P EDP Assistant
Rincy Program Assistant
2. Clinical Research and Biostatistics Division Dr. B Binukumar, PhD Lecturer in Biostatistics
Bindu T Lecturer in Biostatistics
3. Medical Records Division Jayadev Medical Records Officer
Suraj Kumar Medical Records Assistant
Ajesh Medical Records Attender
4. Information Technology Division Ranjith M.K System Manager
Bhavina Junior System Analyst
MCC Annual Report – HBCR 2011
18
DEPARTMENT OF CANCER REGISTRY AND EPIDEMIOLOGY
Department of Cancer Registry and Epidemiology was established in the year 2010
partially supported by National Cancer Registry Programme (ICMR), Bangalore. This is the
second Annual report of Hospital Based Cancer Registry of 2011 that is published.
Activities Publications:
1. Scientific papers published in indexed journals
i. Lung Cancer in Malabar Cancer Center in Kerala - A descriptive Analysis in APJCP 2012
Binukumar Bhaskarpillai Mhil, PhD, Saina sunilkumar MBBS, Satheesan
Balasubramanian MS, DNB, MCh(Oncosurgery)
ii. A descriptive analysis of cancer cases from endosulfan- affected areas of Kasaragod
district, Kerala in Health sciences 2012:1(2): JS004 and open access peer reviewed E-
journal.
Binukumar Bhaskarpillai Mhil, PhD, Saina sunilkumar MBBS, Satheesan
Balasubramanian MS, DNB, MCh(Oncosurgery)
Presentation:
1. At National level Cancer Registry Workshop on 6th February 2012 at Banglore.
2. Poster presentationon HBCR at KANASICON ASI Kerala Chapter Peripheral conference
held at Kannur 2012.
Workshop attended:
Pattern of care & survival studies on cancer cervix, Breast & Head & Neck cancers at
NCRP-ICMR Bangalore-6/02/2012 to 9/02/2012.
Awards:
Best poster presentation at KANASICON ASI Kerala Chapter Peripheral conference held
at Kannur 2012(Best poster award)
On Going Major Research Programme:
1. HBCR -2012[ Partially Supported by NCRP-ICMR]
2. Patterns of Care and Survival Studies on Cancer of Cervix, Female Breast and
Head & Neck [ Partially Supported by NCRP-ICMR]
MCC Annual Report – HBCR 2011
19
HOSPITAL BASED CANCER REGISTRY
Cancer Registration is the process of systematically and continuously collecting information
on malignant neoplasm reported. Broadly there are two types of cancer registries –Hospital
Based (HBCR) and Population Based (PBCR).
Hospital Based (HBCR):
• Cancer Registration
• Medical Records
Hospital based cancer registries collect information of cancers reported in a given
hospital, regardless of where that person with cancer resides. Hospital based registries help in
assessing cancer patient care in a given hospital and aid in hospital administration including the
individual hospital’s cancer control programmes. The items of patient information collected by a
hospital registry are slightly different from those collected by a population registry, though all of the
items collected by it are normally also collected by the hospital registry. Therefore, the additional
items that a hospital registry collects pertain to clinical stage, treatment and follow up which would
include disease status – whether a given patient is disease free, has recurrence or has widespread
disease. Hospital registries help in planning and monitoring survival studies and clinical trials.
Hospital registries contribute cases to the population based cancer registry in the area.
The cancer registry is an essential part of any rational programme of cancer control. Its
data can be used in a wide variety of areas of cancer control ranging from etiological research,
through primary and secondary prevention to health-care planning and patient care, so benefiting
both the individual and society. Although most cancer registries are not obliged to do more than
provide the basis for such uses of the data, cancer registries possess the potential for
developing and supporting important research programmes using the information which they
collect. The main objective of the cancer registry is to collect and classify information on all cancer
cases in order to produce statistics on the occurrence of cancer in a defined population and to
provide a framework for assessing and controlling the impact of cancer on the community. The
collection of information on cancer cases and the production of cancer statistics are only
justified, however, if use is made of the data collected. Cancer registry information may be used
in a multitude of areas, and the value of the data increases if comparability over time is
maintained.
MCC Annual Report – HBCR 2011
20
Epidemiological research
Cancer epidemiologists use their knowledge of the distribution .of cancer in human
populations to search for determinants of the disease. Evidently, the cancer registry provides a
crucial basis for epidemiology since it holds information on the distribution of cancer,
including non-fatal cases. However, in addition to the production of incidence figures, the
collection of records of cancer patients from a defined population facilitates the in-depth study of
cancer in individuals whilst minimizing the selection bias found in clinical series. In the following, a
distinction is made between the use of the cancer register for descriptive studies and for analytical
studies. It must be emphasized, however, that these two aspects of epidemiology are
complementary and often overlap.
Medical Records
Medical records are a major source of information for all cancer registry operations apart
from sources mentioned below. Recording of an event means that the event is set down for
remembrance or reference and it assumes a permanent form.Many problems can be avoided by
keeping proper records. In the fields of medicine and public health also records provide much help
at the hospital level, at the community level and also at the national level. Generally medical
records contain information about the admission of the patient and history, which states the
patient’s present complaint, family history and behavioral factors such as smoking, alcohol use,
drug abuse, diet and other factors which might be related to the present disease. A physician can
do something to cure the disease of the patient. But in wider perspective, he may not be abole to
say whether the disease is to be tackled at the community level and whether anything can be done
against it without the helop of a group of medical personnel. And this group of medical persons
can do something against it only if they get information about the nature of the disease, history of
the patients regarding the disease, the circumstances which led the patient to contact the disease
and the prevalence and incidence of the particular disease. Medical records fulfill these
requirements.
MCC Annual Report – HBCR 2011
21
National Cancer Registry Programme (Indian Council of Medical Research)
The Indian Council of Medical Research initiated a network of cancer registries across the
country under the National Cancer Registry Programme (NCRP) in December 1981. This move
followed the recognition that there was an urgent need for strengthening the existing cancer
registries and organization of new cancer registries in different regions of the country.
The programme was commenced with the following objectives:
1. To generate reliable data on the magnitude and patterns of cancer – this would be
based on morbidity and mortality rates including incidence rates according to gender,
age andresidence of the patient, anatomical site of cancer andproportion of histological
type or microscopic confirmation for each site; pattern of different types of cancer
according to relative proportions or ratios in various population sub-groups such as
religion, language spoken, educational status; clinical stage of disease when patients
come to hospital for treatmentand where possible the nature of treatment received and
outcome;
2. To undertake epidemiologic studies in the form of case control or cohort studies based
on observations of registry data;
3. Provide research base for developing appropriate strategies to aid in National Cancer
Control Programme; this would bein the form of planning, monitoring and evaluation of
activities under this programme;
4. Develop human resource in cancer registration and Epidemiology.
MCC Annual Report – HBCR 2011
22
NCRP Network
Figure .1 : NCRP Network
MCC Annual Report – HBCR 2011
23
HOSPITAL BASED CANCER REGISTRY
The primary purpose of Hospital Based Cancer Registries is to contribute to patient care
by providing readily accessible information on the patients with cancer, the treatment
received and its results. The data is also used for clinical research and for epidemiological
purposes. Hospital based cancer registries are concerned with recording of information on
the cancer patients seen in a particular hospital (Isabel dos Santos Silva et al, 1999). Within
the hospital, a registry is often considered to be an integral part of the hospital’s cancer
programme or health care delivery system.
The stated Objectives of Hospital Based Cancer Registries (HBCRs) (Maclennan et al, 1978;
Young, J.L. 1991) are outlined below:
1. GENERAL:
1.1 Assess Patient Care
1.2 Participate in Clinical Research to Evaluate Therapy
1.3 Provide an idea of the patterns of cancer in the area
1.4 Help plan hospital facilities.
2. SPECIFIC:
a. Contribute to active follow-up of the cancer patient
b. Describe length and quality of survival in relation to anatomical site, clinical stage
and aspects of types of treatment.
c. Contribute to the Population Based Cancer Registries (PBCRs) in the given area
d. Undertake epidemiological research through short-term case control studies
e. Show time trends in proportion of early to late stages at the time of diagnosis
f. Help assess quality of hospital care and cancer services in covered area.
Data collection is done by the individual registries using a standardized common core form.
The information in this form mainly consists of patient identifying and demographic
information, details of diagnosis the clinical stage of the disease and the broad type of
treatment instituted.
The Hospital Based Cancer Registry (HBCR) of the Malabar Cancer Centre (MCC) ,
Thalassery, Kannur was started in 2010 under the network of Indian Council of Medical
Research (ICMR) with code MCC 524. Malabar Cancer Centre is an exclusive Cancer
Speciality Hospital established in 2000. The registry is restricted to patients from MCC only.
MCC Annual Report – HBCR 2011
24
A total of 2641 patients were registered in the MCC in 2011. The total HBCR cases recorded
were 2575 (males -1375 -53.4% and females -1200-46.6%).
FUNCTIONING OF HBCR The data abstraction and entry are done using the hospital files. The demographic data are
collected and entered into the computer at the time of new patient registration at MCC and
transfer to the core- pro forma of the National Cancer Registry Progamme (NCRP) of Indian
Council of Medical Research (ICMR). The data transfer of the ICMR Core pro forma- first
part (demographic details) and second part (diagnostic treatment and follow up details) is
entered using the ICMR software after retrieving case sheets from the MCC Medical Records
division. All variables in the core pro forma except age and various dates are directly
selected. The selection box contains all the codes along with their descriptions for each
variable. Hence, this helps to avoid mistakes beyond the range of values for each variable.
The selection box corresponding to the variable topography and morphology contains the
third edition of international classification of diseases for oncology (ICD-O-3) and the
international classification of diseases (ICD-10).
2. DATA PROCESSING ANALYSIS
After abstraction, coding and data entry the data were sent to the coordinating unit of the
NCRP of ICMR, Bangalore in an electronic format and the data was subjected to various
range, consistency, unlikely combinations, and duplicate checks. Necessary corrections are
done based on the error list of the cases sent by the coordinating unit and this report is
generated.
MCC Annual Report – HBCR 2011
25
Patterns of Patient Registration/District-wise
Table:1 Pattern of patient registration (Malabar Cancer Centre, Kannur, 2011)
State/District wise attendance of Cancer Patients reported in 2011
MCC caters patients from Kannur, Kozhikode, Kasaragod, Wayanad, Malappuram,
Palakkad, Kottayam, Kollam, Pathanamthitta, Ernakulam, Idukki and Thrissur districts in Kerala
and the neighbouring states Pondicherry(Mahe), Maharashtra, Lakshadweep, Rajasthan, West
Bengal, Orissa, Tamil Nadu, Karnataka. MCC registers all patients reporting to the centre and the
HBCR abstracts information is of only the cancer patients.
Table:2
Type Total
Malignant Tumours 2575
Non‐Neoplastic 20
Benign 25
Pre‐NeoPlastic Tumours(Mild/Mod./Insitu) 9
Borderline/Uncertian(Evaluation Incomplete) 6
Borderline/Uncertian(Evaluation Complete) 6
Total 2641
Districts of Kerala(n=2526)
Kannur 1671Kozhikode 457Kasaragod 238Waynad 87Malappuram 50Palakkad 9Thrissur 60Pathanamthitta 3Kollam 2Ernakulam 1Idukki 1Kottayam 1
Other States(n=53)
Pondicherry 31Karnataka 14Maharashtra 2Tamilnadu 2Lakshadweep 1Rajasthan 1West Bengal 1Orissa 1
Other Countries(n=1)
Kenya 1
MCC Annual Report – HBCR 2011
26
MCC Annual Report – HBCR 2011
27
Summary of Results
A total of 2633 new patients were registered in 2011 and a definite rise in patient
registration was noted in 2011, when compared to the previous year. Among these, a total of
2575 (1375 (53.4%) males and 1200 (46.6%) females) were invasive cancers during the year
2011
Total proportion of tobacco related cancers (TRC) relative to all sites are 52.9% and
18.7% among males and females respectively. TRC with respect to all sites, lung cancer
predominates (22.71%) among males, where as in females, it is mouth (6.9%). TRC with
respect to specific site, among males it is Lung cancer(42.9%) and among females, it is mouth
cancer(37.1%).
The 10 leading cancers found in males were cancers of Lung(22.7%), Stomach(8.0%),
Mouth(7.6%) ,Tongue(4.9%), ,Esophagus(4.4%) ,Larynx(4.0%), ,Oth.Oropharynx(3.8%),
Rectum(3.6%), NHL(3.4%) , and Hypo pharynx(3.3%). Where as in females-cancers of
Breast(29.7%), Cervix Uteri(8.6%), Ovary(7.5%) ,Mouth(6.9%), , Corpus Uteri(3.9%),
Tongue(3.8%) , Rectum(3.7%), NHL(3.3%), Lung(2.9%) and Thyroid(2.8%).
As per educational status, the primary education was 48.7% in males and 41.0% in
females. According to the marital status, 90% were married males and 57.3% were married
females . The relative percentages of marital status in Hindu males and females were 62.5%
and 64.4% respectively. According to broad age group both in males and females the
maximum was in 35-64 .ie, 53.4% in males and 61.1% in females. As per language spoken , the
Malayalam was the most common spoken language among 99.4% of males and 99.3% of
females.
Based on different types of Microscopic Diagnosis Primary Histology was 75.9% in
males and 85.4% in females. Microscopic mode was method of diagnosis in 88.4% of males
and 89.7% of females.
According to specific treatment relative to all treatment procedures any radiotherapy (R
) was 41.1% in males and in females it was 31.7. According to the broad group of treatment at
RI and /or elsewhere, prior treatment taken only was 18.5% in males and 18.4% in females.
Prior treatment elsewhere and treatment at RI among males and females were 16.2% and 20.8
% respectively. Treatment only at RI was 40.5% among males and 44.1% among females. No
treatment was received by 24.8% males and 16.7% females. According to clinical extent of
disease treatment only at RI, localized disease was in 5.5% of males and 6.0 of females,
MCC Annual Report – HBCR 2011
28
regional 39.8% in males and 53.1% in females and distant 43% in males and 31.6% in
females. Those who took treatment only at RI in localized disease category- Surgery was done
in 64.7% of Males and 53.8% of females. Among regional lymph node involvement group -
Radiation was given in 39.7% of males and 33.6% of females. In distant metastasis group,
Radiation was given to 44.1% of males and Chemotherapy (CT) was given to 43.1% of
females.
The leading cancers with respect to system wise were Head& Neck 528(20.5%). Among
them 67.23% were males and 32.77% were females.The second was in Digestive system
488(18.95%) , 65.98% were males and 34.02% were females. The third was Breast
367(14.25%), 2.99% were males and 97% were females. The fourth leading was Respiratory
system 355(13.79%), 88.45% males and 11.55 females. The fifth leading was
Gyneaecological 251(9.75)%, males 0% and 100% in females. The sixth was primary
unknown 77(2.99%), 64.94% in males and 35.06 % in females. The seventh was Lymphoma
71 (2.76%), males (56.34%) and females (43.66%). The eighth was Male Genital organ
59(2.29%), 100% males. In the nineth position was Leukemia 57(2.21%), 59.65% males and
40.35% females. And the tenth leading was Urological 56(2.17%), 78.57% males and 21.43%
females.
In 355 respiratory system cancer patients , 103(29.01%) have smoking habit. In 488
digestive system, 67(13.73%) has alcoholism habit and in 528 head & neck cancers,
76(14.39%) has panchewing habit. Among hereditary cancers, 101 (27.52%) breast cancer
patients and in Colon 19(30.16%) have family history of cancer.
The ten leading cancers irrespective of sex were recorded as Breast(14.25%),
Lung(13.48%), Mouth (7.26%), Stomach (5.51%), Tongue(4.39%), Cervix(4%),
Rectum(3.65%), Ovary(3.49%), Oesophagus(3.38%) and NHL(3.34%) respectively.
Among 33 childhood cancers the leading cancers were bone(36.36%) and Brain
(12.12%).
Among 2575 patients registered 26 were ST patients, and among them 15(57.69%) had
head& neck cancers.
Among 2575 patients,in 1375 males 65.3% were new cases and 34.7% were old cases
and in 1200 females, 60.7% were new cases and 39.3 were old cases.
MCC Annual Report – HBCR 2011
29
Results Magnitude of Total Cancers
According to cancer registration in the Hospital Based Cancer Registry of MCC,
Thalassery, Kannur during the year 2011, the number of cancer patients and their relative
proportion according to sex and sex ratio percentage have been represented in Table 1. The
number of cancer patients recorded in the HBCR was 2575 [males 1375 (53.4%) and females 1200
(46.6%)]
Table 3 : Number (#) and Proportion (%) according to Sex
Tobacco Related Cancers(TRC)
Total proportion of tobacco related cancers (TRC) relative to all sites is 52.9% and 18.7%
among males and females respectively. TRC with respect to all sites, lung cancer predominates
(22.7%) among male, where as in females, it is mouth (6.9%). TRC with respect to specific site,
among males it is Lung (42.9%) and among females, it is mouth (37.1%).
Table 4: Number and Proportion of Cancers associated with Use of Tobacco relative to all sites of Cancer
MCC Annual Report – HBCR 2011
30
Fig.2 Table 5:
Number(#) and Proportion(%) of Tobacco Related Cancers (TRC) relative to all sites of Cancer
Fig. 3
Per
cent
age
MCC Annual Report – HBCR 2011
31
Per
cent
age
MCC Annual Report – HBCR 2011
32
Fig. 4
Table 6 :
Number(#) and Proportion(%) of Specific Sites of Cancers among Tobacco Related Cancers (TRC)
Per
cent
age
MCC Annual Report – HBCR 2011
33
Fig.5
Number(#) and Proportion(%) of Specific Sites of Cancers among Tobacco Related Cancers (TRC)
Fig.6
Per
cent
age
Per
c en
tage
MCC Annual Report – HBCR 2011
34
LEADING SITES OF CANCER AND MAGNITUDE
Table 7: Rank, Number (#) and Relative Proportion (%) of Leading Sites of Cancer –Male
Relative Proportion(%) of Leading Sites of Cancer-Male
Fig.7
MCC Annual Report – HBCR 2011
35
Table 8: Rank, Number(#) and Relative Proportion(%) of Leading Sites of Cancer –Female
Relative Proportion(%) of Leading Sites of Cancer-Female
Fig.8
MCC Annual Report – HBCR 2011
36
Table 9:
Number(#) and Relative Proportion(%) by Language Spoken(All Sites of Cancer)
MCC Annual Report – HBCR 2011
37
MCC Annual Report – HBCR 2011
38
SUMMARY OF STATISTICS NCRP-ICMR
(Demographic, Diagnostic And Clinical Details)
MCC Annual Report – HBCR 2011
39
MCC Annual Report – HBCR 2011
40
SUMMARY OF STATISTICS
Table 10:
Fig.9
Per
c en
tage
MCC Annual Report – HBCR 2011
41
Table 11:
Number(#) and Proportion(%) of Cancers by Broad Age Groups
Fig.10
Per
cent
age
MCC Annual Report – HBCR 2011
42
Table 12:
Fig. 11
Per
c en
tage
MCC Annual Report – HBCR 2011
43
Table 13:
Fig. 12
Per
c en
tage
MCC Annual Report – HBCR 2011
44
Table 14:
Table 15:
MCC Annual Report – HBCR 2011
45
Table 16:
Fig .13
Per
cent
age
MCC Annual Report – HBCR 2011
46
Table 17:
Number(#) and Relative Proportion(%) of Cancers based on Different Methods of Diagnosis
Fig. 14
Per
cent
age
MCC Annual Report – HBCR 2011
47
Table 18:
Number(#) and Relative Proportion(%) by Religion (All Sites of Cancer)
MCC Annual Report – HBCR 2011
48
Table:19
Number (#) and Relative proportion (%) of any Specific Treatment relative to all Treated Patients according to Clinical Extent of Disease
Treatment Only at RI
MCC Annual Report – HBCR 2011
49
Table 20:
MCC Annual Report – HBCR 2011
50
Descriptive Statistics –NCRP‐ICMR (Demographic,Diagnostic And Clinical Details)
MCC Annual Report – HBCR 2011
51
MCC Annual Report – HBCR 2011
52
MCC Annual Report – HBCR 2011
53
DIAGNOSTIC INFORMATION
Number of cancers by site (ICD-10) and Five Year Age Group – Males Table 21:
ICD10 Site 00 05 10 15 20 25 30 35 40 45 50 55 60 65 70 > Un
Total % 04 09 14 19 24 29 34 39 44 49 54 59 64 69 74 75 Kn
C00 Lip - - - - - - - - - - 1 - - 1 1 1 - 4 0.3
C01-02 Tongue - - - - - - 2 3 7 7 6 11 7 13 3 8 - 67 4.9
C03-06 Mouth - - 1 - - - - - 6 7 10 10 20 16 18 16 - 104 7.6
C07-08 Salivary Gland - - - - - - 2 2 - 1 - - - - 2 1 - 8 0.6
C09 Tonsil - - - - - - - - 1 1 1 1 - 1 - 1 - 6 0.4
C10 Oth. Oropharynx - - - - - 1 - - 2 - 5 5 13 10 9 7 - 52 3.8
C11 Nasopharynx - - - - - - - - 1 1 1 1 1 1 1 - - 7 0.5
C12-13 Hypopharynx - - - - - - - - 2 4 5 8 10 10 2 4 - 45 3.3
C14 Pharynx Unspecified - - - - - - - - - - - - - - - 1 - 1 0.1
C15 Oesophagus - - - - - - - - - 4 6 10 10 5 16 10 - 61 4.4
C16 Stomach - - - - - - 1 1 4 5 11 18 23 16 14 17 - 110 8
C17 Small Intestine - - - - - - - - 1 1 2 1 1 - - - - 6 0.4
C18 Colon - - - - - - - - 2 4 2 2 1 11 4 6 - 32 2.3
C19-20 Rectum - - - - - 1 3 1 3 2 5 6 5 8 8 8 - 50 3.6
C21 Anus & Anal Canal - - - - - - - 1 - - - 1 - - - - - 2 0.1
C22 Liver - - - - - - - 1 - 1 3 5 6 2 4 6 - 28 2.0
C23-24 Gallbladder - - - - - - - - 3 - - 1 - 1 - 2 - 7 0.5
C25 Pancreas - - - - - - - 2 1 1 1 1 4 - 3 - - 13 0.9
C30-31 Nose,Sinuses - - - - - - - - - - 2 - 1 1 - - - 4 0.3
C32 Larynx - - - - - - - - 2 1 1 8 15 7 4 17 - 55 4
C33-34 Lung - - - - - 1 - 5 4 14 35 56 63 57 50 27 - 312 22.7
C37-38 Other Thoracic Organs - - - - - - - 1 - - - - - - - - - 1 0.1
C40-41 Bone 1 - 3 5 2 1 2 - 1 - 2 1 1 1 - - - 20 1.5
C43 Melanoma of Skin - - - - - - - 1 - - - - 2 1 2 1 - 7 0.5
C44 Other Skin - - - 1 2 - 1 - 1 2 4 1 6 2 6 2 - 28 2.0
C45 Mesothelioma - - - - - - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue - - 2 1 2 1 3 3 1 2 1 3 4 2 2 1 - 28 2.0
MCC Annual Report – HBCR 2011
54
ICD10 Site 00 05 10 15 20 25 30 35 40 45 50 55 60 65 70 > Un
Total % 04 09 14 19 24 29 34 39 44 49 54 59 64 69 74 75 Kn
C50 Breast - - - - - - - - - 2 - 2 2 1 1 3 - 11 0.8
C60 Penis - - - - - - - - - - 2 - - 1 1 1 - 5 0.4
C61 Prostate - - - - - - - - 1 - 3 2 8 9 12 10 - 45 3.3
C62 Testis - - - - - 1 2 - - - - - - 1 - 1 - 5 0.4
C63 Other Male Genital - - - - - - - - - - - - - - - - - - -
C64 Kidney - - - - - - - - - 2 3 1 4 3 2 1 - 16 1.2
C65 Renal Pelvis - - - - - - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - - - 1 - 1 0.1
C67 Bladder - - - - - - - 1 2 1 4 1 5 3 5 5 - 27 2.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - - - - - - -
C70-72 Brain, NS 1 - 1 - - 1 4 - 1 2 2 2 1 1 - 1 - 17 1.2
C73 Thyroid - - - - - - - 2 - 1 1 4 2 1 2 2 - 15 1.1
C74 Adrenal Gland - - - - - - - - - - - - - - - - - - -
C81 Hodgkins Disease - - - - 1 - - 1 - 3 1 1 1 - 1 2 - 11 0.8
C82-85,C96 NHL - - 1 - - - 3 2 5 3 7 6 8 2 1 9 - 47 3.4
C88 Malig Imn.Prol D - - - - - - - - - - - - 1 - - - - 1 0.1
C90 Multiple Myeloma - - - - - - 1 - 1 - 3 1 1 3 1 4 - 15 1.1
C91 Lymphoid Leuk. - 1 1 2 1 1 1 1 1 - 1 2 2 - - - - 14 1.0
C92-94 Myeloid Leukaemia - - - - - 1 - - 3 5 2 5 1 3 1 1 - 22 1.6
C95 Leukaemia Uns - - - - - - - - - - - - 1 1 - - - 2 0.1
O&U Other and Uns - - 1 - - - - 1 1 6 5 3 17 10 9 10 - 63 4.6
All Sites 2 1 10 9 8 9 25 29 57 83 138 180 247 205 185 187 - 1375 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
55
Table 22: Number of cancers by site (ICD-10) and Five Year Age Group – Females
ICD10 Site 00 05 10 15 20 25 30 35 40 45 50 55 60 65 70 > Un
Total % 04 09 14 19 24 29 34 39 44 49 54 59 64 69 74 75 Kn
C00 Lip - - - - - - - - - - - 1 - 1 3 2 - 7 0.6
C01-02 Tongue - - - - 1 1 - 2 1 3 5 4 8 6 9 6 - 46 3.8
C03-06 Mouth - - - - - - 1 - 1 1 6 9 9 14 16 26 - 83 6.9
C07-08 Salivary Gland - - - - 1 2 - - 1 - 1 - - 1 - 2 - 8 0.7
C09 Tonsil - - - - - - - - - - - - - - - 1 - 1 0.1
C10 Oth. Oropharynx - - - - - - - - 1 - - 1 - 1 1 1 - 5 0.4
C11 Nasopharynx - - - - - - - - - 1 - - - - 1 - - 2 0.2
C12-13 Hypopharynx - - - - - - - - 1 3 - 3 2 - 1 2 - 12 1
C14 Pharynx Unspecified - - - - - - - - - - - - - - 1 - - 1 0.1
C15 Oesophagus - - - - - - - 1 1 1 1 - 4 1 4 13 - 26 2.2
C16 Stomach - - - - - - - 2 1 3 2 4 4 6 5 5 - 32 2.7
C17 Small Intestine - - - - - - - - - - 1 1 1 - - - - 3 0.2
C18 Colon - - - - 1 - - 2 2 4 5 5 2 4 4 2 - 31 2.6
C19-20 Rectum - - - 1 - 2 - 3 3 6 5 3 5 4 6 6 - 44 3.7
C21 Anus & Anal Canal - - - - - - - - - - - 1 - - 1 1 - 3 0.2
C22 Liver - - - - - - - - - - - - - 3 - - - 3 0.2
C23-24 Gallbladder - - - - - - - 1 1 2 - - - 1 1 1 - 7 0.6
C25 Pancreas - - - - - - 2 1 1 2 3 2 - 1 - - - 12 1
C30-31 Nose,Sinuses - - - - - - - - - 1 1 - 1 1 - 2 - 6 0.5
C32 Larynx - - - - - - - 1 - - 1 - - - - 1 - 3 0.2
C33-34 Lung - - - - - - - - 2 6 3 4 5 4 5 6 - 35 2.9
C37-38 Other Thoracic Organs - - - - 1 - - - 1 - - - - - - 1 - 3 0.2
C40-41 Bone - - 1 1 1 2 1 2 1 - - 1 1 - 1 1 - 13 1.1
C43 Melanoma of Skin - - - - - - - - - - - 1 - 1 - 1 - 3 0.2
C44 Other Skin - - - - - - 2 - 1 1 2 2 4 5 2 2 - 21 1.8
C45 Mesothelioma - - - - - - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue - - 1 - 1 1 2 4 - - 1 1 2 - 4 - - 17 1.4
C50 Breast - - - - - 3 11 31 53 59 64 39 34 21 23 18 - 356 29.7
C51 Vulva - - - - - - - - - - - - 1 - - - - 1 0.1
C52 Vagina - - - - - - - - - 2 1 - 1 - 1 1 - 6 0.5
C53 Cervix Uteri - - - - - - 1 2 5 14 15 20 14 11 8 13 - 103 8.6
MCC Annual Report – HBCR 2011
56
ICD10 Site 00 05 10 15 20 25 30 35 40 45 50 55 60 65 70 > Un
Total % 04 09 14 19 24 29 34 39 44 49 54 59 64 69 74 75 Kn
C54 Corpus Uteri - - - - - - - - 4 2 13 7 8 3 5 5 - 47 3.9
C55 Uterus Unspecified - - - - - - - - - - - - - - - - - - -
C56 Ovary - - - 1 1 3 5 6 9 8 11 15 8 9 10 4 - 90 7.5
C57 Other Female Genital - - - - - - - - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - - - - - - - - -
C64 Kidney - - - - - - - - 1 - 1 2 1 1 - - - 6 0.5
C65 Renal Pelvis - - - - - - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - - - - - - -
C67 Bladder - - - - - - - - - 1 - - 2 1 - 2 - 6 0.5
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - - - - -
C69 Eye 1 - 1 - - - - - - - - - - - - - - 2 0.2
C70-72 Brain, NS - 1 - 1 - - - - 1 2 - 1 1 1 - - - 8 0.7
C73 Thyroid - - - - - 1 1 5 5 - 2 5 2 6 2 5 - 34 2.8
C74 Adrenal Gland - - - - - - - - - - - - - - - - - - -
C81 Hodgkins Disease - - - - - - 1 1 - - - - - 3 - 2 - 7 0.6
C82-85,C96 NHL - - - - 1 1 - 1 2 1 2 8 6 3 6 8 - 39 3.2
C88 Malig Imn.Prol D - - - - - - - - - - - - - - - - - - -
C90 Multiple Myeloma - - - - - - - - - - 1 4 6 4 2 - - 17 1.4
C91 Lymphoid Leuk. - - - 1 - 1 - - - - - - 1 - - 2 - 5 0.4
C92-94 Myeloid Leukaemia - - - 1 1 1 - - 4 2 2 1 2 2 3 2 - 21 1.8
C95 Leukaemia Uns - - - - - - - - - - - - - - - - - - -
O&U Other and Uns - - - - - - - 1 1 5 - 3 1 5 1 8 - 25 2.1
All Sites 1 1 3 6 9 18 27 66 104 130 149 148 136 124 126 152 - 1200 100
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
57
Table 23: Number(#) and Proportion(%) of cancers by site (ICD‐10) and Method of Diagnosis ‐ Males
ICD10 Site Microscopic
X-Ray / Imaging
Clinical Others Unknown Total
# % # % # % # % # % # %
C00 Lip 4 100.0 - - - - - - - - 4 100.0
C01-02 Tongue 58 86.6 - - 3 4.5 6 9.0 - - 67 100.0
C03-06 Mouth 91 87.5 1 1.0 2 1.9 10 9.6 - - 104 100.0
C07-08 Salivary Gland 8 100.0 - - - - - - - - 8 100.0
C09 Tonsil 6 100.0 - - - - - - - - 6 100.0
C10 Oth. Oropharynx 48 92.3 - - - - 4 7.7 - - 52 100.0
C11 Nasopharynx 6 85.7 - - - - 1 14.3 - - 7 100.0
C12-13 Hypopharynx 39 86.7 - - 1 2.2 5 11.1 - - 45 100.0
C14 Pharynx Unspecified 1 100.0 - - - - - - - - 1 100.0
C15 Oesophagus 58 95.1 - - - - 3 4.9 - - 61 100.0
C16 Stomach 98 89.1 - - - - 12 10.9 - - 110 100.0
C17 Small Intestine 6 100.0 - - - - - - - - 6 100.0
C18 Colon 26 81.2 1 3.1 - - 5 15.6 - - 32 100.0
C19-20 Rectum 46 92 - - - - 4 8 - - 50 100.0
C21 Anus & Anal Canal 2 100.0 - - - - - - - - 2 100.0
C22 Liver 16 57.1 9 32.1 - - 3 10.7 - - 28 100.0
C23-24 Gallbladder 5 71.4 1 14.3 - - 1 14.3 - - 7 100.0
C25 Pancreas 7 53.8 5 38.5 - - 1 7.7 - - 13 100.0
C30-31 Nose,Sinuses 4 100.0 - - - - - - - - 4 100.0
C32 Larynx 49 89.1 - - - - 6 10.9 - - 55 100.0
C33-34 Lung 271 86.9 35 11.2 - - 6 1.9 - - 312 100.0
C37-38 Other Thoracic Organs 1 100.0 - - - - - - - - 1 100.0
C40-41 Bone 20 100.0 - - - - - - - - 20 100.0
C43 Melanoma of Skin 6 85.7 - - 1 14.3 - - - - 7 100.0
C44 Other Skin 27 96.4 - - 1 3.6 - - - - 28 100.0
C45 Mesothelioma - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 28 100.0 - - - - - - - - 28 100.0
C50 Breast 10 90.9 - - - - 1 9.1 - - 11 100.0
C60 Penis 5 100.0 - - - - - - - - 5 100.0
C61 Prostate 35 77.8 - - - - 10 22.2 - - 45 100.0
MCC Annual Report – HBCR 2011
58
ICD10 Site Microscopic
X-Ray / Imaging
Clinical Others Unknown Total
# % # % # % # % # % # %
C62 Testis 5 100.0 - - - - - - - - 5 100.0
C63 Other Male Genital - - - - - - - - - - - -
C64 Kidney 15 93.8 1 6.2 - - - - - - 16 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter 1 100.0 - - - - - - - - 1 100.0
C67 Bladder 26 96.3 - - - - 1 3.7 - - 27 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - -
C70-72 Brain, NS 16 94.1 1 5.9 - - - - - - 17 100.0
C73 Thyroid 15 100.0 - - - - - - - - 15 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease 11 100.0 - - - - - - - - 11 100.0
C82-85,C96 NHL 47 100.0 - - - - - - - - 47 100.0
C88 Malig Imn.Prol D 1 100.0 - - - - - - - - 1 100.0
C90 Multiple Myeloma 12 80 - - - - 3 20 - - 15 100.0
C91 Lymphoid Leuk. 14 100.0 - - - - - - - - 14 100.0
C92-94 Myeloid Leukaemia 22 100.0 - - - - - - - - 22 100.0
C95 Leukaemia Uns 2 100.0 - - - - - - - - 2 100.0
O&U Other and Uns 47 74.6 14 22.2 1 1.6 1 1.6 - - 63 100.0
All Sites 1215 88.4 68 4.9 9 0.7 83 6.0 - - 1375 100
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
59
Table 24:Number(#) and Proportion(%) of cancers by site (ICD-10) and Method of Diagnosis – Females
ICD10 Site Microscopic X-Ray / Imaging Clinical Others Unknown Total
# % # % # % # % # % # %
C00 Lip 6 85.7 - - 1 14.3 - - - - 7 100.0
C01-02 Tongue 41 89.1 - - 2 4.3 3 6.5 - - 46 100.0
C03-06 Mouth 71 85.5 - - 5 6.0 7 8.4 - - 83 100.0
C07-08 Salivary Gland 8 100.0 - - - - - - - - 8 100.0
C09 Tonsil 1 100.0 - - - - - - - - 1 100.0
C10 Oth. Oropharynx 4 80 - - - - 1 20 - - 5 100.0
C11 Nasopharynx 2 100.0 - - - - - - - - 2 100.0
C12-13 Hypopharynx 8 66.7 - - 1 8.3 3 25 - - 12 100.0
C14 Pharynx Unspecified 1 100.0 - - - - - - - - 1 100.0
C15 Oesophagus 25 96.2 - - - - 1 3.8 - - 26 100.0
C16 Stomach 29 90.6 1 3.1 - - 2 6.2 - - 32 100.0
C17 Small Intestine 3 100.0 - - - - - - - - 3 100.0
C18 Colon 27 87.1 3 9.7 - - 1 3.2 - - 31 100.0
C19-20 Rectum 38 86.4 1 2.3 1 2.3 4 9.1 - - 44 100.0
C21 Anus & Anal Canal 3 100.0 - - - - - - - - 3 100.0
C22 Liver 2 66.7 1 33.3 - - - - - - 3 100.0
C23-24 Gallbladder 5 71.4 1 14.3 - - 1 14.3 - - 7 100.0
C25 Pancreas 7 58.3 5 41.7 - - - - - - 12 100.0
C30-31 Nose,Sinuses 6 100.0 - - - - - - - - 6 100.0
C32 Larynx 2 66.7 - - - - 1 33.3 - - 3 100.0
C33-34 Lung 30 85.7 4 11.4 - - 1 2.9 - - 35 100.0
C37-38 Other Thoracic Organs 3 100.0 - - - - - - - - 3 100.0
C40-41 Bone 13 100.0 - - - - - - - - 13 100.0
C43 Melanoma of Skin 3 100.0 - - - - - - - - 3 100.0
C44 Other Skin 21 100.0 - - - - - - - - 21 100.0
C45 Mesothelioma - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 16 94.1 - - - - 1 5.9 - - 17 100.0
C50 Breast 333 93.5 1 0.3 3 0.8 19 5.3 - - 356 100.0
C51 Vulva 1 100.0 - - - - - - - - 1 100.0
C52 Vagina 6 100.0 - - - - - - - - 6 100.0
MCC Annual Report – HBCR 2011
60
ICD10 Site Microscopic X-Ray / Imaging Clinical Others Unknown Total
# % # % # % # % # % # %
C53 Cervix Uteri 93 90.3 1 1.0 1 1.0 8 7.8 - - 103 100.0
C54 Corpus Uteri 46 97.9 1 2.1 - - - - - - 47 100.0
C55 Uterus Unspecified - - - - - - - - - - - -
C56 Ovary 68 75.6 4 4.4 - - 18 20 - - 90 100.0
C57 Other Female Genital - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - -
C64 Kidney 6 100.0 - - - - - - - - 6 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - -
C67 Bladder 5 83.3 1 16.7 - - - - - - 6 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye 2 100.0 - - - - - - - - 2 100.0
C70-72 Brain, NS 7 87.5 1 12.5 - - - - - - 8 100.0
C73 Thyroid 34 100.0 - - - - - - - - 34 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease 7 100.0 - - - - - - - - 7 100.0
C82-85,C96
NHL 39 100.0 - - - - - - - - 39 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - -
C90 Multiple Myeloma 12 70.6 1 5.9 - - 4 23.5 - - 17 100.0
C91 Lymphoid Leuk. 5 100.0 - - - - - - - - 5 100.0
C92-94 Myeloid Leukaemia 21 100.0 - - - - - - - - 21 100.0
C95 Leukaemia Uns - - - - - - - - - - - -
O&U Other and Uns 16 64 9 36 - - - - - - 25 100.0
All Sites 1076 89.7 35 2.9 14 1.2 75 6.2 - - 1200 100
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
61
Table 25: Number(#) and Proportion(%) of cancers by site (ICD-10) and Detailed Microscopic Diagnosis – Males
ICD10 Site Pri. Hist Sec. Hist Cytology Blood Film Bone Marrow Others Total
# % # % # % # % # % # % # %
C00 Lip 4 100.0 - - - - - - - - - - 4 100.0
C01-02 Tongue 57 85.1 1 1.5 - - - - - - 9 13.4 67 100.0
C03-06 Mouth 90 86.5 1 1.0 - - - - - - 13 12.5 104 100.0
C07-08 Salivary Gland 7 87.5 - - 1 12.5 - - - - - - 8 100.0
C09 Tonsil 4 66.7 2 33.3 - - - - - - - - 6 100.0
C10 Oth. Oropharynx 41 78.8 7 13.5 - - - - - - 4 7.7 52 100.0
C11 Nasopharynx 3 42.9 3 42.9 - - - - - - 1 14.3 7 100.0
C12-13 Hypopharynx 35 77.8 4 8.9 - - - - - - 6 13.3 45 100.0
C14 Pharynx Unspecified 1 100.0 - - - - - - - - - - 1 100.0
C15 Oesophagus 55 90.2 3 4.9 - - - - - - 3 4.9 61 100.0
C16 Stomach 93 84.5 5 4.5 - - - - - - 12 10.9 110 100.0
C17 Small Intestine 6 100.0 - - - - - - - - - - 6 100.0
C18 Colon 25 78.1 1 3.1 - - - - - - 6 18.8 32 100.0
C19-20 Rectum 46 92 - - - - - - - - 4 8 50 100.0
C21 Anus & Anal Canal 2 100.0 - - - - - - - - - - 2 100.0
C22 Liver 14 50 1 3.6 1 3.6 - - - - 12 42.9 28 100.0
C23-24 Gallbladder 2 28.6 2 28.6 1 14.3 - - - - 2 28.6 7 100.0
C25 Pancreas 6 46.2 - - 1 7.7 - - - - 6 46.2 13 100.0
C30-31 Nose,Sinuses 4 100.0 - - - - - - - - - - 4 100.0
C32 Larynx 43 78.2 6 10.9 - - - - - - 6 10.9 55 100.0
C33-34 Lung 185 59.3 61 19.6 25 8.0 - - - - 41 13.1 312 100.0
C37-38 Other Thoracic Organs 1 100.0 - - - - - - - - - - 1 100.0
C40-41 Bone 20 100.0 - - - - - - - - - - 20 100.0
C43 Melanoma of Skin 6 85.7 - - - - - - - - 1 14.3 7 100.0
C44 Other Skin 27 96.4 - - - - - - - - 1 3.6 28 100.0
C45 Mesothelioma - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 28 100.0 - - - - - - - - - - 28 100.0
C50 Breast 10 90.9 - - - - - - - - 1 9.1 11 100.0
C60 Penis 5 100.0 - - - - - - - - - - 5 100.0
C61 Prostate 34 75.6 1 2.2 - - - - - - 10 22.2 45 100.0
MCC Annual Report – HBCR 2011
62
ICD10 Site Pri. Hist Sec. Hist Cytology Blood Film Bone Marrow Others Total
# % # % # % # % # % # % # %
C62 Testis 5 100.0 - - - - - - - - - - 5 100.0
C63 Other Male Genital - - - - - - - - - - - - - -
C64 Kidney 14 87.5 - - 1 6.2 - - - - 1 6.2 16 100.0
C65 Renal Pelvis - - - - - - - - - - - - - -
C66 Ureter 1 100.0 - - - - - - - - - - 1 100.0
C67 Bladder 25 92.6 1 3.7 - - - - - - 1 3.7 27 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - -
C70-72 Brain, NS 16 94.1 - - - - - - - - 1 5.9 17 100.0
C73 Thyroid 13 86.7 2 13.3 - - - - - - - - 15 100.0
C74 Adrenal Gland - - - - - - - - - - - - - -
C81 Hodgkins Disease 11 100.0 - - - - - - - - - - 11 100.0
C82-85,C96 NHL 46 97.9 1 2.1 - - - - - - - - 47 100.0
C88 Malig Imn.Prol D 1 100.0 - - - - - - - - - - 1 100.0
C90 Multiple Myeloma 12 80 - - - - - - - - 3 20 15 100.0
C91 Lymphoid Leuk. 14 100.0 - - - - - - - - - - 14 100.0
C92-94 Myeloid Leukaemia 22 100.0 - - - - - - - - - - 22 100.0
C95 Leukaemia Uns 2 100.0 - - - - - - - - - - 2 100.0
O&U Other and Uns 7 11.1 38 60.3 2 3.2 - - - - 16 25.4 63 100.0
All Sites 1043 75.9 140 10.2 32 2.3 - - - - 160 11.6 1375 100
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
63
Table 26: Number(#) and Proportion(%) of cancers by site (ICD-10) and Detailed Microscopic Diagnosis - Females
ICD10 Site
Treatment Groups
Prior Tmt. Only Prior & Tmt. at RI Tmt. Only at RI No Treatment Total
# % # % # % # % # %
C00 Lip 1 25.0 - - 3 75.0 - - 4 100.0
C01-02 Tongue 8 11.9 11 16.4 34 50.7 14 20.9 67 100.0
C03-06 Mouth 16 15.4 19 18.3 56 53.8 13 12.5 104 100.0
C07-08 Salivary Gland 1 12.5 1 12.5 4 50.0 2 25.0 8 100.0
C09 Tonsil - - - - 5 83.3 1 16.7 6 100.0
C10 Oth. Oropharynx 7 13.5 7 13.5 33 63.5 5 9.6 52 100.0
C11 Nasopharynx 1 14.3 1 14.3 4 57.1 1 14.3 7 100.0
C12-13 Hypopharynx 7 15.6 4 8.9 27 60.0 7 15.6 45 100.0
C14 Pharynx Unspecified - - - - 1 100.0 - - 1 100.0
C15 Oesophagus 7 11.5 2 3.3 36 59.0 16 26.2 61 100.0
C16 Stomach 26 23.6 10 9.1 38 34.5 36 32.7 110 100.0
C17 Small Intestine 1 16.7 4 66.7 1 16.7 - - 6 100.0
C18 Colon 7 21.9 9 28.1 12 37.5 4 12.5 32 100.0
C19-20 Rectum 16 32.0 8 16.0 22 44.0 4 8.0 50 100.0
C21 Anus & Anal Canal - - - - 1 50.0 1 50.0 2 100.0
C22 Liver 5 17.9 4 14.3 6 21.4 13 46.4 28 100.0
C23-24 Gallbladder 3 42.9 - - - - 4 57.1 7 100.0
C25 Pancreas 5 38.5 2 15.4 1 7.7 5 38.5 13 100.0
C30-31 Nose,Sinuses 3 75.0 - - - - 1 25.0 4 100.0
C32 Larynx 10 18.2 7 12.7 25 45.5 13 23.6 55 100.0
C33-34 Lung 31 9.9 45 14.4 141 45.2 95 30.4 312 100.0
C37-38 Other Thoracic Organs 1 100.0 - - - - - - 1 100.0
C40-41 Bone 4 20.0 11 55.0 3 15.0 2 10.0 20 100.0
C43 Melanoma of Skin 1 14.3 - - 3 42.9 3 42.9 7 100.0
C44 Other Skin 6 21.4 4 14.3 13 46.4 5 17.9 28 100.0
C45 Mesothelioma - - - - - - - - - -
MCC Annual Report – HBCR 2011
64
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
C46 Kaposi Sarcoma - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 9 32.1 11 39.3 5 17.9 3 10.7 28 100.0
C50 Breast 2 18.2 2 18.2 5 45.5 2 18.2 11 100.0
C60 Penis 1 20.0 1 20.0 3 60.0 - - 5 100.0
C61 Prostate 9 20.0 15 33.3 14 31.1 7 15.6 45 100.0
C62 Testis 2 40.0 2 40.0 1 20.0 - - 5 100.0
C63 Other Male Genital - - - - - - - - - -
C64 Kidney 6 37.5 5 31.2 2 12.5 3 18.8 16 100.0
C65 Renal Pelvis - - - - - - - - - -
C66 Ureter 1 100.0 - - - - - - 1 100.0
C67 Bladder 10 37.0 3 11.1 3 11.1 11 40.7 27 100.0
C68 Uns.Urinary Organs - - - - - - - - - -
C69 Eye - - - - - - - - - -
C70-72 Brain, NS 7 41.2 8 47.1 - - 2 11.8 17 100.0
C73 Thyroid 6 40.0 2 13.3 3 20.0 4 26.7 15 100.0
C74 Adrenal Gland - - - - - - - - - -
C81 Hodgkins Disease 4 36.4 1 9.1 3 27.3 3 27.3 11 100.0
C82-85,C96 NHL 8 17.0 7 14.9 20 42.6 12 25.5 47 100.0
C88 Malig Imn.Prol D - - - - 1 100.0 - - 1 100.0
C90 Multiple Myeloma 6 40.0 5 33.3 1 6.7 3 20.0 15 100.0
C91 Lymphoid Leuk. 4 28.6 7 50.0 1 7.1 2 14.3 14 100.0
C92-94 Myeloid Leukaemia 6 27.3 2 9.1 4 18.2 10 45.5 22 100.0
C95 Leukaemia Uns - - - - - - 2 100.0 2 100.0
O&U Other and Uns 6 9.5 3 4.8 22 34.9 32 50.8 63 100.0
All Sites 254 18.5 223 16.2 557 40.5 341 24.8 1375 100.0
MCC Annual Report – HBCR 2011
65
CLINICAL INFORMATION
Table 27: Number(#) and Proportion(%) of cancers by site (ICD-10) and Broad Treatment Group - Males
ICD10 Site
Treatment Groups
Prior Tmt. Only Prior & Tmt. at RI Tmt. Only at RI No Treatment Total
# % # % # % # % # %
C00 Lip 1 25.0 - - 3 75.0 - - 4 100.0
C01-02 Tongue 8 11.9 11 16.4 34 50.7 14 20.9 67 100.0
C03-06 Mouth 16 15.4 19 18.3 56 53.8 13 12.5 104 100.0
C07-08 Salivary Gland 1 12.5 1 12.5 4 50.0 2 25.0 8 100.0
C09 Tonsil - - - - 5 83.3 1 16.7 6 100.0
C10 Oth. Oropharynx 7 13.5 7 13.5 33 63.5 5 9.6 52 100.0
C11 Nasopharynx 1 14.3 1 14.3 4 57.1 1 14.3 7 100.0
C12-13 Hypopharynx 7 15.6 4 8.9 27 60.0 7 15.6 45 100.0
C14 Pharynx Unspecified - - - - 1 100.0 - - 1 100.0
C15 Oesophagus 7 11.5 2 3.3 36 59.0 16 26.2 61 100.0
C16 Stomach 26 23.6 10 9.1 38 34.5 36 32.7 110 100.0
C17 Small Intestine 1 16.7 4 66.7 1 16.7 - - 6 100.0
C18 Colon 7 21.9 9 28.1 12 37.5 4 12.5 32 100.0
C19-20 Rectum 16 32.0 8 16.0 22 44.0 4 8.0 50 100.0
C21 Anus & Anal Canal - - - - 1 50.0 1 50.0 2 100.0
C22 Liver 5 17.9 4 14.3 6 21.4 13 46.4 28 100.0
C23-24 Gallbladder 3 42.9 - - - - 4 57.1 7 100.0
C25 Pancreas 5 38.5 2 15.4 1 7.7 5 38.5 13 100.0
C30-31 Nose,Sinuses 3 75.0 - - - - 1 25.0 4 100.0
C32 Larynx 10 18.2 7 12.7 25 45.5 13 23.6 55 100.0
C33-34 Lung 31 9.9 45 14.4 141 45.2 95 30.4 312 100.0
C37-38 Other Thoracic Organs 1 100.0 - - - - - - 1 100.0
C40-41 Bone 4 20.0 11 55.0 3 15.0 2 10.0 20 100.0
C43 Melanoma of Skin 1 14.3 - - 3 42.9 3 42.9 7 100.0
C44 Other Skin 6 21.4 4 14.3 13 46.4 5 17.9 28 100.0
C45 Mesothelioma - - - - - - - - - -
MCC Annual Report – HBCR 2011
66
ICD10 Site
Treatment Groups
Prior Tmt. Only Prior & Tmt. at RI Tmt. Only at RI No Treatment Total
# % # % # % # % # %
C46 Kaposi Sarcoma - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 9 32.1 11 39.3 5 17.9 3 10.7 28 100.0
C50 Breast 2 18.2 2 18.2 5 45.5 2 18.2 11 100.0
C60 Penis 1 20.0 1 20.0 3 60.0 - - 5 100.0
C61 Prostate 9 20.0 15 33.3 14 31.1 7 15.6 45 100.0
C62 Testis 2 40.0 2 40.0 1 20.0 - - 5 100.0
C63 Other Male Genital - - - - - - - - - -
C64 Kidney 6 37.5 5 31.2 2 12.5 3 18.8 16 100.0
C65 Renal Pelvis - - - - - - - - - -
C66 Ureter 1 100.0 - - - - - - 1 100.0
C67 Bladder 10 37.0 3 11.1 3 11.1 11 40.7 27 100.0
C68 Uns.Urinary Organs - - - - - - - - - -
C69 Eye - - - - - - - - - -
C70-72 Brain, NS 7 41.2 8 47.1 - - 2 11.8 17 100.0
C73 Thyroid 6 40.0 2 13.3 3 20.0 4 26.7 15 100.0
C74 Adrenal Gland - - - - - - - - - -
C81 Hodgkins Disease 4 36.4 1 9.1 3 27.3 3 27.3 11 100.0
C82-85,C96 NHL 8 17.0 7 14.9 20 42.6 12 25.5 47 100.0
C88 Malig Imn.Prol D - - - - 1 100.0 - - 1 100.0
C90 Multiple Myeloma 6 40.0 5 33.3 1 6.7 3 20.0 15 100.0
C91 Lymphoid Leuk. 4 28.6 7 50.0 1 7.1 2 14.3 14 100.0
C92-94 Myeloid Leukaemia 6 27.3 2 9.1 4 18.2 10 45.5 22 100.0
C95 Leukaemia Uns - - - - - - 2 100.0 2 100.0
O&U Other and Uns 6 9.5 3 4.8 22 34.9 32 50.8 63 100.0
All Sites 254 18.5 223 16.2 557 40.5 341 24.8 1375 100.0
MCC Annual Report – HBCR 2011
67
Table 28: Number(#) and Proportion(%) of cancers by site (ICD-10) and Broad Treatment Group Females
ICD10 Site
Treatment Groups
Prior Tmt. Only Prior & Tmt. at RI Tmt. Only at RI No Treatment Total
# % # % # % # % # %
C00 Lip 2 28.6 - - 3 42.9 2 28.6 7 100.0
C01-02 Tongue 8 17.4 8 17.4 25 54.3 5 10.9 46 100.0
C03-06 Mouth 8 9.6 10 12 51 61.4 14 16.9 83 100.0
C07-08 Salivary Gland 2 25 2 25 2 25 2 25 8 100.0
C09 Tonsil - - - - 1 100 - - 1 100.0
C10 Oth. Oropharynx 2 40 - - 3 60 - - 5 100.0
C11 Nasopharynx - - - - 1 50 1 50 2 100.0
C12-13 Hypopharynx 3 25 1 8.3 6 50 2 16.7 12 100.0
C14 Pharynx Unspecified - - - - - - 1 100 1 100.0
C15 Oesophagus 3 11.5 1 3.8 12 46.2 10 38.5 26 100.0
C16 Stomach 10 31.2 5 15.6 9 28.1 8 25 32 100.0
C17 Small Intestine 1 33.3 1 33.3 1 33.3 - - 3 100.0
C18 Colon 3 9.7 9 29 12 38.7 7 22.6 31 100.0
C19-20 Rectum 4 9.1 6 13.6 25 56.8 9 20.5 44 100.0
C21 Anus & Anal Canal 1 33.3 - - 1 33.3 1 33.3 3 100.0
C22 Liver - - - - - - 3 100 3 100.0
C23-24 Gallbladder 2 28.6 2 28.6 - - 3 42.9 7 100.0
C25 Pancreas 4 33.3 1 8.3 3 25 4 33.3 12 100.0
C30-31 Nose,Sinuses 1 16.7 1 16.7 3 50 1 16.7 6 100.0
C32 Larynx 2 66.7 - - 1 33.3 - - 3 100.0
C33-34 Lung 7 20 8 22.9 13 37.1 7 20 35 100.0
C37-38 Other Thoracic Organs - - 1 33.3 - - 2 66.7 3 100.0
C40-41 Bone 5 38.5 - - 6 46.2 2 15.4 13 100.0
C43 Melanoma of Skin - - 1 33.3 1 33.3 1 33.3 3 100.0
C44 Other Skin 3 14.3 2 9.5 9 42.9 7 33.3 21 100.0
C45 Mesothelioma - - - - - - - - - -
MCC Annual Report – HBCR 2011
68
ICD10 Site
Treatment Groups
Prior Tmt. Only Prior & Tmt. at RI Tmt. Only at RI No Treatment Total
# % # % # % # % # %
C46 Kaposi Sarcoma - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 5 29.4 7 41.2 3 17.6 2 11.8 17 100.0
C50 Breast 48 13.5 97 27.2 176 49.4 35 9.8 356 100.0
C51 Vulva - - - - 1 100 - - 1 100.0
C52 Vagina - - 3 50 3 50 - - 6 100.0
C53 Cervix Uteri 28 27.2 8 7.8 54 52.4 13 12.6 103 100.0
C54 Corpus Uteri 8 17 18 38.3 18 38.3 3 6.4 47 100.0
C55 Uterus Unspecified - - - - - - - - - -
C56 Ovary 18 20 32 35.6 29 32.2 11 12.2 90 100.0
C57 Other Female Genital - - - - - - - - - -
C58 Placenta - - - - - - - - - -
C64 Kidney 2 33.3 2 33.3 2 33.3 - - 6 100.0
C65 Renal Pelvis - - - - - - - - - -
C66 Ureter - - - - - - - - - -
C67 Bladder 2 33.3 1 16.7 - - 3 50 6 100.0
C68 Uns.Urinary Organs - - - - - - - - - -
C69 Eye 1 50 1 50 - - - - 2 100.0
C70-72 Brain, NS 4 50 2 25 - - 2 25 8 100.0
C73 Thyroid 14 41.2 2 5.9 12 35.3 6 17.6 34 100.0
C74 Adrenal Gland - - - - - - - - - -
C81 Hodgkins Disease 1 14.3 1 14.3 2 28.6 3 42.9 7 100.0
C82-85,C96 NHL 9 23.1 4 10.3 19 48.7 7 17.9 39 100.0
C88 Malig Imn.Prol D - - - - - - - - - -
C90 Multiple Myeloma 2 11.8 7 41.2 6 35.3 2 11.8 17 100.0
C91 Lymphoid Leuk. 1 20 2 40 2 40 - - 5 100.0
C92-94 Myeloid Leukaemia 5 23.8 2 9.5 6 28.6 8 38.1 21 100.0
C95 Leukaemia Uns - - - - - - - - - -
O&U Other and Uns 2 8 2 8 8 32 13 52 25 100.0
All Sites 221 18.4 250 20.8 529 44.1 200 16.7 1200 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
69
Table 29: Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease Males
Prior Treatment Only
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C00 Lip - - - - - - 1 100.0 - - 1 100.0
C01-02 Tongue 2 25.0 2 25.0 1 12.5 3 37.5 - - 8 100.0
C03-06 Mouth 1 6.2 5 31.2 1 6.2 9 56.2 - - 16 100.0
C07-08 Salivary Gland - - - - - - 1 100.0 - - 1 100.0
C09 Tonsil - - - - - - - - - - - -
C10 Oth. Oropharynx - - 2 28.6 1 14.3 4 57.1 - - 7 100.0
C11 Nasopharynx - - - - - - 1 100.0 - - 1 100.0
C12-13 Hypopharynx 1 14.3 2 28.6 - - 4 57.1 - - 7 100.0
C14 Pharynx Unspecified - - - - - - - - - - - -
C15 Oesophagus - - 2 28.6 2 28.6 3 42.9 - - 7 100.0
C16 Stomach 1 3.8 7 26.9 12 46.2 6 23.1 - - 26 100.0
C17 Small Intestine - - - - 1 100.0 - - - - 1 100.0
C18 Colon - - - - 5 71.4 2 28.6 - - 7 100.0
C19-20 Rectum - - 5 31.2 7 43.8 4 25.0 - - 16 100.0
C21 Anus & Anal Canal - - - - - - - - - - - -
C22 Liver - - 1 20.0 3 60.0 1 20.0 - - 5 100.0
C23-24 Gallbladder - - - - 3 100.0 - - - - 3 100.0
C25 Pancreas - - 2 40.0 3 60.0 - - - - 5 100.0
C30-31 Nose,Sinuses - - 2 66.7 - - 1 33.3 - - 3 100.0
C32 Larynx 2 20.0 3 30.0 2 20.0 3 30.0 - - 10 100.0
C33-34 Lung 1 3.2 9 29.0 20 64.5 1 3.2 - - 31 100.0
C37-38 Other Thoracic Organs - - - - - - 1 100.0 - - 1 100.0
C40-41 Bone - - - - - - 4 100.0 - - 4 100.0
C43 Melanoma of Skin - - 1 100.0 - - - - - - 1 100.0
C44 Other Skin 2 33.3 - - - - 4 66.7 - - 6 100.0
C45 Mesothelioma - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
70
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C46 Kaposi Sarcoma - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue - - 1 11.1 3 33.3 5 55.6 - - 9 100.0
C50 Breast - - - - 1 50.0 1 50.0 - - 2 100.0
C60 Penis 1 100.0 - - - - - - - - 1 100.0
C61 Prostate - - 1 11.1 6 66.7 2 22.2 - - 9 100.0
C62 Testis - - - - 1 50.0 1 50.0 - - 2 100.0
C63 Other Male Genital - - - - - - - - - - - -
C64 Kidney 1 16.7 1 16.7 2 33.3 2 33.3 - - 6 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter 1 100.0 - - - - - - - - 1 100.0
C67 Bladder - - 1 10.0 2 20.0 7 70.0 - - 10 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - -
C70-72 Brain, NS - - 1 14.3 2 28.6 4 57.1 - - 7 100.0
C73 Thyroid - - 2 33.3 1 16.7 3 50.0 - - 6 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease - - 2 50.0 - - 2 50.0 - - 4 100.0
C82-85,C96 NHL - - 2 25.0 2 25.0 4 50.0 - - 8 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - -
C90 Multiple Myeloma - - - - - - 6 100.0 - - 6 100.0
C91 Lymphoid Leuk. - - - - 1 25.0 3 75.0 - - 4 100.0
C92-94 Myeloid Leukaemia - - 1 16.7 - - 5 83.3 - - 6 100.0
C95 Leukaemia Uns - - - - - - - - - - - -
O&U Other and Uns - - 1 16.7 1 16.7 4 66.7 - - 6 100.0
All Sites 13 5.1 56 22.0 83 32.7 102 40.2 - - 254 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
71
Table 30: Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease - Females
Prior Treatment Only
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C00 Lip - - 1 50 - - 1 50 - - 2 100.0
C01-02 Tongue - - 5 62.5 1 12.5 2 25 - - 8 100.0
C03-06 Mouth 1 12.5 2 25 - - 5 62.5 - - 8 100.0
C07-08 Salivary Gland - - 1 50 - - 1 50 - - 2 100.0
C09 Tonsil - - - - - - - - - - - -
C10 Oth. Oropharynx - - - - - - 2 100 - - 2 100.0
C11 Nasopharynx - - - - - - - - - - - -
C12-13 Hypopharynx - - - - 1 33.3 2 66.7 - - 3 100.0
C14 Pharynx Unspecified - - - - - - - - - - - -
C15 Oesophagus - - 1 33.3 1 33.3 1 33.3 - - 3 100.0
C16 Stomach - - 2 20 5 50 3 30 - - 10 100.0
C17 Small Intestine - - - - 1 100 - - - - 1 100.0
C18 Colon - - - - 2 66.7 1 33.3 - - 3 100.0
C19-20 Rectum - - - - 1 25 3 75 - - 4 100.0
C21 Anus & Anal Canal - - - - - - 1 100 - - 1 100.0
C22 Liver - - - - - - - - - - - -
C23-24 Gallbladder - - - - 2 100 - - - - 2 100.0
C25 Pancreas - - 1 25 3 75 - - - - 4 100.0
C30-31 Nose,Sinuses - - - - - - 1 100 - - 1 100.0
C32 Larynx - - - - - - 2 100 - - 2 100.0
C33-34 Lung - - 3 42.9 4 57.1 - - - - 7 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - -
C40-41 Bone - - 2 40 1 20 2 40 - - 5 100.0
C43 Melanoma of Skin - - - - - - - - - - - -
C44 Other Skin - - 1 33.3 2 66.7 - - - - 3 100.0
C45 Mesothelioma - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
72
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C46 Kaposi Sarcoma - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue - - 2 40 1 20 2 40 - - 5 100.0
C50 Breast 4 8.3 18 37.5 12 25 14 29.2 - - 48 100.0
C51 Vulva - - - - - - - - - - - -
C52 Vagina - - - - - - - - - - - -
C53 Cervix Uteri 2 7.1 9 32.1 7 25 10 35.7 - - 28 100.0
C54 Corpus Uteri 1 12.5 3 37.5 3 37.5 1 12.5 - - 8 100.0
C55 Uterus Unspecified - - - - - - - - - - - -
C56 Ovary 2 11.1 2 11.1 6 33.3 8 44.4 - - 18 100.0
C57 Other Female Genital - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - -
C64 Kidney - - 1 50 1 50 - - - - 2 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - -
C67 Bladder - - - - 1 50 1 50 - - 2 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - 1 100 - - 1 100.0
C70-72 Brain, NS - - 4 100 - - - - - - 4 100.0
C73 Thyroid - - 3 21.4 3 21.4 8 57.1 - - 14 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease - - - - - - 1 100 - - 1 100.0
C82-85,C96 NHL - - 5 55.6 2 22.2 2 22.2 - - 9 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - -
C90 Multiple Myeloma - - - - - - 2 100 - - 2 100.0
C91 Lymphoid Leuk. - - - - - - 1 100 - - 1 100.0
C92-94 Myeloid Leukaemia - - - - 1 20 4 80 - - 5 100.0
C95 Leukaemia Uns - - - - - - - - - - - -
O&U Other and Uns 1 50 - - - - 1 50 - - 2 100.0
All Sites 11 5 66 29.9 61 27.6 83 37.6 - - 221 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
73
Table 31: Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease - Males
Treatment Only at RI
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C00 Lip - - 3 100.0 - - - - - - 3 100.0
C01-02 Tongue 2 5.9 28 82.4 4 11.8 - - - - 34 100.0
C03-06 Mouth 8 14.3 34 60.7 13 23.2 1 1.8 - - 56 100.0
C07-08 Salivary Gland - - 3 75.0 1 25.0 - - - - 4 100.0
C09 Tonsil 1 20.0 4 80.0 - - - - - - 5 100.0
C10 Oth. Oropharynx 1 3.0 29 87.9 3 9.1 - - - - 33 100.0
C11 Na sopharynx - - 2 50.0 2 50.0 - - - - 4 100.0
C12-13 Hypopharynx 1 3.7 16 59.3 10 37.0 - - - - 27 100.0
C14 Pharynx Unspecified - - 1 100.0 - - - - - - 1 100.0
C15 Oesophagus 1 2.8 14 38.9 21 58.3 - - - - 36 100.0
C16 Stomach - - 13 34.2 25 65.8 - - - - 38 100.0
C17 Small Intestine - - 1 100.0 - - - - - - 1 100.0
C18 Colon - - 3 25.0 9 75.0 - - - - 12 100.0
C19-20 Rectum - - 12 54.5 10 45.5 - - - - 22 100.0
C21 Anus & Anal Canal - - 1 100.0 - - - - - - 1 100.0
C22 Liver 1 16.7 1 16.7 4 66.7 - - - - 6 100.0
C23-24 Gallbladder - - - - - - - - - - - -
C25 Pancreas - - - - 1 100.0 - - - - 1 100.0
C30-31 Nose,Sinuses - - - - - - - - - - - -
C32 Larynx 4 16.0 15 60.0 6 24.0 - - - - 25 100.0
C33-34 Lung - - 30 21.3 111 78.7 - - - - 141 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - -
C40-41 Bone - - 3 100.0 - - - - - - 3 100.0
C43 Melanoma of Skin - - 3 100.0 - - - - - - 3 100.0
C44 Other Skin 5 38.5 6 46.2 2 15.4 - - - - 13 100.0
C45 Mesothelioma - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
74
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C46 Kaposi Sarcoma - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 1 20.0 2 40.0 2 40.0 - - - - 5 100.0
C50 Breast - - 4 80.0 1 20.0 - - - - 5 100.0
C60 Penis - - 2 66.7 - - 1 33.3 - - 3 100.0
C61 Prostate - - 5 35.7 9 64.3 - - - - 14 100.0
C62 Testis 1 100.0 - - - - - - - - 1 100.0
C63 Other Male Genital - - - - - - - - - - - -
C64 Kidney 2 100.0 - - - - - - - - 2 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - -
C67 Bladder - - 1 33.3 1 33.3 1 33.3 - - 3 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - -
C70-72 Brain, NS - - - - - - - - - - - -
C73 Thyroid - - 1 33.3 2 66.7 - - - - 3 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease - - 3 100.0 - - - - - - 3 100.0
C82-85,C96 NHL - - 16 80.0 4 20.0 - - - - 20 100.0
C88 Malig Imn.Prol D - - - - - - 1 100.0 - - 1 100.0
C90 Multiple Myeloma - - - - - - 1 100.0 - - 1 100.0
C91 Lymphoid Leuk. - - - - - - 1 100.0 - - 1 100.0
C92-94 Myeloid Leukaemia - - - - - - 4 100.0 - - 4 100.0
C95 Leukaemia Uns - - - - - - - - - - - -
O&U Other and Uns - - 1 4.5 3 13.6 18 81.8 - - 22 100.0
All Sites 28 5.0 257 46.1 244 43.8 28 5.0 - - 557 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
75
Table 32: Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease – Females
Treatment Only at RI
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C00 Lip 1 33.3 2 66.7 - - - - - - 3 100.0
C01-02 Tongue 7 28 16 64 2 8 - - - - 25 100.0
C03-06 Mouth 2 3.9 42 82.4 7 13.7 - - - - 51 100.0
C07-08 Salivary Gland - - 2 100 - - - - - - 2 100.0
C09 Tonsil - - - - 1 100 - - - - 1 100.0
C10 Oth. Oropharynx - - 2 66.7 1 33.3 - - - - 3 100.0
C11 Nasopharynx - - 1 100 - - - - - - 1 100.0
C12-13 Hypopharynx - - 4 66.7 2 33.3 - - - - 6 100.0
C14 Pharynx Unspecified - - - - - - - - - - - -
C15 Oesophagus - - 5 41.7 7 58.3 - - - - 12 100.0
C16 Stomach - - 4 44.4 5 55.6 - - - - 9 100.0
C17 Small Intestine 1 100 - - - - - - - - 1 100.0
C18 Colon - - 4 33.3 7 58.3 1 8.3 - - 12 100.0
C19-20 Rectum 2 8 11 44 12 48 - - - - 25 100.0
C21 Anus & Anal Canal - - 1 100 - - - - - - 1 100.0
C22 Liver - - - - - - - - - - - -
C23-24 Gallbladder - - - - - - - - - - - -
C25 Pancreas - - 2 66.7 1 33.3 - - - - 3 100.0
C30-31 Nose,Sinuses 1 33.3 - - 1 33.3 1 33.3 - - 3 100.0
C32 Larynx - - 1 100 - - - - - - 1 100.0
C33-34 Lung - - 1 7.7 12 92.3 - - - - 13 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - -
C40-41 Bone - - 3 50 2 33.3 1 16.7 - - 6 100.0
C43 Melanoma of Skin - - - - - - 1 100 - - 1 100.0
C44 Other Skin - - 6 66.7 - - 3 33.3 - - 9 100.0
C45 Mesothelioma - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
76
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C46 Kaposi Sarcoma - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 2 66.7 1 33.3 - - - - - - 3 100.0
C50 Breast 10 5.7 118 67 47 26.7 1 0.6 - - 176 100.0
C51 Vulva - - 1 100 - - - - - - 1 100.0
C52 Vagina - - 3 100 - - - - - - 3 100.0
C53 Cervix Uteri 4 7.4 36 66.7 13 24.1 1 1.9 - - 54 100.0
C54 Corpus Uteri 1 5.6 17 94.4 - - - - - - 18 100.0
C55 Uterus Unspecified - - - - - - - - - - - -
C56 Ovary - - 8 27.6 21 72.4 - - - - 29 100.0
C57 Other Female Genital - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - -
C64 Kidney - - - - 2 100 - - - - 2 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - -
C67 Bladder - - - - - - - - - - - -
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - -
C70-72 Brain, NS - - - - - - - - - - - -
C73 Thyroid 1 8.3 6 50 4 33.3 1 8.3 - - 12 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease - - 2 100 - - - - - - 2 100.0
C82-85,C96 NHL - - 12 63.2 6 31.6 1 5.3 - - 19 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - -
C90 Multiple Myeloma - - - - 1 16.7 5 83.3 - - 6 100.0
C91 Lymphoid Leuk. - - - - - - 2 100 - - 2 100.0
C92-94 Myeloid Leukaemia - - - - - - 6 100 - - 6 100.0
C95 Leukaemia Uns - - - - - - - - - - - -
O&U Other and Uns - - - - 2 25 6 75 - - 8 100.0
All Sites 32 6 311 58.8 156 29.5 30 5.7 - - 529 100.0
MCC Annual Report – HBCR 2011
77
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
Table 33: Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease - Males
Prior + Treatment at RI
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C00 Lip - - - - - - - - - - - -
C01-02 Tongue - - 7 63.6 1 9.1 3 27.3 - - 11 100.0
C03-06 Mouth - - 3 15.8 1 5.3 15 78.9 - - 19 100.0
C07-08 Salivary Gland - - 1 100.0 - - - - - - 1 100.0
C09 Tonsil - - - - - - - - - - - -
C10 Oth. Oropharynx - - 1 14.3 2 28.6 4 57.1 - - 7 100.0
C11 Nasopharynx - - - - - - 1 100.0 - - 1 100.0
C12-13 Hypopharynx - - 2 50.0 1 25.0 1 25.0 - - 4 100.0
C14 Pharynx Unspecified - - - - - - - - - - - -
C15 Oesophagus - - - - 2 100.0 - - - - 2 100.0
C16 Stomach - - 2 20.0 7 70.0 1 10.0 - - 10 100.0
C17 Small Intestine - - 1 25.0 2 50.0 1 25.0 - - 4 100.0
C18 Colon - - 4 44.4 4 44.4 1 11.1 - - 9 100.0
C19-20 Rectum - - 4 50.0 3 37.5 1 12.5 - - 8 100.0
C21 Anus & Anal Canal - - - - - - - - - - - -
C22 Liver - - 1 25.0 2 50.0 1 25.0 - - 4 100.0
C23-24 Gallbladder - - - - - - - - - - - -
C25 Pancreas - - 1 50.0 1 50.0 - - - - 2 100.0
C30-31 Nose,Sinuses - - - - - - - - - - - -
C32 Larynx - - 3 42.9 1 14.3 3 42.9 - - 7 100.0
C33-34 Lung 1 2.2 14 31.1 30 66.7 - - - - 45 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - -
C40-41 Bone - - 4 36.4 5 45.5 2 18.2 - - 11 100.0
C43 Melanoma of Skin - - - - - - - - - - - -
C44 Other Skin 2 50.0 1 25.0 1 25.0 - - - - 4 100.0
MCC Annual Report – HBCR 2011
78
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C45 Mesothelioma - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue - - 1 9.1 2 18.2 8 72.7 - - 11 100.0
C50 Breast - - 2 100.0 - - - - - - 2 100.0
C60 Penis - - - - - - 1 100.0 - - 1 100.0
C61 Prostate - - 3 20.0 11 73.3 1 6.7 - - 15 100.0
C62 Testis - - 2 100.0 - - - - - - 2 100.0
C63 Other Male Genital - - - - - - - - - - - -
C64 Kidney - - - - 4 80.0 1 20.0 - - 5 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - -
C67 Bladder - - - - 1 33.3 2 66.7 - - 3 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - -
C70-72 Brain, NS - - 4 50.0 1 12.5 3 37.5 - - 8 100.0
C73 Thyroid - - - - 2 100.0 - - - - 2 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease - - - - - - 1 100.0 - - 1 100.0
C82-85,C96 NHL - - 3 42.9 1 14.3 3 42.9 - - 7 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - -
C90 Multiple Myeloma - - - - 2 40.0 3 60.0 - - 5 100.0
C91 Lymphoid Leuk. - - - - 1 14.3 6 85.7 - - 7 100.0
C92-94 Myeloid Leukaemia - - - - - - 2 100.0 - - 2 100.0
C95 Leukaemia Uns - - - - - - - - - - - -
O&U Other and Uns - - - - - - 3 100.0 - - 3 100.0
All Sites 3 1.3 64 28.7 88 39.5 68 30.5 - - 223 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
79
Table 34: Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease - Females
Prior + Treatment at RI
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C00 Lip - - - - - - - - - - - -
C01-02 Tongue - - 3 37.5 - - 5 62.5 - - 8 100.0
C03-06 Mouth - - 3 30 - - 7 70 - - 10 100.0
C07-08 Salivary Gland - - 2 100 - - - - - - 2 100.0
C09 Tonsil - - - - - - - - - - - -
C10 Oth. Oropharynx - - - - - - - - - - - -
C11 Nasopharynx - - - - - - - - - - - -
C12-13 Hypopharynx - - 1 100 - - - - - - 1 100.0
C14 Pharynx Unspecified - - - - - - - - - - - -
C15 Oesophagus - - - - 1 100 - - - - 1 100.0
C16 Stomach - - 1 20 3 60 1 20 - - 5 100.0
C17 Small Intestine - - - - 1 100 - - - - 1 100.0
C18 Colon - - 4 44.4 2 22.2 3 33.3 - - 9 100.0
C19-20 Rectum - - 2 33.3 3 50 1 16.7 - - 6 100.0
C21 Anus & Anal Canal - - - - - - - - - - - -
C22 Liver - - - - - - - - - - - -
C23-24 Gallbladder - - 1 50 1 50 - - - - 2 100.0
C25 Pancreas - - - - 1 100 - - - - 1 100.0
C30-31 Nose,Sinuses - - - - - - 1 100 - - 1 100.0
C32 Larynx - - - - - - - - - - - -
C33-34 Lung - - 3 37.5 5 62.5 - - - - 8 100.0
C37-38 Other Thoracic Organs - - 1 100 - - - - - - 1 100.0
C40-41 Bone - - - - - - - - - - - -
C43 Melanoma of Skin - - 1 100 - - - - - - 1 100.0
C44 Other Skin - - 1 50 1 50 - - - - 2 100.0
C45 Mesothelioma - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
80
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C46 Kaposi Sarcoma - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue - - 4 57.1 - - 3 42.9 - - 7 100.0
C50 Breast 1 1 58 59.8 27 27.8 11 11.3 - - 97 100.0
C51 Vulva - - - - - - - - - - - -
C52 Vagina - - 1 33.3 1 33.3 1 33.3 - - 3 100.0
C53 Cervix Uteri - - 4 50 2 25 2 25 - - 8 100.0
C54 Corpus Uteri - - 13 72.2 4 22.2 1 5.6 - - 18 100.0
C55 Uterus Unspecified - - - - - - - - - - - -
C56 Ovary - - 7 21.9 10 31.2 15 46.9 - - 32 100.0
C57 Other Female Genital - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - -
C64 Kidney - - - - 1 50 1 50 - - 2 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - -
C67 Bladder - - 1 100 - - - - - - 1 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - 1 100 - - 1 100.0
C70-72 Brain, NS - - 2 100 - - - - - - 2 100.0
C73 Thyroid - - - - 1 50 1 50 - - 2 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease - - 1 100 - - - - - - 1 100.0
C82-85,C96 NHL - - 3 75 - - 1 25 - - 4 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - -
C90 Multiple Myeloma - - - - 2 28.6 5 71.4 - - 7 100.0
C91 Lymphoid Leuk. - - - - 1 50 1 50 - - 2 100.0
C92-94 Myeloid Leukaemia - - - - - - 2 100 - - 2 100.0
C95 Leukaemia Uns - - - - - - - - - - - -
O&U Other and Uns - - - - 1 50 1 50 - - 2 100.0
All Sites 1 0.4 117 46.8 68 27.2 64 25.6 - - 250 100.0
MCC Annual Report – HBCR 2011
81
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
Table 35: Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease - Males
No Treatment
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C00 Lip - - - - - - - - - - - -
C01-02 Tongue 4 28.6 7 50.0 2 14.3 1 7.1 - - 14 100.0
C03-06 Mouth 2 15.4 9 69.2 1 7.7 1 7.7 - - 13 100.0
C07-08 Salivary Gland - - 1 50.0 1 50.0 - - - - 2 100.0
C09 Tonsil - - 1 100.0 - - - - - - 1 100.0
C10 Oth. Oropharynx - - 4 80.0 1 20.0 - - - - 5 100.0
C11 Nasopharynx - - 1 100.0 - - - - - - 1 100.0
C12-13 Hypopharynx 1 14.3 4 57.1 2 28.6 - - - - 7 100.0
C14 Pharynx Unspecified - - - - - - - - - - - -
C15 Oesophagus - - 3 18.8 9 56.2 4 25.0 - - 16 100.0
C16 Stomach 2 5.6 9 25.0 23 63.9 2 5.6 - - 36 100.0
C17 Small Intestine - - - - - - - - - - - -
C18 Colon - - 1 25.0 2 50.0 1 25.0 - - 4 100.0
C19-20 Rectum - - 1 25.0 3 75.0 - - - - 4 100.0
C21 Anus & Anal Canal - - 1 100.0 - - - - - - 1 100.0
C22 Liver - - 1 7.7 8 61.5 4 30.8 - - 13 100.0
C23-24 Gallbladder - - - - 4 100.0 - - - - 4 100.0
C25 Pancreas - - 1 20.0 4 80.0 - - - - 5 100.0
C30-31 Nose,Sinuses - - 1 100.0 - - - - - - 1 100.0
C32 Larynx 2 15.4 6 46.2 5 38.5 - - - - 13 100.0
C33-34 Lung 5 5.3 21 22.1 59 62.1 10 10.5 - - 95 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - -
C40-41 Bone - - - - - - 2 100.0 - - 2 100.0
C43 Melanoma of Skin 1 33.3 2 66.7 - - - - - - 3 100.0
C44 Other Skin 1 20.0 1 20.0 - - 3 60.0 - - 5 100.0
C45 Mesothelioma - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
82
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C46 Kaposi Sarcoma - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue - - - - 3 100.0 - - - - 3 100.0
C50 Breast - - 2 100.0 - - - - - - 2 100.0
C60 Penis - - - - - - - - - - - -
C61 Prostate 1 14.3 3 42.9 2 28.6 1 14.3 - - 7 100.0
C62 Testis - - - - - - - - - - - -
C63 Other Male Genital - - - - - - - - - - - -
C64 Kidney - - 1 33.3 2 66.7 - - - - 3 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - -
C67 Bladder 1 9.1 6 54.5 4 36.4 - - - - 11 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - -
C70-72 Brain, NS - - - - - - 2 100.0 - - 2 100.0
C73 Thyroid - - 4 100.0 - - - - - - 4 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease - - 3 100.0 - - - - - - 3 100.0
C82-85,C96 NHL 1 8.3 6 50.0 3 25.0 2 16.7 - - 12 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - -
C90 Multiple Myeloma - - - - 1 33.3 2 66.7 - - 3 100.0
C91 Lymphoid Leuk. - - - - - - 2 100.0 - - 2 100.0
C92-94 Myeloid Leukaemia - - - - 2 20.0 8 80.0 - - 10 100.0
C95 Leukaemia Uns - - - - - - 2 100.0 - - 2 100.0
O&U Other and Uns - - - - 1 3.1 31 96.9 - - 32 100.0
All Sites 21 6.2 100 29.3 142 41.6 78 22.9 - - 341 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
83
Table 36: Number(#) and Proportion(%) of cancers by site (ICD-10) and Clinical Extent of Disease - Females
No Treatment
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C00 Lip 1 50 - - - - 1 50 - - 2 100.0
C01-02 Tongue 2 40 3 60 - - - - - - 5 100.0
C03-06 Mouth 2 14.3 8 57.1 4 28.6 - - - - 14 100.0
C07-08 Salivary Gland - - 2 100 - - - - - - 2 100.0
C09 Tonsil - - - - - - - - - - - -
C10 Oth. Oropharynx - - - - - - - - - - - -
C11 Nasopharynx - - 1 100 - - - - - - 1 100.0
C12-13 Hypopharynx - - 1 50 1 50 - - - - 2 100.0
C14 Pharynx Unspecified - - - - 1 100 - - - - 1 100.0
C15 Oesophagus - - 2 20 6 60 2 20 - - 10 100.0
C16 Stomach - - 3 37.5 3 37.5 2 25 - - 8 100.0
C17 Small Intestine - - - - - - - - - - - -
C18 Colon - - 2 28.6 4 57.1 1 14.3 - - 7 100.0
C19-20 Rectum 1 11.1 - - 5 55.6 3 33.3 - - 9 100.0
C21 Anus & Anal Canal - - - - 1 100 - - - - 1 100.0
C22 Liver - - - - 2 66.7 1 33.3 - - 3 100.0
C23-24 Gallbladder - - 1 33.3 2 66.7 - - - - 3 100.0
C25 Pancreas - - 2 50 2 50 - - - - 4 100.0
C30-31 Nose,Sinuses - - 1 100 - - - - - - 1 100.0
C32 Larynx - - - - - - - - - - - -
C33-34 Lung 1 14.3 1 14.3 5 71.4 - - - - 7 100.0
C37-38 Other Thoracic Organs - - 1 50 1 50 - - - - 2 100.0
C40-41 Bone - - - - 1 50 1 50 - - 2 100.0
C43 Melanoma of Skin - - 1 100 - - - - - - 1 100.0
C44 Other Skin 1 14.3 5 71.4 - - 1 14.3 - - 7 100.0
MCC Annual Report – HBCR 2011
84
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
C45 Mesothelioma - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue - - 1 50 - - 1 50 - - 2 100.0
C50 Breast 4 11.4 20 57.1 8 22.9 3 8.6 - - 35 100.0
C51 Vulva - - - - - - - - - - - -
C52 Vagina - - - - - - - - - - - -
C53 Cervix Uteri - - 7 53.8 6 46.2 - - - - 13 100.0
C54 Corpus Uteri - - 1 33.3 1 33.3 1 33.3 - - 3 100.0
C55 Uterus Unspecified - - - - - - - - - - - -
C56 Ovary - - 1 9.1 10 90.9 - - - - 11 100.0
C57 Other Female Genital - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - -
C64 Kidney - - - - - - - - - - - -
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - -
C67 Bladder - - 1 33.3 1 33.3 1 33.3 - - 3 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - -
C70-72 Brain, NS - - 1 50 - - 1 50 - - 2 100.0
C73 Thyroid - - 3 50 2 33.3 1 16.7 - - 6 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease - - 2 66.7 1 33.3 - - - - 3 100.0
C82-85,C96 NHL - - 4 57.1 1 14.3 2 28.6 - - 7 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - -
C90 Multiple Myeloma - - - - - - 2 100 - - 2 100.0
C91 Lymphoid Leuk. - - - - - - - - - - - -
C92-94 Myeloid Leukaemia - - - - 3 37.5 5 62.5 - - 8 100.0
C95 Leukaemia Uns - - - - - - - - - - - -
O&U Other and Uns - - 1 7.7 3 23.1 9 69.2 - - 13 100.0
MCC Annual Report – HBCR 2011
85
ICD10 Site
Clinical Extent of Disease
Localised Regional Distant Others Unknown Total
# % # % # % # % # % # %
All Sites 12 6 76 38 74 37 38 19 - - 200 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
Table 37: Number(#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment – Females
Prior Treatment Only
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C00 Lip - - - - - - - - 1 100.0 - - - - - - - - 1 100.0
C01-02 Tongue 2 25.0 1 12.5 - - 3 37.5 - - 2 25.0 - - - - - - 8 100.0
C03-06 Mouth 2 12.5 5 31.2 1 6.2 1 6.2 - - 5 31.2 2 6.2 - - - - 16 100.0
C07-08 Salivary Gland - - - - - - 1 100.0 - - - - - - - - - - 1 100.0
C09 Tonsil - - - - - - - - - - - - - - - - - - - -
C10 Oth. Oropharynx - - - - - - 2 28.6 - - 5 71.4 - - - - - - 7 100.0
C11 Nasopharynx - - - - - - - - - - 1 100.0 - - - - - - 1 100.0
C12-13 Hypopharynx - - 3 42.9 1 14.3 - - - - 3 42.9 - - - - - - 7 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - - - - - - - -
C15 Oesophagus - - 1 14.3 1 14.3 - - 1 14.3 4 57.1 - - - - - - 7 100.0
C16 Stomach 8 30.8 - - 5 19.2 - - 7 26.9 2 7.7 4 0 - - - - 26 100.0
C17 Small Intestine 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C18 Colon 2 28.6 - - 1 14.3 - - 4 57.1 - - - - - - - - 7 100.0
C19-20 Rectum 5 31.2 2 12.5 3 18.8 - - 2 12.5 1 6.2 3 0 - - - - 16 100.0
C21 Anus & Anal Canal - - - - - - - - - - - - - - - - - - - -
C22 Liver 3 60.0 - - 1 20.0 - - - - 1 20.0 - - - - - - 5 100.0
C23-24 Gallbladder 3 100.0 - - - - - - - - - - - - - - - - 3 100.0
C25 Pancreas 3 60.0 - - - - - - 1 20.0 - - 1 0 - - - - 5 100.0
C30-31 Nose,Sinuses 1 33.3 - - - - - - - - 1 33.3 1 0 - - - - 3 100.0
C32 Larynx 2 20.0 4 40.0 - - 1 10.0 - - - - 2 10.0 - - 1 0 10 100.0
C33-34 Lung 3 9.7 6 19.4 12 38.7 - - 1 3.2 9 29.0 - - - - - - 31 100.0
C37-38 Other Thoracic Organs - - - - - - - - 1 100.0 - - - - - - - - 1 100.0
C40-41 Bone - - - - 1 25.0 - - 2 50.0 - - 1 0 - - - - 4 100.0
C43 Melanoma of Skin 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
MCC Annual Report – HBCR 2011
86
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C44 Other Skin 6 100.0 - - - - - - - - - - - - - - - - 6 100.0
C45 Mesothelioma - - - - - - - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 5 55.6 - - - - 1 11.1 1 11.1 2 22.2 - - - - - - 9 100.0
C50 Breast - - - - 1 50.0 - - - - - - 1 0 - - - - 2 100.0
C60 Penis 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C61 Prostate - - - - - - - - - - - - - - 9 0 - - 9 100.0
C62 Testis - - - - - - - - 1 50.0 1 50.0 - - - - - - 2 100.0
C63 Other Male Genital - - - - - - - - - - - - - - - - - - - -
C64 Kidney 5 83.3 - - 1 16.7 - - - - - - - - - - - - 6 100.0
C65 Renal Pelvis - - - - - - - - - - - - - - - - - - - -
C66 Ureter 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C67 Bladder 8 80.0 - - - - 1 10.0 1 10.0 - - - - - - - - 10 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - - - - - - - -
C70-72 Brain, NS 1 14.3 - - - - 3 42.9 - - - - 3 42.9 - - - - 7 100.0
C73 Thyroid 3 50.0 - - - - 3 50.0 - - - - - - - - - - 6 100.0
C74 Adrenal Gland - - - - - - - - - - - - - - - - - - - -
C81 Hodgkins Disease - - - - 3 75.0 - - - - - - 1 0 - - - - 4 100.0
C82-85,C96
NHL - - 1 12.5 6 75.0 - - 1 12.5 - - - - - - - - 8 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - - - - - - - -
C90 Multiple Myeloma - - - - 6 100.0 - - - - - - - - - - - - 6 100.0
C91 Lymphoid Leuk. - - - - 4 100.0 - - - - - - - - - - - - 4 100.0
C92-94 Myeloid Leukaemia - - - - 6 100.0 - - - - - - - - - - - - 6 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - - - - - - - -
O&U Other and Uns 1 16.7 - - 1 16.7 - - 2 33.3 2 33.3 - - - - - - 6 100.0
All Sites 67 26.4 23 9.1 54 21.3 16 6.3 26 10.2 39 15.4 19 7.5 9 3.5 1 0.4 254 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
87
Table 38: Number(#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment - Females Prior Treatment Only
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C00 Lip 2 100.0 - - - - - - - - - - - - - - - - 2 100.0
C01-02 Tongue 1 12.5 1 12.5 1 12.5 1 12.5 - - 2 25.0 2 12.5 - - - - 8 100.0
C03-06 Mouth 3 37.5 1 12.5 - - 2 25.0 - - 2 25.0 - - - - - - 8 100.0
C07-08 Salivary Gland 1 50.0 1 50.0 - - - - - - - - - - - - - - 2 100.0
C09 Tonsil - - - - - - - - - - - - - - - - - - - -
C10 Oth. Oropharynx - - 1 50.0 - - - - - - - - 1 0 - - - - 2 100.0
C11 Nasopharynx - - - - - - - - - - - - - - - - - - - -
C12-13 Hypopharynx - - 1 33.3 1 33.3 1 33.3 - - - - - - - - - - 3 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - - - - - - - -
C15 Oesophagus - - 3 100.0 - - - - - - - - - - - - - - 3 100.0
C16 Stomach 4 40.0 - - 3 30.0 - - 3 30.0 - - - - - - - - 10 100.0
C17 Small Intestine 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C18 Colon 1 33.3 - - - - - - 2 66.7 - - - - - - - - 3 100.0
C19-20 Rectum - - - - - - - - 3 75.0 1 25.0 - - - - - - 4 100.0
C21 Anus & Anal Canal - - - - - - - - - - 1 100.0 - - - - - - 1 100.0
C22 Liver - - - - - - - - - - - - - - - - - - - -
C23-24 Gallbladder 2 100.0 - - - - - - - - - - - - - - - - 2 100.0
C25 Pancreas 1 25.0 - - 2 50.0 - - 1 25.0 - - - - - - - - 4 100.0
C30-31 Nose,Sinuses - - - - - - - - - - 1 100.0 - - - - - - 1 100.0
C32 Larynx 1 50.0 1 50.0 - - - - - - - - - - - - - - 2 100.0
C33-34 Lung - - - - 6 85.7 - - - - 1 14.3 - - - - - - 7 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - - - - - - - - - -
C40-41 Bone 1 20.0 1 20.0 1 20.0 1 20.0 1 20.0 - - - - - - - - 5 100.0
C43 Melanoma of Skin - - - - - - - - - - - - - - - - - - - -
C44 Other Skin 3 100.0 - - - - - - - - - - - - - - - - 3 100.0
C45 Mesothelioma - - - - - - - - - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
88
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 3 60.0 - - - - 2 40.0 - - - - - - - - - - 5 100.0
C50 Breast 9 18.8 - - 1 2.1 1 2.1 11 22.9 - - 13 2.1 1222.
9 1 0 48 100.0
C51 Vulva - - - - - - - - - - - - - - - - - - - -
C52 Vagina - - - - - - - - - - - - - - - - - - - -
C53 Cervix Uteri 8 28.6 5 17.9 - - 2 7.1 - - 11 39.3 2 7.1 - - - - 28 100.0
C54 Corpus Uteri 5 62.5 - - - - 1 12.5 1 12.5 1 12.5 - - - - - - 8 100.0
C55 Uterus Unspecified - - - - - - - - - - - - - - - - - - - -
C56 Ovary 8 44.4 - - 2 11.1 - - 5 27.8 - - 1 0 2 27.
8 - - 18 100.0
C57 Other Female Genital - - - - - - - - - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - - - - - - - - - -
C64 Kidney 1 50.0 - - - - - - - - - - 1 0 - - - - 2 100.0
C65 Renal Pelvis - - - - - - - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - - - - - - - -
C67 Bladder 2 100.0 - - - - - - - - - - - - - - - - 2 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - 1 100.0 - - - - - - 1 100.0
C70-72 Brain, NS 3 75.0 - - - - 1 25.0 - - - - - - - - - - 4 100.0
C73 Thyroid 6 42.9 - - - - 8 57.1 - - - - - - - - - - 14 100.0
C74 Adrenal Gland - - - - - - - - - - - - - - - - - - - -
C81 Hodgkins Disease - - - - - - - - - - 1 100.0 - - - - - - 1 100.0
C82-85,C96 NHL - - 1 11.1 8 88.9 - - - - - - - - - - - - 9 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - - - - - - - -
C90 Multiple Myeloma - - - - 2 100.0 - - - - - - - - - - - - 2 100.0
C91 Lymphoid Leuk. - - - - 1 100.0 - - - - - - - - - - - - 1 100.0
C92-94 Myeloid Leukaemia - - - - 5 100.0 - - - - - - - - - - - - 5 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - - - - - - - -
O&U Other and Uns 1 50.0 - - 1 50.0 - - - - - - - - - - - - 2 100.0
All Sites 67 30.3 16 7.2 34 15.4 20 9.0 27 12.2 22 10.0 20 9.0 14
6.3
1 0.5 221 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
89
Table 39: Number(#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment - Males
Treatment Only at RI
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C00 Lip - - 1 33.3 - - 1 33.3 1 33.3 - - - - - - - - 3 100.0
C01-02 Tongue 8 23.5 2 5.9 2 5.9 7 20.6 1 2.9 8 23.5 6 20.6 - - - - 34 100.0
C03-06 Mouth 12 21.4 8 14.3 - - 8 14.3 - - 21 37.5 7 14.3 - - - - 56 100.0
C07-08 Salivary Gland 2 50.0 1 25.0 - - 1 25.0 - - - - - - - - - - 4 100.0
C09 Tonsil - - 1 20.0 1 20.0 1 20.0 - - 1 20.0 1 20.0 - - - - 5 100.0
C10 Oth. Oropharynx - - 6 18.2 1 3.0 - - - - 25 75.8 1 0 - - - - 33 100.0
C11 Nasopharynx - - 1 25.0 2 50.0 - - - - 1 25.0 - - - - - - 4 100.0
C12-13 Hypopharynx 2 7.4 8 29.6 - - 3 11.1 - - 13 48.1 1 11.1 - - - - 27 100.0
C14 Pharynx Unspecified - - 1 100.0 - - - - - - - - - - - - - - 1 100.0
C15 Oesophagus 1 2.8 17 47.2 3 8.3 - - - - 13 36.1 2 0 - - - - 36 100.0
C16 Stomach 9 23.7 3 7.9 13 34.2 - - 8 21.1 3 7.9 2 0 - - - - 38 100.0
C17 Small Intestine - - - - 1 100.0 - - - - - - - - - - - - 1 100.0
C18 Colon 5 41.7 - - 4 33.3 - - 3 25.0 - - - - - - - - 12 100.0
C19-20 Rectum 3 13.6 1 4.5 1 4.5 - - 1 4.5 7 31.8 9 0 - - - - 22 100.0
C21 Anus & Anal Canal - - - - - - - - - - 1 100.0 - - - - - - 1 100.0
C22 Liver 1 16.7 2 33.3 3 50.0 - - - - - - - - - - - - 6 100.0
C23-24 Gallbladder - - - - - - - - - - - - - - - - - - - -
C25 Pancreas - - - - 1 100.0 - - - - - - - - - - - - 1 100.0
C30-31 Nose,Sinuses - - - - - - - - - - - - - - - - - - - -
C32 Larynx 1 4.0 13 52.0 3 12.0 - - 1 4.0 6 24.0 1 0 - - - - 25 100.0
C33-34 Lung 1 0.7 33 23.4 47 33.3 - - 1 0.7 59 41.8 - - - - - - 141 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - - - - - - - - - -
C40-41 Bone 2 66.7 - - - - - - 1 33.3 - - - - - - - - 3 100.0
C43 Melanoma of Skin 2 66.7 - - 1 33.3 - - - - - - - - - - - - 3 100.0
C44 Other Skin 9 69.2 1 7.7 - - - - - - 1 7.7 2 0 - - - - 13 100.0
C45 Mesothelioma - - - - - - - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 2 40.0 - - - - 1 20.0 - - 1 20.0 1 20.0 - - - - 5 100.0
C50 Breast - - - - - - - - - - - - - - 5 0 - - 5 100.0
C60 Penis 3 100.0 - - - - - - - - - - - - - - - - 3 100.0
MCC Annual Report – HBCR 2011
90
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C61 Prostate - - 2 14.3 - - - - - - 1 7.1 - - 11 0 - - 14 100.0
C62 Testis 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C63 Other Male Genital - - - - - - - - - - - - - - - - - - - -
C64 Kidney 2 100.0 - - - - - - - - - - - - - - - - 2 100.0
C65 Renal Pelvis - - - - - - - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - - - - - - - -
C67 Bladder 2 66.7 1 33.3 - - - - - - - - - - - - - - 3 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - - - - - - - -
C70-72 Brain, NS - - - - - - - - - - - - - - - - - - - -
C73 Thyroid 1 33.3 1 33.3 - - 1 33.3 - - - - - - - - - - 3 100.0
C74 Adrenal Gland - - - - - - - - - - - - - - - - - - - -
C81 Hodgkins Disease - - - - 2 66.7 - - - - 1 33.3 - - - - - - 3 100.0
C82-85,C96 NHL 1 5.0 1 5.0 14 70.0 - - - - 3 15.0 1 0 - - - - 20 100.0
C88 Malig Imn.Prol D - - - - 1 100.0 - - - - - - - - - - - - 1 100.0
C90 Multiple Myeloma - - - - 1 100.0 - - - - - - - - - - - - 1 100.0
C91 Lymphoid Leuk. - - - - 1 100.0 - - - - - - - - - - - - 1 100.0
C92-94 Myeloid Leukaemia - - - - 4 100.0 - - - - - - - - - - - - 4 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - - - - - - - -
O&U Other and Uns - - 11 50.0 5 22.7 - - 1 4.5 4 18.2 1 0 - - - - 22 100.0
All Sites 70 12.6 115 20.6 111 19.9 23 4.1 18 3.2 169 30.3 35 6.3 16 2.9 - - 557 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
91
Table 40: Number(#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment - Females
Treatment Only at RI
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C00 Lip 2 66.7 1 33.3 - - - - - - - - - - - - - - 3 100.0
C01-02 Tongue 11
44.0 1 4.0 2 8.0 5 20.0 - - 5 20.0 1 20.0 - - - - 25 100.0
C03-06 Mouth 6 11.8 14 27.5 4 7.8 4 7.8 - - 22 43.1 1 7.8 - - - - 51 100.0
C07-08 Salivary Gland 1 50.0 - - - - 1 50.0 - - - - - - - - - - 2 100.0
C09 Tonsil - - 1 100.0 - - - - - - - - - - - - - - 1 100.0
C10 Oth. Oropharynx - - 2 66.7 - - - - - - 1 33.3 - - - - - - 3 100.0
C11 Nasopharynx - - - - - - - - - - 1 100.
0 - - - - - - 1 100.0
C12-13 Hypopharynx 2 33.3 2 33.3 - - - - - - 1 16.7 1 0 - - - - 6 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - - - - - - - -
C15 Oesophagus 1 8.3 8 66.7 - - - - - - 3 25.0 - - - - - - 12 100.0
C16 Stomach 3 33.3 - - 3 33.3 - - 2 22.2 - - 1 0 - - - - 9 100.0
C17 Small Intestine 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C18 Colon 5 41.7 - - - - - - 6 50.0 1 8.3 - - - - - - 12 100.0
C19-20 Rectum 2 8.0 2 8.0 2 8.0 1 4.0 2 8.0 4 16.0 12 4.0 - - - - 25 100.0
C21 Anus & Anal Canal - - - - - - - - - - - - 1 0 - - - - 1 100.0
C22 Liver - - - - - - - - - - - - - - - - - - - -
C23-24 Gallbladder - - - - - - - - - - - - - - - - - - - -
C25 Pancreas - - - - 2 66.7 - - - - 1 33.3 - - - - - - 3 100.0
C30-31 Nose,Sinuses 1 33.3 2 66.7 - - - - - - - - - - - - - - 3 100.0
C32 Larynx - - 1 100.0 - - - - - - - - - - - - - - 1 100.0
C33-34 Lung - - 1 7.7 3 23.1 - - - - 9 69.2 - - - - - - 13 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - - - - - - - - - -
C40-41 Bone - - 1 16.7 - - - - 3 50.0 2 33.3 - - - - - - 6 100.0
C43 Melanoma of Skin 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C44 Other Skin 6 66.7 - - - - 2 22.2 1 11.1 - - - - - - - - 9 100.0
C45 Mesothelioma - - - - - - - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 2 66.7 - - - - - - - - - - 1 0 - - - - 3 100.0
MCC Annual Report – HBCR 2011
92
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C50 Breast 9 5.1 1 0.6 10 5.7 3 1.7 16 9.1 8 4.5 71 1.7 58 9.1 - - 176 100.0
C51 Vulva - - 1 100.0 - - - - - - - - - - - - - - 1 100.0
C52 Vagina - - - - - - - - - - 3 100.0 - - - - - - 3 100.0
C53 Cervix Uteri 2 3.7 14 25.9 - - 1 1.9 - - 37 68.5 - - - - - - 54 100.0
C54 Corpus Uteri 4 22.2 1 5.6 - - 10
55.6 - - - - 3 55.6 - - - - 18 100.0
C55 Uterus Unspecified - - - - - - - - - - - - - - - - - - - -
C56 Ovary - - - - 11 37.9 2 6.9 15 51.7 - - 1 6.9 - - - - 29 100.0
C57 Other Female Genital - - - - - - - - - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - - - - - - - - - -
C64 Kidney - - 1 50.0 - - - - - - 1 50.0 - - - - - - 2 100.0
C65 Renal Pelvis - - - - - - - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - - - - - - - -
C67 Bladder - - - - - - - - - - - - - - - - - - - -
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - - - - - - - -
C70-72 Brain, NS - - - - - - - - - - - - - - - - - - - -
C73 Thyroid 9 75.0 3 25.0 - - - - - - - - - - - - - - 12 100.0
C74 Adrenal Gland - - - - - - - - - - - - - - - - - - - -
C81 Hodgkins Disease - - 1 50.0 1 50.0 - - - - - - - - - - - - 2 100.0
C82-85,C96 NHL - - - - 13 68.4 - - - - 5 26.3 1 0 - - - - 19 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - - - - - - - -
C90 Multiple Myeloma - - - - 6 100.0 - - - - - - - - - - - - 6 100.0
C91 Lymphoid Leuk. - - - - 2 100.0 - - - - - - - - - - - - 2 100.0
C92-94 Myeloid Leukaemia - - - - 6 100.0 - - - - - - - - - - - - 6 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - - - - - - - -
O&U Other and Uns - - 3 37.5 4 50.0 - - - - - - - - 1 0 - - 8 100.0
All Sites 68 12.9 61 11.5 69 13.0 29 5.5 45 8.5 104 19.7 94 17.8 59 11.2 - - 529 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
93
Table 41: Number(#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment – Males
Prior + Treatment at RI(Prior Tmt)
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R +
C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C00 Lip - - - - - - - - - - - - - - - - - - - -
C01-02 Tongue 8 72.7 2 18.2 - - - - - - - - 1 0 - - - - 11 100.0
C03-06 Mouth 5 26.3 5 26.3 1 5.3 - - 1 5.3 7 36.8 - - - - - - 19 100.0
C07-08 Salivary Gland 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C09 Tonsil - - - - - - - - - - - - - - - - - - - -
C10 Oth. Oropharynx 1 14.3 1 14.3 2 28.6 1 14.3 - - 2 28.6 - - - - - - 7 100.0
C11 Nasopharynx - - - - - - - - - - 1 100.0 - - - - - - 1 100.0
C12-13 Hypopharynx 2 50.0 1 25.0 - - - - - - 1 25.0 - - - - - - 4 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - - - - - - - -
C15 Oesophagus - - - - 1 50.0 - - - - - - 1 0 - - - - 2 100.0
C16 Stomach 3 30.0 - - 3 30.0 - - 4 40.0 - - - - - - - - 10 100.0
C17 Small Intestine 1 25.0 - - - - - - 3 75.0 - - - - - - - - 4 100.0
C18 Colon 4 44.4 - - - - - - 3 33.3 - - 2 0 - - - - 9 100.0
C19-20 Rectum 2 25.0 - - 1 12.5 - - 2 25.0 1 12.5 2 0 - - - - 8 100.0
C21 Anus & Anal Canal - - - - - - - - - - - - - - - - - - - -
C22 Liver 3 75.0 - - 1 25.0 - - - - - - - - - - - - 4 100.0
C23-24 Gallbladder - - - - - - - - - - - - - - - - - - - -
C25 Pancreas 1 50.0 - - 1 50.0 - - - - - - - - - - - - 2 100.0
C30-31 Nose,Sinuses - - - - - - - - - - - - - - - - - - - -
C32 Larynx 2 28.6 3 42.9 1 14.3 - - - - 1 14.3 - - - - - - 7 100.0
C33-34 Lung 4 8.9 7 15.6 23 51.1 - - - - 10 22.2 1 0 - - - - 45 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - - - - - - - - - -
C40-41 Bone 2 18.2 - - 8 72.7 1 9.1 - - - - - - - - - - 11 100.0
C43 Melanoma of Skin - - - - - - - - - - - - - - - - - - - -
C44 Other Skin 4 100.0 - - - - - - - - - - - - - - - - 4 100.0
C45 Mesothelioma - - - - - - - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
94
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R +
C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C47+C49 Conn. & Soft Tissue 7 63.6 - - - - 1 9.1 1 9.1 1 9.1 1 9.1 - - - - 11 100.0
C50 Breast - - - - - - - - 1 50.0 - - - - 1 50.0 - - 2 100.0
C60 Penis 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C61 Prostate - - - - 2 13.3 - - 1 6.7 - - - - 12 6.7 - - 15 100.0
C62 Testis 1 50.0 - - - - - - - - - - - - 1 0 - - 2 100.0
C63 Other Male Genital - - - - - - - - - - - - - - - - - - - -
C64 Kidney 4 80.0 - - - - 1 20.0 - - - - - - - - - - 5 100.0
C65 Renal Pelvis - - - - - - - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - - - - - - - -
C67 Bladder 2 66.7 - - - - - - 1 33.3 - - - - - - - - 3 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - - - - - - - -
C70-72 Brain, NS 6 75.0 - - - - 1 12.5 1 12.5 - - - - - - - - 8 100.0
C73 Thyroid - - - - - - 1 50.0 - - - - - - 1 0 - - 2 100.0
C74 Adrenal Gland - - - - - - - - - - - - - - - - - - - -
C81 Hodgkins Disease - - - - - - - - 1 100.0 - - - - - - - - 1 100.0
C82-85,C96 NHL 1 14.3 - - 6 85.7 - - - - - - - - - - - - 7 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - - - - - - - -
C90 Multiple Myeloma - - 1 20.0 4 80.0 - - - - - - - - - - - - 5 100.0
C91 Lymphoid Leuk. - - - - 6 85.7 - - - - 1 14.3 - - - - - - 7 100.0
C92-94 Myeloid Leukaemia - - - - 2 100.0 - - - - - - - - - - - - 2 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - - - - - - - -
O&U Other and Uns 2 66.7 - - - - - - 1 33.3 - - - - - - - - 3 100.0
All Sites 67 30.0 20 9.0 62 27.8 6 2.7 20 9.0 25 11.2 8 3.6 15 6.7 - - 223 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
95
Table 42: Number(#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment - Females
Prior + Treatment at RI(Prior Tmt)
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C00 Lip - - - - - - - - - - - - - - - - - - - -
C01-02 Tongue 3 37.5 2 25.0 1 12.5 - - 1 12.5 1 12.5 - - - - - - 8 100.0
C03-06 Mouth 3 30.0 2 20.0 - - 2 20.0 1 10.0 2 20.0 - - - - - - 10 100.0
C07-08 Salivary Gland 2 100.0 - - - - - - - - - - - - - - - - 2 100.0
C09 Tonsil - - - - - - - - - - - - - - - - - - - -
C10 Oth. Oropharynx - - - - - - - - - - - - - - - - - - - -
C11 Nasopharynx - - - - - - - - - - - - - - - - - - - -
C12-13 Hypopharynx - - - - - - - - - - 1 100.0 - - - - - - 1 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - - - - - - - -
C15 Oesophagus - - - - 1 100.0 - - - - - - - - - - - - 1 100.0
C16 Stomach 3 60.0 - - 1 20.0 - - 1 20.0 - - - - - - - - 5 100.0
C17 Small Intestine 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C18 Colon 5 55.6 - - - - - - 4 44.4 - - - - - - - - 9 100.0
C19-20 Rectum 3 50.0 - - - - - - - - 1 16.7 2 0 - - - - 6 100.0
C21 Anus & Anal Canal - - - - - - - - - - - - - - - - - - - -
C22 Liver - - - - - - - - - - - - - - - - - - - -
C23-24 Gallbladder - - - - 1 50.0 - - 1 50.0 - - - - - - - - 2 100.0
C25 Pancreas 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C30-31 Nose,Sinuses - - - - - - - - - - - - 1 0 - - - - 1 100.0
C32 Larynx - - - - - - - - - - - - - - - - - - - -
C33-34 Lung 1 12.5 - - 5 62.5 - - - - 2 25.0 - - - - - - 8 100.0
C37-38 Other Thoracic Organs 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C40-41 Bone - - - - - - - - - - - - - - - - - - - -
C43 Melanoma of Skin 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C44 Other Skin 2 100.0 - - - - - - - - - - - - - - - - 2 100.0
C45 Mesothelioma - - - - - - - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 5 71.4 - - - - - - 1 14.3 - - 1 0 - - - - 7 100.0
C50 Breast 26 26.8 1 1.0 7 7.2 4 4.1 32 33.0 - - 6 4.1 21 33.0 - - 97 100.0
C51 Vulva - - - - - - - - - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
96
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C52 Vagina 1 33.3 - - 1 33.3 - - - - 1 33.3 - - - - - - 3 100.0
C53 Cervix Uteri 2 25.0 3 37.5 - - 1 12.5 - - 2 25.0 - - - - - - 8 100.0
C54 Corpus Uteri 16 88.9 - - - - 2 11.1 - - - - - - - - - - 18 100.0
C55 Uterus Unspecified - - - - - - - - - - - - - - - - - - - -
C56 Ovary 16 50.0 - - - - - - 12 37.5 2 6.2 2 0 - - - - 32 100.0
C57 Other Female Genital - - - - - - - - - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - - - - - - - - - -
C64 Kidney 1 50.0 - - - - - - 1 50.0 - - - - - - - - 2 100.0
C65 Renal Pelvis - - - - - - - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - - - - - - - -
C67 Bladder 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - - - - - -
C69 Eye 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C70-72 Brain, NS 1 50.0 - - - - - - - - - - 1 0 - - - - 2 100.0
C73 Thyroid 1 50.0 - - - - 1 50.0 - - - - - - - - - - 2 100.0
C74 Adrenal Gland - - - - - - - - - - - - - - - - - - - -
C81 Hodgkins Disease - - - - 1 100.0 - - - - - - - - - - - - 1 100.0
C82-85,C96 NHL - - - - 4 100.0 - - - - - - - - - - - - 4 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - - - - - - - -
C90 Multiple Myeloma 1 14.3 1 14.3 5 71.4 - - - - - - - - - - - - 7 100.0
C91 Lymphoid Leuk. - - - - 2 100.0 - - - - - - - - - - - - 2 100.0
C92-94 Myeloid Leukaemia - - - - 2 100.0 - - - - - - - - - - - - 2 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - - - - - - - -
O&U Other and Uns 1 50.0 - - 1 50.0 - - - - - - - - - - - - 2 100.0
All Sites 99 39.6 9 3.6 32 12.8 10 4.0 54 21.6 12 4.8 13 5.2 21 8.4 - - 250 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
97
Table 43: Number(#) and Proportion(%) of cancers by site (ICD‐10) and Type of Treatment ‐ Males
Prior + Treatment at RI(RI Tmt)
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C00 Lip - - - - - - - - - - - - - - - - - - - -
C01-02 Tongue 3 27.3 5 45.5 - - 2 18.2 - - 1 9.1 - - - - - - 11 100.0
C03-06 Mouth 3 15.8 3 15.8 8 42.1 1 5.3 - - 4 21.1 - - - - - - 19 100.0
C07-08 Salivary Gland - - - - - - 1 100.0 - - - - - - - - - - 1 100.0
C09 Tonsil - - - - - - - - - - - - - - - - - - - -
C10 Oth. Oropharynx - - 1 14.3 3 42.9 - - - - 3 42.9 - - - - - - 7 100.0
C11 Nasopharynx - - 1 100.0 - - - - - - - - - - - - - - 1 100.0
C12-13 Hypopharynx - - 1 25.0 2 50.0 - - - - 1 25.0 - - - - - - 4 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - - - - - - - -
C15 Oesophagus - - - - 1 50.0 1 50.0 - - - - - - - - - - 2 100.0
C16 Stomach - - 2 20.0 7 70.0 - - - - 1 10.0 - - - - - - 10 100.0
C17 Small Intestine - - - - 3 75.0 - - 1 25.0 - - - - - - - - 4 100.0
C18 Colon - - - - 9 100.0 - - - - - - - - - - - - 9 100.0
C19-20 Rectum - - - - 4 50.0 1 12.5 1 12.5 2 25.0 - - - - - - 8 100.0
C21 Anus & Anal Canal - - - - - - - - - - - - - - - - - - - -
C22 Liver - - 3 75.0 1 25.0 - - - - - - - - - - - - 4 100.0
C23-24 Gallbladder - - - - - - - - - - - - - - - - - - - -
C25 Pancreas - - - - 1 50.0 1 50.0 - - - - - - - - - - 2 100.0
C30-31 Nose,Sinuses - - - - - - - - - - - - - - - - - - - -
C32 Larynx 3 42.9 3 42.9 - - - - - - 1 14.3 - - - - - - 7 100.0
C33-34 Lung - - 10 22.2 20 44.4 - - - - 15 33.3 - - - - - - 45 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - - - - - - - - - -
C40-41 Bone 4 36.4 1 9.1 1 9.1 - - 4 36.4 - - 1 0 - - - - 11 100.0
C43 Melanoma of Skin - - - - - - - - - - - - - - - - - - - -
C44 Other Skin 3 75.0 1 25.0 - - - - - - - - - - - - - - 4 100.0
C45 Mesothelioma - - - - - - - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 3 27.3 1 9.1 4 36.4 1 9.1 2 18.2 - - - - - - - - 11 100.0
C50 Breast - - 1 50.0 - - - - - - - - - - 1 0 - - 2 100.0
MCC Annual Report – HBCR 2011
98
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C60 Penis - - - - - - - - - - 1 100.0 - - - - - - 1 100.0
C61 Prostate 1 6.7 6 40.0 1 6.7 - - - - - - - - 7 0 - - 15 100.0
C62 Testis - - 1 50.0 1 50.0 - - - - - - - - - - - - 2 100.0
C63 Other Male Genital - - - - - - - - - - - - - - - - - - - -
C64 Kidney - - 1 20.0 2 40.0 - - - - 2 40.0 - - - - - - 5 100.0
C65 Renal Pelvis - - - - - - - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - - - - - - - -
C67 Bladder - - 2 66.7 - - - - - - - - 1 0 - - - - 3 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - - - - - - - -
C70-72 Brain, NS - - 2 25.0 2 25.0 - - 1 12.5 3 37.5 - - - - - - 8 100.0
C73 Thyroid - - 1 50.0 - - - - - - - - - - 1 0 - - 2 100.0
C74 Adrenal Gland - - - - - - - - - - - - - - - - - - - -
C81 Hodgkins Disease - - - - 1 100.0 - - - - - - - - - - - - 1 100.0
C82-85,C96 NHL - - 2 28.6 3 42.9 - - - - 2 28.6 - - - - - - 7 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - - - - - - - -
C90 Multiple Myeloma - - - - 5 100.0 - - - - - - - - - - - - 5 100.0
C91 Lymphoid Leuk. - - 3 42.9 4 57.1 - - - - - - - - - - - - 7 100.0
C92-94 Myeloid Leukaemia - - - - 2 100.0 - - - - - - - - - - - - 2 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - - - - - - - -
O&U Other and Uns - - - - 2 66.7 - - - - 1 33.3 - - - - - - 3 100.0
All Sites 20 9.0 51 22.9 87 39.0 8 3.6 9 4.0 37 16.6 2 0.9 9 4.0 - - 223 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
99
Table 44: Number(#) and Proportion(%) of cancers by site (ICD-10) and Type of Treatment - Females
Prior + Treatment at RI(RI Tmt)
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C00 Lip - - - - - - - - - - - - - - - - - - - -
C01-02 Tongue - - 4 50.0 2 25.0 - - - - 1 12.5 1 0 - - - - 8 100.0
C03-06 Mouth - - 4 40.0 3 30.0 - - 1 10.0 2 20.0 - - - - - - 10 100.0
C07-08 Salivary Gland - - 1 50.0 - - 1 50.0 - - - - - - - - - - 2 100.0
C09 Tonsil - - - - - - - - - - - - - - - - - - - -
C10 Oth. Oropharynx - - - - - - - - - - - - - - - - - - - -
C11 Nasopharynx - - - - - - - - - - - - - - - - - - - -
C12-13 Hypopharynx - - 1 100.0 - - - - - - - - - - - - - - 1 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - - - - - - - -
C15 Oesophagus - - 1 100.0 - - - - - - - - - - - - - - 1 100.0
C16 Stomach - - 2 40.0 2 40.0 - - - - 1 20.0 - - - - - - 5 100.0
C17 Small Intestine - - - - 1 100.0 - - - - - - - - - - - - 1 100.0
C18 Colon 1 11.1 - - 6 66.7 - - 2 22.2 - - - - - - - - 9 100.0
C19-20 Rectum - - - - 3 50.0 - - - - 3 50.0 - - - - - - 6 100.0
C21 Anus & Anal Canal - - - - - - - - - - - - - - - - - - - -
C22 Liver - - - - - - - - - - - - - - - - - - - -
C23-24 Gallbladder - - 1 50.0 1 50.0 - - - - - - - - - - - - 2 100.0
C25 Pancreas - - - - 1 100.0 - - - - - - - - - - - - 1 100.0
C30-31 Nose,Sinuses - - - - 1 100.0 - - - - - - - - - - - - 1 100.0
C32 Larynx - - - - - - - - - - - - - - - - - - - -
C33-34 Lung - - - - 8 100.0 - - - - - - - - - - - - 8 100.0
C37-38 Other Thoracic Organs - - 1 100.0 - - - - - - - - - - - - - - 1 100.0
C40-41 Bone - - - - - - - - - - - - - - - - - - - -
C43 Melanoma of Skin 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C44 Other Skin 1 50.0 - - - - - - 1 50.0 - - - - - - - - 2 100.0
C45 Mesothelioma - - - - - - - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 4 57.1 1 14.3 - - - - 1 14.3 - - 1 0 - - - - 7 100.0
C50 Breast - - 22 22.7 8 8.2 1 1.0 5 5.2 13
13.4 4 1.0 44
5.2 - - 97 100.0
MCC Annual Report – HBCR 2011
100
ICD10 Site
Type of Treatment
Surgery R-Therapy C-Therapy S + R S + C R + C S + R + C Others Unknown Total
# % # % # % # % # % # % # % # % # % # %
C51 Vulva - - - - - - - - - - - - - - - - - - - -
C52 Vagina - - 1 33.3 - - - - 1 33.3 - - 1 0 - - - - 3 100.0
C53 Cervix Uteri 1 12.5 4 50.0 1 12.5 - - - - 2 25.0 - - - - - - 8 100.0
C54 Corpus Uteri - - 13 72.2 1 5.6 - - - - 2 11.1 - - 2 0 - - 18 100.0
C55 Uterus Unspecified - - - - - - - - - - - - - - - - - - - -
C56 Ovary 3 9.4 - - 21 65.6 - - 7 21.9 1 3.1 - - - - - - 32 100.0
C57 Other Female Genital - - - - - - - - - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - - - - - - - - - -
C64 Kidney - - - - 1 50.0 - - - - 1 50.0 - - - - - - 2 100.0
C65 Renal Pelvis - - - - - - - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - - - - - - - -
C67 Bladder - - 1 100.0 - - - - - - - - - - - - - - 1 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - - - - - -
C69 Eye 1 100.0 - - - - - - - - - - - - - - - - 1 100.0
C70-72 Brain, NS - - - - 1 50.0 - - - - 1 50.0 - - - - - - 2 100.0
C73 Thyroid - - 2 100.0 - - - - - - - - - - - - - - 2 100.0
C74 Adrenal Gland - - - - - - - - - - - - - - - - - - - -
C81 Hodgkins Disease - - - - - - - - - - 1 100.0 - - - - - - 1 100.0
C82-85,C96 NHL - - - - 4 100.0 - - - - - - - - - - - - 4 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - - - - - - - -
C90 Multiple Myeloma - - 1 14.3 5 71.4 - - - - 1 14.3 - - - - - - 7 100.0
C91 Lymphoid Leuk. - - 1 50.0 1 50.0 - - - - - - - - - - - - 2 100.0
C92-94 Myeloid Leukaemia - - - - 2 100.0 - - - - - - - - - - - - 2 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - - - - - - - -
O&U Other and Uns - - - - 1 50.0 - - - - 1 50.0 - - - - - - 2 100.0
All Sites
12
4.8 61 24.4 74 29.6 2 0.8 18
7.2 30
12.0 7 2.8 46
18.4 - - 250 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
101
Table 45: Number(#) and Proportion(%) of cancers by site (ICD-10) and Any Specific Treatment - Males
Prior Treatment Only
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C00 Lip 1 50.0 - - 1 50.0 - - - - - - 2 100.0
C01-02 Tongue 5 38.5 6 46.2 2 15.4 - - - - - - 13 100.0
C03-06 Mouth 5 19.2 13 50.0 8 30.8 - - - - - - 26 100.0
C07-08 Salivary Gland 1 50.0 1 50.0 - - - - - - - - 2 100.0
C09 Tonsil - - - - - - - - - - - - - -
C10 Oth. Oropharynx 2 14.3 7 50.0 5 35.7 - - - - - - 14 100.0
C11 Nasopharynx - - 1 50.0 1 50.0 - - - - - - 2 100.0
C12-13 Hypopharynx - - 6 60.0 4 40.0 - - - - - - 10 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - -
C15 Oesophagus 1 8.3 5 41.7 6 50.0 - - - - - - 12 100.0
C16 Stomach 19 44.2 6 14.0 18 41.9 - - - - - - 43 100.0
C17 Small Intestine 1 100.0 - - - - - - - - - - 1 100.0
C18 Colon 6 54.5 - - 5 45.5 - - - - - - 11 100.0
C19-20 Rectum 10 40.0 6 24.0 9 36.0 - - - - - - 25 100.0
C21 Anus & Anal Canal - - - - - - - - - - - - - -
C22 Liver 3 50.0 1 16.7 2 33.3 - - - - - - 6 100.0
C23-24 Gallbladder 3 100.0 - - - - - - - - - - 3 100.0
C25 Pancreas 5 62.5 1 12.5 2 25.0 - - - - - - 8 100.0
C30-31 Nose,Sinuses 2 33.3 2 33.3 2 33.3 - - - - - - 6 100.0
C32 Larynx 5 33.3 7 46.7 2 13.3 - - - - 1 6.7 15 100.0
C33-34 Lung 4 9.8 15 36.6 22 53.7 - - - - - - 41 100.0
C37-38 Other Thoracic Organs 1 50.0 - - 1 50.0 - - - - - - 2 100.0
C40-41 Bone 3 37.5 1 12.5 4 50.0 - - - - - - 8 100.0
C43 Melanoma of Skin 1 100.0 - - - - - - - - - - 1 100.0
C44 Other Skin 6 100.0 - - - - - - - - - - 6 100.0
C45 Mesothelioma - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
102
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C47+C49 Conn. & Soft Tissue 7 53.8 3 23.1 3 23.1 - - - - - - 13 100.0
C50 Breast 1 25.0 1 25.0 2 50.0 - - - - - - 4 100.0
C60 Penis 1 100.0 - - - - - - - - - - 1 100.0
C61 Prostate 1 8.3 1 8.3 1 8.3 9 75.0 - - - - 12 100.0
C62 Testis 1 25.0 1 25.0 2 50.0 - - - - - - 4 100.0
C63 Other Male Genital - - - - - - - - - - - - - -
C64 Kidney 5 83.3 - - 1 16.7 - - - - - - 6 100.0
C65 Renal Pelvis - - - - - - - - - - - - - -
C66 Ureter 1 100.0 - - - - - - - - - - 1 100.0
C67 Bladder 10 83.3 1 8.3 1 8.3 - - - - - - 12 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - -
C70-72 Brain, NS 7 43.8 6 37.5 3 18.8 - - - - - - 16 100.0
C73 Thyroid 6 66.7 3 33.3 - - - - - - - - 9 100.0
C74 Adrenal Gland - - - - - - - - - - - - - -
C81 Hodgkins Disease 1 16.7 1 16.7 4 66.7 - - - - - - 6 100.0
C82-85,C96 NHL 1 11.1 1 11.1 7 77.8 - - - - - - 9 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - -
C90 Multiple Myeloma - - - - 6 100.0 - - - - - - 6 100.0
C91 Lymphoid Leuk. - - - - 4 100.0 - - - - - - 4 100.0
C92-94 Myeloid Leukaemia - - - - 6 100.0 - - - - - - 6 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - -
O&U Other and Uns 3 30.0 2 20.0 5 50.0 - - - - - - 10 100.0
All Sites 129 34.3 98 26.1 139 37.0 9 2.4 - - 1 0.3 376 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
103
Table 46: Number(#) and Proportion(%) of cancers by site (ICD-10) and Any Specific Treatment - Females
Prior Treatment Only
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C00 Lip 2 100 - - - - - - - - - - 2 100.0
C01-02 Tongue 4 26.7 6 40 5 33.3 - - - - - - 15 100.0
C03-06 Mouth 5 41.7 5 41.7 2 16.7 - - - - - - 12 100.0
C07-08 Salivary Gland 1 50 1 50 - - - - - - - - 2 100.0
C09 Tonsil - - - - - - - - - - - - - -
C10 Oth. Oropharynx 1 25 2 50 1 25 - - - - - - 4 100.0
C11 Nasopharynx - - - - - - - - - - - - - -
C12-13 Hypopharynx 1 25 2 50 1 25 - - - - - - 4 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - -
C15 Oesophagus - - 3 100 - - - - - - - - 3 100.0
C16 Stomach 7 53.8 - - 6 46.2 - - - - - - 13 100.0
C17 Small Intestine 1 100 - - - - - - - - - - 1 100.0
C18 Colon 3 60 - - 2 40 - - - - - - 5 100.0
C19-20 Rectum 3 37.5 1 12.5 4 50 - - - - - - 8 100.0
C21 Anus & Anal Canal - - 1 50 1 50 - - - - - - 2 100.0
C22 Liver - - - - - - - - - - - - - -
C23-24 Gallbladder 2 100 - - - - - - - - - - 2 100.0
C25 Pancreas 2 40 - - 3 60 - - - - - - 5 100.0
C30-31 Nose,Sinuses - - 1 50 1 50 - - - - - - 2 100.0
C32 Larynx 1 50 1 50 - - - - - - - - 2 100.0
C33-34 Lung - - 1 12.5 7 87.5 - - - - - - 8 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - - - -
C40-41 Bone 3 42.9 2 28.6 2 28.6 - - - - - - 7 100.0
C43 Melanoma of Skin - - - - - - - - - - - - - -
C44 Other Skin 3 100 - - - - - - - - - - 3 100.0
C45 Mesothelioma - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
104
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C47+C49 Conn. & Soft Tissue 5 71.4 2 28.6 - - - - - - - - 7 100.0
C50 Breast 46 39.3 22 18.8 36 30.8 12 10.3 - - 1 0.9 117 100.0
C51 Vulva - - - - - - - - - - - - - -
C52 Vagina - - - - - - - - - - - - - -
C53 Cervix Uteri 12 26.7 20 44.4 13 28.9 - - - - - - 45 100.0
C54 Corpus Uteri 7 63.6 2 18.2 2 18.2 - - - - - - 11 100.0
C55 Uterus Unspecified - - - - - - - - - - - - - -
C56 Ovary 16 53.3 2 6.7 10 33.3 2 6.7 - - - - 30 100.0
C57 Other Female Genital - - - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - - - -
C64 Kidney 2 50 1 25 1 25 - - - - - - 4 100.0
C65 Renal Pelvis - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - -
C67 Bladder 2 100 - - - - - - - - - - 2 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - -
C69 Eye - - 1 50 1 50 - - - - - - 2 100.0
C70-72 Brain, NS 4 80 1 20 - - - - - - - - 5 100.0
C73 Thyroid 14 63.6 8 36.4 - - - - - - - - 22 100.0
C74 Adrenal Gland - - - - - - - - - - - - - -
C81 Hodgkins Disease - - 1 50 1 50 - - - - - - 2 100.0
C82-85,C96 NHL - - 1 11.1 8 88.9 - - - - - - 9 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - -
C90 Multiple Myeloma - - - - 2 100 - - - - - - 2 100.0
C91 Lymphoid Leuk. - - - - 1 100 - - - - - - 1 100.0
C92-94 Myeloid Leukaemia - - - - 5 100 - - - - - - 5 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - -
O&U Other and Uns 1 50 - - 1 50 - - - - - - 2 100.0
All Sites 148 40.4 87 23.8 116 31.7 14 3.8 - - 1 0.3 366 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
105
Table 47: Number(#) and Proportion(%) of cancers by site (ICD‐10) and Any Specific Treatment ‐ Males Treatment Only at RI
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C00 Lip 2 40.0 2 40.0 1 20.0 - - - - - - 5 100.0
C01-02 Tongue 22 35.5 23 37.1 17 27.4 - - - - - - 62 100.0
C03-06 Mouth 27 27.3 44 44.4 28 28.3 - - - - - - 99 100.0
C07-08 Salivary Gland 3 60.0 2 40.0 - - - - - - - - 5 100.0
C09 Tonsil 2 22.2 4 44.4 3 33.3 - - - - - - 9 100.0
C10 Oth. Oropharynx 1 1.7 32 53.3 27 45.0 - - - - - - 60 100.0
C11 Nasopharynx - - 2 40.0 3 60.0 - - - - - - 5 100.0
C12-13 Hypopharynx 6 13.3 25 55.6 14 31.1 - - - - - - 45 100.0
C14 Pharynx Unspecified - - 1 100.0 - - - - - - - - 1 100.0
C15 Oesophagus 3 5.7 32 60.4 18 34.0 - - - - - - 53 100.0
C16 Stomach 19 35.8 8 15.1 26 49.1 - - - - - - 53 100.0
C17 Small Intestine - - - - 1 100.0 - - - - - - 1 100.0
C18 Colon 8 53.3 - - 7 46.7 - - - - - - 15 100.0
C19-20 Rectum 13 27.1 17 35.4 18 37.5 - - - - - - 48 100.0
C21 Anus & Anal Canal - - 1 50.0 1 50.0 - - - - - - 2 100.0
C22 Liver 1 16.7 2 33.3 3 50.0 - - - - - - 6 100.0
C23-24 Gallbladder - - - - - - - - - - - - - -
C25 Pancreas - - - - 1 100.0 - - - - - - 1 100.0
C30-31 Nose,Sinuses - - - - - - - - - - - - - -
C32 Larynx 3 8.8 20 58.8 11 32.4 - - - - - - 34 100.0
C33-34 Lung 2 1.0 92 45.8 107 53.2 - - - - - - 201 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - - - -
C40-41 Bone 3 75.0 - - 1 25.0 - - - - - - 4 100.0
C43 Melanoma of Skin 2 66.7 - - 1 33.3 - - - - - - 3 100.0
C44 Other Skin 11 61.1 4 22.2 3 16.7 - - - - - - 18 100.0
C45 Mesothelioma - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 4 44.4 3 33.3 2 22.2 - - - - - - 9 100.0
C50 Breast 3 20.0 4 26.7 3 20.0 5 33.3 - - - - 15 100.0
C60 Penis 3 100.0 - - - - - - - - - - 3 100.0
C61 Prostate - - 8 38.1 2 9.5 11 52.4 - - - - 21 100.0
C62 Testis 1 100.0 - - - - - - - - - - 1 100.0
MCC Annual Report – HBCR 2011
106
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C63 Other Male Genital - - - - - - - - - - - - - -
C64 Kidney 2 100.0 - - - - - - - - - - 2 100.0
C65 Renal Pelvis - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - -
C67 Bladder 2 66.7 1 33.3 - - - - - - - - 3 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - -
C70-72 Brain, NS - - - - - - - - - - - - - -
C73 Thyroid 2 50.0 2 50.0 - - - - - - - - 4 100.0
C74 Adrenal Gland - - - - - - - - - - - - - -
C81 Hodgkins Disease - - 1 25.0 3 75.0 - - - - - - 4 100.0
C82-85,C96 NHL 2 8.0 5 20.0 18 72.0 - - - - - - 25 100.0
C88 Malig Imn.Prol D - - - - 1 100.0 - - - - - - 1 100.0
C90 Multiple Myeloma - - - - 1 100.0 - - - - - - 1 100.0
C91 Lymphoid Leuk. - - - - 1 100.0 - - - - - - 1 100.0
C92-94 Myeloid Leukaemia - - - - 4 100.0 - - - - - - 4 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - -
O&U Other and Uns 2 6.9 16 55.2 11 37.9 - - - - - - 29 100.0
All Sites 149 17.5 351 41.1 337 39.5 16 1.9 - - - - 853 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
107
Table 48:
Number(#) and Proportion(%) of cancers by site (ICD-10) and Any Specific Treatment – Females
Treatment Only at RI
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C00 Lip 2 66.7 1 33.3 - - - - - - - - 3 100.0
C01-02 Tongue 17 45.9 12 32.4 8 21.6 - - - - - - 37 100.0
C03-06 Mouth 11 13.9 41 51.9 27 34.2 - - - - - - 79 100.0
C07-08 Salivary Gland 2 66.7 1 33.3 - - - - - - - - 3 100.0
C09 Tonsil - - 1 100 - - - - - - - - 1 100.0
C10 Oth. Oropharynx - - 3 75 1 25 - - - - - - 4 100.0
C11 Nasopharynx - - 1 50 1 50 - - - - - - 2 100.0
C12-13 Hypopharynx 3 33.3 4 44.4 2 22.2 - - - - - - 9 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - -
C15 Oesophagus 1 6.7 11 73.3 3 20 - - - - - - 15 100.0
C16 Stomach 6 46.2 1 7.7 6 46.2 - - - - - - 13 100.0
C17 Small Intestine 1 100 - - - - - - - - - - 1 100.0
C18 Colon 11 57.9 1 5.3 7 36.8 - - - - - - 19 100.0
C19-20 Rectum 17 30.4 19 33.9 20 35.7 - - - - - - 56 100.0
C21 Anus & Anal Canal 1 33.3 1 33.3 1 33.3 - - - - - - 3 100.0
C22 Liver - - - - - - - - - - - - - -
C23-24 Gallbladder - - - - - - - - - - - - - -
C25 Pancreas - - 1 25 3 75 - - - - - - 4 100.0
C30-31 Nose,Sinuses 1 33.3 2 66.7 - - - - - - - - 3 100.0
C32 Larynx - - 1 100 - - - - - - - - 1 100.0
C33-34 Lung - - 10 45.5 12 54.5 - - - - - - 22 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - - - -
C40-41 Bone 3 27.3 3 27.3 5 45.5 - - - - - - 11 100.0
C43 Melanoma of Skin 1 100 - - - - - - - - - - 1 100.0
MCC Annual Report – HBCR 2011
108
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C44 Other Skin 9 75 2 16.7 1 8.3 - - - - - - 12 100.0
C45 Mesothelioma - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 3 60 1 20 1 20 - - - - - - 5 100.0
C50 Breast 135 29.5 114 24.9 151 33 58 12.7 - - - - 458 100.0
C51 Vulva - - 1 100 - - - - - - - - 1 100.0
C52 Vagina - - 3 50 3 50 - - - - - - 6 100.0
C53 Cervix Uteri 3 3.3 52 56.5 37 40.2 - - - - - - 92 100.0
C54 Corpus Uteri 17 50 14 41.2 3 8.8 - - - - - - 34 100.0
C55 Uterus Unspecified - - - - - - - - - - - - - -
C56 Ovary 18 37.5 3 6.2 27 56.2 - - - - - - 48 100.0
C57 Other Female Genital - - - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - - - -
C64 Kidney - - 2 66.7 1 33.3 - - - - - - 3 100.0
C65 Renal Pelvis - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - -
C67 Bladder - - - - - - - - - - - - - -
C68 Uns.Urinary Organs - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - -
C70-72 Brain, NS - - - - - - - - - - - - - -
C73 Thyroid 9 75 3 25 - - - - - - - - 12 100.0
C74 Adrenal Gland - - - - - - - - - - - - - -
C81 Hodgkins Disease - - 1 50 1 50 - - - - - - 2 100.0
C82-85,C96 NHL 1 3.8 6 23.1 19 73.1 - - - - - - 26 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - -
C90 Multiple Myeloma - - - - 6 100 - - - - - - 6 100.0
C91 Lymphoid Leuk. - - - - 2 100 - - - - - - 2 100.0
C92-94 Myeloid Leukaemia - - - - 6 100 - - - - - - 6 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - -
O&U Other and Uns - - 4 44.4 4 44.4 1 11.1 - - - - 9 100.0
All Sites 272 27 320 31.7 358 35.5 59 5.8 - - - - 1009 100.0
MCC Annual Report – HBCR 2011
109
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
Table 49: Number(#) and Proportion(%) of cancers by site (ICD‐10) and Any Specific Treatment ‐ Males Prior + Treatment at RI(Prior Tmt)
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C00 Lip - - - - - - - - - - - - - -
C01-02 Tongue 9 69.2 3 23.1 1 7.7 - - - - - - 13 100.0
C03-06 Mouth 6 22.2 12 44.4 9 33.3 - - - - - - 27 100.0
C07-08 Salivary Gland 1 100.0 - - - - - - - - - - 1 100.0
C09 Tonsil - - - - - - - - - - - - - -
C10 Oth. Oropharynx 2 20.0 4 40.0 4 40.0 - - - - - - 10 100.0
C11 Nasopharynx - - 1 50.0 1 50.0 - - - - - - 2 100.0
C12-13 Hypopharynx 2 40.0 2 40.0 1 20.0 - - - - - - 5 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - -
C15 Oesophagus 1 25.0 1 25.0 2 50.0 - - - - - - 4 100.0
C16 Stomach 7 50.0 - - 7 50.0 - - - - - - 14 100.0
C17 Small Intestine 4 57.1 - - 3 42.9 - - - - - - 7 100.0
C18 Colon 9 56.2 2 12.5 5 31.2 - - - - - - 16 100.0
C19-20 Rectum 6 40.0 3 20.0 6 40.0 - - - - - - 15 100.0
C21 Anus & Anal Canal - - - - - - - - - - - - - -
C22 Liver 3 75.0 - - 1 25.0 - - - - - - 4 100.0
C23-24 Gallbladder - - - - - - - - - - - - - -
C25 Pancreas 1 50.0 - - 1 50.0 - - - - - - 2 100.0
C30-31 Nose,Sinuses - - - - - - - - - - - - - -
C32 Larynx 2 25.0 4 50.0 2 25.0 - - - - - - 8 100.0
C33-34 Lung 5 8.8 18 31.6 34 59.6 - - - - - - 57 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - - - -
C40-41 Bone 3 25.0 1 8.3 8 66.7 - - - - - - 12 100.0
C43 Melanoma of Skin - - - - - - - - - - - - - -
C44 Other Skin 4 100.0 - - - - - - - - - - 4 100.0
C45 Mesothelioma - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 10 62.5 3 18.8 3 18.8 - - - - - - 16 100.0
C50 Breast 1 33.3 - - 1 33.3 1 33.3 - - - - 3 100.0
C60 Penis 1 100.0 - - - - - - - - - - 1 100.0
MCC Annual Report – HBCR 2011
110
C61 Prostate 1 5.3 1 5.3 5 26.3 12 63.2 - - - - 19 100.0
C62 Testis 1 50.0 - - - - 1 50.0 - - - - 2 100.0
C63 Other Male Genital - - - - - - - - - - - - - -
C64 Kidney 5 83.3 1 16.7 - - - - - - - - 6 100.0
C65 Renal Pelvis - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - -
C67 Bladder 3 75.0 - - 1 25.0 - - - - - - 4 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - -
C70-72 Brain, NS 8 80.0 1 10.0 1 10.0 - - - - - - 10 100.0
C73 Thyroid 1 33.3 1 33.3 - - 1 33.3 - - - - 3 100.0
C74 Adrenal Gland - - - - - - - - - - - - - -
C81 Hodgkins Disease 1 50.0 - - 1 50.0 - - - - - - 2 100.0
C82-85,C96 NHL 1 14.3 - - 6 85.7 - - - - - - 7 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - -
C90 Multiple Myeloma - - 1 20.0 4 80.0 - - - - - - 5 100.0
C91 Lymphoid Leuk. - - 1 12.5 7 87.5 - - - - - - 8 100.0
C92-94 Myeloid Leukaemia - - - - 2 100.0 - - - - - - 2 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - -
O&U Other and Uns 3 75.0 - - 1 25.0 - - - - - - 4 100.0
All Sites 101 34.5 60 20.5 117 39.9 15 5.1 - - - - 293 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
111
Table 50: Number(#) and Proportion(%) of cancers by site (ICD‐10) and Any Specific Treatment ‐ Females
Prior + Treatment at RI(Prior Tmt)
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C00 Lip - - - - - - - - - - - - - -
C01-02 Tongue 4 40 3 30 3 30 - - - - - - 10 100.0
C03-06 Mouth 6 40 6 40 3 20 - - - - - - 15 100.0
C07-08 Salivary Gland 2 100 - - - - - - - - - - 2 100.0
C09 Tonsil - - - - - - - - - - - - - -
C10 Oth. Oropharynx - - - - - - - - - - - - - -
C11 Nasopharynx - - - - - - - - - - - - - -
C12-13 Hypopharynx - - 1 50 1 50 - - - - - - 2 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - -
C15 Oesophagus - - - - 1 100 - - - - - - 1 100.0
C16 Stomach 4 66.7 - - 2 33.3 - - - - - - 6 100.0
C17 Small Intestine 1 100 - - - - - - - - - - 1 100.0
C18 Colon 9 69.2 - - 4 30.8 - - - - - - 13 100.0
C19-20 Rectum 5 45.5 3 27.3 3 27.3 - - - - - - 11 100.0
C21 Anus & Anal Canal - - - - - - - - - - - - - -
C22 Liver - - - - - - - - - - - - - -
C23-24 Gallbladder 1 33.3 - - 2 66.7 - - - - - - 3 100.0
C25 Pancreas 1 100 - - - - - - - - - - 1 100.0
C30-31 Nose,Sinuses 1 33.3 1 33.3 1 33.3 - - - - - - 3 100.0
C32 Larynx - - - - - - - - - - - - - -
C33-34 Lung 1 10 2 20 7 70 - - - - - - 10 100.0
C37-38 Other Thoracic Organs 1 100 - - - - - - - - - - 1 100.0
C40-41 Bone - - - - - - - - - - - - - -
C43 Melanoma of Skin 1 100 - - - - - - - - - - 1 100.0
C44 Other Skin 2 100 - - - - - - - - - - 2 100.0
C45 Mesothelioma - - - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
112
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C46 Kaposi Sarcoma - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 7 70 1 10 2 20 - - - - - - 10 100.0
C50 Breast 85 45 24 12.7 59 31.2 21 11.1 - - - - 189 100.0
C51 Vulva - - - - - - - - - - - - - -
C52 Vagina 1 25 1 25 2 50 - - - - - - 4 100.0
C53 Cervix Uteri 3 27.3 6 54.5 2 18.2 - - - - - - 11 100.0
C54 Corpus Uteri 18 90 2 10 - - - - - - - - 20 100.0
C55 Uterus Unspecified - - - - - - - - - - - - - -
C56 Ovary 30 60 4 8 16 32 - - - - - - 50 100.0
C57 Other Female Genital - - - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - - - -
C64 Kidney 2 66.7 - - 1 33.3 - - - - - - 3 100.0
C65 Renal Pelvis - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - -
C67 Bladder 1 100 - - - - - - - - - - 1 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - -
C69 Eye 1 100 - - - - - - - - - - 1 100.0
C70-72 Brain, NS 2 50 1 25 1 25 - - - - - - 4 100.0
C73 Thyroid 2 66.7 1 33.3 - - - - - - - - 3 100.0
C74 Adrenal Gland - - - - - - - - - - - - - -
C81 Hodgkins Disease - - - - 1 100 - - - - - - 1 100.0
C82-85,C96 NHL - - - - 4 100 - - - - - - 4 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - -
C90 Multiple Myeloma 1 14.3 1 14.3 5 71.4 - - - - - - 7 100.0
C91 Lymphoid Leuk. - - - - 2 100 - - - - - - 2 100.0
C92-94 Myeloid Leukaemia - - - - 2 100 - - - - - - 2 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - -
O&U Other and Uns 1 50 - - 1 50 - - - - - - 2 100.0
All Sites 193 48.7 57 14.4 125 31.6 21 5.3 - - - - 396 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
113
Table 51: Number(#) and Proportion(%) of cancers by site (ICD‐10) and Any Specific Treatment ‐ Males Prior + Treatment at RI(RI Tmt)
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C00 Lip - - - - - - - - - - - - - -
C01-02 Tongue 5 35.7 8 57.1 1 7.1 - - - - - - 14 100.0
C03-06 Mouth 4 16.7 8 33.3 12 50.0 - - - - - - 24 100.0
C07-08 Salivary Gland 1 50.0 1 50.0 - - - - - - - - 2 100.0
C09 Tonsil - - - - - - - - - - - - - -
C10 Oth. Oropharynx - - 4 40.0 6 60.0 - - - - - - 10 100.0
C11 Nasopharynx - - 1 100.0 - - - - - - - - 1 100.0
C12-13 Hypopharynx - - 2 40.0 3 60.0 - - - - - - 5 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - -
C15 Oesophagus 1 33.3 1 33.3 1 33.3 - - - - - - 3 100.0
C16 Stomach - - 3 27.3 8 72.7 - - - - - - 11 100.0
C17 Small Intestine 1 20.0 - - 4 80.0 - - - - - - 5 100.0
C18 Colon - - - - 9 100.0 - - - - - - 9 100.0
C19-20 Rectum 2 16.7 3 25.0 7 58.3 - - - - - - 12 100.0
C21 Anus & Anal Canal - - - - - - - - - - - - - -
C22 Liver - - 3 75.0 1 25.0 - - - - - - 4 100.0
C23-24 Gallbladder - - - - - - - - - - - - - -
C25 Pancreas 1 33.3 1 33.3 1 33.3 - - - - - - 3 100.0
C30-31 Nose,Sinuses - - - - - - - - - - - - - -
C32 Larynx 3 37.5 4 50.0 1 12.5 - - - - - - 8 100.0
C33-34 Lung - - 25 41.7 35 58.3 - - - - - - 60 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - - - -
C40-41 Bone 9 52.9 2 11.8 6 35.3 - - - - - - 17 100.0
C43 Melanoma of Skin - - - - - - - - - - - - - -
C44 Other Skin 3 75.0 1 25.0 - - - - - - - - 4 100.0
C45 Mesothelioma - - - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
114
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C46 Kaposi Sarcoma - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 6 42.9 2 14.3 6 42.9 - - - - - - 14 100.0
C50 Breast - - 2 66.7 - - 1 33.3 - - - - 3 100.0
C60 Penis - - 1 50.0 1 50.0 - - - - - - 2 100.0
C61 Prostate 2 9.5 10 47.6 2 9.5 7 33.3 - - - - 21 100.0
C62 Testis - - 1 50.0 1 50.0 - - - - - - 2 100.0
C63 Other Male Genital - - - - - - - - - - - - - -
C64 Kidney - - 3 42.9 4 57.1 - - - - - - 7 100.0
C65 Renal Pelvis - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - -
C67 Bladder 1 20.0 3 60.0 1 20.0 - - - - - - 5 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - -
C70-72 Brain, NS 1 8.3 5 41.7 6 50.0 - - - - - - 12 100.0
C73 Thyroid - - 1 50.0 - - 1 50.0 - - - - 2 100.0
C74 Adrenal Gland - - - - - - - - - - - - - -
C81 Hodgkins Disease - - - - 1 100.0 - - - - - - 1 100.0
C82-85,C96 NHL - - 4 44.4 5 55.6 - - - - - - 9 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - -
C90 Multiple Myeloma - - - - 5 100.0 - - - - - - 5 100.0
C91 Lymphoid Leuk. - - 3 42.9 4 57.1 - - - - - - 7 100.0
C92-94 Myeloid Leukaemia - - - - 2 100.0 - - - - - - 2 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - -
O&U Other and Uns - - 1 25.0 3 75.0 - - - - - - 4 100.0
All Sites 40 13.9 103 35.8 136 47.2 9 3.1 - - - - 288 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
115
Table 52: Number(#) and Proportion(%) of cancers by site (ICD-10) and Any Specific Treatment - Females
Prior + Treatment at RI(RI Tmt)
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C00 Lip - - - - - - - - - - - - - -
C01-02 Tongue 1 9.1 6 54.5 4 36.4 - - - - - - 11 100.0
C03-06 Mouth 1 7.7 6 46.2 6 46.2 - - - - - - 13 100.0
C07-08 Salivary Gland 1 33.3 2 66.7 - - - - - - - - 3 100.0
C09 Tonsil - - - - - - - - - - - - - -
C10 Oth. Oropharynx - - - - - - - - - - - - - -
C11 Nasopharynx - - - - - - - - - - - - - -
C12-13 Hypopharynx - - 1 100 - - - - - - - - 1 100.0
C14 Pharynx Unspecified - - - - - - - - - - - - - -
C15 Oesophagus - - 1 100 - - - - - - - - 1 100.0
C16 Stomach - - 3 50 3 50 - - - - - - 6 100.0
C17 Small Intestine - - - - 1 100 - - - - - - 1 100.0
C18 Colon 3 27.3 - - 8 72.7 - - - - - - 11 100.0
C19-20 Rectum - - 3 33.3 6 66.7 - - - - - - 9 100.0
C21 Anus & Anal Canal - - - - - - - - - - - - - -
C22 Liver - - - - - - - - - - - - - -
C23-24 Gallbladder - - 1 50 1 50 - - - - - - 2 100.0
C25 Pancreas - - - - 1 100 - - - - - - 1 100.0
C30-31 Nose,Sinuses - - - - 1 100 - - - - - - 1 100.0
C32 Larynx - - - - - - - - - - - - - -
C33-34 Lung - - - - 8 100 - - - - - - 8 100.0
C37-38 Other Thoracic Organs - - 1 100 - - - - - - - - 1 100.0
C40-41 Bone - - - - - - - - - - - - - -
C43 Melanoma of Skin 1 100 - - - - - - - - - - 1 100.0
C44 Other Skin 2 66.7 - - 1 33.3 - - - - - - 3 100.0
C45 Mesothelioma - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
116
ICD10 Site Any S Any R Any C Any H Others Unknown Total
# % # % # % # % # % # % # %
C47+C49 Conn. & Soft Tissue 6 60 2 20 2 20 - - - - - - 10 100.0
C50 Breast 20 11.6 65 37.6 44 25.4 44 25.4 - - - - 173 100.0
C51 Vulva - - - - - - - - - - - - - -
C52 Vagina 2 33.3 2 33.3 2 33.3 - - - - - - 6 100.0
C53 Cervix Uteri 1 10 6 60 3 30 - - - - - - 10 100.0
C54 Corpus Uteri - - 16 72.7 4 18.2 2 9.1 - - - - 22 100.0
C55 Uterus Unspecified - - - - - - - - - - - - - -
C56 Ovary 10 25 1 2.5 29 72.5 - - - - - - 40 100.0
C57 Other Female Genital - - - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - - - -
C64 Kidney - - 1 33.3 2 66.7 - - - - - - 3 100.0
C65 Renal Pelvis - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - -
C67 Bladder - - 1 100 - - - - - - - - 1 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - -
C69 Eye 1 100 - - - - - - - - - - 1 100.0
C70-72 Brain, NS - - 1 33.3 2 66.7 - - - - - - 3 100.0
C73 Thyroid - - 2 100 - - - - - - - - 2 100.0
C74 Adrenal Gland - - - - - - - - - - - - - -
C81 Hodgkins Disease - - 1 50 1 50 - - - - - - 2 100.0
C82-85,C96 NHL - - - - 4 100 - - - - - - 4 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - -
C90 Multiple Myeloma - - 2 25 6 75 - - - - - - 8 100.0
C91 Lymphoid Leuk. - - 1 50 1 50 - - - - - - 2 100.0
C92-94 Myeloid Leukaemia - - - - 2 100 - - - - - - 2 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - -
O&U Other and Uns - - 1 33.3 2 66.7 - - - - - - 3 100.0
All Sites 49 13.4 126 34.5 144 39.5 46 12.6 - - - - 365 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
117
Table 53: Number(#) and Proportion(%) of cancers by site (ICD-10) and Treatment Status at Reporting Institution (Excluding the Cancers Previously Treated) – Males
ICD10 Site Received Not Received Not Accepted Incomplete Unknown Total
# % # % # % # % # % # %
C00 Lip 3 100.0 - - - - - - - - 3 100.0
C01-02 Tongue 31 64.6 13 27.1 1 2.1 3 6.2 - - 48 100.0
C03-06 Mouth 53 76.8 12 17.4 - - 3 4.3 1 1.4 69 100.0
C07-08 Salivary Gland 4 66.7 2 33.3 - - - - - - 6 100.0
C09 Tonsil 5 83.3 1 16.7 - - - - - - 6 100.0
C10 Oth. Oropharynx 31 81.6 5 13.2 - - 2 5.3 - - 38 100.0
C11 Nasopharynx 3 60.0 1 20.0 - - 1 20.0 - - 5 100.0
C12-13 Hypopharynx 25 73.5 7 20.6 - - 2 5.9 - - 34 100.0
C14 Pharynx Unspecified 1 100.0 - - - - - - - - 1 100.0
C15 Oesophagus 34 65.4 15 28.8 1 1.9 2 3.8 - - 52 100.0
C16 Stomach 32 43.2 34 45.9 - - 6 8.1 2 2.7 74 100.0
C17 Small Intestine 1 100.0 - - - - - - - - 1 100.0
C18 Colon 11 68.8 4 25.0 - - 1 6.2 - - 16 100.0
C19-20 Rectum 21 80.8 3 11.5 1 3.8 1 3.8 - - 26 100.0
C21 Anus & Anal Canal 1 50.0 1 50.0 - - - - - - 2 100.0
C22 Liver 3 15.8 13 68.4 - - 3 15.8 - - 19 100.0
C23-24 Gallbladder - - 4 100.0 - - - - - - 4 100.0
C25 Pancreas 1 16.7 5 83.3 - - - - - - 6 100.0
C30-31 Nose,Sinuses - - 1 100.0 - - - - - - 1 100.0
C32 Larynx 21 55.3 13 34.2 - - 4 10.5 - - 38 100.0
C33-34 Lung 95 40.3 94 39.8 - - 46 19.5 1 0.4 236 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - -
C40-41 Bone 3 60.0 2 40.0 - - - - - - 5 100.0
C43 Melanoma of Skin 2 33.3 3 50.0 - - 1 16.7 - - 6 100.0
C44 Other Skin 13 72.2 4 22.2 - - - - 1 5.6 18 100.0
C45 Mesothelioma - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 5 62.5 3 37.5 - - - - - - 8 100.0
MCC Annual Report – HBCR 2011
118
ICD10 Site Received Not Received Not Accepted Incomplete Unknown Total
# % # % # % # % # % # %
C50 Breast 5 71.4 2 28.6 - - - - - - 7 100.0
C60 Penis 3 100.0 - - - - - - - - 3 100.0
C61 Prostate 14 66.7 7 33.3 - - - - - - 21 100.0
C62 Testis 1 100.0 - - - - - - - - 1 100.0
C63 Other Male Genital - - - - - - - - - - - -
C64 Kidney 2 40.0 2 40.0 1 20.0 - - - - 5 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - -
C67 Bladder 3 21.4 11 78.6 - - - - - - 14 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - -
C70-72 Brain, NS - - 2 100.0 - - - - - - 2 100.0
C73 Thyroid 3 42.9 4 57.1 - - - - - - 7 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease 2 33.3 3 50.0 - - 1 16.7 - - 6 100.0
C82-85,C96 NHL 15 46.9 12 37.5 - - 5 15.6 - - 32 100.0
C88 Malig Imn.Prol D 1 100.0 - - - - - - - - 1 100.0
C90 Multiple Myeloma 1 25.0 3 75.0 - - - - - - 4 100.0
C91 Lymphoid Leuk. 1 33.3 2 66.7 - - - - - - 3 100.0
C92-94 Myeloid Leukaemia 3 21.4 10 71.4 - - 1 7.1 - - 14 100.0
C95 Leukaemia Uns - - 2 100.0 - - - - - - 2 100.0
O&U Other and Uns 15 27.8 31 57.4 1 1.9 7 13.0 - - 54 100.0
All Sites 468 52.1 331 36.9 5 0.6 89 9.9 5 0.6 898 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
119
Table 54: Number(#) and Proportion(%) of cancers by site (ICD-10) and Treatment Status at Reporting Institution (Excluding the Cancers Previously Treated) –
Females
ICD10 Site Received Not Received Not Accepted Incomplete Unknown Total
# % # % # % # % # % # %
C00 Lip 3 60 2 40 - - - - - - 5 100.0
C01-02 Tongue 24 80 5 16.7 - - 1 3.3 - - 30 100.0
C03-06 Mouth 46 70.8 14 21.5 - - 5 7.7 - - 65 100.0
C07-08 Salivary Gland 2 50 2 50 - - - - - - 4 100.0
C09 Tonsil 1 100 - - - - - - - - 1 100.0
C10 Oth. Oropharynx 3 100 - - - - - - - - 3 100.0
C11 Nasopharynx 1 50 1 50 - - - - - - 2 100.0
C12-13 Hypopharynx 6 75 2 25 - - - - - - 8 100.0
C14 Pharynx Unspecified - - 1 100 - - - - - - 1 100.0
C15 Oesophagus 12 54.5 10 45.5 - - - - - - 22 100.0
C16 Stomach 7 41.2 8 47.1 - - 2 11.8 - - 17 100.0
C17 Small Intestine 1 100 - - - - - - - - 1 100.0
C18 Colon 11 57.9 7 36.8 - - 1 5.3 - - 19 100.0
C19-20 Rectum 22 64.7 8 23.5 1 2.9 3 8.8 - - 34 100.0
C21 Anus & Anal Canal 1 50 1 50 - - - - - - 2 100.0
C22 Liver - - 3 100 - - - - - - 3 100.0
C23-24 Gallbladder - - 3 100 - - - - - - 3 100.0
C25 Pancreas 2 28.6 4 57.1 - - 1 14.3 - - 7 100.0
C30-31 Nose,Sinuses 3 75 1 25 - - - - - - 4 100.0
C32 Larynx 1 100 - - - - - - - - 1 100.0
C33-34 Lung 12 60 7 35 - - 1 5 - - 20 100.0
C37-38 Other Thoracic Organs - - 2 100 - - - - - - 2 100.0
C40-41 Bone 6 75 2 25 - - - - - - 8 100.0
C43 Melanoma of Skin 1 50 1 50 - - - - - - 2 100.0
C44 Other Skin 8 50 7 43.8 - - 1 6.2 - - 16 100.0
C45 Mesothelioma - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
120
ICD10 Site Received Not Received Not Accepted Incomplete Unknown Total
# % # % # % # % # % # %
C47+C49 Conn. & Soft Tissue 3 60 2 40 - - - - - - 5 100.0
C50 Breast 165 78.2 34 16.1 1 0.5 11 5.2 - - 211 100.0
C51 Vulva 1 100 - - - - - - - - 1 100.0
C52 Vagina 3 100 - - - - - - - - 3 100.0
C53 Cervix Uteri 54 80.6 13 19.4 - - - - - - 67 100.0
C54 Corpus Uteri 18 85.7 3 14.3 - - - - - - 21 100.0
C55 Uterus Unspecified - - - - - - - - - - - -
C56 Ovary 22 55 11 27.5 - - 7 17.5 - - 40 100.0
C57 Other Female Genital - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - -
C64 Kidney 2 100 - - - - - - - - 2 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - -
C67 Bladder - - 3 100 - - - - - - 3 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - -
C70-72 Brain, NS - - 2 100 - - - - - - 2 100.0
C73 Thyroid 12 66.7 6 33.3 - - - - - - 18 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease 2 40 3 60 - - - - - - 5 100.0
C82-85,C96 NHL 18 69.2 6 23.1 - - 1 3.8 1 3.8 26 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - -
C90 Multiple Myeloma 5 62.5 2 25 - - 1 12.5 - - 8 100.0
C91 Lymphoid Leuk. - - - - - - 2 100 - - 2 100.0
C92-94 Myeloid Leukaemia 2 14.3 8 57.1 - - 4 28.6 - - 14 100.0
C95 Leukaemia Uns - - - - - - - - - - - -
O&U Other and Uns 5 23.8 12 57.1 - - 3 14.3 1 4.8 21 100.0
All Sites 485 66.5 196 26.9 2 0.3 44 6 2 0.3 729 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
121
Table 55: Number(#) and Proportion(%) of cancers by site (ICD-10) and Intention to Treat at Reporting Institution (Excluding the Cancers Previously Treated) – Males
ICD10 Site Radical Palliative Pain Relief Only Symptomatic Unknown Total
# % # % # % # % # % # %
C00 Lip 3 100.0 - - - - - - - - 3 100.0
C01-02 Tongue 24 70.6 10 29.4 - - - - - - 34 100.0
C03-06 Mouth 29 51.8 27 48.2 - - - - - - 56 100.0
C07-08 Salivary Gland 3 75.0 1 25.0 - - - - - - 4 100.0
C09 Tonsil 2 40.0 3 60.0 - - - - - - 5 100.0
C10 Oth. Oropharynx 12 36.4 21 63.6 - - - - - - 33 100.0
C11 Nasopharynx 1 25.0 3 75.0 - - - - - - 4 100.0
C12-13 Hypopharynx 17 63.0 10 37.0 - - - - - - 27 100.0
C14 Pharynx Unspecified - - 1 100.0 - - - - - - 1 100.0
C15 Oesophagus 15 41.7 21 58.3 - - - - - - 36 100.0
C16 Stomach 7 18.4 31 81.6 - - - - - - 38 100.0
C17 Small Intestine - - 1 100.0 - - - - - - 1 100.0
C18 Colon 5 41.7 7 58.3 - - - - - - 12 100.0
C19-20 Rectum 9 40.9 13 59.1 - - - - - - 22 100.0
C21 Anus & Anal Canal 1 100.0 - - - - - - - - 1 100.0
C22 Liver 1 16.7 5 83.3 - - - - - - 6 100.0
C23-24 Gallbladder - - - - - - - - - - - -
C25 Pancreas - - 1 100.0 - - - - - - 1 100.0
C30-31 Nose,Sinuses - - - - - - - - - - - -
C32 Larynx 16 64.0 9 36.0 - - - - - - 25 100.0
C33-34 Lung 10 7.1 127 90.1 1 0.7 3 2.1 - - 141 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - -
C40-41 Bone 3 100.0 - - - - - - - - 3 100.0
C43 Melanoma of Skin 2 66.7 1 33.3 - - - - - - 3 100.0
C44 Other Skin 11 84.6 2 15.4 - - - - - - 13 100.0
C45 Mesothelioma - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 4 80.0 1 20.0 - - - - - - 5 100.0
MCC Annual Report – HBCR 2011
122
ICD10 Site Radical Palliative Pain Relief Only Symptomatic Unknown Total
# % # % # % # % # % # %
C50 Breast 3 60.0 2 40.0 - - - - - - 5 100.0
C60 Penis 3 100.0 - - - - - - - - 3 100.0
C61 Prostate 7 50.0 7 50.0 - - - - - - 14 100.0
C62 Testis 1 100.0 - - - - - - - - 1 100.0
C63 Other Male Genital - - - - - - - - - - - -
C64 Kidney 2 100.0 - - - - - - - - 2 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - -
C67 Bladder 2 66.7 1 33.3 - - - - - - 3 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - -
C70-72 Brain, NS - - - - - - - - - - - -
C73 Thyroid 2 66.7 1 33.3 - - - - - - 3 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease 3 100.0 - - - - - - - - 3 100.0
C82-85,C96 NHL 13 65.0 7 35.0 - - - - - - 20 100.0
C88 Malig Imn.Prol D 1 100.0 - - - - - - - - 1 100.0
C90 Multiple Myeloma 1 100.0 - - - - - - - - 1 100.0
C91 Lymphoid Leuk. 1 100.0 - - - - - - - - 1 100.0
C92-94 Myeloid Leukaemia 3 75.0 1 25.0 - - - - - - 4 100.0
C95 Leukaemia Uns - - - - - - - - - - - -
O&U Other and Uns 2 9.1 20 90.9 - - - - - - 22 100.0
All Sites 219 39.3 334 60.0 1 0.2 3 0.5 - - 557 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
123
Table 56: Number(#) and Proportion(%) of cancers by site (ICD-10) and
Intention to Treat at Reporting Institution (Excluding the Cancers Previously Treated) – Females
ICD10 Site Radical Palliative Pain Relief Only Symptomatic Unknown Total
# % # % # % # % # % # %
C00 Lip 2 66.7 1 33.3 - - - - - - 3 100.0
C01-02 Tongue 18 72 7 28 - - - - - - 25 100.0
C03-06 Mouth 19 37.3 32 62.7 - - - - - - 51 100.0
C07-08 Salivary Gland 2 100 - - - - - - - - 2 100.0
C09 Tonsil - - 1 100 - - - - - - 1 100.0
C10 Oth. Oropharynx - - 3 100 - - - - - - 3 100.0
C11 Nasopharynx - - 1 100 - - - - - - 1 100.0
C12-13 Hypopharynx 2 33.3 4 66.7 - - - - - - 6 100.0
C14 Pharynx Unspecified - - - - - - - - - - - -
C15 Oesophagus 3 25 9 75 - - - - - - 12 100.0
C16 Stomach 6 66.7 3 33.3 - - - - - - 9 100.0
C17 Small Intestine 1 100 - - - - - - - - 1 100.0
C18 Colon 7 58.3 5 41.7 - - - - - - 12 100.0
C19-20 Rectum 14 56 11 44 - - - - - - 25 100.0
C21 Anus & Anal Canal 1 100 - - - - - - - - 1 100.0
C22 Liver - - - - - - - - - - - -
C23-24 Gallbladder - - - - - - - - - - - -
C25 Pancreas - - 3 100 - - - - - - 3 100.0
C30-31 Nose,Sinuses 1 33.3 2 66.7 - - - - - - 3 100.0
C32 Larynx 1 100 - - - - - - - - 1 100.0
C33-34 Lung 1 7.7 12 92.3 - - - - - - 13 100.0
C37-38 Other Thoracic Organs - - - - - - - - - - - -
C40-41 Bone 5 83.3 1 16.7 - - - - - - 6 100.0
C43 Melanoma of Skin 1 100 - - - - - - - - 1 100.0
C44 Other Skin 6 66.7 3 33.3 - - - - - - 9 100.0
C45 Mesothelioma - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
124
ICD10 Site Radical Palliative Pain Relief Only Symptomatic Unknown Total
# % # % # % # % # % # %
C47+C49 Conn. & Soft Tissue 3 100 - - - - - - - - 3 100.0
C50 Breast 131 74.4 45 25.6 - - - - - - 176 100.0
C51 Vulva 1 100 - - - - - - - - 1 100.0
C52 Vagina 3 100 - - - - - - - - 3 100.0
C53 Cervix Uteri 48 88.9 6 11.1 - - - - - - 54 100.0
C54 Corpus Uteri 17 94.4 1 5.6 - - - - - - 18 100.0
C55 Uterus Unspecified - - - - - - - - - - - -
C56 Ovary 13 44.8 16 55.2 - - - - - - 29 100.0
C57 Other Female Genital - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - -
C64 Kidney - - 2 100 - - - - - - 2 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - -
C67 Bladder - - - - - - - - - - - -
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - -
C70-72 Brain, NS - - - - - - - - - - - -
C73 Thyroid 8 66.7 4 33.3 - - - - - - 12 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease 2 100 - - - - - - - - 2 100.0
C82-85,C96 NHL 11 57.9 8 42.1 - - - - - - 19 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - -
C90 Multiple Myeloma 2 33.3 4 66.7 - - - - - - 6 100.0
C91 Lymphoid Leuk. 1 50 1 50 - - - - - - 2 100.0
C92-94 Myeloid Leukaemia 5 83.3 1 16.7 - - - - - - 6 100.0
C95 Leukaemia Uns - - - - - - - - - - - -
O&U Other and Uns - - 8 100 - - - - - - 8 100.0
All Sites 335 63.3 194 36.7 - - - - - - 529 100.0
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
125
DEMOGRAPHIC DETAILS
Table 57: Number(#) and Proportion(%) of cancers by site (ICD-10) and Marital Status – Males
ICD10 Site Unmarried Married Widowed Divorced Seperated Others Unknown Total
# % # % # % # % # % # % # % # %
C00 Lip - - 4 100.0 - - - - - - - - - - 4 100.0
C01-02 Tongue 3 4.5 62 92.5 2 3.0 - - - - - - - - 67 100.0
C03-06 Mouth 3 2.9 98 94.2 3 2.9 - - - - - - - - 104 100.0
C07-08 Salivary Gland 1 12.5 7 87.5 - - - - - - - - - - 8 100.0
C09 Tonsil - - 6 100.0 - - - - - - - - - - 6 100.0
C10 Oth. Oropharynx 3 5.8 43 82.7 6 11.5 - - - - - - - - 52 100.0
C11 Nasopharynx - - 7 100.0 - - - - - - - - - - 7 100.0
C12-13 Hypopharynx 1 2.2 43 95.6 1 2.2 - - - - - - - - 45 100.0
C14 Pharynx Unspecified - - - - 1 100.0 - - - - - - - - 1 100.0
C15 Oesophagus 1 1.6 58 95.1 2 3.3 - - - - - - - - 61 100.0
C16 Stomach 4 3.6 100 90.9 6 5.5 - - - - - - - - 110 100.0
C17 Small Intestine - - 6 100.0 - - - - - - - - - - 6 100.0
C18 Colon - - 30 93.8 2 6.2 - - - - - - - - 32 100.0
C19-20 Rectum 1 2 46 92 3 6 - - - - - - - - 50 100.0
C21 Anus & Anal Canal 1 50 1 50 - - - - - - - - - - 2 100.0
C22 Liver 2 7.1 26 92.9 - - - - - - - - - - 28 100.0
C23-24 Gallbladder - - 7 100.0 - - - - - - - - - - 7 100.0
C25 Pancreas - - 13 100.0 - - - - - - - - - - 13 100.0
C30-31 Nose,Sinuses - - 4 100.0 - - - - - - - - - - 4 100.0
C32 Larynx 3 5.5 47 85.5 5 9.1 - - - - - - - - 55 100.0
C33-34 Lung 3 1.0 301 96.5 8 2.6 - - - - - - - - 312 100.0
C37-38 Other Thoracic Organs - - 1 100.0 - - - - - - - - - - 1 100.0
C40-41 Bone 12 60 8 40 - - - - - - - - - - 20 100.0
C43 Melanoma of Skin 2 28.6 4 57.1 1 14.3 - - - - - - - - 7 100.0
C44 Other Skin 4 14.3 20 71.4 4 14.3 - - - - - - - - 28 100.0
C45 Mesothelioma - - - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 6 21.4 22 78.6 - - - - - - - - - - 28 100.0
C50 Breast - - 7 63.6 4 36.4 - - - - - - - - 11 100.0
MCC Annual Report – HBCR 2011
126
ICD10 Site Unmarried Married Widowed Divorced Seperated Others Unknown Total
# % # % # % # % # % # % # % # %
C60 Penis - - 4 80 1 20 - - - - - - - - 5 100.0
C61 Prostate 1 2.2 40 88.9 3 6.7 - - - - - - 1 2.2 45 100.0
C62 Testis 3 60 2 40 - - - - - - - - - - 5 100.0
C63 Other Male Genital - - - - - - - - - - - - - - - -
C64 Kidney 1 6.2 15 93.8 - - - - - - - - - - 16 100.0
C65 Renal Pelvis - - - - - - - - - - - - - - - -
C66 Ureter - - 1 100.0 - - - - - - - - - - 1 100.0
C67 Bladder - - 27 100.0 - - - - - - - - - - 27 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - - - -
C70-72 Brain, NS 6 35.3 10 58.8 1 5.9 - - - - - - - - 17 100.0
C73 Thyroid - - 15 100.0 - - - - - - - - - - 15 100.0
C74 Adrenal Gland - - - - - - - - - - - - - - - -
C81 Hodgkins Disease 2 18.2 9 81.8 - - - - - - - - - - 11 100.0
C82-85,C96 NHL 1 2.1 44 93.6 2 4.3 - - - - - - - - 47 100.0
C88 Malig Imn.Prol D - - 1 100.0 - - - - - - - - - - 1 100.0
C90 Multiple Myeloma - - 14 93.3 1 6.7 - - - - - - - - 15 100.0
C91 Lymphoid Leuk. 7 50 7 50 - - - - - - - - - - 14 100.0
C92-94 Myeloid Leukaemia 2 9.1 18 81.8 2 9.1 - - - - - - - - 22 100.0
C95 Leukaemia Uns - - 2 100.0 - - - - - - - - - - 2 100.0
O&U Other and Uns 3 4.8 58 92.1 2 3.2 - - - - - - - - 63 100.0
All Sites 76 5.5 1238 90.0 60 4.4 - - - - - - 1 0.1 1375 100
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
127
Table 58: Number(#) and Proportion(%) of cancers by site (ICD-10) and Marital Status – Females
ICD10 Site Unmarried Married Widowed Divorced Seperated Others Unknown Total # % # % # % # % # % # % # % # %
C00 Lip - - 1 14.3 6 85.7 - - - - - - - - 7 100.0 C01-02 Tongue 1 2.2 26 56.5 19 41.3 - - - - - - - - 46 100.0 C03-06 Mouth 5 6.0 24 28.9 52 62.7 1 1.2 - - 1 1.2 - - 83 100.0 C07-08 Salivary Gland 1 12.5 6 75 - - 1 12.5 - - - - - - 8 100.0 C09 Tonsil - - - - 1 100.0 - - - - - - - - 1 100.0 C10 Oth. Oropharynx - - 2 40 3 60 - - - - - - - - 5 100.0 C11 Nasopharynx - - 1 50 1 50 - - - - - - - - 2 100.0 C12-13 Hypopharynx 2 16.7 4 33.3 6 50 - - - - - - - - 12 100.0 C14 Pharynx Unspecified - - - - 1 100.0 - - - - - - - - 1 100.0 C15 Oesophagus - - 11 42.3 15 57.7 - - - - - - - - 26 100.0 C16 Stomach 1 3.1 16 50 15 46.9 - - - - - - - - 32 100.0 C17 Small Intestine - - 1 33.3 2 66.7 - - - - - - - - 3 100.0 C18 Colon 4 12.9 14 45.2 13 41.9 - - - - - - - - 31 100.0 C19-20 Rectum 2 4.5 24 54.5 18 40.9 - - - - - - - - 44 100.0 C21 Anus & Anal Canal - - 1 33.3 2 66.7 - - - - - - - - 3 100.0 C22 Liver - - 2 66.7 1 33.3 - - - - - - - - 3 100.0 C23-24 Gallbladder - - 5 71.4 2 28.6 - - - - - - - - 7 100.0 C25 Pancreas 1 8.3 10 83.3 1 8.3 - - - - - - - - 12 100.0 C30-31 Nose,Sinuses - - 5 83.3 1 16.7 - - - - - - - - 6 100.0 C32 Larynx - - 2 66.7 1 33.3 - - - - - - - - 3 100.0 C33-34 Lung 3 8.6 20 57.1 12 34.3 - - - - - - - - 35 100.0 C37-38 Other Thoracic Organs 1 33.3 1 33.3 1 33.3 - - - - - - - - 3 100.0 C40-41 Bone 6 46.2 5 38.5 2 15.4 - - - - - - - - 13 100.0 C43 Melanoma of Skin - - 2 66.7 1 33.3 - - - - - - - - 3 100.0 C44 Other Skin 1 4.8 11 52.4 9 42.9 - - - - - - - - 21 100.0 C45 Mesothelioma - - - - - - - - - - - - - - - - C46 Kaposi Sarcoma - - - - - - - - - - - - - - - - C47+C49 Conn. & Soft Tissue 1 5.9 11 64.7 5 29.4 - - - - - - - - 17 100.0 C50 Breast 27 7.6 248 69.7 81 22.8 - - - - - - - - 356 100.0 C51 Vulva - - - - 1 100.0 - - - - - - - - 1 100.0 C52 Vagina - - 5 83.3 1 16.7 - - - - - - - - 6 100.0 C53 Cervix Uteri 1 1.0 64 62.1 38 36.9 - - - - - - - - 103 100.0 C54 Corpus Uteri 7 14.9 29 61.7 11 23.4 - - - - - - - - 47 100.0 C55 Uterus Unspecified - - - - - - - - - - - - - - - - C56 Ovary 15 16.7 53 58.9 22 24.4 - - - - - - - - 90 100.0 C57 Other Female Genital - - - - - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
128
ICD10 Site Unmarried Married Widowed Divorced Seperated Others Unknown Total # % # % # % # % # % # % # % # %
C58 Placenta - - - - - - - - - - - - - - - - C64 Kidney 1 16.7 2 33.3 3 50 - - - - - - - - 6 100.0 C65 Renal Pelvis - - - - - - - - - - - - - - - - C66 Ureter - - - - - - - - - - - - - - - - C67 Bladder 2 33.3 1 16.7 3 50 - - - - - - - - 6 100.0 C68 Uns.Urinary Organs - - - - - - - - - - - - - - - - C69 Eye 2 100.0 - - - - - - - - - - - - 2 100.0 C70-72 Brain, NS 2 25 5 62.5 1 12.5 - - - - - - - - 8 100.0 C73 Thyroid 2 5.9 17 50 15 44.1 - - - - - - - - 34 100.0 C74 Adrenal Gland - - - - - - - - - - - - - - - - C81 Hodgkins Disease - - 4 57.1 3 42.9 - - - - - - - - 7 100.0 C82-85,C96 NHL 3 7.7 19 48.7 17 43.6 - - - - - - - - 39 100.0 C88 Malig Imn.Prol D - - - - - - - - - - - - - - - - C90 Multiple Myeloma - - 10 58.8 7 41.2 - - - - - - - - 17 100.0 C91 Lymphoid Leuk. 1 20 3 60 1 20 - - - - - - - - 5 100.0 C92-94 Myeloid Leukaemia 3 14.3 14 66.7 4 19.0 - - - - - - - - 21 100.0 C95 Leukaemia Uns - - - - - - - - - - - - - - - - O&U Other and Uns 1 4 9 36 15 60 - - - - - - - - 25 100.0
All Sites 96 8 688 57.3 413 34.4 2 0.2 - - 1 0.1 - - 1200 100
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
129
Table 59: Number(#) and Proportion(%) of cancers by site (ICD‐10) and Mother Tongue – Males
ICD10 Site Malayalam Kannada Tamil Rajasthani Oriya Others Unknown Total
# % # % # % # % # % # % # % # %
C00 Lip 4 100.0 - - - - - - - - - - - - 4 100.0
C01-02 Tongue 67 100.0 - - - - - - - - - - - - 67 100.0
C03-06 Mouth 103 99.0 - - - - 1 1.0 - - - - - - 104 100.0
C07-08 Salivary Gland 8 100.0 - - - - - - - - - - - - 8 100.0
C09 Tonsil 6 100.0 - - - - - - - - - - - - 6 100.0
C10 Oth. Oropharynx 52 100.0 - - - - - - - - - - - - 52 100.0
C11 Nasopharynx 7 100.0 - - - - - - - - - - - - 7 100.0
C12-13 Hypopharynx 42 93.3 1 2.2 1 2.2 - - - - - - 1 2.2 45 100.0
C14 Pharynx Unspecified 1 100.0 - - - - - - - - - - - - 1 100.0
C15 Oesophagus 61 100.0 - - - - - - - - - - - - 61 100.0
C16 Stomach 110 100.0 - - - - - - - - - - - - 110 100.0
C17 Small Intestine 6 100.0 - - - - - - - - - - - - 6 100.0
C18 Colon 32 100.0 - - - - - - - - - - - - 32 100.0
C19-20 Rectum 50 100.0 - - - - - - - - - - - - 50 100.0
C21 Anus & Anal Canal 2 100.0 - - - - - - - - - - - - 2 100.0
C22 Liver 28 100.0 - - - - - - - - - - - - 28 100.0
C23-24 Gallbladder 7 100.0 - - - - - - - - - - - - 7 100.0
C25 Pancreas 12 92.3 - - 1 7.7 - - - - - - - - 13 100.0
C30-31 Nose,Sinuses 4 100.0 - - - - - - - - - - - - 4 100.0
C32 Larynx 55 100.0 - - - - - - - - - - - - 55 100.0
C33-34 Lung 311 99.7 1 0.3 - - - - - - - - - - 312 100.0
C37-38 Other Thoracic Organs 1 100.0 - - - - - - - - - - - - 1 100.0
C40-41 Bone 20 100.0 - - - - - - - - - - - - 20 100.0
C43 Melanoma of Skin 7 100.0 - - - - - - - - - - - - 7 100.0
C44 Other Skin 27 96.4 - - - - - - 1 3.6 - - - - 28 100.0
C45 Mesothelioma - - - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 27 96.4 - - - - - - - - 1 3.6 - - 28 100.0
C50 Breast 11 100.0 - - - - - - - - - - - - 11 100.0
C60 Penis 5 100.0 - - - - - - - - - - - - 5 100.0
C61 Prostate 45 100.0 - - - - - - - - - - - - 45 100.0
MCC Annual Report – HBCR 2011
130
ICD10 Site Malayalam Kannada Tamil Rajasthani Oriya Others Unknown Total
# % # % # % # % # % # % # % # %
C62 Testis 5 100.0 - - - - - - - - - - - - 5 100.0
C63 Other Male Genital - - - - - - - - - - - - - - - -
C64 Kidney 16 100.0 - - - - - - - - - - - - 16 100.0
C65 Renal Pelvis - - - - - - - - - - - - - - - -
C66 Ureter 1 100.0 - - - - - - - - - - - - 1 100.0
C67 Bladder 27 100.0 - - - - - - - - - - - - 27 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - - - -
C70-72 Brain, NS 17 100.0 - - - - - - - - - - - - 17 100.0
C73 Thyroid 15 100.0 - - - - - - - - - - - - 15 100.0
C74 Adrenal Gland - - - - - - - - - - - - - - - -
C81 Hodgkins Disease 11 100.0 - - - - - - - - - - - - 11 100.0
C82-85,C96 NHL 47 100.0 - - - - - - - - - - - - 47 100.0
C88 Malig Imn.Prol D 1 100.0 - - - - - - - - - - - - 1 100.0
C90 Multiple Myeloma 15 100.0 - - - - - - - - - - - - 15 100.0
C91 Lymphoid Leuk. 14 100.0 - - - - - - - - - - - - 14 100.0
C92-94 Myeloid Leukaemia 22 100.0 - - - - - - - - - - - - 22 100.0
C95 Leukaemia Uns 2 100.0 - - - - - - - - - - - - 2 100.0
O&U Other and Uns 63 100.0 - - - - - - - - - - - - 63 100.0
All Sites 1367 99.4 2 0.1 2 0.1 1 0.1 1 0.1 1 0.1 1 0.1 1375 100
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
131
Table 60:
Number(#) and Proportion(%) of cancers by site (ICD-10) and Mother Tongue – Females
ICD10 Site Malayalam Kannada Assamese Others Unknown Total # % # % # % # % # % # %
C00 Lip 7 100.0 - - - - - - - - 7 100.0 C01-02 Tongue 46 100.0 - - - - - - - - 46 100.0 C03-06 Mouth 81 97.6 - - 1 1.2 - - 1 1.2 83 100.0 C07-08 Salivary Gland 8 100.0 - - - - - - - - 8 100.0 C09 Tonsil 1 100.0 - - - - - - - - 1 100.0 C10 Oth. Oropharynx 5 100.0 - - - - - - - - 5 100.0 C11 Nasopharynx 2 100.0 - - - - - - - - 2 100.0 C12-13 Hypopharynx 12 100.0 - - - - - - - - 12 100.0 C14 Pharynx Unspecified 1 100.0 - - - - - - - - 1 100.0 C15 Oesophagus 26 100.0 - - - - - - - - 26 100.0 C16 Stomach 32 100.0 - - - - - - - - 32 100.0 C17 Small Intestine 3 100.0 - - - - - - - - 3 100.0 C18 Colon 31 100.0 - - - - - - - - 31 100.0 C19-20 Rectum 43 97.7 1 2.3 - - - - - - 44 100.0 C21 Anus & Anal Canal 3 100.0 - - - - - - - - 3 100.0 C22 Liver 3 100.0 - - - - - - - - 3 100.0 C23-24 Gallbladder 7 100.0 - - - - - - - - 7 100.0 C25 Pancreas 12 100.0 - - - - - - - - 12 100.0 C30-31 Nose,Sinuses 6 100.0 - - - - - - - - 6 100.0 C32 Larynx 3 100.0 - - - - - - - - 3 100.0 C33-34 Lung 35 100.0 - - - - - - - - 35 100.0 C37-38 Other Thoracic Organs 3 100.0 - - - - - - - - 3 100.0 C40-41 Bone 13 100.0 - - - - - - - - 13 100.0 C43 Melanoma of Skin 3 100.0 - - - - - - - - 3 100.0 C44 Other Skin 21 100.0 - - - - - - - - 21 100.0 C45 Mesothelioma - - - - - - - - - - - - C46 Kaposi Sarcoma - - - - - - - - - - - - C47+C49 Conn. & Soft Tissue 17 100.0 - - - - - - - - 17 100.0 C50 Breast 356 100.0 - - - - - - - - 356 100.0 C51 Vulva 1 100.0 - - - - - - - - 1 100.0 C52 Vagina 6 100.0 - - - - - - - - 6 100.0 C53 Cervix Uteri 101 98.1 2 1.9 - - - - - - 103 100.0
MCC Annual Report – HBCR 2011
132
ICD10 Site Malayalam Kannada Assamese Others Unknown Total # % # % # % # % # % # %
C54 Corpus Uteri 46 97.9 1 2.1 - - - - - - 47 100.0 C55 Uterus Unspecified - - - - - - - - - - - - C56 Ovary 89 98.9 1 1.1 - - - - - - 90 100.0 C57 Other Female Genital - - - - - - - - - - - - C58 Placenta - - - - - - - - - - - - C64 Kidney 6 100.0 - - - - - - - - 6 100.0 C65 Renal Pelvis - - - - - - - - - - - - C66 Ureter - - - - - - - - - - - - C67 Bladder 6 100.0 - - - - - - - - 6 100.0 C68 Uns.Urinary Organs - - - - - - - - - - - - C69 Eye 2 100.0 - - - - - - - - 2 100.0 C70-72 Brain, NS 8 100.0 - - - - - - - - 8 100.0 C73 Thyroid 34 100.0 - - - - - - - - 34 100.0 C74 Adrenal Gland - - - - - - - - - - - - C81 Hodgkins Disease 7 100.0 - - - - - - - - 7 100.0 C82-85,C96 NHL 39 100.0 - - - - - - - - 39 100.0 C88 Malig Imn.Prol D - - - - - - - - - - - - C90 Multiple Myeloma 16 94.1 - - - - 1 5.9 - - 17 100.0 C91 Lymphoid Leuk. 5 100.0 - - - - - - - - 5 100.0 C92-94 Myeloid Leukaemia 21 100.0 - - - - - - - - 21 100.0 C95 Leukaemia Uns - - - - - - - - - - - - O&U Other and Uns 25 100.0 - - - - - - - - 25 100.0
All Sites 1192 99.3 5 0.4 1 0.1 1 0.1 1 0.1 1200 100
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
133
Table 61:
Number(#) and Proportion(%) of cancers by site (ICD-10) and Religion – Males
ICD10 Site Hindu Muslim Christian Others Unknown Total
# % # % # % # % # % # %
C00 Lip 4 100.0 - - - - - - - - 4 100.0
C01-02 Tongue 51 76.1 10 14.9 6 9.0 - - - - 67 100.0
C03-06 Mouth 71 68.3 18 17.3 15 14.4 - - - - 104 100.0
C07-08 Salivary Gland 3 37.5 4 50 - - - - 1 12.5 8 100.0
C09 Tonsil 5 83.3 1 16.7 - - - - - - 6 100.0
C10 Oth. Oropharynx 33 63.5 15 28.8 4 7.7 - - - - 52 100.0
C11 Nasopharynx 3 42.9 3 42.9 1 14.3 - - - - 7 100.0
C12-13 Hypopharynx 31 68.9 10 22.2 4 8.9 - - - - 45 100.0
C14 Pharynx Unspecified - - 1 100.0 - - - - - - 1 100.0
C15 Oesophagus 46 75.4 10 16.4 5 8.2 - - - - 61 100.0
C16 Stomach 63 57.3 38 34.5 9 8.2 - - - - 110 100.0
C17 Small Intestine 4 66.7 1 16.7 1 16.7 - - - - 6 100.0
C18 Colon 19 59.4 11 34.4 2 6.2 - - - - 32 100.0
C19-20 Rectum 34 68 12 24 4 8 - - - - 50 100.0
C21 Anus & Anal Canal 1 50 1 50 - - - - - - 2 100.0
C22 Liver 21 75 6 21.4 1 3.6 - - - - 28 100.0
C23-24 Gallbladder 4 57.1 3 42.9 - - - - - - 7 100.0
C25 Pancreas 7 53.8 3 23.1 3 23.1 - - - - 13 100.0
C30-31 Nose,Sinuses 2 50 2 50 - - - - - - 4 100.0
C32 Larynx 35 63.6 14 25.5 6 10.9 - - - - 55 100.0
C33-34 Lung 168 53.8 113 36.2 30 9.6 - - 1 0.3 312 100.0
C37-38 Other Thoracic Organs - - - - 1 100.0 - - - - 1 100.0
C40-41 Bone 12 60 7 35 1 5 - - - - 20 100.0
C43 Melanoma of Skin 6 85.7 - - 1 14.3 - - - - 7 100.0
C44 Other Skin 19 67.9 7 25 2 7.1 - - - - 28 100.0
C45 Mesothelioma - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
134
ICD10 Site Hindu Muslim Christian Others Unknown Total
# % # % # % # % # % # %
C47+C49 Conn. & Soft Tissue 15 53.6 12 42.9 1 3.6 - - - - 28 100.0
C50 Breast 7 63.6 2 18.2 2 18.2 - - - - 11 100.0
C60 Penis 3 60 - - 2 40 - - - - 5 100.0
C61 Prostate 32 71.1 9 20 4 8.9 - - - - 45 100.0
C62 Testis 2 40 3 60 - - - - - - 5 100.0
C63 Other Male Genital - - - - - - - - - - - -
C64 Kidney 6 37.5 10 62.5 - - - - - - 16 100.0
C65 Renal Pelvis - - - - - - - - - - - -
C66 Ureter 1 100.0 - - - - - - - - 1 100.0
C67 Bladder 16 59.3 8 29.6 3 11.1 - - - - 27 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - -
C70-72 Brain, NS 11 64.7 5 29.4 1 5.9 - - - - 17 100.0
C73 Thyroid 9 60 6 40 - - - - - - 15 100.0
C74 Adrenal Gland - - - - - - - - - - - -
C81 Hodgkins Disease 6 54.5 4 36.4 1 9.1 - - - - 11 100.0
C82-85,C96 NHL 32 68.1 10 21.3 5 10.6 - - - - 47 100.0
C88 Malig Imn.Prol D 1 100.0 - - - - - - - - 1 100.0
C90 Multiple Myeloma 10 66.7 4 26.7 1 6.7 - - - - 15 100.0
C91 Lymphoid Leuk. 10 71.4 4 28.6 - - - - - - 14 100.0
C92-94 Myeloid Leukaemia 9 40.9 10 45.5 3 13.6 - - - - 22 100.0
C95 Leukaemia Uns 1 50 1 50 - - - - - - 2 100.0
O&U Other and Uns 47 74.6 13 20.6 3 4.8 - - - - 63 100.0
All Sites 860 62.5 391 28.4 122 8.9 - - 2 0.1 1375 100
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
135
Table 62:
Number(#) and Proportion(%) of cancers by site (ICD-10) and Religion – Females
ICD10 Site Hindu Muslim Christian Others Unknown Total
# % # % # % # % # % # % # %
C00 Lip 4 57.1 2 28.6 1 14.3 - - - - - - 7 100.0
C01-02 Tongue 31 67.4 10 21.7 5 10.9 - - - - - - 46 100.0
C03-06 Mouth 46 55.4 32 38.6 5 6.0 - - - - - - 83 100.0
C07-08 Salivary Gland 4 50 1 12.5 3 37.5 - - - - - - 8 100.0
C09 Tonsil 1 100.0 - - - - - - - - - - 1 100.0
C10 Oth. Oropharynx 5 100.0 - - - - - - - - - - 5 100.0
C11 Nasopharynx 1 50 1 50 - - - - - - - - 2 100.0
C12-13 Hypopharynx 7 58.3 4 33.3 1 8.3 - - - - - - 12 100.0
C14 Pharynx Unspecified - - 1 100.0 - - - - - - - - 1 100.0
C15 Oesophagus 20 76.9 5 19.2 1 3.8 - - - - - - 26 100.0
C16 Stomach 22 68.8 9 28.1 1 3.1 - - - - - - 32 100.0
C17 Small Intestine 1 33.3 1 33.3 1 33.3 - - - - - - 3 100.0
C18 Colon 19 61.3 10 32.3 2 6.5 - - - - - - 31 100.0
C19-20 Rectum 25 56.8 18 40.9 1 2.3 - - - - - - 44 100.0
C21 Anus & Anal Canal 2 66.7 - - 1 33.3 - - - - - - 3 100.0
C22 Liver 2 66.7 - - 1 33.3 - - - - - - 3 100.0
C23-24 Gallbladder 5 71.4 2 28.6 - - - - - - - - 7 100.0
C25 Pancreas 6 50 5 41.7 1 8.3 - - - - - - 12 100.0
C30-31 Nose,Sinuses 5 83.3 - - 1 16.7 - - - - - - 6 100.0
C32 Larynx 1 33.3 2 66.7 - - - - - - - - 3 100.0
C33-34 Lung 25 71.4 8 22.9 2 5.7 - - - - - - 35 100.0
C37-38 Other Thoracic Organs 2 66.7 1 33.3 - - - - - - - - 3 100.0
C40-41 Bone 5 38.5 5 38.5 3 23.1 - - - - - - 13 100.0
C43 Melanoma of Skin 2 66.7 1 33.3 - - - - - - - - 3 100.0
C44 Other Skin 9 42.9 10 47.6 2 9.5 - - - - - - 21 100.0
C45 Mesothelioma - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
136
ICD10 Site Hindu Muslim Christian Others Unknown Total
# % # % # % # % # % # % # %
C47+C49 Conn. & Soft Tissue 8 47.1 7 41.2 2 11.8 - - - - - - 17 100.0
C50 Breast 238 66.9 80 22.5 38 10.7 - - - - - - 356 100.0
C51 Vulva 1 100.0 - - - - - - - - - - 1 100.0
C52 Vagina 6 100.0 - - - - - - - - - - 6 100.0
C53 Cervix Uteri 76 73.8 20 19.4 7 6.8 - - - - - - 103 100.0
C54 Corpus Uteri 38 80.9 5 10.6 4 8.5 - - - - - - 47 100.0
C55 Uterus Unspecified - - - - - - - - - - - - - -
C56 Ovary 57 63.3 24 26.7 9 10 - - - - - - 90 100.0
C57 Other Female Genital - - - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - - - -
C64 Kidney 1 16.7 3 50 2 33.3 - - - - - - 6 100.0
C65 Renal Pelvis - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - -
C67 Bladder 5 83.3 1 16.7 - - - - - - - - 6 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - -
C69 Eye 2 100.0 - - - - - - - - - - 2 100.0
C70-72 Brain, NS 3 37.5 3 37.5 2 25 - - - - - - 8 100.0
C73 Thyroid 20 58.8 11 32.4 3 8.8 - - - - - - 34 100.0
C74 Adrenal Gland - - - - - - - - - - - - - -
C81 Hodgkins Disease 2 28.6 2 28.6 3 42.9 - - - - - - 7 100.0
C82-85,C96 NHL 25 64.1 10 25.6 4 10.3 - - - - - - 39 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - -
C90 Multiple Myeloma 8 47.1 5 29.4 3 17.6 1 5.9 - - - - 17 100.0
C91 Lymphoid Leuk. 4 80 1 20 - - - - - - - - 5 100.0
C92-94 Myeloid Leukaemia 15 71.4 3 14.3 3 14.3 - - - - - - 21 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - -
O&U Other and Uns 14 56 10 40 1 4 - - - - - - 25 100.0
All Sites 773 64.4 313 26.1 113 9.4 1 0.1 - - - - 1200 100
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
137
Table 63:
Number(#) and Proportion(%) of cancers by site (ICD-10) and Education – Males
ICD10 Site Primary Secondary Illiterate Literate College Others Unknown Total
# % # % # % # % # % # % # % # %
C00 Lip 2 50 1 25 1 25 - - - - - - - - 4 100.0
C01-02 Tongue 33 49.3 22 32.8 3 4.5 3 4.5 4 6.0 2 3.0 - - 67 100.0
C03-06 Mouth 51 49.0 18 17.3 12 11.5 10 9.6 6 5.8 5 4.8 2 1.9 104 100.0
C07-08 Salivary Gland 2 25 3 37.5 - - - - 2 25 1 12.5 - - 8 100.0
C09 Tonsil 3 50 2 33.3 - - - - - - 1 16.7 - - 6 100.0
C10 Oth. Oropharynx 32 61.5 9 17.3 4 7.7 7 13.5 - - - - - - 52 100.0
C11 Nasopharynx 5 71.4 1 14.3 - - - - - - - - 1 14.3 7 100.0
C12-13 Hypopharynx 26 57.8 7 15.6 7 15.6 3 6.7 1 2.2 1 2.2 - - 45 100.0
C14 Pharynx Unspecified 1 100.0 - - - - - - - - - - - - 1 100.0
C15 Oesophagus 31 50.8 13 21.3 7 11.5 4 6.6 4 6.6 2 3.3 - - 61 100.0
C16 Stomach 53 48.2 37 33.6 9 8.2 6 5.5 2 1.8 3 2.7 - - 110 100.0
C17 Small Intestine 1 16.7 3 50 - - - - 2 33.3 - - - - 6 100.0
C18 Colon 16 50 10 31.2 - - 1 3.1 3 9.4 1 3.1 1 3.1 32 100.0
C19-20 Rectum 17 34 17 34 7 14 - - 5 10 4 8 - - 50 100.0
C21 Anus & Anal Canal - - 2 100.0 - - - - - - - - - - 2 100.0
C22 Liver 12 42.9 12 42.9 - - 1 3.6 2 7.1 1 3.6 - - 28 100.0
C23-24 Gallbladder 6 85.7 - - - - 1 14.3 - - - - - - 7 100.0
C25 Pancreas 3 23.1 6 46.2 - - 1 7.7 3 23.1 - - - - 13 100.0
C30-31 Nose,Sinuses 3 75 1 25 - - - - - - - - - - 4 100.0
C32 Larynx 33 60 9 16.4 2 3.6 5 9.1 3 5.5 3 5.5 - - 55 100.0
C33-34 Lung 182 58.3 58 18.6 30 9.6 24 7.7 9 2.9 8 2.6 1 0.3 312 100.0
C37-38 Other Thoracic Organs - - - - - - - - 1 100.0 - - - - 1 100.0
C40-41 Bone - - 14 70 - - - - 2 10 4 20 - - 20 100.0
C43 Melanoma of Skin 3 42.9 2 28.6 1 14.3 - - - - 1 14.3 - - 7 100.0
C44 Other Skin 13 46.4 4 14.3 3 10.7 2 7.1 5 17.9 1 3.6 - - 28 100.0
C45 Mesothelioma - - - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - -
MCC Annual Report – HBCR 2011
138
ICD10 Site Primary Secondary Illiterate Literate College Others Unknown Total
# % # % # % # % # % # % # % # %
C47+C49 Conn. & Soft Tissue 12 42.9 9 32.1 - - 2 7.1 4 14.3 1 3.6 - - 28 100.0
C50 Breast 3 27.3 2 18.2 2 18.2 2 18.2 2 18.2 - - - - 11 100.0
C60 Penis 2 40 2 40 1 20 - - - - - - - - 5 100.0
C61 Prostate 13 28.9 15 33.3 6 13.3 1 2.2 5 11.1 4 8.9 1 2.2 45 100.0
C62 Testis - - 3 60 - - 1 20 1 20 - - - - 5 100.0
C63 Other Male Genital - - - - - - - - - - - - - - - -
C64 Kidney 7 43.8 4 25 1 6.2 1 6.2 2 12.5 1 6.2 - - 16 100.0
C65 Renal Pelvis - - - - - - - - - - - - - - - -
C66 Ureter - - - - - - 1 100.0 - - - - - - 1 100.0
C67 Bladder 14 51.9 5 18.5 2 7.4 4 14.8 - - 2 7.4 - - 27 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - -
C69 Eye - - - - - - - - - - - - - - - -
C70-72 Brain, NS 6 35.3 5 29.4 1 5.9 1 5.9 3 17.6 1 5.9 - - 17 100.0
C73 Thyroid 6 40 5 33.3 - - 2 13.3 - - 2 13.3 - - 15 100.0
C74 Adrenal Gland - - - - - - - - - - - - - - - -
C81 Hodgkins Disease 5 45.5 1 9.1 1 9.1 1 9.1 2 18.2 1 9.1 - - 11 100.0
C82-85,C96 NHL 20 42.6 16 34.0 2 4.3 2 4.3 4 8.5 3 6.4 - - 47 100.0
C88 Malig Imn.Prol D 1 100.0 - - - - - - - - - - - - 1 100.0
C90 Multiple Myeloma 6 40 5 33.3 1 6.7 2 13.3 - - 1 6.7 - - 15 100.0
C91 Lymphoid Leuk. 6 42.9 5 35.7 - - - - 2 14.3 1 7.1 - - 14 100.0
C92-94 Myeloid Leukaemia 9 40.9 7 31.8 2 9.1 - - 3 13.6 1 4.5 - - 22 100.0
C95 Leukaemia Uns 1 50 - - 1 50 - - - - - - - - 2 100.0
O&U Other and Uns 30 47.6 19 30.2 4 6.3 5 7.9 2 3.2 1 1.6 2 3.2 63 100.0
All Sites 669 48.7 354 25.7 110 8 93 6.8 84 6.1 57 4.1 8 0.6 1375 100
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
139
Table 64:
Number(#) and Proportion(%) of cancers by site (ICD-10) and Education – Females
ICD10 Site Primary Secondary Illiterate College Literate Others Unknown Total
# % # % # % # % # % # % # % # %
C00 Lip 4 57.1 1 14.3 2 28.6 - - - - - - - - 7 100.0
C01-02 Tongue 20 43.5 7 15.2 15 32.6 1 2.2 2 4.3 1 2.2 - - 46 100.0
C03-06 Mouth 30 36.1 4 4.8 45 54.2 - - 3 3.6 - - 1 1.2 83 100.0
C07-08 Salivary Gland 2 25 1 12.5 2 25 2 25 1 12.5 - - - - 8 100.0
C09 Tonsil - - - - 1 100.0 - - - - - - - - 1 100.0
C10 Oth. Oropharynx 2 40 - - 2 40 - - 1 20 - - - - 5 100.0
C11 Nasopharynx 1 50 - - 1 50 - - - - - - - - 2 100.0
C12-13 Hypopharynx 8 66.7 1 8.3 1 8.3 - - 2 16.7 - - - - 12 100.0
C14 Pharynx Unspecified 1 100.0 - - - - - - - - - - - - 1 100.0
C15 Oesophagus 12 46.2 2 7.7 10 38.5 - - 2 7.7 - - - - 26 100.0
C16 Stomach 13 40.6 5 15.6 12 37.5 2 6.2 - - - - - - 32 100.0
C17 Small Intestine 2 66.7 - - 1 33.3 - - - - - - - - 3 100.0
C18 Colon 17 54.8 9 29.0 3 9.7 1 3.2 1 3.2 - - - - 31 100.0
C19-20 Rectum 13 29.5 9 20.5 10 22.7 5 11.4 6 13.6 1 2.3 - - 44 100.0
C21 Anus & Anal Canal - - 1 33.3 1 33.3 - - 1 33.3 - - - - 3 100.0
C22 Liver 1 33.3 2 66.7 - - - - - - - - - - 3 100.0
C23-24 Gallbladder 2 28.6 3 42.9 1 14.3 - - - - - - 1 14.3 7 100.0
C25 Pancreas 5 41.7 3 25 2 16.7 2 16.7 - - - - - - 12 100.0
C30-31 Nose,Sinuses 4 66.7 1 16.7 1 16.7 - - - - - - - - 6 100.0
C32 Larynx 2 66.7 1 33.3 - - - - - - - - - - 3 100.0
C33-34 Lung 14 40 11 31.4 7 20 1 2.9 1 2.9 1 2.9 - - 35 100.0
C37-38 Other Thoracic Organs 1 33.3 - - 1 33.3 1 33.3 - - - - - - 3 100.0
C40-41 Bone 2 15.4 8 61.5 1 7.7 2 15.4 - - - - - - 13 100.0
C43 Melanoma of Skin 2 66.7 - - - - - - 1 33.3 - - - - 3 100.0
C44 Other Skin 8 38.1 5 23.8 3 14.3 - - 2 9.5 3 14.3 - - 21 100.0
C45 Mesothelioma - - - - - - - - - - - - - - - -
C46 Kaposi Sarcoma - - - - - - - - - - - - - - - -
C47+C49 Conn. & Soft Tissue 8 47.1 4 23.5 1 5.9 2 11.8 2 11.8 - - - - 17 100.0
MCC Annual Report – HBCR 2011
140
ICD10 Site Primary Secondary Illiterate College Literate Others Unknown Total
# % # % # % # % # % # % # % # %
C50 Breast 135 37.9 111 31.2 26 7.3 50 14.0 8 2.2 23 6.5 3 0.8 356 100.0
C51 Vulva - - 1 100.0 - - - - - - - - - - 1 100.0
C52 Vagina 3 50 3 50 - - - - - - - - - - 6 100.0
C53 Cervix Uteri 50 48.5 16 15.5 20 19.4 6 5.8 4 3.9 6 5.8 1 1.0 103 100.0
C54 Corpus Uteri 19 40.4 17 36.2 3 6.4 3 6.4 2 4.3 3 6.4 - - 47 100.0
C55 Uterus Unspecified - - - - - - - - - - - - - - - -
C56 Ovary 38 42.2 23 25.6 11 12.2 8 8.9 4 4.4 6 6.7 - - 90 100.0
C57 Other Female Genital - - - - - - - - - - - - - - - -
C58 Placenta - - - - - - - - - - - - - - - -
C64 Kidney 3 50 1 16.7 1 16.7 1 16.7 - - - - - - 6 100.0
C65 Renal Pelvis - - - - - - - - - - - - - - - -
C66 Ureter - - - - - - - - - - - - - - - -
C67 Bladder 4 66.7 2 33.3 - - - - - - - - - - 6 100.0
C68 Uns.Urinary Organs - - - - - - - - - - - - - - - -
C69 Eye - - 1 50 - - - - - - 1 50 - - 2 100.0
C70-72 Brain, NS 2 25 5 62.5 - - - - 1 12.5 - - - - 8 100.0
C73 Thyroid 15 44.1 9 26.5 3 8.8 4 11.8 2 5.9 1 2.9 - - 34 100.0
C74 Adrenal Gland - - - - - - - - - - - - - - - -
C81 Hodgkins Disease 4 57.1 1 14.3 1 14.3 1 14.3 - - - - - - 7 100.0
C82-85,C96 NHL 12 30.8 12 30.8 8 20.5 2 5.1 2 5.1 3 7.7 - - 39 100.0
C88 Malig Imn.Prol D - - - - - - - - - - - - - - - -
C90 Multiple Myeloma 8 47.1 3 17.6 4 23.5 1 5.9 - - 1 5.9 - - 17 100.0
C91 Lymphoid Leuk. 1 20 2 40 1 20 - - 1 20 - - - - 5 100.0
C92-94 Myeloid Leukaemia 8 38.1 9 42.9 1 4.8 1 4.8 1 4.8 1 4.8 - - 21 100.0
C95 Leukaemia Uns - - - - - - - - - - - - - - - -
O&U Other and Uns 16 64 3 12 4 16 - - 1 4 - - 1 4 25 100.0
All Sites 492 41 297 24.8 206 17.2 96 8 51 4.2 51 4.2 7 0.6 1200 100
O & U : C26, C39, C48, C75, C76, C77, C78, C79, C80, C97
MCC Annual Report – HBCR 2011
141
MCC Annual Report – HBCR 2011
142
Descriptive Statistics ‐ MCC (Demographic,Diagnostic And Clinical Details)
MCC Annual Report – HBCR 2011
143
MCC Annual Report – HBCR 2011
144
Number of New and Old Cancer Cases
Out of 2575 cases registered, new cases in males was 898 ( 65.3% ) and in females was 731 (60.7%). In males, 477 (34.7%) and in females 469 (39.3%) were old cases.
Table 65:
Sex New Old
Total Frequency Percentage Frequency Percentage
Male 898 65.3 477 34.7 1375
Female 731 60.7 469 39.3 1200
Total 1629 946 2575
MCC Annual Report – HBCR 2011
145
TEN LEADING CANCERS – SYSTEM WISE Rank, Number(#), and Relative Proportion (%) of 10 leading cancer-system wise
Table 66:
Rank System # %
1 HEAD & NECK 528 20.50
2 DIGESTIVE SYSTEM 488 18.95
3 BREAST 367 14.25
4 RESPIRATORY SYSTEM 355 13.79
5 GYNAECOLOGICAL 251 9.75
6 PRIMARY UNKNOWN 77 2.99
7 LYMPHATIC 71 2.76
8 MALE GENITAL ORGAN 59 2.29
9 HAEMATOLOGY 57 2.21
10 UROLOGICAL 56 2.17
Total 2309 89.67
All Systems 2575 100.0
MCC Annual Report – HBCR 2011
146
Table 67: Number(#) and Proportion(%) of System Wise & Sex Wise Cancer
Incidence
Sl. No. Site Sex
Total Male % Female %
1 HEAD & NECK 355 67.23 173 32.77 528
2 DIGESTIVE SYSTEM 322 65.98 166 34.02 488
3 BREAST 11 2.99 356 97 367
4 RESPIRATORY SYSTEM 314 88.45 41 11.55 355
5 GYNAECOLOGICAL 0 0 251 100 251
6 PRIMARY UNKNOWN 50 64.94 22 35.06 77
7 LYMPHATIC 40 56.34 31 43.66 71
8 MALE GENITAL ORGAN 59 100 0 0 59
9 HAEMATOLOGY 34 59.65 23 40.35 57
10 UROLOGICAL 44 78.57 12 21.43 56
11 SKIN 33 61.11 21 38.89 54
12 ENDOCRINE GLANDS 15 29.41 36 70.59 51
13 SKELETAL(Bone Marrow) 18 43.90 23 56.09 41
14 SOFT TISSUE TUMOUR 22 57.89 16 42.11 38
15 SKELETAL 23 65.71 12 34.29 35
16 CNS 15 71.43 6 28.57 21
17 OPHTHALMIC 4 50 4 50 8
18 PNS/ANS 6 75 2 25 8
19 BRAIN 3 60 2 40 5
20 INTRATHORACIC 2 40 3 60 5
Total 1375 1200 2575
MCC Annual Report – HBCR 2011
147
MCC Annual Report – HBCR 2011
148
Habits [ Smoking, Alcohol & Panchewing]
Table 68: Number(#) and Relative Proportion (%) of System Wise & Smoking Habit
Abbreviations S - Smokers S/C/B - Chronic Beedi Smokers S/Occ - Occasionally smokers S/B - Beedi Smokers S/C/Ex - Ex Chronic –Smokers S/P - Passive smokers S/C - Chronic Smokers S/Ex - Ex Smokers
Rank Tumours # Smoking
NIL % S % S/B % S/C % S/CB % S/C/Ex % S/Ex % S/Occ % S/P %
1 HEAD & NECK 528 292 55.30 124 23.50 3 0.57 53 10.04 0 0 5 0.009 49 9.28 1 0.19 0 0
2 DIGESTIVE SYSTEM 488 316 64.75 100 20.49 1 0.20 29 5.94 1 0.20 3 0.61 37 7.58 1 0.20 0 0
3 BREAST 367 364 99.18 3 0.82 0 0 0 0 0 0 0 0 0 0 0 0 0 0
4 RESPIRATORY SYSTEM 355 163 45.92 103 29.01 3 0.85 37 10.42 1 0.28 2 0.56 44 12.39 1 0.28 1 0.28
5 GYNAECOLOGICAL 251 251 100.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
6 PRIMARY UNKNOWN 77 47 61.03 21 27.27 0 0 4 5.19 0 0 0 0 5 6.49 0 0 0 0
7 LYMPHATIC 71 51 71.83 10 14.08 0 0 5 7.04 0 0 1 1.40 4 5.63 0 0 0 0
8 MALE GENITAL ORGAN 59 41 69.49 12 20.34 0 0 2 3.39 0 0 0 0 4 6.78 0 0 0 0
9 HAEMATOLOGY 57 41 71.93 7 12.28 0 0 4 7.02 0 0 1 1.75 3 5.26 1 1.75 0 0
10 UROLOGICAL 56 28 50.00 17 30.36 0 0 5 8.93 0 0 0 0 6 10.71 0 0 0 0
11 SKIN 54 40 74.07 8 14.81 0 0 2 3.70 0 0 0 0 4 7.41 0 0 0 0
12 ENDOCRINE GLANDS 51 35 68.63 8 15.69 0 0 1 1.96 0 0 0 0 7 13.73 0 0 0 0
13 SKELETAL(Bone Marrow) 41 32 78.05 5 12.19 0 0 3 7.32 0 0 0 0 1 2.44 0 0 0 0
14 SOFT TISSUE TUMOUR 38 33 86.84 1 2.63 0 2 5.26 0 0 0 0 2 5.26 0 0 0
15 SKELETAL 35 28 80.00 7 20.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0
16 CNS 21 17 80.95 2 9.52 0 0 2 9.52 0 0 0 0 0 0 0 0 0 0
17 OPHTHALMIC 8 5 62.5 3 37.50 0 0 0 0 0 0 0 0 0 0 0 0 0 0
18 PNS/ANS 8 7 87.5 1 12.50 0 0 0 0 0 0 0 0 0 0 0 0 0 0
19 BRAIN 5 4 80.00 1 20.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0
20 INTRATHORACIC 5 4 80.00 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
TOTAL 2575 1708 66.33 471 18.29 8 0.31 178 6.91 2 0.08 13 0.50 190 7.38 4 0.16 1 0.04
MCC Annual Report – HBCR 2011
149
Table 69: Number(#) and Proportion(%) of System Wise & Alcohol Habit
Abbreviations A _ Alcoholics A-C _ Chronic Alcoholics A-Ex _ Ex Alcoholics A-C-Ex _ Ex- Chronic Alcoholics A-Occ _ Occasionally
Rank Tumours Frequency Alcoholic
NIL % A % A-C % A-C-Ex % A-Ex % A-Occ %
1 HEAD & NECK 528 381 72.16 91 17.23 32 6.06 0 0 16 3.03 8 1.52 2 DIGESTIVE SYSTEM 488 392 80.33 67 13.73 15 3.07 2 0.41 6 1.23 6 1.23 3 BREAST 367 367 100.00 0 0 0 0 0 0 0 0 0 0 4 RESPIRATORY SYSTEM 355 268 75.49 64 18.03 12 3.38 0 0 5 1.41 6 1.69 5 GYNAECOLOGICAL 251 251 100.00 0 0 0 0 0 0 0 0 0 0 6 PRIMARY UNKNOWN 77 58 75.32 17 22.08 1 1.29 0 0 1 1.29 0 0
7 LYMPHATIC 71 57 80.28 7 9.86 3 4.23 1 1.41 1 1.41 2 2.82 8 MALE GENITAL ORGAN 59 47 79.66 9 15.25 1 1.69 0 0 1 1.69 1 1.69 9 HAEMATOLOGY 57 49 85.96 6 10.53 2 3.51 0 0 0 0 0 0 10 UROLOGICAL 56 44 78.57 9 16.07 2 3.57 0 0 1 1.79 0 0 11 SKIN 54 49 90.74 3 5.56 0 0 0 0 0 0 2 12 ENDOCRINE GLANDS 51 44 86.27 6 11.76 0 0 0 1 0 0 13 SKELETAL(Bone Marrow) 41 36 87.80 3 7.32 2 4.88 0 0 0 0 0 0 14 SOFT TISSUE TUMOUR 38 34 89.47 2 5.26 1 2.63 0 0 1 2.63 0 0 15 SKELETAL 35 32 91.43 3 8.57 0 0 0 0 0 0 0 0 16 CNS 21 18 85.71 1 4.76 2 9.52 0 0 0 0 0 0 17 OPHTHALMIC 8 7 87.50 1 12.50 0 0 0 0 0 0 0 0 18 PNS/ANS 8 7 87.50 1 12.50 0 0 0 0 0 0 0 0 19 BRAIN 5 4 80.00 1 20.00 0 0 0 0 0 0 0 0 20 INTRATHORACIC 5 4 80.00 1 20.00 0 0 0 0 0 0 0 0 TOTAL 2575 2149 83.46 292 11.34 73 2.83 3 0.12 33 1.28 25 0.97
MCC Annual Report – HBCR 2011
150
Table 70: Number(#) and Proportion(%) of System Wise & Panchewing Habit
Abbreviations P - Pan chewing Habit P-C - Chronic Panchewing P-Ex - Ex - Panchewing Habit P-C-Ex - Ex – Chronic Panchewing P- Occ - Occasionally Panchewing habit P-H - Hans chewing
Rank Tumours FrequencyPanchewing
NIL % P % P-C % P-Ex % P-C-
Ex % P-H % P-Occ %
1 HEAD & NECK 528 382 72.35 76 14.39 54 10.23 11 2.08 2 37.88 1 0.19 2 37.88 2 DIGESTIVE SYSTEM 488 434 88.93 36 7.38 11 2.25 4 0.82 0 0 1 0.20 2 0.41 3 BREAST 367 343 93.46 13 3.54 9 2.45 2 0.54 0 0 0 0 0 0 4 RESPIRATORY SYSTEM 355 304 85.63 44 12.39 6 1.69 1 0.28 0 0 0 0 0 0 5 GYNAECOLOGICAL 251 225 89.64 17 6.78 8 3.19 1 39.8 0 0 0 0 0 0 6 PRIMARY UNKNOWN 77 67 87.01 8 10.39 2 2.59 0 0 0 0 0 0 0 0 7 LYMPHATIC 71 62 87.32 5 7.04 2 2.82 1 1.41 0 0 0 0 1 1.41 8 MALE GENITAL ORGAN 59 51 86.44 8 13.56 0 0 0 0 0 0 0 0 0 0 9 HAEMATOLOGY 57 50 87.72 6 10.53 1 1.75 0 0 0 0 0 0 0 0 10 UROLOGICAL 56 50 89.29 3 5.36 1 1.79 1 1.79 0 0 0 0 1 1.79 11 SKIN 54 45 83.33 8 14.81 0 0 1 1.85 0 0 0 0 0 0 12 ENDOCRINE GLANDS 51 49 96.08 2 3.92 0 0 0 0 0 0 0 0 0 0 13 SKELETAL(Bone Marrow) 41 37 90.24 4 9.76 0 0 0 0 0 0 0 0 0 0 14 SOFT TISSUE TUMOUR 38 32 84.21 3 7.89 3 7.89 0 0 0 0 0 0 0 0 15 SKELETAL 35 31 88.57 2 5.71 2 5.71 0 0 0 0 0 0 0 0 16 CNS 21 18 85.71 1 4.76 2 9.52 0 0 0 0 0 0 0 0 17 OPHTHALMIC 8 6 75 2 25 0 0 0 0 0 0 0 0 0 0 18 PNS/ANS 8 7 87.5 1 12.5 0 0 0 0 0 0 0 0 0 0 19 BRAIN 5 5 100 0 0 0 0 0 0 0 0 0 0 0 0 20 INTRATHORACIC 5 4 80 0 0 1 20 0 0 0 0 0 0 0 0 TOTAL 2575 2202 85.51 239 9.28 102 3.96 22 0.85 2 0.08 2 0.08 6 0.23
MCC Annual Report – HBCR 2011
151
Family History/Hereditary Cancers Table 71: Number(#) and Proportion(%) of System Wise & Family History
Table 72: Number(#) and Proportion(%) of Family History with Hereditary Cancers
Site of Tumour Family History
Total Present % Absent %
Skeletal 4 11.43 31 88.57 35 Brain 2 40.00 3 60.00 5 Breast 101 27.52 266 72.48 367 CNS 5 23.81 16 76.19 21 Endocrine Glands 11 21.57 40 78.43 51 Eye 1 12.50 7 87.50 8 Female Genital 46 18.33 205 81.67 251 GIT 110 22.54 378 77.46 488 Head & Neck 84 15.91 446 84.47 528 Intrathoracic 2 40.00 3 60.00 5 Haematology 6 10.53 51 89.47 57 Lymphatic 9 12.68 62 87.32 71 Male Genital Organ 9 15.25 50 84.75 59 Skeletal(Bone marrow) 6 14.63 35 85.37 41 Peripheral Nerves 0 0.00 8 100.00 8 Primary Unknown 16 20.78 61 79.22 77 Respiratory System 64 18.03 291 81.97 355 Skin 8 14.81 46 85.19 54 Soft Tissue Tumour 6 15.79 32 84.21 38 Urinary System 7 12.50 49 87.50 56
Total 497 19.30 2078 80.69 2575
SITE Family history Total
NO % YES %
BREAST 266 72.48 101 27.52 367
COLON 44 68.75 20 31.25 64
OVARY 72 80 18 20 90
PROSTATE 38 84.4 7 15.56 45
Total 420 146 566
MCC Annual Report – HBCR 2011
152
Table 73: Relative/Next of Kin(including parent) Accompanying Person
Accompanying Person
Female(N=1200) Male(N=1375) Total (N=2575) # % # %
Father 8 0.66 4 0.29 12 Mother 3 0.25 3 0.22 6 Husband 24 1.98 0 24 Wife 10 0.73 10 Son 93 7.68 113 8.25 206 Daughter 63 5.20 29 2.12 92 Other Relative/Friend/Neighbour
975 81.17 1154 84.3
2129 Others(including accompany person)
29 2.39 40 2.9269
Unknown 5 0.66 22 1.17 27
STAGING
Table 74 : TNM(Tumour, Node, Metastasis) Staging
T‐Tumour Female(N=567) Male(N=487)
Total(N=1054) # % # %
T0 111 19.58 160 32.85 271
T1 54 9.52 45 9.24 99
T 1a 0 0 3 0.62 3
T1b 0 0 5 1.03 5
T1c 2 0.35 2 0.41 4
T2 179 31.57 83 17.04 262
T 2a 0 0 1 0.21 1
T 2c 0 0 1 0.21 1
T3 94 16.58 81 16.63 175
T4 53 9.35 56 11.5 109
T 4a 18 3.17 40 8.21 58
T 4b 45 7.94 2 0.41 47
T 4c 2 0.35 0 2
T x 9 1.59 8 1.64 17
MCC Annual Report – HBCR 2011
153
Table75 : N-Nodes
N‐Nodes Female(N=567) Male(N=487) Total
(N=1054) # % # % N0 268 47.27 292 59.96 560 N1 150 26.46 74 15.20 224 N 1a 1 0.18 0 1 N1b 0 1 0.21 1 N2 54 9.52 15 3.08 69 N 2a 7 1.23 4 0.82 11 N2b 21 3.70 44 9.03 65 N2c 14 2.47 32 6.57 46 N3 40 7.05 12 2.46 52 N 3a 5 0.88 0 5 N3b 0 1 0.21 1 N x 7 1.23 12 2.46 19
Table 76: M-Metastasis
M‐Metastasis Female(N=567) Male(N=487) Total
(N=1054) # % # %
M0 400 70.55 374 76.80 774 M1 77 13.58 36 7.39 113
Mx 90 15.87 77 15.81 167
Table 77: Composite Stage TNM(C50) – Breast Cancer
Stage Female(N=359) Male(N=11) Total
(N=370) # % # %
1 18 5.50 0 0 18
2 56 17.13 3 0.92 59
2A 14 4.28 0 0 14
2B 45 13.76 1 0.31 46
3 13 3.98 0 0 13
3A 59 18.04 2 0.61 61
3B 35 10.70 1 0.31 36
4 87 26.61 1 0.31 88
Unknown 32 9.79 3 0.92 35
MCC Annual Report – HBCR 2011
154
Table 78: Composite Stage TNM(C00-13)Oral Cancer-Lip and Oral Cavity
Stage Female(N=166) Male(N=296) Total
(N=462) # % # % 1 16 9.64 24 8.11 40 1A 1 0.6 1 0.34 2 2 16 9.64 28 9.46 44 2A 1 0.6 0 0 1 2B 1 0.6 0 0 1 2C 0 0 1 0.34 1 3 59 35.54 82 27.7 141 4 38 22.89 98 33.11 136 4A 1 0.6 2 0.68 3 4B 1 0.6 3 1.01 4 Unknown 32 19.28 57 19.26 89
Table 79: Composite Stage TNM(C30-32) (Nasal cavity & middle ear, accessory sinus and larynx)
Stage Female(N=13) Male(N=60)
Total # % # %
1 1 7.69 8 13.33 9 1A 1 7.69 0 0 1 2 2 15.38 4 6.67 6 2B 1 7.69 1 1.67 2 3 0 0 28 46.67 28 4 2 15.38 11 18.33 13 Unknown 6 46.15 8 13.33 14
Table 80: Composite Stage TNM(C43-44) Skin Cancer
Stage Female(N=25) Male(N=37) Total
(N=60) # % # % 1 7 28 13 35.14 20 1A 0 0 1 2.7 1 1B 1 4 0 0 1 2 3 12 6 16.22 9 3 5 20 2 5.41 7 4 1 4 0 0 1 Unknown 8 32 15 40.54 23
MCC Annual Report – HBCR 2011
155
Table 81: Composite Stage TNM(C60-68) Male Genital Organs
Stage Male(N=103) Total (N=115)
# % 1 7 6.8 71A 3 2.91 32 8 7.77 82C 1 0.97 13 1 0.97 13B 0 14 44 42.72 50Unknown 39 37.86 44
Table 82: Composite Stage FIGO(C51-57) Female Genital Organs
Stage Female(N=250)
# % 1 3 1.2 1A 7 2.8 1B 20 8 1C 12 4.82 7 2.8 2A 9 3.6 2B 33 13.23 5 2 3A 6 2.4 3B 35 14 3C 15 6.04 43 17.2 4A 7 2.8 4B 2 0.8
Unknown 46 18.4
MCC Annual Report – HBCR 2011
156
Table 83: Composite Stage ANN ARBOUR-Non Hodgkins Lymphoma
Stage Female(N=27) Male(N=31) Total
(N=58) # % # % 1A 2 7.41 3 9.68 5
1B 1 3.7 1 3.23 2
2 1 3.7 1 3.23 2
2A 0 0 1 3.23 1
2B 1 3.7 1 3.23 2
3 0 0 3 9.68 3
3A 0 0 1 3.23 1
3B 10 37.04 5 16.13 15
4 1 3.7 5 16.13 6
4A 1 3.7 1 3.23 2
4B 4 14.81 1 3.23 5
Unknown 6 22.22 8 25.81 14
Table 84: Composite Stage ANN ARBOUR - Hodgkins Lymphoma
Stage Female(N=7) Male(N=11) Total
(N=18) # % # % 1A 1 14.29 1 9.09 2
2A 1 14.29 2 18.18 3
2C 0 0 1 9.09 1
3B 4 57.14 2 18.18 6
4 0 0 2 18.18 2
4B 1 14.29 1 9.09 2
Unknown 0 0 2 18.18 2
Table 85: Composite Stage Clinical Extent Digestive Organs(C15-C25)
Stage code
Female(N=159) Male(N=310) # % # %
1 14 8.81 27 8.71
2 36 22.64 68 21.94
3 94 59.12 193 62.26
4 0 0 3 0.97
8 15 9.43 19 6.31
MCC Annual Report – HBCR 2011
157
Table 86: Composite Stage Clinical Extent - Bronchus and Lung(C34)
Stage code
Female(N=35) Male(N=310) # % # %
1 1 2.86 14 4.522 7 20 57 18.393 26 74.29 230 74.194 1 2.86 0 08 0 0 9 2.9
Table 87: Composite Stage Clinical Extent Bones,Joints and Articular Cartilage(C40)
Stage code
Female(N=7) Male(N=12) # % # %
1 1 14.29 2 16.67 2 0 0 4 33.33 3 5 71.43 5 41.67 8 1 14.29 1 8.33
Table 88: Composite Stage Clinical Extent (Bones,Joints and Articular Cartilage of other and unspecified sites(C41))
Stage code
Female(N=3) Male(N=5)
# % # %
2 2 66.67 0 03 1 33.33 3 608 0 0 2 40
Table 89: Composite Stage Clinical Extent (Peripheral Nerves and autonomic nervous system, Retro peritoneum and Peritoneum,
connective,subcutaneous and other soft tissues(C47-C49))
Stage code
Female(N=19) Male(N=34) # % # %
1 7 36.84 5 14.71 2 1 5.26 2 5.88 3 6 31.58 21 61.76 4 0 0 1 2.94 8 5 26.32 5 14.71
MCC Annual Report – HBCR 2011
158
Table 90: Composite Stage Clinical Extent (Meninges,Brain,Spinal Cord, Cranial Nerves and other parts of CNS and Thyroid(C70-C73) )
Table 91: Diagnostic Status of all cancers at Registration at Source of Registration/Reporting institution(RI)
Stage code
Female(N=1200) Male(N=1375) # % # %
0 148 12.33 135 9.821 920 76.67 964 70.112 59 4.92 181 13.163 1 0.08 0 04 72 6 94 6.845 0 0 1 0.07
Stage code
Female(N=29) Male(N=26) # % # %
1 7 24.14 3 11.54 2 8 27.59 5 19.23 3 10 34.48 14 53.85 4 1 3.45 0 0 8 3 10.34 4 15.38
MCC Annual Report – HBCR 2011
159
Table 92: Diagnostic Status of all cancers at Registration at Source of
Registration/Reporting institution(RI)
Method Female(N=1200) Male(N=1375)
# % # %
Clinical Only 14 1.16 9 0.65
X‐Ray 1 0.08 2 0.15
Isotopes 0 0 0 0
Endoscopy 6 0.50 13 0.94
Angiography 0 0 0 0
Exploratory Surgery or Autopsy without Histology
1 0.08 0 0
Specific Biochemical and / or Immu 17 1.41 12 0.87
Cytology 15 1.25 32 2.33
Blood Film 0 0 0 0
Bone Marrow 0 0 0 0
Histology of Primary 1027 85.30 1044 75.87
Histology of Metastasis 36 2.99 140 10.17
Autopsy with Concurrent or Prior Histology
0 0 0 0
Death Certificate Only 0 0 0 0
Others (No Documents) 48 4.0 51 3.7
Ultrasonogram 14 1.16 11 0.80
All Other Dianostic imaging Techniques including CT, MRI, PET
21 1.74 55 4
Unknown 0 0 0 0
MCC Annual Report – HBCR 2011
160
Table 93: Comparison of Performance Status(WHO) before treatment at RI &
After treatment in females
Performance Status Female(N=1200) Female(N=893 )
# % # %
Able to carry out all normal activity without restriction 10 0.83 7 0.58Restricted in physically strenuous activity but ambulatory and able to carry out light work 853 71.08 525 43.75Ambulatory and capable of all self-care but unable to carry out any work: up and about more than 50% of waking hours 261 21.75 126 10.5Capable of only limited self-care; confined to bed or chair more than 50% waking hours 67 5.58 209 17.42Completely disabled; cannot carry on any self-care totally confined to bed or chair 6 0.5 26 2.17Unknown 3 0.25 307 25.58
Table 94: Comparison of Performance Status(WHO) before treatment at RI & After treatment in males
Performance Status Male(1375) Male(N=993)
# % # %Able to carry out all normal activity without restriction 8 0.58 3 0.22
Restricted in physically strenuous activity but ambulatory and able to carry out light work 826 60.07 341 24.8
Ambulatory and capable of all self-care but unable to carry out any work: up and about more than 50% of waking hours 415 30.18 231 16.8
Capable of only limited self-care; confined to bed or chair more than 50% waking hours 114 8.29 363 26.4
Completely disabled; cannot carry on any self-care totally confined to bed or chair 6 0.44 55 4
Unknown 6 0.44 382 27.78
MCC Annual Report – HBCR 2011
161
Table 95: Intention to treat at RI (All Cancers)
Intention Female(N=1200) Male(N=1375) # % # %
Curative / Radical 541 44.93 380 27.62 Palliative 418 34.72 636 46.22 Pain Relief Only 1 0.08 5 0.36 Symptomatic 104 8.64 189 13.74 No Treatment 69 5.73 59 4.29 Unknown 67 5.58 101 7.35
Table 96: Cancer directed treatment at RI (All Cancers)
Treatment Female(N=1200) Male(N=1375) # % # %
Yes 705 58.55 653 47.46 No 414 34.55 577 41.93 Treatment advised but not accepted 4 0.33 14 1.02 Incomplete Treatment 76 6.31 128 9.30 Unknown 1 0.08 3 0.22
Table 97: Treatment Advised but not received at RI (All Cancers)
Treatment Female(N=4) Male(N=9)
# % # %
Surgery (s) 0 0.00 3 33.33
Radiotherapy (R) 1 25.00 2 22.22
Chemotherapy (C) 2 50.00 2 22.22
R+C 0 0.00 1 11.11
S+R+C 1 25.00 1 11.11
Table 98: Reason for Non-Treatment/Partial Treatment/Incomplete Treatment (All Cancers)
Reason Female(N=486) Male(N=692) # % # %
Declined Treatment 7 1.44 17 2.46
Advised to take Planned Treatment outside the Reporting institution 37 7.61 46 6.65
Adviced to take Symptomatic Treatment elsewhere 103 21.19 191 27.60
Death during Treatment 7 1.44 22 3.18
Death before initiating Treatment 12 2.47 23 3.32
Others (On follow up /not reported cases) 291 59.88 344 49.71
Discontinued because of Inability to Tolerate Treatment
28 5.76 48 6.94
Unknown 1 0.21 1 0.14
MCC Annual Report – HBCR 2011
162
Table 99: Disease Status at First follow-up at 6 Months whichever is earlier
Stage code Female(N=1200) Male(N=1375) # % # %
No Evidence of Disease (NED) 367 30.63 181 13.29
NED but Second Primary Present 25 2.09 28 2.06
NED but Non-Malignant Present 4 0.33 3 0.22
Cancer in Regression / Residual Disease 131 10.93 135 9.91
Cancer in Progression / Recurrence 306 25.54 466 34.21
Too Advanced / Cachexia 76 6.34 121 8.88
Patient Dead 46 3.84 96 7.05
Others (Not reported) 238 19.87 328 24.08
Unknown 7 0.58 17 1.24
MCC Annual Report – HBCR 2011
163
TEN LEADING CANCERS – DETAILED INFORMATION
MCC Annual Report – HBCR 2011
164
MCC Annual Report – HBCR 2011
165
Ten Leading cancers irrespective of Sex
Table 100:
I. BREAST CANCER
Total Number(ICD10:C50):367 (98.92% females and 1.08% males)
Breast Cancer in females ranks first among all the cancers. 1st leading Cancer among Females (28.6%)
Male to Female ratio: 0.03 :1
Average age at diagnosis : 53.33years.
Peak age group: >75 years in males & 40-50 years in Females.
Method of Diagnosis: Microscopic Diagnosis in Males 90.9% & in Females 93.5%
Detailed Microscopic Diagnosis: Primary Histology 90.9% in males & in Females -91.6%.
Broad Treatment Group: Prior & treatment at RI – 18.2 % in males & 27.2% in Females and Treatment only at RI - 45.5% in males & 49.4 % in Females
Clinical Extent of Disease
Prior+treatment at RI - Localised(0%), Regional(100%) in males. Localised (1%), Regional (59.8%), distant (27.8%) and others (11.3%) in females. Treatment only at RI: regional (80%) and distant (20%) in males Localised (5.71%), regional(67%), distant (26.7%) and others (0.6%) in females
Type of Treatment:
Prior+ treatment at RI : Males : S+C - 50% & Others -50% Females : S-26.8%, R-1.0%, C-7.2%, S+R – 4.1% , S+C -33.0%, S+R+C – 4.1 %
Sl. No Site # %
1. Breast 367 14.25 2. Lung 347 13.48 3. Mouth 187 7.26 4. Stomach 142 5.51 5. Tongue 113 4.39 6. Cervix 103 4 7. Rectum 94 3.65 8. Ovary 90 3.49 9. Oesophagus 87 3.38
10. NHL 86 3.34
MCC Annual Report – HBCR 2011
166
Treatment only at RI
Males : Others 100% Females : S-5.1%, R-0.6%, C-5.7%, S+R-1.7%, S+C – 9.1%, R+C – 4.5%, S+R+C –
1.7%, Others 9.1 % Specific Treatment
Prior+ treatment at RI (RI treatment) Males : Any R(66.7%) Any H(33.3%) Females: Any S(11.6%), Any R(37.6%), AND Any C (25.4%) and any H (25.4%) Treatment Only at MCC Males : Any S(20%), Any R(26.7%), Any C (20.0%) & Any H (33.3%) Females: Any S(29.5%), Any R(24.9%), Any C (33%) and any H (12.7) • Treatment Status (Excluding cancer previously treated): Males : Received (71.4%) and not received (28.6%) Females : Received (78.2%) Not Received (16.1%) Not Accepted (0.5%) and
incomplete (5.2%)
Intent to treat: Males : Radical (60%) and Palliative (40%) Females : Radical (74.4%) and Palliative (25.6%)
• Marital status: Males : Married (63.6%) Females : Married(69.7%),
Religion: Males : Hindu(63.6%) Females : Hindu(66.9%)
Education : Males : Primary(27.3%) Females : Primary(37.9%)
Mother Tongue: Malayalam 100% in males & females.
Family History: 27.29% has family history
MCC Annual Report – HBCR 2011
167
Table 101: Number and Relative Proportion of Breast cancer by five year age group
Age group
Male(n=11) Female(n=356) Total(367)
# % # % # %
25-29 - - 3 0.84 3 0.82
30-34 - - 11 3.09 11 2.99
35-39 - - 31 8.71 31 8.45
40-44 - - 53 14.89 53 14.44
45-49 2 18.18 59 16.57 61 16.62
50-54 - - 64 17.98 64 17.44
55-59 2 18.18 39 10.96 41 11.17
60-64 2 18.18 34 9.55 36 9.81
65-69 1 9.09 21 5.89 22 5.99
69-74 1 9.09 23 6.46 24 6.54
>75 3 27.27 18 5.06 21 5.72
Unknown - - - - -
Table 102: Number and Relative Proportion of Breast cancer by method of diagnosis
Method of Diagnosis
Male(n=11) Female(n=356) Total(367)
# % # % # %
Microscopic 10 90.9 333 93.5 343 93.46
X-ray/Imaging - - 1 0.3 1 0.27
Clinical - - 3 0.8 3 0.82
Others 1 9.1 19 5.3 20 5.45
Table 103: Number and Relative Proportion of Breast cancer by detailed microscopic diagnosis
Microscopic Diagnosis
Male(n=11) Female(n=356) Total(367)
# % # % # %
Primary Histology 10 90.9 326 91.6 336 91.55
Secondary Histology - - 3 0.8 3 0.82
Cytology - - 4 1.1 4 1.09
Others 1 9.1 23 6.5 24 6.54
MCC Annual Report – HBCR 2011
168
Table 104: Number (#) and relative proportion(%) of breast cancer by histology
Type of Histology Male(n=11) Female(n=356) Total(n=367)
# % # % # % Infiltrating Duct Carcinoma 9 81.82 301 84.55 310 84.46
Adenocarcinoma 0 0 1 0.28 1 0.27
Adenosquamous Carcinoma 0 0 1 0.28 1 0.27
Carcinoma 0 0 4 1.12 4 1.09
Cribriform 0 0 1 0.28 1 0.27
Hodgkins Lymphoma- Nodular Cymphocyte Predominant 0 0 1 0.28 1 0.27
Lobular Carcinoma 1 9.09 10 2.81 11 3.00
Malignant Phylloides Tumour 0 0 3 0.84 3 0.82
Metaplastic Carcinoma 0 0 5 1.40 5 1.36
Mucinous Carcinoma 0 0 2 0.56 2 0.54
Neoplasm Malignant 1 9.09 23 6.46 24 6.54
Papillary Carcinoma 0 0 4 1.12 4 1.09
Clinical Information
Table 105: Number and Relative Proportion of Breast cancer by Broad Treatment Group
Broad Treatment Group
Male(n=11) Female(n=356) Total(367)
# % # % # % Prior Trmt only 2 18.2 48 13.5 50 13.62
Prior & Trmt at RI 2 18.2 97 27.2 99 26.98
Trmt only at RI 5 45.5 176 49.4 181 49.32
No Treatment 2 18.2 35 9.8 37 10.08
MCC Annual Report – HBCR 2011
169
Table 106: Number and Relative Proportion of Breast cancer by Clinical Extent of Disease
i. Prior Treatment only
Clinical extent
Male(n=2) Female(n=48) Total(50)
# % # % # %
Localised - - 4 8.3 4 8
Regional - - 18 37.5 18 36
Distant 1 50 12 25 13 26
Others 1 50 14 29.2 15 30
Table 107:
ii. Treatment Only at RI
Clinical Extent
Male(n=5) Female(n=176) Total(181)
# % # % # %
Localised - - 10 5.7 10 5.52
Regional 4 80 118 67 122 67.4
Distant 1 20 47 26.7 48 26.52
Others - - 1 0.6 1 0.55 Table 108:
iii. Prior + Treatment at RI
Clinical extent
Male(n=2) Female(n=97) Total(99)
# % # % # %
Localised - - 1 1 1 1.01
Regional 2 100 58 59.8 60 60.61
Distant - - 27 27.8 27 27.27
Others - - 11 11.3 11 11.11 Table 109:
iv. No Treatment
Clinical extent
Male(n=2) Female(n=35) Total(37)
# % # % # %
Localised - - 4 11.4 4 10.81
Regional 2 100 20 57.1 22 59.46
Distant - - 8 22.9 8 21.62
Others - - 3 8.6 3 8.11
MCC Annual Report – HBCR 2011
170
Table 110: Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI, No Treatment
Clinical extent
Male(n=11) Female(n=356) Total(367)
# % # % # %
Localised - - 19 5.3 19 5.18
Regional 8 72.7 214 60.1 222 60.49
Distant 2 18.2 94 26.4 96 26.16
Others 1 9.1 29 8.1 1 0.27
Table 111: Number and Relative Proportion of Breast cancer by Type of treatment
i . Prior Treatment only, No Treatment
Type of Treatment
Male(n=2) Female(n=48) Total(50)
# % # % # %
Surgery - - 9 18.8 9 18
R-therapy - - - - - -
C-Therapy 1 50 1 2.1 2 4
S+R - - 1 2.1 1 2
S+C - - 11 22.9 11 22
R+C - - - - - -
S+R+C 1 50 13 2.1 14 28
Others - - 12 22.9 12 24
Unknown - - 1 0 1 2
Table 112: ii . Treatment Only at RI, No Treatment
Type of Treatment
Male(n=5) Female(n=176) Total(n=181)
# % # % # %
Surgery - - 9 5.1 9 4.97 R-therapy - - 1 0.6 1 0.55
C-Therapy - - 10 5.7 10 5.52
S+R - - 3 1.7 3 1.66
S+C - - 16 9.1 16 8.84
R+C - - 8 4.5 8 4.42
S+R+C - - 71 1.7 71 39.23
Others 5 100 58 9.1 63 34.81
Unknown - - - -
MCC Annual Report – HBCR 2011
171
Table 113:
iii . Prior + Treatment at RI, No Treatment: Prior Treatment
Type of Treatment
Male(n=2) Female(n=97) Total(99)
# % # % # %
Surgery - - 26 26.8 26 26.26
R-therapy - - 1 1 1 1.01
C-Therapy - - 7 7.2 7 7.07
S+R - - 4 4.1 4 4.04
S+C 1 50 32 33 33 33.33
R+C - - - - -
S+R+C - - 6 4.1 6 6.06
Others 1 50 21 33 22 22.22
Unknown - - - - - -
Table 114: iv . Prior + Treatment at RI, No Treatment: RI Treatment
Type of Treatment
Male(n=2) Female(n=97) Total(99)
# % # % # %
Surgery - - - - - -
R-therapy 1 50 22 22.7 23 23.23
C-Therapy - - 8 8.2 8 8.08
S+R - - 1 1 1 1.01
S+C - - 5 5.2 5 5.05
R+C - - 13 13.4 13 13.13
S+R+C - - 4 1 4 4.04
Others 1 50 44 5.2 45 45.45
Unknown - - - - - -
Table 115: v . Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment
Type of treatment
Male(n=9) Female(n=321) Total(330) # % # % # %
Surgery - - 44 13.7 44 13.33
R-therapy - - 2 0.6 2 0.61
C-Therapy 1 11.1 18 5.6 19 5.76
S+R - - 8 2.5 8 2.42
S+C 1 11.1 59 18.4 60 18.18
R+C - - 8 2.5 8 2.42
S+R+C 1 11.1 90 2.5 91 27.58
Others 6 66.67 91 18.4 97 29.39
MCC Annual Report – HBCR 2011
172
Unknown - - 1 2.5 1 0.3 Table 116: vi . Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt), No Treatment:
Type of Treatment
Male(n=9) Female(n=321) Total(330)
# % # % # %
Surgery - - 18 5.6 18 5.45
R-therapy 1 11.1 23 7.2 24 7.27
C-Therapy 1 11.1 19 5.9 20 6.06
S+R - - 5 1.6 5 1.51 Table 117: Number and Relative Proportion of Breast cancer by Specific Treatment. i . Prior Treatment Only, No Treatment
Specific Treatment
Male(n=4) Female(n=117) Total(121) # % # % # %
Any S 1 25 46 39.3 47 38.84
Any R 1 25 22 18.8 23 19.01
Any C 2 50 36 30.8 38 31.4
Any H - - 12 10.3 12 9.92
Others - - - - - - Unknown - - 1 0.9 1 0.83
Table 118: ii . Treatment Only at RI, No Treatment
Specific Treatment
Male(n=15) Female(n=458) Total(n=473) # % # % # %
Any S 3 20 135 29.5 138 29.18
Any R 4 26.7 114 24.9 118 24.95
Any C 3 20 151 33 154 32.56
Any H 5 33.3 58 12.7 63 13.32
Others - - - - - -
Unknown - - - - - - Table 119: iii . Prior + Treatment at RI (Prior Tmt), , No Treatment
Specific Treatment
Male(n=3) Female(n=189) Total(n=192)
# % # % # %
Any S 1 33.3 85 45 86 44.79
Any R - - 24 12.7 24 12.5
Any C 1 33.3 59 31.2 60 31.25
Any H 1 33.3 21 11.1 22 11.46
Others - - - - - -
MCC Annual Report – HBCR 2011
173
Unknown - - - - - - Table 120: iv . Prior + Treatment at RI (RI Tmt), , No Treatment
Specific Treatment
Male(n=3) Female(n=173) Total(n=176)
# % # % # %
Any S - - 20 11.6 20 11.36
Any R 2 66.7 65 37.6 67 38.07
Any C - - 44 25.4 44 25
Any H 1 33.3 44 25.4 45 25.57
Table 121: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment
Specific Treatment Male(n=22) Female(n=764) Total(n=786)
# % # % # %
Any S 5 22.7 266 34.8 271 34.48
Any R 5 22.7 160 20.9 165 20.99
Any C 6 27.3 246 32.2 252 32.06
Any H 6 27.3 91 11.9 97 12.34
Others - - - - - -
Unknown - - 1 0.1 1 0.13
Table 122: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt),, No Treatment:
Specific Treatment
Male(n=22) Female(n=748) Total(n=770)
# % # % # %
Any S 4 18.2 201 26.9 205 26.62
Any R 7 31.8 201 26.9 208 27.01
Any C 5 22.7 231 30.9 236 30.65
Any H 6 27.3 114 15.2 120 15.58
Others - - - - - - Unknown - - 1 0.1 1 0.13
MCC Annual Report – HBCR 2011
174
Table 123: Number and Relative Proportion of Breast cancer by Treatment Status
(Excluding the Cancers Previously Treated)
Treatment Status
Male(n=7) Female(n=211) Total(n=218)
# % # % # %
Received 5 71.4 165 78.2 170 77.98
Not Received 2 28.6 34 16.1 36 16.51
Not Accepted - - 1 0.5 1 0.46 Incomplete - - 11 5.2 11 5.05
Unknown - - - - - -
Table 124: Number and Relative Proportion of Breast cancer by Intention to Treat (Excluding the Cancers Previously Treated)
Intention to Treat
Male(n=5) Female(n=176) Total(n=181)
# % # % # %
Radical 3 60 131 74.4 134 74.03
Palliative 2 40 45 25.6 47 25.97
Pain Relief Only - - - - - -
Symptomatic - - - - - -
Unknown - - - - - -
Basic Demographic Parameters
Table 125: Number and Relative Proportion of Breast cancer by marital status
Marital Status
Male (n=11) Female(356) Total(367)
# % # % # %
Unmarried NIL - 27 7.6 27 7.36
Married 7 63.6 248 69.7 255 69.48
Widowed 4 36.4 81 22.8 85 23.16
Divorced - - - - - -
Table 126: Number and Relative Proportion of Breast cancer by religion
Religion
Male(n=11) Female(n=356) Total(367)
# % # % # %
Hindu 7 63.6 238 66.9 245 66.76
Muslim 2 18.2 80 22.5 82 22.34
Christian 2 18.2 38 10.7 40 10.89
MCC Annual Report – HBCR 2011
175
Table 127: Number and Relative Proportion of Breast cancer by education
Education
Male(n=11) Female(n=356) Total(n=367)
# % # % # %
Primary 3 27.3 135 37.9 138 37.6
Secondary 2 18.2 111 31.2 113 30.79
Illiterate 2 18.2 26 7.3 28 7.63
Literate 2 18.2 50 14 52 14.17
College 2 18.2 8 2.2 10 2.72
Others - - 23 6.5 23 6.27
Unknown - - 3 0.8 3 0.82
Table 128: Number and Relative Proportion of Breast cancer by mother tongue
Mother Tongue
Male(n=11) Female(n=356) Total(367)
# % # % # %
Malayalam 11 100 356 100 367 100
MCC Annual Report – HBCR 2011
176
II. LUNG CANCER
Total Number(ICD10:C50):347 (10.09% females and 89.91% males)
Lung Cancer rank 2nd among all the cancers. First leading cancer among males and 9th leading cancer among females
Male to Female ratio: 8.91:1
Peak age group: 60-64 in males & 45-49 &>75 in Females
Average age at diagnosis :62.76
Method of Diagnosis: Microscopic: 86.9% in Males & 85.7% in Females
Detailed Microscopic Diagnosis: Primary Histology: 59.3% in males & 51.4% in Females.
Broad Treatment Group: Prior & treatment at RI – 14.4 % in males and 22.9% in Females . Treatment only at RI Females 37.1 % and 45.2% in males
Clinical Extent of Disease Prior+treatment at RI - Localised(2.2%), Regional(31.1%), Distant(66.7%) & in males Regional (37.5%), distant (62.5%) in females. Treatment only at RI , regional (21.3%) and distant (78.7%) in males regional(7.7%), distant (92.3%) in females
Type of Treatment:
Prior+treatment at RI: R-(22.2%), C-(44.4)%, R+C – (33.3) % in males C-(100%) in females Treatment only at MCC S-(0.7%), R-(23.4%), C-(33.3%), S+C –(0.7%), R+C – (41.8) % in males R-(7.7%), C-(23.1%), R+C – (69.2%), in females.
Specific Treatment
Prior+treatment at RI: Any R(41.7%), AND Any C (58.3%) in Males Any C (100%) in Females Treatment Only at MCC Any S(1%), Any R(45.8%), Any C (53.2%) & Any H (nil) in Males Any S(0%), Any R(45.5%), Any C (54.5%) and any H (nil) in Females
Treatment Status (Excluding cancer previously treated):
Received (40.3%) and not received (39.8%) , incomplete(19.5%) in males Received (60%) Not Received (35%) and incomplete (5%) in females.
Intent to treat: Radical (7.1%) and Palliative (90.1%) in males Radical (7.7%) and Palliative (92.3%) in females.
Marital status:
Males : Married (96.5%) Females : Married(57.1%)
MCC Annual Report – HBCR 2011
177
Religion: Males : Hindu(53.8%) Females : Hindu(71.4%)
Education : Males : Primary(58.3%) Females : Primary(40%)
Mother Tongue: Males : Malayalam(99.7%) Females : Malayalam(100%)
Table 129: Number and Relative Proportion of Lung cancer by five year age group
Age group
Male(n=312) Female(n=35) Total(347)
# % # % # %
25-29 1 0.32 - - 1 0.29
30-34 - - - - - -
35-39 5 1.6 - - 5 1.44
40-44 4 1.28 2 5.71 6 1.73
45-49 14 4.49 6 17.14 20 5.76
50-54 35 11.22 3 8.57 38 10.95
55-59 56 17.95 4 11.43 60 17.29
60-64 63 20.19 5 14.29 68 19.59
65-69 57 18.27 4 11.43 61 17.58
70-74 50 16.03 5 14.29 55 15.85
>75 27 8.65 6 17.14 33 9.51
Unknown - -
Table 130: Number and Relative Proportion of Lung cancer by method of diagnosis
Method of Diagnosis
Male(n=312) Female(n=35) Total(347)
# % # % # %
Microscopic 271 86.9 30 85.7 301 86.74
X-ray/Imaging 35 11.2 4 11.4 39 11.24
Clinical - - - - - -
Others 6 1.9 1 2.9 7 2.02
Unknown - - - - - -
MCC Annual Report – HBCR 2011
178
Table 131: Number and Relative Proportion of Lung cancer by detailed microscopic diagnosis
Microscopic Diagnosis Male(n=312) Female(n=35) Total(n=347)
# % # % # %
Primary Histology 185 59.3 18 51.4 203 58.5
Secondary Histology 61 19.6 6 17.1 67 19.31
Cytology 25 8 6 17.1 31 8.96
Blood Film - - - - - -
Bone Marrow - - - - - -
Others 41 13.1 5 14.3 46 13.26
Table 132: Number (#) and relative proportion(%) of Lung cancer by histology
Type of Histology Male(n=312) Female(n=35) Total(n=347)
# % # % # %
Acinar Carcinoma 1 0.32 0 0 1 0.29
Adenocarcinoma 60 19.23 10 28.57 71 20.18
Adenosquamous Carcinoma 1 0.32 0 0 1 0.29
Bronchiolo-Alveolar Carcinoma 0 0.00 1 2.86 1 0.29
Carcinoma 13 4.17 3 8.57 15 4.32
Large Cell Carcinoma 1 0.32 0 0 1 0.29
Neoplasm Malignant 106 33.97 13 37.14 119 34.29
Non-Small Cell Carcinoma 27 8.65 3 8.57 30 8.65
Small Cell Carcinoma 21 6.73 1 2.86 22 6.34
Squamous Cell Carcinoma 82 26.28 4 11.43 86 24.78
Clinical Information
Table 133: Number and Relative Proportion of Lung cancer by Broad Treatment Group
Broad Treatment Group
Male(n=312) Female(n=35) Total(347)
# % # % # %
Prior Trmt only 31 9.9 7 20 38 10.95
Prior & Trmt at RI 45 14.4 8 22.9 53 15.27
Trmt only at RI 141 45.2 13 37.1 154 44.38
No Treatment 95 30.4 7 20 102 29.39
MCC Annual Report – HBCR 2011
179
Table 134: Number and Relative Proportion of Lung cancer by Clinical Extent of Disease i . Prior Treatment only
Clinical extent
Male(n=31) Female(n=7) Total(n=38)
# % # % # %
Localised 1 3.2 - - 1 2.63
Regional 9 29 3 42.9 12 31.58
Distant 20 64.5 4 57.1 24 63.16
Others 1 3.2 - - 1 2.63
Unknown - - - - - - Table 135: ii. Treatment Only at RI
Clinical Extent Male(n=141) Female(n=13) Total(154)
# % # % # %
Localised - - - - - -
Regional 30 21.3 1 7.7 31 20.13
Distant 111 78.7 12 92.3 123 79.87
Others - - - - - -
Unknown - - - - - - Table 136: iii. Prior + Treatment at RI
Clinical extent
Male(n=45) Female(n=8) Total(n=53)
# % # % # %
Localised 1 2.2 - - 1 1.89
Regional 14 31.1 3 37.5 17 32.08
Distant 30 66.7 5 62.5 35 66.04
Others - - - - - -
Unknown - - - - - - Table 137: iv. No Treatment
Clinical extent
Male(n=95) Female(n=7) Total(102)
# % # % # %
Localised 5 5.3 1 14.3 6 5.88
Regional 21 22.1 1 14.3 22 21.57
Distant 59 62.1 5 71.4 64 62.75
Others 10 10.5 - - 10 9.8
MCC Annual Report – HBCR 2011
180
Unknown - - - - - -
Table 138: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI, No Treatment
Clinical extent
Male(n=312) Female(n=35) Total(347)
# % # % # %
Localised 7 2.2 1 2.9 8 2.31
Regional 74 23.7 8 22.9 82 23.63
Distant 220 70.5 26 74.3 246 70.89
Others 11 3.5 - - 11 3.17 Unknown - - - - - -
Table 139: Number and Relative Proportion of Lung cancer by Type of treatment i. Prior Treatment only, No Treatment
Type of Treatment
Male(n=31) Female(n=7) Total(n=38)
# % # % # %
Surgery 3 9.7 - - 3 7.89
R-therapy 6 19.4 - - 6 15.79
C-Therapy 12 38.7 6 85.7 18 47.37
S+R - - - - - -
S+C 1 3.2 - - 1 2.63
R+C 9 29 1 14.3 10 26.32
S+R+C - - - - - -
Others - - - - - -
Unknown - - - - - - Table 140: ii. Treatment Only at RI, No Treatment
Type of Treatment
Male(n=141) Female(n=13) Total(154)
# % # % # %
Surgery 1 0.7 - - 1 0.65
R-therapy 33 23.4 1 7.7 34 22.08 C-Therapy 47 33.3 3 23.1 50 32.47
S+R - - - - - -
S+C 1 0.7 - - 1 0.65
R+C 59 41.8 9 69.2 68 44.16
S+R+C - - - - - -
Others - - - - - -
Unknown - - - - - -
MCC Annual Report – HBCR 2011
181
Table 141: iii. Prior + Treatment at RI (Prior Treatment), No Treatment:
Type of Treatment
Male(n=45) Female(n=8) Total(53)
# % # % # %
Surgery 4 8.9 1 12.5 5 9.43
R-therapy 7 15.6 - - 7 13.21
C-Therapy 23 51.1 5 62.5 28 52.83
S+R - - - - - -
S+C - - - - - -
R+C 10 22.2 2 25 12 22.64
S+R+C 1 0 - - 1 1.89
Others - - - - - -
Unknown - - - - - - Table 142: iv. Prior + Treatment at RI (RI Treatment), No Treatment:
Type of Treatment
Male(n=45) Female(n=8) Total(n=53)
# % # % # %
Surgery - - - - - -
R-therapy 10 22.2 - - 10 18.87
C-Therapy 20 44.4 8 100 28 52.83
S+R - - - - - -
S+C - - - - - -
R+C 15 33.3 - - 15 28.3
S+R+C - - - - - -
Others - - - - - -
Unknown - - - - - - Table 143: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Type of treatment
Male(n=217) Female(n=28) Total(245)
# % # % # %
Surgery 8 3.7 1 3.6 9 3.67
R-therapy 46 21.2 1 3.6 47 19.18
C-Therapy 82 37.8 14 50 96 39.18
S+R - - - - - -
S+C 2 0.9 - - 2 0.82
R+C 78 35.9 12 42.9 90 36.73
S+R+C 1 0 - - 1 0.41
MCC Annual Report – HBCR 2011
182
Others - - - - - -
Unknown - - - - - - Table 144: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt),, No Treatment:
Type of Treatment
Male(n=217) Female(n=28) Total(245)
# % # % # %
Surgery 4 1.8 - - 4 1.63
R-therapy 49 22.6 1 3.6 50 20.41 C-Therapy 79 36.4 17 60.7 96 39.18
S+R - - - - - -
S+C 2 0.9 - - 2 0.82
R+C 83 38.2 10 35.7 93 37.96
S+R+C - - - - - -
Others - - - - - -
Unknown - - - - - - Table 145: Number and Relative Proportion of Lung cancer by Specific Treatment i. Prior Treatment Only, No Treatment
Specific Treatment
Male(n=41) Female(n=8) Total(49)
# % # % # %
Any S 4 9.8 - - 4 8.16
Any R 15 36.6 1 12.5 16 32.65
Any C 22 53.7 7 87.5 29 59.18
Any H - - - - - -
Others - - - - - - Unknown - - - - - -
Table 146: ii. Treatment Only at RI, No Treatment
Specific Treatment
Male(n=201) Female(n=22) Total(223)
# % # % # %
Any S 2 1 - - 2 0.89
Any R 92 45.8 10 45.5 102 45.74
Any C 107 53.2 12 54.5 119 53.36
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
MCC Annual Report – HBCR 2011
183
Table 147: iii. Prior + Treatment at RI (Prior Tmt), , No Treatment
Specific Treatment
Male(n=57) Female(n=10) Total(67)
# % # % # %
Any S 5 8.8 1 10 6 8.96
Any R 18 31.6 2 20 20 29.85
Any C 34 59.6 7 70 41 61.19
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 148: iv. Prior + Treatment at RI (RI Tmt), No Treatment
Specific Treatment
Male(n=60) Female(n=8) Total(68)
# % # % # %
Any S - - - - - -
Any R 25 41.7 - - 25 36.76
Any C 35 58.3 8 100 43 63.24
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 149: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Specific Treatment
Male(n=299) Female(n=40) Total(339)
# % # % # %
Any S 11 3.7 1 2.5 12 3.54
Any R 125 41.8 13 32.5 138 40.71
Any C 163 54.5 26 65 189 55.75
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
MCC Annual Report – HBCR 2011
184
Table 150: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt),, No Treatment:
Specific Treatment
Male(n=302) Female(n=38) Total(340)
# % # % # %
Any S 6 2 - - 6 1.76
Any R 132 43.7 11 28.9 143 42.06
Any C 164 54.3 27 71.1 191 56.18
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 151: Number and Relative Proportion of Lung Cancer by Treatment Status (Excluding the Cancers Previously Treated)
Treatment
Status Male(n=236) Female(n=20) Total(256)
# % # % # %
Received 95 40.3 12 60 107 41.79
Not Received 94 39.8 7 35 101 39.45
Not Accepted - - - - - -
Incomplete 46 19.5 1 5 47 18.36
Unknown 1 0.4 - - 1 0.39
Table 152: Number and Relative Proportion of Lung cancer by Intention to Treat (Excluding the Cancers Previously Treated)
Intention to Treat
Male(n=141) Female(n=13) Total (154 )
# % # % # %
Radical 10 7.1 1 7.7 11 7.14
Palliative 127 90.1 12 92.3 139 90.25
Pain Relief Only 1 0.7 - - 1 0.65
Symptomatic 3 2.1 - - 3 1.95
Unknown - - - - - -
MCC Annual Report – HBCR 2011
185
DEMOGRAPHIC PARAMETERS
Table 153: Number and Relative Proportion of Lung cancer by marital status
Marital Status
Male (312) Female(35) Total(347)
# % # % # %
Unmarried 3 1 3 8.6 6 1.73
Married 301 96.5 20 57.1 321 92.51
Widowed 8 2.6 12 34.3 20 5.76
Divorced - - - - - -
Table 154: Number and Relative Proportion of Lung cancer by religion
Religion Male(n=312) Female(n=35) Total(347)
# % # % # %
Hindu 168 53.8 25 71.4 193 55.62
Muslim 113 36.2 8 22.9 121 34.87
Christian 30 9.6 2 5.7 32 9.22
Unknown 1 0.3 - - 1 0.29
Table 155: Number and Relative Proportion of Lung cancer by education
Education Male(n=312) Female(n=35) Total(347)
# % # % # % Primary 182 58.3 14 40 196 56.48
Secondary 58 18.6 11 31.4 69 19.88 Illiterate 30 9.6 7 20 37 10.66
College 9 2.9 1 2.9 10 2.88 Literate 24 7.7 1 2.9 25 7.2
Others 8 2.6 1 2.9 9 2.59 Unknown 1 0.3 - - 1 0.29
Table 156: Number and Relative Proportion of Lung cancer by mother tongue
Mother Tongue
Male(n=312) Female(n=35) Total(347)
# % # % # %
Malayalam 311 99.7 35 100 346 99.71
Kannada 1 0.3 - - 1 0.29
MCC Annual Report – HBCR 2011
186
III. MOUTH CANCER
Total Number(ICD10:C-03-06):187 (44.39% females and 55.61% males)
Mouth Cancer rank 3rd among all the cancers. The 3rd leading cancer among males and 4th leading cancer among females.
Male to Female ratio:1.25:1
Peak age group: >75 in Females and 60-64 in males.
Average age at diagnosis:65.31 years.
Method of Diagnosis: Microscopic: Males in 87.5% &85.5% in Females
Detailed Microscopic Diagnosis: Primary Histology: 86.5% in males &-84.3% in Females
Broad Treatment Group: Prior & treatment at RI – 12% in Females and 18.3 % in males Treatment only at RI: 61.4 % in Females and 53.8% in males
Clinical Extent of Disease Prior+ treatment at RI - Regional(15.8%), Distant(5.3%), others (78.9%) in males Regional (30%), distant (0%), others(70%) in females. Treatment only at MCC, Localised(14.3%), regional (60.7%) and distant (23.2%) in males Localised(3.9%), regional(82.4%), distant (13.7%) in females
Type of Treatment: Prior+ treatment at RI: S-(15.8%), R-(15.8%), C-(42.1)%, , S+R(5.3%), in males R-(40%), C-(30%), S+C – (10%) in females Treatment only at RI S-(21.4%), R-(14.3%), C-(0%), , S+R –(14.3%), R+C – (37.5), & S+R+C(14.3 %) in males S(11.8%) R(27.5%), C(7.8%), S+R(7.8%), R+C(43.3%) & S+R+C(7.8%) in females.
Specific Treatment Prior+ treatment at RI Any S(16.7%), Any R(33.3%), AND Any C (50.0%) in Males Any S(7.7), Any R(46.2%), AND Any C (46.2%) in Females Treatment Only at RI Any S(27.3%), Any R(44.4%), Any C (27%) in Males Any S(13.9%), Any R(51.9%), Any C (34.2%) and any H (nil) in Females
Treatment Status (Excluding cancer previously treated): Received (76.8%) and not received (17.4%) , incomplete(4.3%) in males Received (70.8%) Not Received (21.5%) and incomplete (7.7%) in females.
Intent to treat: Radical (51.8%) and Palliative (48.2%) in males Radical (37.3%) and Palliative (62.7%) in females.
Marital status: Males : Married (94.2%) Females : Married(28.9%)
Religion: Males : Hindu(68.3%) Females: Hindu(55.4%)
Education : Males : Primary(49.0%) Females : Primary(36.1%)
Mother Tongue: Males : Malayalam(99%) Females : Malayalam(97.6%)
MCC Annual Report – HBCR 2011
187
Table 157: Number and Relative Proportion of Mouth cancer by five year age group
Age group Male(n=104) Female(n=83) Total(187)
# % # % # % Oct-14 1 0.96 - - 1 0.53
15-19 - - - - - - 20-24 - - - - - - 25-29 - - - - - - 30-34 - - 1 1.2 1 0.53 35-39 - - - - - -
40-44 6 5.77 1 1.2 7 3.74
45-49 7 6.73 1 1.2 8 4.28
50-54 10 9.62 6 7.23 16 8.56
55-59 10 9.62 9 10.84 19 10.16
60-64 20 19.23 9 10.84 29 15.51
65-69 16 15.38 14 16.87 30 16.04
69-74 18 17.31 16 19.28 34 18.18
>75 16 15.38 26 31.33 42 22.46
Unknown - - - - - -
Table 158: Number and Relative Proportion of Mouth cancer by method of diagnosis
Method of diagnosis
Male(n=104) Female(n=83) Total(187)
# % # % # % Microscopic 91 87.5 71 85.5 162 86.63 X-ray/Imaging 1 1 - - 1 0.533.74 Clinical 2 1.9 5 6 7 3.74
Others 10 9.6 7 8.4 17 9.09
Unknown - - - - - -
Table 159: Number and Relative Proportion of Mouth cancer by detailed microscopic diagnosis
Microscopic Diagnosis Male(n=104) Female(n=83) Total(187)
# % # % # %
Primary Histology 90 86.5 70 84.3 160 85.56
Secondary Histology 1 1 1 1.2 2 1.07
Cytology - - - - - -
Blood Film - - - - - -
Bone Marrow - - - - - -
Others 13 12.5 12 14.5 25 13.37
MCC Annual Report – HBCR 2011
188
Table 160: Number (#) and relative proportion(%) of Mouth cancer by histology
Type of Histology Male(n=104) Female(n=83) Total(n=187)
# % # % # %
Squamous Cell Carcinoma 83 79.81 68 81.93 151 80.75
Adenoid Cystic Carcinoma 0 0 1 1.2 1 0.53
Carcinoma 1 0.96 0 0 1 0.53
Mucinous Cystadenocarcinoma 1 0.96 0 0 1 0.53
Mucoepidermoid Carcinoma 1 0.96 0 0 1 0.53
Neoplasm Malignant 13 12.5 12 14.46 25 13.37
NHL 1 0.96 1 1.2 2 1.07
Verrucous Carcinoma 4 3.85 1 1.2 5 2.67
Clinical Information
Table 161: Number and Relative Proportion of Mouth cancer by Broad Treatment Group
Broad Treatment Group
Male(n=104) Female(n=83) Total(187)
# % # % # %
Prior Trmt only 16 15.4 8 9.6 24 12.83 Prior & Trmt at RI 19 18.3 10 12 29 15.51
Trmt only at RI 56 53.8 51 61.4 107 57.22
No Treatment 13 12.5 14 16.9 27 14.44
Table 162: Number and Relative Proportion of Mouth cancer by Clinical Extent of Disease i. Prior Treatment only
Clinical extent
Male(n=16) Female(n=8) Total(n=24)
# % # % # %
Localised 1 6.2 1 12.5 2 8.33
Regional 5 31.2 2 25 7 29.17
Distant 1 6.2 - - 1 4.17
Others 9 56.2 5 62.5 14 58.33
Unknown - - - - -
MCC Annual Report – HBCR 2011
189
Table 163:
ii. Treatment Only at RI
Clinical Extent
Male(n=56) Female(n=51) Total(107)
# % # % # %
Localised 8 14.3 2 3.9 10 9.35
Regional 34 60.7 42 82.4 76 71.03
Distant 13 23.2 7 13.7 20 18.69
Others 1 1.8 - - 1 0.93
Unknown - - - - - - Table 164:
iii. Prior + Treatment at RI
Clinical extent
Male(n=19) Female(n=10) Total(29)
# % # % # %
Localised - - - - - -
Regional 3 15.8 3 30 6 20.69
Distant 1 5.3 - - 1 3.45
Others 15 78.9 7 70 22 75.86
Unknown - - - - - - Table 165:
iv. No Treatment
Clinical extent
Male(n=13) Female(n=14) Total(27)
# % # % # %
Localised 2 15.4 2 14.3 4 14.81
Regional 9 69.2 8 57.1 17 62.96
Distant 1 7.7 4 28.6 5 18.52
Others 1 7.7 - - 1 3.7
Unknown - - - - - -
Table 166: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI, No Treatment
Clinical extent
Male(n=104) Female(n=83) Tota(187)
# % # % # %
Localised 11 10.6 5 6 16 8.56
Regional 51 49 55 66.3 106 56.68
Distant 16 15.4 11 13.3 27 14.44
Others 26 25 12 14.5 38 20.32
MCC Annual Report – HBCR 2011
190
Unknown - - - - - - Table 167: Number and Relative Proportion of Mouth cancer by Type of treatment
i. Prior Treatment only, No Treatment
Type of Treatment
Male(n=16) Female(n=8) Total(24)
# % # % # %
Surgery 2 12.5 3 37.5 5 20.83
R-therapy 5 31.2 1 12.5 6 25
C-Therapy 1 6.2 - - 1 4.17
S+R 1 6.2 2 25 3 12.5
S+C - - - - - -
R+C 5 31.2 2 25 7 29.17
S+R+C 2 6.2 - - 2 8.33
Others - - - - -
Unknown - - -
Table 168: ii. Treatment Only at RI, No Treatment
Type of Treatment
Male(n=56) Female(n=51) Total(107) # % # % # %
Surgery 12 21.4 6 11.8 18 16.82
R-therapy 8 14.3 14 27.5 22 20.56
C-Therapy - - 4 7.8 4 3.74
S+R 8 14.3 4 7.8 12 11.21
S+C - - - - - -
R+C 21 37.5 22 43.3 43 40.19
S+R+C 7 14.3 1 7.8 8 7.48
Others - - - - - -
Unknown - - - - - -
Table 169: iii. Prior + Treatment at RI (Prior Treatment), No Treatment:
Type of Treatment
Male(n=19) Female(n=10) Total(29)
# % # % # %
Surgery 5 26.3 3 30 8 27.59
R-therapy 5 26.3 2 20 7 24.14
C-Therapy 1 5.3 - - 1 3.45
S+R - - 2 20 2 6.89
S+C 1 5.3 1 10 2 6.89
R+C 7 36.8 2 20 9 31.03
S+R+C - - - - - -
Others - - - - - -
MCC Annual Report – HBCR 2011
191
Unknown - - - -
Table 170: iv. Prior + Treatment at RI( RI Treatment), No Treatment:
Type of Treatment
Male(n=19) Female(n=10) Total(29)
# % # % # %
Surgery 3 15.8 - - 3 10.34
R-therapy 3 15.8 4 40 7 24.14
C-Therapy 8 42.1 3 30 11 37.93
S+R 1 5.3 - - 1 3.45
S+C - - 1 10 1 3.45
R+C 4 21.1 2 20 6 20.69
S+R+C - - - - - -
Others - - - - - -
Unknown
Table 171: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Type of treatment
Male(n=91) Female(n=69) Total(160)
# % # % # %
Surgery 19 20.9 12 17.4 31 19.38
R-therapy 18 19.8 17 24.6 35 21.88
C-Therapy 2 2.2 4 5.8 6 3.75
S+R 9 9.9 8 11.6 17 10.63
S+C 1 1.1 1 1.4 2 1.25
R+C 33 36.3 26 37.7 59 36.88
S+R+C 9 9.9 1 11.6 10 6.25
Others - - - - - -
Unknown - - - - - -
Table 172: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt), No Treatment:
Type of Treatment
Male(n=91) Female(n=69) Total(160) # % # % # %
Surgery 17 18.7 9 13 26 16.25
R-therapy 16 17.6 19 27.5 35 21.88
C-Therapy 9 9.9 7 10.1 16 10
S+R 10 11 6 8.7 16 10
S+C - - 1 1.4 1 0.63
R+C 30 33 26 37.7 56 35
S+R+C 9 11 1 8.7 10 6.25
Others - - - - - -
MCC Annual Report – HBCR 2011
192
Unknown - - - - - Table 173: Number and Relative Proportion of Mouth cancer by Specific Treatment
i. Prior Treatment Only, No Treatment
Specific Treatment
Male(n=26) Female(n=12) Total(38)
# % # % # %
Any S 5 19.2 5 41.7 10 26.32
Any R 13 50 5 41.7 18 47.37
Any C 8 30.8 2 16.7 10 26.32
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 174: ii. Treatment Only at RI, No Treatment
Specific Treatment
Male(n=99) Female(n=79) Total(178)
# % # % # %
Any S 27 27.3 11 13.9 38 21.35
Any R 44 44.4 41 51.9 85 47.75
Any C 28 28.3 27 34.2 55 30.89
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 175: iii. Prior + Treatment at RI (Prior Tmt), No Treatment
Specific Treatment
Male(n=27) Female(n=15) Total(42)
# % # % # %
Any S 6 22.2 6 40 12 28.57
Any R 12 44.4 6 40 18 42.86
Any C 9 33.3 3 20 12 28.57
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
MCC Annual Report – HBCR 2011
193
Table 176: iv. Prior + Treatment at RI (RI Tmt), No Treatment
Specific Treatment
Male(n=24) Female(n=13) Total(37)
# % # % # %
Any S 4 16.7 1 7.7 5 13.51
Any R 8 33.3 6 46.2 14 37.84
Any C 12 50 6 46.2 18 48.65
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 177: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Specific Treatment
Male(n=152) Female(n=106) Total(258)
# % # % # %
Any S 38 25 22 20.8 60 23.26
Any R 69 45.4 52 49.1 121 46.89
Any C 45 29.6 32 30.2 77 29.84
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 178: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt),, No Treatment:
Specific Treatment
Male(n=149) Female(n=104) Total(253)
# % # % # %
Any S 36 24.2 17 16.3 53 20.95
Any R 65 43.6 52 50 117 46.25
Any C 48 32.2 35 33.7 83 32.81
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
MCC Annual Report – HBCR 2011
194
Table 179: Number and Relative Proportion of Mouth cancer by Treatment Status (Excluding the Cancers Previously Treated)
Treatment Status
Male(n=69) Female(n=65) Total(134)
# % # % # %
Received 53 76.8 46 70.8 99 73.88 Not Received 12 17.4 14 21.5 26 19.4
Not Accepted - - - - - -
Incomplete 3 4.3 5 7.7 8 5.97
Unknown 1 1.4 - - 1 0.75
Table 180: Number and Relative Proportion of Mouth cancer by Intention to Treat (Excluding the Cancers Previously Treated)
Intention to Treat Male(n=56) Female(n=51) Total(107)
# % # % # %
Radical 29 51.8 19 37.3 48 44.86
Palliative 27 48.2 32 62.7 59 55.14
Pain Relief Only - - - - - -
Symptomatic - - - - - -
Unknown - - - - - -
DEMOGRAPHIC PARAMETERS
Table 181: Number and Relative Proportion of Mouth cancer by marital status
Marital Status
Male (n=104) Female(n=83) Total(n= 187)
# % # % # %
Unmarried 3 2.9 5 6 8 4.28
Married 98 94.2 24 28.9 122 65.24
Widowed 3 2.9 52 62.7 55 29.41
Divorced - - 1 1.2 1 0.53
Others - - 1 1.2 1 0.53
Table 182: Number and Relative Proportion of Mouth cancer by religion
Religion Male(n=104) Female(n=83) Total(187)
# % # % # %
Hindu 71 68.3 46 55.4 117 62.57
Muslim 18 17.3 32 38.6 50 26.74
Christian 15 14.4 5 6 20 10.69
MCC Annual Report – HBCR 2011
195
Table 183: Number and Relative Proportion of Mouth cancer by education
Education Male(n=104) Female(n=83) Total(n=187)
# % # % # %
Primary 51 49 30 36.1 81 43.32
Secondary 18 17.3 4 4.8 22 11.76
Illiterate 12 11.5 45 54.2 57 30.48
Literate 10 9.6 3 3.6 13 6.95
College 6 5.8 - - 6 3.21
Others 5 4.8 - - 5 2.67
Unknown 2 1.9 1 1.2 3 1.6
Table 184: Number and Relative Proportion of Mouth cancer by mother tongue
Mother Tongue
Male(n=104) Female(n=83) Total(187)
# % # % # %
Malayalam 103 99 81 97.6 184 98.39
Rajastani 1 1 - - 1 0.53
Assamese - - 1 1.2 1 0.53
MCC Annual Report – HBCR 2011
196
IV. STOMACH Total Number(ICD10:C16):142 (22.54% females and 77.46% males) Stomach Cancer rank 4th among all the cancers. The 2nd leading cancer among males and
in females has rank >10 Male to Female ratio:3.44:1 Peak age group: 60-64(20.91%) in males & 65-69(18.75%) in Females Average age at diagnosis:62.96 Method of Diagnosis: Microscopic: (89.1%) in Males & 90.6% in Females Detailed Microscopic Diagnosis: Primary Histology: 84.5% in males &90.6% in Females
Broad Treatment Group: Prior & treatment at RI – 9.1 % in males & 15.6% in Females Treatment only at RI 34.5% in males & 28.1 % in Females
Clinical Extent of Disease: Prior+ treatment at RI - Regional(20%), Distant(70%) in males Regional (20%), distant (60%) in females. Treatment only at MCC, Localised(0%), regional (34.2%) and distant (65.8%) in males Localised(0%), regional(44.4%), distant (55.6%) in females
Type of Treatment: Prior+ treatment at RI: R-(20%), C-(70)%, , in males R(40%), C(40%) in females Treatment only at MCC S-(23.7%), R-(7.9%), C-(34.2%), , S+C –(21.1%), R+C – (7.9), in males S(33.3%), R(0%), C(33.3%), S+C(22.2%), & S+R+C(0%) in females.
Specific Treatment: Prior + Treatment at RI Any R(27.3%), AND Any C (72.7%) in Males Any R(50%), AND Any C (50%) in Females Treatment Only at MCC Any S(35.8%), Any R(15.1%), Any C (49.1%) in Males Any S(46.2%), Any R(7.7%), Any C (46.2%) in Females
Treatment Status (Excluding cancer previously treated): Received (43.2%) and not received (45.9%) , incomplete(8.1%) in males Received (41.2%) Not Received (47.1%) and incomplete (11.8%) in females.
Intent to Treat: Radical (18.4%) and Palliative (81.6%) in males Radical (66.7%) and Palliative (33.3%) in females.
Marital status: Males : Married (9.09%) Females Married(50%)
Religion: Males : Hindu(57.3%) Females : Hindu(68.8%),
Education : Males: Primary(48.2%) Females : Primary(40.6%)
Mother Tongue: Malayalam(100%), in males & Females
MCC Annual Report – HBCR 2011
197
Table 185: Number and Relative Proportion of Stomach cancer by five year age group
Age group Male(n=110) Female(n=32) Total(n=142)
# % # % # %
Oct-14 - - - - - -
15-19 - - - - - -
20-24 - - - - - -
25-29 - - - - - -
30-34 1 0.91 - - 1 0.7
35-39 1 0.91 2 6.25 3 2.11
40-44 4 3.64 1 3.13 5 3.52
45-49 5 4.55 3 9.38 8 5.63
50-54 11 10 2 6.25 13 9.15
55-59 18 16.36 4 12.5 22 15.49
60-64 23 20.91 4 12.5 27 19.01
65-69 16 14.55 6 18.75 22 15.49
69-74 14 12.73 5 15.63 19 13.38
>75 17 15.45 5 15.63 22 15.49
Unknown - - -
Table 186: Number and Relative Proportion of Stomach cancer by method of diagnosis
Method of diagnosis
Male(n=104) Female(n=32) Total(n=142) # % # % # %
Microscopic 98 89.1 29 90.6 127 89.44
X-ray/Imaging - - 1 3.1 1 0.7
Clinical - - - - - -
Others 12 10.9 2 6.2 14 9.86
Unknown - - - - - -
Table 187: Number and Relative Proportion of Stomach cancer by detailed microscopic diagnosis
Microscopic Diagnosis
Male(n=110) Female(n=32) Total(n=142)
# % # % # %
Primary Histology 93 84.5 29 90.6 122 85.92
Secondary Histology 5 4.5 - - 5 3.52
Cytology - - - - - -
Blood Film - - - - - -
Bone Marrow - - - - - -
Others 12 10.9 3 9.4 15 10.56
MCC Annual Report – HBCR 2011
198
Table 188: Number (#) and relative proportion(%) of Stomach cancer by histology
Type of Histology Male(n=110) Female(n=32) Total(n=142)
# % # % # %
Adenocarcinoma 73 66.36 25 78.13 98 69.01 Adenocarcinoma With Neuroendocrine Differentiation 1 0.91 0 0 1 0.7
Carcinoma 4 3.64 0 0 4 2.82
Gist 2 1.82 1 3.13 3 2.11
Neoplasm Malignant 14 12.73 1 3.13 15 10.56
Neuroendocrine Carcinoma 1 0.91 0 0 1 0.7
Nhl 2 1.82 2 6.25 4 2.82
Signet Ring Cell Carcinoma 9 8.18 2 6.25 11 7.75
Squamous Cell Carcinoma 4 3.64 1 3.13 5 3.52
Clinical Information
Table 189: Number and Relative Proportion of Stomach cancer by Broad Treatment Group
Broad Treatment Group
Male(n=110) Female(n=32) Total(n=142)
# % # % # %
Prior Trmt only 26 23.6 10 31.2 36 25.35
Prior & Trmt at RI 10 9.1 5 15.6 15 10.56
Trmt only at RI 38 34.5 9 28.1 47 33.09
No Treatment 36 32.7 8 25 44 30.98
Table 190: Number and Relative Proportion of Stomach cancer by Clinical Extent of
Disease i. Prior Treatment only
Clinical extent Male(n=26) Female(n=10) Total(n=36)
# % # % # %
Localised 1 3.8 - - 1 2.78
Regional 7 26.9 2 20 9 25
Distant 12 46.2 5 50 17 47.22
Others 6 23.1 3 30 9 25
Unknown - - - -
MCC Annual Report – HBCR 2011
199
Table 191: ii. Treatment Only at RI
Clinical Extent
Male(n=38) Female(n=9) Total(n=47)
# % # % # %
Localised - - - - - -
Regional 13 34.2 4 44.4 17 36.17
Distant 25 65.8 5 55.6 30 63.83
Others - - - - - -
Unknown - - - - - -
Table 192: iii. Prior + Treatment at RI
Clinical extent
Male(n=10) Female(n=5) Total(n=15)
# % # % # %
Localised - - - - - -
Regional 2 20 1 20 3 20
Distant 7 70 3 60 10 66.67
Others 1 10 1 20 2 13.33
Unknown - - - - - -
Table 193: iv. No Treatment
Clinical extent
Male(n=36) Female(n=8) Total(n=44)
# % # % # %
Localised 2 5.6 - - 2 4.55
Regional 9 25 3 37.5 12 27.27
Distant 23 63.9 3 37.5 26 59.09
Others 2 5.6 2 25 4 9.09
Unknown
Table 194: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI, No Treatment
Clinical extent
Male(n=110) Female(n=32) Total(n=142)
# % # % # %
Localised 3 2.7 - - 3 2.11
Regional 31 28.2 10 31.2 41 28.87
Distant 67 60.9 16 50 83 58.45
Others 9 8.2 6 18.8 15 10.56
Unknown - - - -
MCC Annual Report – HBCR 2011
200
Table 195: Number and Relative Proportion of Stomach cancer by Type of treatment
i. Prior Treatment only, No Treatment
Type of Treatment
Male(n=26) Female(n=10) Total(n=36)
# % # % # %
Surgery 8 30.8 4 40 12 33.33
R-therapy - - - - - -
C-Therapy 5 19.2 3 30 8 22.22
S+R - - - - - -
S+C 7 26.9 3 30 10 27.78
R+C 2 7.7 - - 2 5.56
S+R+C 4 0 - - 4 11.11
Others - - - - - -
Unknown - - - - - -
Table 196: ii. Treatment Only at RI, No Treatment
Type of Treatment
Male(n=38) Female(n=9) Total(47)
# % # % # %
Surgery 9 23.7 3 33.3 12 25.53
R-therapy 3 7.9 - - 3 6.38
C-Therapy 13 34.2 3 33.3 16 34.04
S+R - - - - - -
S+C 8 21.1 2 22.2 10 21.28
R+C 3 7.9 - - 3 6.38
S+R+C 2 0 1 0 3 6.38
Others - - - - - -
Unknown - - - -
Table 197: iii. Prior + Treatment at RI (Prior Treatment), No Treatment:
Type of Treatment
Male(n=10) Female(n=5) Total(n=15)
# % # % # %
Surgery 3 30 3 60 6 40
R-therapy - - - - - -
C-Therapy 3 30 1 20 4 26.67
S+R - - - - - -
S+C 4 40 1 20 5 33.33
R+C - - - - - -
S+R+C - - - - - -
Others - - - - - -
MCC Annual Report – HBCR 2011
201
Unknown - - - - - - Table 198: iv. Prior + Treatment at RI( RI Treatment), No Treatment:
Type of Treatment
Male(n=10) Female(n=5) Total(n=15)
# % # % # %
Surgery - - - - - -
R-therapy 2 20 2 40 4 26.67
C-Therapy 7 70 2 40 9 60
S+R - - - - - -
S+C - - - - - -
R+C 1 10 1 20 2 13.33
S+R+C - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 199: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Type of treatment
Male(n=74) Female(n=24) Total(n=98)
# % # % # %
Surgery 20 27 10 41.7 30 30.61
R-therapy 3 4.1 - - 3 3.06
C-Therapy 21 28.4 7 29.2 28 28.57
S+R - - - - - -
S+C 19 25.7 6 25 25 25.51
R+C 5 6.8 - - 5 5.1
S+R+C 6 0 1 0 7 7.14
Others - - - - - -
Unknown - - - - - -
Table 120: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt), No Treatment:
Type of Treatment
Male(n=74) Female(n=24) Total(n=98)
# % # % # %
Surgery 17 23 7 29.2 24 24.49
R-therapy 5 6.8 2 8.3 7 7.14
C-Therapy 25 33.8 8 33.3 33 33.67
S+R - - - - - -
S+C 15 20.3 5 20.8 20 20.41
R+C 6 8.1 1 4.2 7 7.14
S+R+C 6 0 1 0 7 7.14
Others - - - - - -
Unknown - - - - - -
MCC Annual Report – HBCR 2011
202
Table 121: Number and Relative Proportion of Stomach cancer by Specific Treatment i. Prior Treatment Only, No Treatment
Specific Treatment
Male(n=43) Female(n=13) Total(n=56)
# % # % # %
Any S 19 44.2 7 53.8 26 46.43
Any R 6 14 - - 6 10.71
Any C 18 41.9 6 46.2 24 42.86
Any H - - - - - -
Others - - - - - -
Unknown - - - - - - Table 122: ii. Treatment Only at RI, No Treatment
Specific Treatment
Male(n=53) Female(n=13) Total(n=66)
# % # % # %
Any S 19 35.8 6 46.2 25 37.88
Any R 8 15.1 1 7.7 9 13.64
Any C 26 49.1 6 46.2 32 48.48
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 123: iii. Prior + Treatment at RI (Prior Tmt) , No Treatment
Specific Treatment
Male(n=14) Female(n=6) Total(n=20)
# % # % # %
Any S 7 50 4 66.7 11 55
Any R - - - - - -
Any C 7 50 2 33.3 9 45
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 124: iv. Prior + Treatment at RI (RI Tmt), No Treatment
Specific Treatment
Male(n=11) Female(n=6) Total(n=17)
# % # % # %
Any S - - - - - -
Any R 3 27.3 3 50 6 35.29
Any C 8 72.7 3 50 11 64.71
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
MCC Annual Report – HBCR 2011
203
Table 125: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Specific Treatment
Male(n=110) Female(n=32) Total(n=142)
# % # % # %
Any S 45 40.9 17 53.1 62 43.66
Any R 14 12.7 1 3.1 15 10.56
Any C 51 46.4 14 43.8 65 45.77
Any H - - - - - -
Others - - - - - -
Unknown - - - -
Table 126: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt), No Treatment:
Specific Treatment
Male(n=107) Female(n=32) Total(n=139)
# % # % # %
Any S 38 35.5 13 40.6 51 36.69
Any R 17 15.9 4 12.5 21 15.11
Any C 52 48.6 15 46.9 67 48.2
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 127: Number and Relative Proportion of Stomach cancer by Treatment Status (Excluding the Cancers Previously Treated)
Treatment Status
Male(n=74) Female(n=17) Total(n=91)
# % # % # %
Received 32 43.2 7 41.2 39 42.86
Not Received 34 45.9 8 47.1 42 46.15
Not Accepted - - - - - -
Incomplete 6 8.1 2 11.8 8 8.79
Unknown 2 2.7 - - 2 2.19
Table 128: Number and Relative Proportion of Stomach cancer by Intention to Treat (Excluding the Cancers Previously Treated)
Intention to Treat
Male(n=38) Female(n=9) Total(n=47)
# % # % # %
Radical 7 18.4 6 66.7 13 27.66
Palliative 31 81.6 3 33.3 34 72.34
Pain Relief Only - - - - - -
Symptomatic - - - - - -
MCC Annual Report – HBCR 2011
204
Unknown - - - - - -
DEMOGRAPHIC PARAMETERS
Table 129: Number and Relative Proportion of Stomach cancer by marital status
Intention to Treat Male(n=38) Female(n=9) Total(n=47)
# % # % # %
Radical 7 18.4 6 66.7 13 27.66
Palliative 31 81.6 3 33.3 34 72.34
Pain Relief Only - - - - - -
Symptomatic - - - - - -
Unknown - - - - - -
Table 130: Number and Relative Proportion of Stomach cancer by religion
Religion Male(n=110) Female(n=32) Total(n=142) # % # % # %
Hindu 63 57.3 22 68.8 85 59.86
Muslim 38 34.5 9 28.1 47 33.09
Christian 9 8.2 1 3.1 10 7.04
Table 131: Number and Relative Proportion of Stomach cancer by education
Education Male(n=110) Female(n=32) Total(n=142)
# % # % # %
Primary 53 48.2 13 40.6 66 46.48 Secondary 37 33.6 5 15.6 42 29.58
Illiterate 9 8.2 12 37.5 21 14.79
Literate 6 5.5 2 6.2 8 5.69
College 2 1.8 - - 2 1.41
Others 3 2.7 - - 3 2.11
Unknown - - - - - -
Table 132: Number and Relative Proportion of Stomach cancer by mother tongue
Mother Tongue
Male(n=110) Female(n=32) Total(n=142)
# % # % # %
Malayalam 110 100 32 100 142 100
Unknown - - - - - -
MCC Annual Report – HBCR 2011
205
V. TONGUE Total Number(ICD10:C01-02):113 (40.71% females and 59.29% males)
Tongue Cancer rank 5th among all the cancers. 4th leading cancer among males and 6th leading cancer among females
Male to Female ratio:1.46:1
Peak age group: 65-69(25.37%) in males & 70-74(19.57%) in Females
Average age at diagnosis :59.58 years.
Method of Diagnosis: Microscopic-86.6% in Males & 89.1% in Females
Detailed Microscopic Diagnosis: Primary Histology: 85.1% in males &87.0% in Females
Broad Treatment Group: Prior & treatment at RI – 16.4 % in males & 17.4% in Females Treatment only at RI 50.7% in males & 54.3 % in Females
Clinical Extent of Disease Prior + treatment at RI - Regional(63.6%), Distant(9.1%), others(27.3%) in males Regional (37.5%), others (62.5%) in females. Treatment only at MCC, Localised(5.9%), regional (82.4%) and distant (11.8%) in males Localised(28%), regional(64%), distant (8%) in females
Type of Treatment: Prior + treatment at RI: S-(27.3%), R-(45.5%), S+R(18.2%), R+C – (9.1) % in males R-(50%), C-(25%), R+C – (12.5%),& in females Treatment only at MCC S-(23.5%), R-(5.9%), C-(5.9%), , S+R –(20.6%), R+C – (23.5), & S+R+C(20.6 %), S+C(2.9%) in males S(44%) R(4%), C(8%), S+R(20%), R+C(20%) & S+R+C(20%) in females.
Specific Treatment Prior+ Treatment at RI Any S(35.7%), Any R(57.1%), AND Any C (7.1%) in Males Any S(9.1), Any R(54.5%), AND Any C (36.4%) in Females Treatment Only at MCC Any S(35.5%), Any R(37.1%), Any C (27.4%) in Males Any S(45.9%), Any R(32.4%), Any C (21.6%) and any H (nil) in Females
Treatment Status (Excluding cancer previously treated): Received (64.6%) and not received (27.1%) , incomplete(6.2%) in males Received (80%) Not Received (16.7%) and incomplete (3.3%) in females.
Intent to treat: Radical (70.6%) and Palliative (29.4%) in males Radical (72%) and Palliative (28%) in females.
Marital status: Males : Married (92.5%) Females : Married(56.5%)
Religion: Males : Hindu(76.1%) Females: Hindu(67.4%)
Education : Males : Primary(49.3%) Females: Primary(43.5%)
MCC Annual Report – HBCR 2011
206
Mother Tongue: Malayalam(100%), in males & females.
Table 133: Number and Relative Proportion of Tongue cancer by five year age group
Age group
Male(n=67) Female(n=46) Total(113)
# % # % # %
Oct-14 - - - - -
15-19 - - - - - -
20-24 - - 1 2.17 1 0.88
25-29 - - 1 2.17 1 0.88
30-34 2 2.99 - - 2 1.77
35-39 3 4.48 2 4.35 5 4.42
40-44 7 1045 1 2.17 8 7.07
45-49 7 10.45 3 6.52 10 8.84
50-54 6 8.96 5 10.87 11 9.73
55-59 11 16.42 4 8.69 15 13.27
60-64 17 25.37 8 17.39 25 22.12
65-69 13 19.4 6 13.04 19 16.81
70-74 3 4.48 9 19.57 12 10.61
>75 8 11.94 6 13.04 14 12.39
Unknown - - - -
Table 134: Number and Relative Proportion of Tongue cancer by method of diagnosis
Method of Diagnosis
Male(n=67) Female(n=46) Total(113)
# % # % # %
Microscopic 58 86.6 41 89.1 99 87.61 X-ray/Imaging - - - - - -
Clinical 3 4.5 2 4.3 5 4.42
Others 6 9 3 6.5 9 7.96
Unknown - - - - - -
Table 135: Number and Relative Proportion of Tongue cancer by detailed microscopic
diagnosis
Microscopic Diagnosis Male(n=67) Female(n=46) Total( 113)
# % # % # %
Primary Histology 57 85.1 40 87 97 85.84
Secondary Histology 1 1.5 1 2.2 2 1.77
Cytology - - - - - -
Blood Film - - - - - -
Bone Marrow - - - - - -
MCC Annual Report – HBCR 2011
207
Others 9 13.4 5 10.9 14 12.39
Table 136: Number (#) and relative proportion(%) of Tongue cancer by histology
Type of Histology Male(n=67) Female(n=46) Total(n=113)
# % # % # %
Squamous Cell Carcinoma 57 85.07 38 82.61 95 84.07
Neoplasm Malignant 9 13.43 5 10.87 14 12.39
NHL 1 1.49 1 2.17 2 1.77
Verrucous Carcinoma 0 0 2 4.35 2 1.77
Clinical Information
Table 137: Number and Relative Proportion of Tongue cancer by Broad Treatment Group
Table 138: Number and Relative Proportion of Tongue cancer by Clinical Extent of Disease
i. Prior Treatment only
Clinical extent Male(n=8) Female(n=8) Total(16)
# % # % # %
Localised 2 25 - - 2 12.5
Regional 2 25 5 62.5 7 43.75
Distant 1 12.5 1 12.5 2 12.5
Others 3 37.5 2 25 5 31.25
Unknown - - - - - -
Table 139: ii. Treatment Only at RI
Clinical Extent Male(n=34) Female(n=25) Total(59) # % # % # %
Localised 2 5.9 7 28 9 15.25
Regional 28 82.4 16 64 44 74.58
Distant 4 11.8 2 8 6 10.17
Others - - - - - -
Unknown - - - - - -
Broad Treatment Group
Male(n=67) Female(n=46) Total(113)
# % # % # %
Prior Trmt only 8 11.9 8 17.4 16 14.16
Prior & Trmt at RI 11 16.4 8 17.4 19 16.81
Trmt only at RI 34 50.7 25 54.3 59 52.21
No Treatment 14 20.9 5 10.9 19 16.81
MCC Annual Report – HBCR 2011
208
Table 140: iii. Prior + Treatment at RI
Clinical extent Male(n=11) Female(n=8) Total(n= 19)
# % # % # %
Localised - - - - - -
Regional 7 63.6 3 37.5 10 52.63
Distant 1 9.1 - - 1 5.26
Others 3 27.3 5 62.5 8 42.11
Unknown - - - - - - Table 141: iv. No Treatment
Clinical extent Male(n=11) Female(n=8) Total(n= 19)
# % # % # %
Localised - - - - - -
Regional 7 63.6 3 37.5 10 52.63
Distant 1 9.1 - - 1 5.26
Others 3 27.3 5 62.5 8 42.11
Unknown - - - - - -
Table 142: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI, No Treatment
Clinical extent Male(n=67) Female(n=46) Total(113)
# % # % # %
Localised 8 11.9 9 19.6 17 15.04
Regional 44 65.7 27 58.7 71 62.83
Distant 8 11.9 3 6.5 11 9.73
Others 7 10.4 7 15.2 14 12.39
Unknown - - - - - - Table 143: Number and Relative Proportion of Tongue cancer by Type of treatment i. Prior Treatment only, No Treatment
Type of Treatment Male(n=8) Female(n=8) Total(16) # % # % # %
Surgery 2 25 1 12.5 3 18.75
R-therapy 1 12.5 1 12.5 2 12.5
C-Therapy - - 1 12.5 1 6.25
S+R 3 37.5 1 12.5 4 25
S+C - - - - - -
R+C 2 25 2 25 4 25
S+R+C - - 2 25 2 12.5
MCC Annual Report – HBCR 2011
209
Others - - - - - -
Unknown
Table 144: ii. Treatment Only at RI, No Treatment
Type of Treatment Male(n=34) Female(n=25) Total(59) # % # % # %
Surgery 8 23.5 11 44 19 32.2
R-therapy 2 5.9 1 4 3 5.08
C-Therapy 2 5.9 2 8 4 6.78
S+R 7 20.6 5 20 12 20.34
S+C 1 2.9 - - 1 1.69
R+C 8 23.5 5 20 13 22.03
S+R+C 6 20.6 1 20 7 11.86
Others - - - - - -
Unknown - - - - - - Table 145: iii. Prior + Treatment at RI (Prior Treatment), No Treatment:
Type of Treatment Male(n=11) Female(n=8) Total(19) # % # % # %
Surgery 8 72.7 3 37.5 11 57.89
R-therapy 2 18.2 2 25 4 21.05
C-Therapy - - 1 12.5 1 5.26
S+R - - - - - -
S+C - - 1 12.5 1 5.26
R+C 1 0 1 12.5 2 10.53
S+R+C - - - - - -
Others - - - - -
Unknown - - - - - Table 146: iv. Prior + Treatment at RI (RI Treatment), No Treatment:
Type of Treatment Male(n=11) Female(n=8) Total(19)
# % # % # %
Surgery 3 27.3 - - 3 15.79
R-therapy 5 45.5 4 50 9 47.37
C-Therapy - - 2 25 2 10.53
S+R 2 18.2 - - 2 10.53
S+C - - - - - -
R+C 1 9.1 1 12.5 2 10.53
S+R+C - - 1 0 1 5.26
MCC Annual Report – HBCR 2011
210
Others - - - - - -
Unknown - - - - - -
Table 147: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt),, No Treatment:
Type of treatment Male(n=53) Female(n=41) Total(94) # % # % # %
Surgery 18 34 15 36.6 33 35.11
R-therapy 5 9.4 4 9.8 9 9.57
C-Therapy 2 3.8 4 9.8 6 6.38
S+R 10 18.9 6 14.6 16 17.02
S+C 1 1.9 1 2.4 2 2.13
R+C 10 18.9 8 19.5 18 19.15
S+R+C 7 18.9 3 14.6 10 10.64
Others - - - - - -
Unknown -
Table 148: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt),, No Treatment:
Type of Treatment Male(n=53) Female(n=41) Total(94) # % # % # %
Surgery 13 24.5 12 29.3 25 26.59
R-therapy 8 15.1 6 14.6 14 14.89
C-Therapy 2 3.8 5 12.2 7 7.45
S+R 12 22.6 6 14.6 18 19.15
S+C 1 1.9 - - 1 1.06
R+C 11 20.8 8 19.5 19 20.21
S+R+C 6 22.6 4 14.6 10 10.64
Others - - - - - -
Unknown - - - - Table 149: Number and Relative Proportion of Tongue cancer by Specific Treatment i. Prior Treatment Only, No Treatment
Specific Treatment Male(n=13) Female(n=15) Total(28) # % # % # %
Any S 5 38.5 4 26.7 9 32.14
Any R 6 46.2 6 40 12 42.86
Any C 2 15.4 5 33.3 7 25
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
MCC Annual Report – HBCR 2011
211
Table 150: ii. Treatment Only at RI, No Treatment
Specific Treatment Male(n=62) Female(n=37) Total(99) # % # % # %
Any S 22 35.5 17 45.9 39 39.39
Any R 23 37.1 12 32.4 35 35.35
Any C 17 27.4 8 21.6 25 25.25
Any H - - - - -
Others - - - - -
Unknown - - - - -
Table 151: iii. Prior + Treatment at RI (Prior Tmt), No Treatment
Specific Treatment Male(n=13) Female(n=10) Total(23) # % # % # %
Any S 9 69.2 4 40 13 56.52
Any R 3 23.1 3 30 6 26.09
Any C 1 7.7 3 30 4 17.39
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 152: iv. Prior + Treatment at RI (RI Tmt), No Treatment
Specific Treatment
Male(n=14) Female(n=11) Total(25) # % # % # %
Any S 5 35.7 1 9.1 6 24
Any R 8 57.1 6 54.5 14 56
Any C 1 7.1 4 36.4 5 20
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 153: iv. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Specific Treatment Male(n=88) Female(n=62) Total(150) # % # % # %
Any S 36 40.9 25 40.3 61 40.67
MCC Annual Report – HBCR 2011
212
Any R 32 36.4 21 33.9 53 35.33
Any C 20 22.7 16 25.8 36 24
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 154: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt),, No Treatment:
Specific Treatment Male(n=89) Female(n=63) Total(152) # % # % # %
Any S 32 36 22 34.9 54 35.53
Any R 37 41.6 24 38.1 61 40.13
Any C 20 22.5 17 27 37 24.34
Any H - - - - - -
Others - - - - - -
Unknown
Table 155: Number and Relative Proportion of Tongue Cancer by Treatment Status (Excluding the Cancers Previously Treated)
Treatment Status Male(n=48) Female(n=30) Total(78) # % # % # %
Received 31 64.6 24 80 55 70.51
Not Received 13 27.1 5 16.7 18 23.08
Not Accepted 1 2.1 - - 1 1.28
Incomplete 3 6.2 1 3.3 4 5.13
Unknown - - - - - -
Table 156: Number and Relative Proportion of Tongue cancer by Intention to Treat (Excluding the Cancers Previously Treated)
Intention to Treat Male(n=34) Female(n=25) Total ( 59 ) # % # % # %
Radical 24 70.6 18 72 42 71.19
Palliative 10 29.4 7 28 17 28.81
Pain Relief Only - - - - - -
Symptomatic - - - - - -
Unknown - - - - - -
DEMOGRAPHIC PARAMETERS
Table 157: Number and Relative Proportion of Tongue cancer by marital status
Marital Status Male (n=67) Female(46) Total(113)
MCC Annual Report – HBCR 2011
213
# % # % # %
Unmarried 3 4.5 1 2.2 4 3.54
Married 62 92.5 26 56.5 88 77.88
Widowed 2 3 19 41.3 21 18.58
Divorced -
Table 158: Number and Relative Proportion of Tongue cancer by religion
Religion Male(n=67) Female(n=46) Total(113)
# % # % # %
Hindu 51 76.1 31 67.4 82 72.57
Muslim 10 14.9 10 21.7 20 17.69
Christian 6 9 5 10.9 11 9.73
Unknown - - - -
Table 159: Number and Relative Proportion of Tongue cancer by education
Education Male(n=67) Female(n=46) Total(113) # % # % # %
Primary 33 49.3 20 43.5 53 46.9
Secondary 22 32.8 7 15.2 29 25.66
Illiterate 3 4.5 15 32.6 18 15.93
Literate 3 4.5 2 4.3 5 4.42
College 4 6 1 2.2 5 4.42
Others 2 3 1 2.2 3 2.65
Unknown - - - - - -
Table 160: Number and Relative Proportion of Tongue cancer by mother tongue
Mother Tongue Male(n=67) Female(n=46) Total(113) # % # % # %
Malayalam 67 100 46 100 113 100
Kannada - - - -
MCC Annual Report – HBCR 2011
214
VI. CERVIX CANCER
Total Number(ICD10:C50):103
Cervical Cancer rank 6th among all the cancers. 2nd leading cancer among females.
Peak age group: 55-59(19.42%) .
Average age at diagnosis :59.49 years.
Method of Diagnosis: Microscopic-90.3%
Detailed Microscopic Diagnosis: Primary Histology-90.3
Broad Treatment Group: Prior & treatment at RI – 7.8% Treatment only at RI : 52.4%
Clinical Extent of Disease Prior + treatment at RI - Regional (50%), distant (25%) & others (25%) Treatment only at RI, Localised(7.4%), regional(66.7%), distant (24.1%)
Type of Treatment: Prior + treatment at RI: S(12.5), R-(50%), C-(12.5%), R+C – (25%) Treatment only at RI S(3.7%) R(25.9%), S+R(1.9%), R+C(68.5%)
Specific Treatment Prior + treatment at RI: Any S(10%), Any R(60%), AND Any C (30%) Treatment Only at RI Any S(3.3%), Any R(56.5%), Any C (40.2%) and any H (nil)
Treatment Status (Excluding cancer previously treated): Received (80.6%) Not Received (19.4%) and incomplete (0%)
Intent to treat:- Radical (88.9%) and Palliative (11.1%)
Marital status: - Married(62.1%)
Religion: - Hindu(73.8%)
Education :- Primary(48.5%)
Mother Tongue:- Malayalam(98.1%)
MCC Annual Report – HBCR 2011
215
Table 161: Number and Relative Proportion of Cervix cancer by five year age group
Age group Female (n=103) # %
Oct-14 - -
15-19 - -
20-24 - -
25-29 - -
30-34 1 0.97
35-39 2 1.94
40-44 5 4.85
45-49 14 13.59
50-54 15 14.56
55-59 20 19.42
60-64 14 13.59
65-69 11 10.68
70-74 8 7.77
>75 13 12.62
Unknown -
Table 162: Number and Relative Proportion of Cervix cancer by method of diagnosis
Method of Diagnosis
Female (n=103)
# %
Microscopic 93 90.3
X-ray/Imaging 1 1
Clinical 1 1
Others 8 7.8
Unknown - -
Table 163: Number and Relative Proportion of Cervix cancer by detailed microscopic diagnosis
Microscopic Diagnosis
Female (n=103) # %
Primary Histology 93 90.3
Secondary Histology - -
Cytology - -
Blood Film - -
Bone Marrow - -
Others 10 9.7
MCC Annual Report – HBCR 2011
216
Table 164: Number (#) and relative proportion(%) of Cervix cancer by histology
Clinical Information
Table 165: Number and Relative Proportion of Cervix cancer by Broad Treatment Group
Broad Treatment Group
Female (n=103) # %
Prior Trmt only 28 27.2
Prior & Trmt at RI 8 7.8
Trmt only at RI 54 52.4
No Treatment 13 12.6
Table 166: Number and Relative Proportion of Cervix cancer by Clinical Extent of Disease
i. Prior Treatment only
Clinical extent Female (n=28)
# %
Localised 2 7.1
Regional 9 32.1
Distant 7 25
Others 10 35.7
Unknown
Type of Histology Female(n=356) # %
Squamous Cell Carcinoma 30 29.13
Squamous Cell Carcinoma Large Cell Nonkeratinizing 30 29.13
Squamous Cell Carcinoma Nonkeratinizing 13 12.62
Neoplasm Malignant 10 9.71
Adenocarcinoma 8 7.77
Squamous Cell Carcinoma -Large Cell Keratinizing 4 3.88
Squamous Cell Carcinoma Keratinizing 4 3.88
Large Cell Squamous Cell Carcinoma 1 0.97
Leiomyosarcoma 1 0.97
Papillary Squamous Cell Carcinoma 1 0.97
Squamous Cell Carcinoma Small Cell Nonkeratinizing 1 0.97
MCC Annual Report – HBCR 2011
217
Table 167: ii. Treatment Only at RI
Clinical Extent Female (n=54)
# %
Localised 4 7.4
Regional 36 66.7
Distant 13 24.1
Others 1 1.9
Unknown - -
Table 168: iii. Prior + Treatment at RI
Clinical extent Femal (n=8) # %
Localised - -
Regional 4 50
Distant 2 25
Others 2 25
Unknown Table 169: iv. No Treatment
Clinical extent Female (n=13)
# %
Localised - -
Regional 7 53.8
Distant 6 46.2
Others - -
Unknown - -
Table 170: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI, No Treatment
Clinical extent Female (n=103)
# %
Localised 6 5.8
Regional 56 54.4
Distant 28 27.2
Others 13 12.6
Unknown - -
MCC Annual Report – HBCR 2011
218
Table 171: Number and Relative Proportion of Cervix cancer by Type of treatment i. Prior Treatment only, No Treatment
Type of Treatment
Female (n=28) # %
Surgery 8 28.6
R-therapy 5 17.9
C-Therapy - -
S+R 2 7.1
S+C - -
R+C 11 39.3
S+R+C 2 7.1
Others - -
Unknown - -
Table 172: ii. Treatment Only at RI, No Treatment
Type of Treatment Female (n=54)
# %
Surgery 2 3.7
R-therapy 14 25.9 C-Therapy - -
S+R 1 1.9
S+C - -
R+C 37 68.5
S+R+C - -
Others - -
Unknown - -
Table 173: iii. Prior + Treatment at RI (Prior Treatment), No Treatment:
Type of Treatment Female (n=8)
# %
Surgery 2 25
R-therapy 3 37.5
C-Therapy - -
S+R 1 12.5
S+C - -
R+C 2 25
S+R+C - -
Others - -
Unknown - -
MCC Annual Report – HBCR 2011
219
Table 174: iv. Prior + Treatment at RI (RI Treatment), No Treatment:
Type of Treatment Female (n=8)
# %
Surgery 1 12.5
R-therapy 4 50
C-Therapy 1 12.5
S+R - -
S+C - -
R+C 2 25
S+R+C - -
Others - -
Unknown - -
Table 175: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Type of treatment Female (n=90)
# %
Surgery 12 13.3
R-therapy 22 24.4
C-Therapy - -
S+R 4 4.4
S+C - -
R+C 50 55.6
S+R+C 2 4.4
Others - -
Unknown - -
Table 176: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt), No Treatment:
Type of Treatment Female (n=90)
# %
Surgery 11 12.2
R-therapy 23 25.6
C-Therapy 1 1.1
S+R 3 3.3
S+C - -
R+C 50 55.6
S+R+C 2 3.3
Others - -
Unknown - -
MCC Annual Report – HBCR 2011
220
Table 177: Number and Relative Proportion of Cervix cancer by Specific Treatment i. Prior Treatment Only, No Treatment
Specific Treatment Female (n=45) # %
Any S 12 26.7
Any R 20 44.4
Any C 13 28.9
Any H - -
Others - -
Unknown - - Table 178: ii. Treatment Only at RI, No Treatment
Specific Treatment Female (n=92)
# %
Any S 3 3.3
Any R 52 56.5
Any C 37 40.2
Any H - -
Others - -
Unknown - -
Table 179: iii. Prior + Treatment at RI (Prior Tmt), , No Treatment
Specific Treatment Female (n=11)
# %
Any S 3 27.3
Any R 6 54.5
Any C 2 18.2
Any H - -
Others - -
Unknown - -
Table 180: iv. Prior + Treatment at RI (RI Tmt), No Treatment
Specific Treatment Female (n=10)
# %
Any S 1 10
Any R 6 60
Any C 3 30
Any H - -
Others - -
MCC Annual Report – HBCR 2011
221
Unknown - - Table 181: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Specific Treatment
Female (n=148) # %
Any S 18 12.2
Any R 78 52.7
Any C 52 35.1
Any H - -
Others - -
Unknown - -
Table 182: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt), No Treatment:
Specific Treatment
Female (n=147)
# %
Any S 16 10.9
Any R 78 53.1
Any C 53 36.1
Any H - -
Others - -
Unknown
Table 183: Number and Relative Proportion of Cervix Cancer by Treatment Status (Excluding the Cancers Previously Treated)
Treatment Status Female (n=67)
# %
Received 54 80.6
Not Received 13 19.4
Not Accepted - -
Incomplete - -
Unknown - -
Table 184: Number and Relative Proportion of Tongue cancer by Intention to Treat (Excluding the Cancers Previously Treated)
Intention to Treat Female (n=54)
# %
Radical 48 88.9
Palliative 6 11.1
Pain Relief Only - - Symptomatic - -
MCC Annual Report – HBCR 2011
222
Unknown - -
DEMOGRAPHIC PARAMETERS
Table 185: Number and Relative Proportion of Cervix cancer by marital status
Marital Status Female (n=103)
# %
Unmarried 1 1
Married 64 62.1
Widowed 38 36.9
Divorced
Table 186: Number and Relative Proportion of Cervix cancer by religion
Religion Female (n=103)
# %
Hindu 76 73.8
Muslim 20 19.4
Christian 7 6.8
Unknown - -
Table 187: Number and Relative Proportion of Cervix cancer by education
Education Female (n=103)
# %
Primary 50 48.5
Secondary 16 15.5
Illiterate 20 19.4
Literate 4 3.9
College 6 5.8
Others 6 5.8
Unknown 1 1
Table 188: Number and Relative Proportion of Cervix cancer by mother tongue
Mother Tongue Female (n=103)
# %
Malayalam 101 98.1
Kannada 2 1.9
MCC Annual Report – HBCR 2011
223
VII. RECTUM Total Number(ICD10:C19-20):94 (48.81% females and 53.19% males)
Rectal cancer ranks 7th among all the cancers. 8th leading cancers among males and 7th leading cancer among females.
Male to Female ratio:1.14:1
Peak age group: 65-69, 70-74 >75(16%) in males & 45-49,70-74,>75 (13.64%) in Females
Average age at diagnosis:59.15 years.
Method of Diagnosis: Microscopic : 92% in Males & 86.4% in Females
Detailed Microscopic Diagnosis: Primary Histology : 92% in males &86.4% in Females.
Broad Treatment Group: Prior & treatment at RI – 16 % in males & 13.6% in Females Treatment only at RI : 44% in males 56.8 % in Females
Clinical Extent of Disease Prior+ treatment at RI – Males : Regional(50%) Distant (37.5%), others(12.5%) Females : Regional (33.3%), distant (50%), others (16.7%) Males : Treatment only at MCC regional (54.4%) and distant (45.5%) i Females : Localised (8%), regional(44%), distant (48%)
Type of Treatment: Prior + treatment at RI : Males : C(50%) S+R(12.5%) S+C(12.5%) R+C (25%) Females : C(50%) ,R+C – 50 % Treatment only at MCC Males: S(13.6%), R(4.5%), C(4.5%), S+C(4.5%), R+C(31.8%) Females : S(8.0%), R-(8.0%,) C-(8%), S+R-4%, S+C – 8%, R+C – 16%
Specific Treatment Prior + treatment at RI Males : Any S(16.7%), Any R(25.0%), & Any C (58.3%) Females: Any R(33.3%), & Any C (66.7%) Treatment Only at RI Males : Any S(27.1%), Any R(35.4%), Any C (37.5%) Females : Any S(30.4%), Any R(33.9%), Any C (35.7%)
Treatment Status (Excluding cancer previously treated): Males : Received (80.8%) and not received (11.5%) & Incomplete (3.8%) Females : Received (64.7%) Not Received (23.5%) and incomplete (88%)
Intent to treat: Males : Radical (40.9%) and Palliative (59.1%) Females : Radical (56%) and Palliative (44%)
Marital status: Males : Married (92%). Females : Married(54.5%)
Religion: Males : Hindu(68%) Females: Hindu(56.8%)
Education : Males : Primary(34%) Females : Primary(29.5%)
Mother Tongue: Males : Malayalam 100%
MCC Annual Report – HBCR 2011
224
Females : Malayalam(97.7%)
Table 189: Number and Relative Proportion of Rectum cancer by five year age group
Age group Males (n=50) Females (n=44) Total(n=94)
# % # % # %
Oct-14 - - - - - -
15-19 - - 1 2.27 1 1.06
20-24 - - - - - -
25-29 1 2 2 4.55 3 3.19
30-34 3 6 - - 3 3.19
35-39 1 2 3 6.82 4 4.26
40-44 3 6 3 6.82 6 6.38
45-49 2 4 6 13.64 8 8.51
50-54 5 10 5 11.36 10 10.64
55-59 6 12 3 6.82 9 9.57
60-64 5 10 5 11.36 10 10.64
65-69 8 16 4 9.09 12 12.77
70-74 8 16 6 13.64 14 14.89
>75 8 16 6 13.64 14 14.89
Unknown - - - - - -
Table 190: Number and Relative Proportion of Rectum cancer by method of diagnosis
Method of diagnosis
Males (n=50) Females (n=44) Total(n=94)
# % # % # %
Microscopic 46 92 38 86.4 84 89.36
X-ray/Imaging - - 1 2.3 1 1.06
Clinical - - 1 2.3 1 1.06
Others 4 8 4 9.1 8 8.51
Unknown - - - -
Table 191: Number and Relative Proportion of Rectum cancer by detailed microscopic diagnosis
Microscopic Diagnosis
Males (n=50) Females (n=44) Total(n=94)
# % # % # % Primary Histology 46 92 38 86.4 84 89.36 Secondary Histology - - - - - -
Cytology - - - - - -
Blood Film - - - - - -
Bone Marrow - - - - - -
Others 4 8 6 13.6 10 10.64
MCC Annual Report – HBCR 2011
225
Table 192: Number (#) and relative proportion(%) of Rectum cancer by histology
Type of Histology Male(n=50) Female(n=44) Total(n=94) # % # % # %
Adenocarcinoma 42 84 34 77.27 76 80.85
Mucinous Carcinoma 1 2 1 2.27 2 2.13
Neoplasm Malignant 5 10 6 13.64 11 11.7
Papillary Adenocarcinoma 0 0 2 4.55 2 2.13 Squamous Cell Carcinoma 1 2 0 0 1 1.06 Villous Adenocarcinoma 1 2 1 2.27 2 2.13
Clinical Information
Table 193: Number and Relative Proportion of Rectum cancer by Broad Treatment Group
Broad Treatment Group
Males (n=50) Females(n=44) Total(n=94) # % # % # %
Prior Trmt only 16 32 4 9.1 20 21.28
Prior & Trmt at RI 8 16 6 13.6 14 14.89
Trmt only at RI 22 44 25 56.8 47 50
No Treatment 4 8 9 20.5 13 13.83
Table 194: Number and Relative Proportion of Rectum cancer by Clinical Extent of Disease
i. Prior Treatment only
Clinical extent Female (n=16) Female(n=4) Total(n=20)
# % # % # %
Localised - - - - - -
Regional 5 31.2 - - 5 25
Distant 7 43.8 1 25 8 40
Others 4 25 3 75 7 35
Unknown - - - - - -
Table 195: ii. Treatment Only at RI
Clinical Extent Males (n=22) Female(n=25) Total(n=47)
# % # % # %
Localised - - 2 8 2 4.26
Regional 12 54.5 11 44 23 48.94
Distant 10 45.5 12 48 22 46.81
Others - - - - - -
MCC Annual Report – HBCR 2011
226
Unknown - - - - - - Table 196: iii. Prior + Treatment at RI
Clinical extent Males (n=8) Female(n=6) Total(n=14)
# % # % # %
Localised - - - - - -
Regional 4 50 2 33.3 6 42.86
Distant 3 37.5 3 50 6 42.86
Others 1 12.5 1 16.7 2 14.29
Unknown - - - -
Table 197: iii. No Treatment
Clinical extent Males (n=4) Female(n=9) Total(n=13) # % # % # %
Localised - - 1 11.1 1 7.69
Regional 1 25 - - 1 7.69
Distant 3 75 5 55.6 8 61.54
Others - - 3 33.3 3 23.08
Unknown - - - - - -
Table 198: iv. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI, No Treatment
Clinical extent Male(n=50) Female(n=44) Total(n=94) # % # % # %
Localised - - 3 6.8 3 3.19
Regional 22 44 13 29.5 35 37.23
Distant 23 46 21 47.7 44 46.81
Others 5 10 7 15.9 12 12.77
Unknown - - - - - -
Table 199: Number and Relative Proportion of Rectum cancer by Type of treatment i. Prior Treatment only, No Treatment
Type of Treatment
Males (n=16) Female(n=4) Total(n=20)
# % # % # %
Surgery 5 31.2 - - 5 25
R-therapy 2 12.5 - - 2 10
C-Therapy 3 18.8 - - 3 15
S+R - - - - - -
S+C 2 12.5 3 75 5 25
R+C 1 6.2 1 25 2 10
S+R+C 3 0 - - 3 15
MCC Annual Report – HBCR 2011
227
Others - -
Unknown Table 200: ii. Treatment Only at RI, No Treatment
Type of Treatment
Males (n=22) Females(n=25) Total(n=47)
# % # % # %
Surgery 3 13.6 2 8 5 10.64
R-therapy 1 4.5 2 8 3 6.38
C-Therapy 1 4.5 2 8 3 6.38
S+R - - 1 4 1 2.13
S+C 1 4.5 2 8 3 6.38
R+C 7 31.8 4 16 11 23.4
S+R+C 9 0 12 4 21 44.68
Others - - - - - -
Unknown - - - - - -
Table 201: iii. Prior + Treatment at RI (Prior Treatment), No Treatment:
Type of Treatment
Male(n=8) Female(n=6) Total(n=14)
# % # % # %
Surgery 2 25 3 50 5 35.71
R-therapy - - - - - -
C-Therapy 1 12.5 - - 1 7.14
S+R - - - - - -
S+C 2 25 - - 2 14.29
R+C 1 12.5 1 16.7 2 14.29
S+R+C 2 0 2 0 4 28.57
Others -
Unknown -
Table 202: iv. Prior + Treatment at RI( RI Treatment), No Treatment:
Type of Treatment
Males (n=8) Female(n=6) Total(n=14)
# % # % # %
Surgery - - - - - -
R-therapy - - - - - -
C-Therapy 4 50 3 50 7 50
S+R 1 12.5 - - 1 7.14
S+C 1 12.5 - - 1 7.14
R+C 2 25 3 50 5 35.71
S+R+C - - - -
Others - - - -
Unknown - - - -
MCC Annual Report – HBCR 2011
228
Table 203: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt),, No Treatment:
Type of treatment
Males (n=46) Female(n=35) Total(n=81)
# % # % # %
Surgery 10 21.7 5 14.3 15 18.52
R-therapy 3 6.5 2 5.7 5 6.17
C-Therapy 5 10.9 2 5.7 7 8.64
S+R - - 1 2.9 1 1.23
S+C 5 10.9 5 14.3 10 12.35
R+C 9 19.6 6 17.1 15 18.52
S+R+C 14 0 14 2.9 28 34.57
Others
Unknown
Table 204: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt),, No Treatment:
Type of Treatment
Males (n=46) Females(n=35) Total(n=81)
# % # % # %
Surgery 8 17.4 2 5.7 10 12.35
R-therapy 3 6.5 2 5.7 5 6.17
C-Therapy 8 17.4 5 14.3 13 16.05
S+R 1 2.2 1 2.9 2 2.47
S+C 4 8.7 5 14.3 9 11.11
R+C 10 21.7 8 22.9 18 22.22
S+R+C 12 2.2 12 2.9 24 29.63
Others - - - - - -
Unknown - - - - -
Table 205: Number and Relative Proportion of Rectum by Specific Treatment i. Prior Treatment Only, No Treatment
Specific Treatment
Males (n=25) Female(n=8) Total(n=33)
# % # % # %
Any S 10 40 3 37.5 13 39.39
Any R 6 24 1 12.5 7 21.21
Any C 9 36 4 50 13 39.39
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
MCC Annual Report – HBCR 2011
229
Table 206: ii. Treatment Only at RI, No Treatment
Specific Treatment
Males (n=48) Female(n=56) Total(n=104)
# % # % # %
Any S 13 27.1 17 30.4 30 28.85
Any R 17 35.4 19 33.9 36 34.62
Any C 18 37.5 20 35.7 38 36.54
Any H
Others
Unknown
Table 207: iii. Prior + Treatment at RI (Prior Tmt), No Treatment
Specific Treatment
Males (n=15) Female(n=11) Total(n=26)
# % # % # %
Any S 6 40 5 45.5 11 42.31
Any R 3 20 3 27.3 6 23.08
Any C 6 40 3 27.3 9 34.62
Any H
Others
Unknown
Table 208: iv. Prior + Treatment at RI (RI Tmt), No Treatment
Specific Treatment
Males (n=12) Female(n=9) Total(n=21)
# % # % # %
Any S 2 16.7 - - 2 9.52
Any R 3 25 3 33.3 6 28.57
Any C 7 58.3 6 66.7 13 61.9
Any H
Others
Unknown
Table 209: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Specific Treatment
Males (n=88) Female(n=75) Total(n=163)
# % # % # %
Any S 29 33 25 33.3 54 33.13
Any R 26 29.5 23 30.7 49 30.06
Any C 33 37.5 27 36 60 36.81
Any H
Others
Unknown
MCC Annual Report – HBCR 2011
230
Table 210: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt),, No Treatment:
Specific Treatment
Males (n=85) Female(n=73) Total(n=158)
# % # % # %
Any S 25 29.4 20 27.4 45 28.48
Any R 26 30.6 23 31.5 49 31.01
Any C 34 40 30 41.1 74 46.84
Table 211: Number and Relative Proportion of Rectum cancer by Treatment Status (Excluding the Cancers Previously Treated)
Treatment Status
Males (n=26) Female(n=34) Total(n=60)
# % # % # %
Received 21 80.8 22 64.7 43 71.67 Not Received 3 11.5 8 23.5 11 18.33 Not Accepted 1 3.8 1 2.9 2 3.33
Incomplete 1 3.8 3 8.8 4 6.67
Unknown - - - - - -
Table 212: Number and Relative Proportion of Rectum cancer by Intention to Treat (Excluding the Cancers Previously Treated)
Intention to Treat
Male(n=22) Female(n=25) Total(n=47)
# % # % # %
Radical 9 40.9 14 56 23 48.94
Palliative 13 59.1 11 44 24 51.06
Pain Relief Only - -
Symptomatic - -
Unknown - -
MCC Annual Report – HBCR 2011
231
Basic Demographic Parameters
Table 213: Number and Relative Proportion of Rectum cancer by marital status
Marital Status
Males (n=50) Females (n=44) Total(n=94)
# % # % # %
Unmarried 1 2 2 4.5 3 3.19
Married 46 92 24 54.5 70 74.47
Widowed 3 6 18 40.9 21 22.34
Divorced - - - - - -
Others - - - - - -
Table 214: Number and Relative Proportion of Rectum cancer by religion
Religion Males (n=50) Females (n=44) Total(n=94) # % # % # %
Hindu 34 68 25 56.8 59 62.77
Muslim 12 24 18 40.9 30 31.91
Christian 4 8 1 2.3 5 5.32
Table 215: Number and Relative Proportion of Rectum cancer by education
Education Males (n=50) Females (n=44) Total(n=94)
# % # % # %
Primary 17 34 13 29.5 30 31.91
Secondary 17 34 9 20.5 26 27.66
Illiterate 7 14 10 22.7 17 18.09
Literate - - 6 13.6 6 6.38
College 5 10 5 11.4 10 10.64
Others 4 8 1 2.3 5 5.32
Unknown - - - - - -
Table 216: Number and Relative Proportion of Rectum cancer by mother tongue
Mother Tongue
Males(n=50) Females(n=44) Total(n=94)
# % # % # %
Malayalam 50 100 43 97.7 93 98.94
Kannada - - 1 2.3 1 1.06
MCC Annual Report – HBCR 2011
232
VIII. OVARY
Total Number(ICD10:C56):90
Ovary Cancer in ranks 8th among all the cancers. And 3rd leading cancer among females.
Peak age group: 55-59(16.67%)
Average age at diagnosis:53.94 years.
Method of Diagnosis: Microscopic-75.6%
Detailed Microscopic Diagnosis: Primary Histology-66.7
Broad Treatment Group: Prior & treatment at RI –35.6% Treatment only at RI 32.2%
Clinical Extent of Disease Prior+ treatment at RI –Regional(21.9%) Distant( 31.2% ), others (46.9%) Treatment only at RI regional(27.6%), distant (72.4%) in females
Type of Treatment: Prior + treatment at RI : S(9.4%), C(65.6%), S +C - (21.9%) , R+C(3.1%) Treatment only at RI C-37.9%, S+R-6.9%, S+C – 51.7%,
Specific Treatment Prior + Treatment at RI Any S(25%), Any R(2.5%), & Any C (72.5%) Treatment Only at RI Any S(37.5%), Any R(6.2%), Any C (56.2%)
Treatment Status (Excluding cancer previously treated): Received (55%) Not Received (27.5%) and incomplete (17.5%) .
Intent to treat:- Radical (44.8%) and Palliative (55.2%) .
Marital status: - Married(58.9%)
Religion: - Hindu(63.3%)
Education : - Primary(42.2%)
Mother Tongue: - Malayalam (98.9%)
MCC Annual Report – HBCR 2011
233
Table 217: Number and Relative Proportion of Ovary cancer by five year age group
Age group Female (n=90)
# %
Oct-14 -
15-19 1 1.11
20-24 1 1.11
25-29 3 3.33
30-34 5 5.56
35-39 6 6.67
40-44 9 10
45-49 8 8.89
50-54 11 12.22
55-59 15 16.67
60-64 8 8.89
65-69 9 10
69-74 10 11.11
>75 4 4.44
Unknown
Table 218: Number and Relative Proportion of Ovary cancer by method of diagnosis
Method of diagnosis
Female (n=90)
# %
Microscopic 68 75.6
X-ray/Imaging 4 4.4
Clinical - -
Others 18 20
Unknown - -
Table 219: Number and Relative Proportion of Ovary cancer by detailed microscopic diagnosis
Microscopic Diagnosis Female (n=90)
# %
Primary Histology 60 66.7
Secondary Histology 7 7.8
Cytology 1 1.1
Blood Film - -
Bone Marrow - -
Others 22 24.4
MCC Annual Report – HBCR 2011
234
Clinical Information
Table 220: Number and Relative Proportion of Ovary cancer by Broad Treatment Group
Broad Treatment Group
Female (n=90)
# %
Prior Trmt only 18 20
Prior & Trmt at RI 32 35.6
Trmt only at RI 29 32.2
No Treatment 11 12.2 Table 221: Number and Relative Proportion of Ovary cancer by Clinical Extent of Disease
i. Prior Treatment only
Clinical extent Female (n=18)
# %
Localised 2 11.1
Regional 2 11.1
Distant 6 33.3
Others 8 44.4
Unknown - -
Table 222: ii. Treatment Only at RI
Clinical Extent Female (n=29)
# %
Localised - -
Regional 8 27.6
Distant 21 72.4
Others - -
Unknown - - Table 223: iii. Prior + Treatment at RI
Clinical extent Female (n=32)
# %
Localised - -
Regional 7 21.9
Distant 10 31.2
Others 15 46.9
Unknown - -
MCC Annual Report – HBCR 2011
235
Table 224: iv. No Treatment
Clinical extent Female (n=11)
# %
Localised - -
Regional 1 9.1
Distant 10 90.9
Others - -
Unknown Table 225: iv. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI, No Treatment
Clinical extent
Female (n=90)
# %
Localised 2 2.2
Regional 18 20
Distant 47 52.2
Others 23 25.6
Unknown - - Table 226: Number and Relative Proportion of Ovary cancer by Type of treatment i. Prior Treatment only, No Treatment
Type of Treatment
Female (n=18)
# % Surgery 8 44.4
R-therapy - -
C-Therapy 2 11.1
S+R - -
S+C 5 27.8
R+C - -
S+R+C 1 0
Others 2 27.8
Unknown - -
MCC Annual Report – HBCR 2011
236
Table 227: ii. Treatment Only at RI, No Treatment
Type of Treatment Female (n=29)
# %
Surgery - -
R-therapy - -
C-Therapy 11 37.9
S+R 2 6.9
S+C 15 51.7
R+C - -
S+R+C 1 6.9
Others - -
Unknown - -
Table 228: iii. Prior + Treatment at RI (Prior Treatment), No Treatment:
Type of Treatment Female (n=32) # %
Surgery 16 50
R-therapy - -
C-Therapy - -
S+R - -
S+C 12 37.5
R+C 2 6.2
S+R+C 2 0
Others - -
Unknown - -
Table 229: iv. Prior + Treatment at RI( RI Treatment), No Treatment:
Type of Treatment Female (n=32)
# %
Surgery 3 9.4
R-therapy - -
C-Therapy 21 65.6
S+R - -
S+C 7 21.9
R+C 1 3.1
S+R+C - -
Others - -
Unknown
MCC Annual Report – HBCR 2011
237
Table 230: iv. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Type of treatment Female (n=79)
# %
Surgery 24 30.4
R-therapy - -
C-Therapy 13 16.5
S+R 2 2.5
S+C 32 40.5
R+C 2 2.5
S+R+C 4 2.5
Others 2 40.5
Unknown - - Table 231: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt), No Treatment:
Type of Treatment Female (n=79)
# % Surgery 11 13.9
R-therapy - -
C-Therapy 34 43
S+R 2 2.5
S+C 27 34.2
R+C 1 1.9
S+R+C 2 2.5
Others 2 34.2
Unknown - -
Table 232: Number and Relative Proportion of Ovary cancer by Specific Treatment i. Prior Treatment Only, No Treatment
Specific Treatment Female (n=30)
# %
Any S 16 53.3
Any R 2 6.7
Any C 10 33.3
Any H 2 6.7
Others - -
Unknown - -
MCC Annual Report – HBCR 2011
238
Table 233: ii. Treatment Only at RI, No Treatment
Specific Treatment Female (n=48)
# %
Any S 18 37.5
Any R 3 6.2
Any C 27 56.2
Any H - -
Others - -
Unknown - -
Table 234: iii. Prior + Treatment at RI (Prior Tmt), No Treatment
Specific Treatment Female (n=50)
# %
Any S 30 60
Any R 4 8
Any C 16 32
Any H - -
Others - -
Unknown - -
Table 235: iv. Prior + Treatment at RI (RI Tmt), No Treatment
Specific Treatment Female (n=40)
# %
Any S 10 25
Any R 1 2.5
Any C 29 72.5
Any H - -
Others - -
Unknown - -
MCC Annual Report – HBCR 2011
239
Table 236: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Specific Treatment Female (n=128)
# %
Any S 64 50
Any R 9 7
Any C 53 41.4
Any H 2 1.6
Others - -
Unknown - - Table 237: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt),, No Treatment:
Specific Treatment Female (n=118)
# %
Any S 44 37.3
Any R 6 5.1
Any C 66 55.9
Any H 2 1.7
Others - -
Unknown - -
Table 238: Number and Relative Proportion of Ovary cancer by Treatment Status (Excluding the Cancers Previously Treated)
Treatment Status Female (n=40)
# %
Received 22 55
Not Received 11 27.5
Not Accepted - -
Incomplete 7 17.5
Unknown - -
Table 239: Number and Relative Proportion of Ovary cancer by Intention to Treat (Excluding the Cancers Previously Treated)
Intention to Treat Female (n=29)
# %
Radical 13 44.8
Palliative 16 55.2
Pain Relief Only - -
Symptomatic - -
Unknown - -
MCC Annual Report – HBCR 2011
240
Demographic Parameters
Table 240: Number and Relative Proportion of Ovary cancer by marital status
Marital Status Female (n=90)
# %
Unmarried 15 16.7
Married 53 58.9
Widowed 22 24.4
Divorced - -
Others - -
Table 241: Number and Relative Proportion of Ovary cancer by religion
Religion Female (n=90)
# %
Hindu 57 63.3
Muslim 24 26.7
Christian 9 10
Table 242: Number and Relative Proportion of Ovary cancer by education
Education Female (n=90)
# %
Primary 32 42.2
Secondary 23 25.6
Illiterate 11 12.2
Literate 4 4.4
College 8 8.9
Others 6 6.7
Unknown
Table 243: Number and Relative Proportion of Ovary cancer by mother tongue
Mother Tongue Females (n=90)
# %
Malayalam 89 98.9
Unknown 1 1.1
MCC Annual Report – HBCR 2011
241
IX. OESOPHAGUS Total Number(ICD10:C15):87(29.89% females and 70.11% males)
Oesophagus ranks 9th among all the cancers. And 5th leading cancer among males and in females the rank >10.
Male to Female ratio:2.35:1
Peak age group70-74 (26.23%) in males & >75(50%) in Females
Average age at diagnosis : 66.35 years.
Method of Diagnosis: Microscopic : 95.11% in Males & 96.2% in Females
Detailed Microscopic Diagnosis: Primary Histology : 90.2% in males & 88.5% in Females.
Broad Treatment Group: Prior & treatment at RI – 3.3 % in males & 3.8% in Females Treatment only at RI- 59% in males & 46.2 % in Females
Clinical Extent of Disease Males : Prior + treatment at RI –Distant (100%) Females : distant (100%) Males : Treatment only at RI : Localised(2.8%) regional (38.9%) and distant (58.3%) Females : Localised (0%), regional(41.7%), distant (58.3%)
Type of Treatment: Prior + treatment at RI : Males : C(50%), S+R(50%) Females : R(100%) Treatment only at RI Males : S(2.8%), R(47.2%), C(8.3%), R+C(36.1%) Females : S-(8.3%), R-66.7%, R+C – 25%
Specific Treatment Prior + treatment at RI Males : Any S(33.3%), Any R(33.3%), AND Any C (33.3%) Females : Any R(100%) Treatment Only at RI Males : Any S(5.7%), Any R(60.4%), Any C (34%) Females : Any S(6.7%), Any R(73.3%), Any C (20%)
Treatment Status (Excluding cancer previously treated): Males Received (65.4%) and not received (28.8%) & incomplete (3.8%) Females : Received (54.5%) Not Received (45.5%)
Intent to treat: Males : Radical (41.7%) and Palliative (58.3%) Females :.Radical (25%) and Palliative (75%)
Marital status: Males : Married (95.1%) Females : widowed (57.7%)
Religion: Males : Hindu(75.4%) Females : Hindu(76.9%)
Education : Males : Primary(50.8%) Females : Primary(46.2%)
Mother Tongue: Malayalam 100% in males & females.
MCC Annual Report – HBCR 2011
242
Table 244: Number and Relative Proportion of Oesophagus cancer by five year age group
Age
group male (n=61) Female(n=26) Total(87)
# % # % # %
35-39 - - 1 3.85 1 1.15
40-44 - - 1 3.85 1 1.15
45-49 4 6.56 1 3.85 5 5.75
50-54 6 9.84 1 3.85 7 8.05
55-59 10 16.39 - - 10 11.49
60-64 10 16.39 4 15.38 14 16.09
65-69 5 8.19 1 3.85 6 6.89
70-74 16 26.23 4 15.38 20 22.99
>75 10 16.39 13 50 23 26.44
Unknown - - - - - -
Table 245: Number and Relative Proportion of Oesophagus cancer by method of diagnosis
Method of Diagnosis
Male(n=61) Female(n=26) Total(87)
# % # % # %
Microscopic 58 95.1 25 96.2 83 95.4
X-ray/Imaging - - - - - -
Clinical - - - - - -
Others 3 4.9 1 3.8 4 4.59
Unknown - - - - - -
Table 246: Number and Relative Proportion of Oesophagus cancer by detailed microscopic
diagnosis
Microscopic Diagnosis
Female (n=61) Female(n=26) Total(n=87)
# % # % # %
Primary Histology 55 90.2 23 88.5 78 89.66
Secondary Histology 3 4.9 2 7.7 5 5.75
Cytology - - - - - -
Blood Film - - - - - -
Bone Marrow - - - - - -
Others 3 4.9 1 3.8 4 4.59
Table 247: Number (#) and relative proportion(%) of Oesophagus cancer by histology
Type of Histology Male(n=61) Female(n=26) Total(n=87)
# % # % # %Squamous Cell Carcinoma 44 72.13 21 80.77 65 74.71 Adenocarcinoma 9 14.75 0 0 9 10.34 Carcinoma 1 1.64 1 3.85 2 2.30
MCC Annual Report – HBCR 2011
243
Neoplasm Malignant 6 9.84 4 15.38 10 11.49 Signet Ring Cell Carcinoma 1 1.64 0 0 1 1.15
Clinical Information
Table 248: Number and Relative Proportion of Oesophagus cancer by Broad Treatment Group
Broad Treatment Group Female (n=61) Male (n=26) Total(n=87)
# % # % # %
Prior Trmt only 7 11.5 3 11.5 10 11.49
Prior & Trmt at RI 2 3.3 1 3.8 3 3.45
Trmt only at RI 36 59 12 46.2 48 55.17
No Treatment 16 26.2 10 38.5 26 29.88
Table 249: Number and Relative Proportion of Oesophagus cancer by Clinical Extent of Disease
i. Prior Treatment only
Clinical extent Male(n=7) Female(n=3) Total(n=10)
# % # % # %
Localised - - - - - -
Regional 2 28.6 1 33.3 3 30
Distant 2 28.6 1 33.3 3 30
Others 3 42.9 1 33.3 4 40
Unknown - - - - - -
Table 250: ii. Treatment Only at RI
Clinical Extent Male(n=36) Female(n=12) Total(n=48)
# % # % # %
Localised 1 2.8 - - 1 2.08
Regional 14 38.9 5 41.7 19 39.58
Distant 21 58.3 7 58.3 28 58.33
Others - - - - - -
Unknown - - - - - -
Table 251: iii. Prior + Treatment at RI
Clinical extent Male(n=2) Female(n=1) Total(n=3)
# % # % # %
Localised - - - - - -
Regional - - - - - -
Distant 2 100 1 100 3 100
Others - - - - - -
Unknown - - - - - -
MCC Annual Report – HBCR 2011
244
Table 252: iv. No Treatment
Clinical extent Male(n=16) Female(n=10) Total(n=26)
# % # % # %
Localised - - - - - -
Regional 3 18.8 2 20 5 19.23
Distant 9 56.2 6 60 15 57.69
Others 4 25 2 20 6 23.08
Unknown - - - - - -
Table 253: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI, No Treatment
Clinical extent Female (n=61) Female(n=26) Total(n=87)
# % # % # %
Localised 1 1.6 - - 1 1.15
Regional 19 31.1 8 30.8 27 31.03
Distant 34 55.7 15 57.7 49 56.32
Others 7 11.5 3 11.5 10 11.49
Unknown - - - - - - Table 254: Number and Relative Proportion of Oesophagus cancer by Type of treatment i. Prior Treatment only, No Treatment
Type of Treatment Male (n=7) Female (n=3) Total(n=10)
# % # % # %
Surgery - - - - - -
R-therapy 1 14.3 3 100 4 40
C-Therapy 1 14.3 - - 1 10
S+R - - - - - -
S+C 1 14.3 - - 1 10
R+C 4 57.1 - - 4 40
S+R+C - - - - - -
Others
Unknown Table 255: ii. Treatment Only at RI, No Treatment
Type of Treatment Male (n=36) Female (n=12) Total(n=48)
# % # % # %
Surgery 1 2.8 1 8.3 2 4.17
R-therapy 17 47.2 8 66.7 25 52.08
C-Therapy 3 8.3 - - 3 6.25
MCC Annual Report – HBCR 2011
245
Type of Treatment Male (n=36) Female (n=12) Total(n=48)
# % # % # %
S+R - - - - - -
S+C - - - - - -
R+C 13 36.1 3 25 16 33.33
S+R+C 2 0 - - 2 4.17
Others - - - -
Unknown
Table 256: iii. Prior + Treatment at RI (Prior Treatment), No Treatment:
Type of Treatment Male (n=2) Female (n=1) Total(n=3)
# % # % # %
Surgery - - - - - -
R-therapy - - - - - -
C-Therapy 1 50 1 100 2 66.67
S+R - - - - - -
S+C - - - - - -
R+C - - - - - -
S+R+C 1 0 - - 1 33.33
Others - - - -
Unknown Table 257: iv. Prior + Treatment at RI (RI Treatment), No Treatment:
Type of Treatment
Male (n=2) Female (n=1) Total(n=3)
# % # % # %
Surgery - - - - - -
R-therapy - - 1 100 1 33.33
C-Therapy 1 50 - - 1 33.33
S+R 1 50 - - 1 33.33
S+C - - - - - -
R+C - - - - - -
S+R+C - - - -
Others - - - -
Unknown - - - -
Table 258: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt),, No Treatment:
Type of treatment
Male (n=45) Female (n=16) Total(n=61)
# % # % # %
Surgery 1 2.2 1 6.2 2 3.28
R-therapy 18 40 11 68.8 29 47.54
MCC Annual Report – HBCR 2011
246
Type of treatment
Male (n=45) Female (n=16) Total(n=61)
# % # % # %
C-Therapy 5 11.1 1 6.2 6 9.84
S+R - - - - - -
S+C 1 2.2 - - 1 1.64
R+C 17 37.8 3 18.8 20 32.79
S+R+C 3 0 - - 3 4.92
Others - - - - - -
Unknown - - - - - -
Table 259: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt),, No Treatment:
Type of Treatment
Male (n=45) Female (n=16) Total(n=61)
# % # % # %
Surgery 1 2.2 1 6.2 2 3.28
R-therapy 18 40 12 75 30 49.18
C-Therapy 5 11.1 - - 5 8.19
S+R 1 2.2 - - 1 1.64
S+C 1 2.2 - - 1 1.64
R+C 17 37.8 3 18.8 20 32.79
S+R+C 2 2.2 - - 2 3.28
Others - - - - - -
Unknown Table 260: Number and Relative Proportion of Oesophagus cancer by Specific Treatment i. Prior Treatment Only, No Treatment
Specific Treatment
Male (n=12) Females(n=3) Total(n=15)
# % # % # %
Any S 1 8.3 - - 1 6.67
Any R 5 41.7 3 100 8 53.33
Any C 6 50 - - 6 40
Any H - - - - - -
Others - - - - - -
Unknown - - - - - - Table 261: ii. Treatment Only at RI, No Treatment
Specific Treatment
Male (n=53) Female (n=15) Total(n=68)
# % # % # %
Any S 3 5.7 1 6.7 4 5.88
Any R 32 60.4 11 73.3 43 63.24
Any C 18 34 3 20 21 30.88
Any H - - - - - -
MCC Annual Report – HBCR 2011
247
Others - - - - - -
Unknown - - - - - - Table 262: iii. Prior + Treatment at RI (Prior Tmt), , No Treatment
Specific Treatment
Male (n=4) Female (n=1) Total(n=5)
# % # % # %
Any S 1 25 - - 1 20
Any R 1 25 - - 1 20
Any C 2 50 1 100 3 60
Any H - - - - - -
Others - - - - - -
Unknown - - - - - - Table 263: iv. Prior + Treatment at RI (RI Tmt), , No Treatment
Specific Treatment
Male (n=3) Female(n=1) Total(n=4)
# % # % # %
Any S 1 33.3 - - 1 25
Any R 1 33.3 1 100 2 50
Any C 1 33.3 - - 1 25
Any H - - - - - -
Others - - - - - -
Unknown - - - - - - Table 264: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt),, No Treatment:
Specific Treatment
Male (n=69) Female (n=19) Total(n=88)
# % # % # %
Any S 5 7.2 1 5.3 6 6.82
Any R 38 55.1 14 73.7 52 59.09
Any C 26 37.7 4 21.1 30 34.09
Any H - - - - - -
Others - - - - - -
Unknown - - - -
Table 265: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt), No Treatment:
Specific Treatment
Male (n=68) Female (n=19) Total(n=87)
# % # % # %
Any S 5 7.4 1 5.3 6 6.89
Any R 38 55.9 15 78.9 53 60.92
Any C 25 36.8 3 15.8 28 32.18
Any H - - - - - -
MCC Annual Report – HBCR 2011
248
Others - - - - - -
Unknown - - - - - -
Table 266: Number and Relative Proportion of Oesophagus Cancer by Treatment Status (Excluding the Cancers Previously Treated)
Treatment Status Males (n=52) Females(n=22) Total(n=74)
# % # % # %
Received 34 65.4 12 54.5 46 62.16
Not Received 15 28.8 10 45.5 25 33.78
Not Accepted 1 1.9 - - 1 1.35
Incomplete 2 3.8 - - 2 2.7
Unknown - - - - - -
Table 267: Number and Relative Proportion of Oesophagus cancer by Intention to Treat (Excluding the Cancers Previously Treated)
Intention to Treat Male (n=36) Female (n=12) Total (n=48 ) # % # % # %
Radical 15 41.7 3 25 18 37.5
Palliative 21 58.3 9 75 30 62.5
Pain Relief Only - - - - - -
Symptomatic - - - - - -
Unknown - - - - - -
DEMOGRAPHIC PARAMETERS
Table 268: Number and Relative Proportion of Oesophagus cancer by marital status
Marital Status Female (n=61) Female(n=26) Total(n=87)
# % # % # %
Unmarried 1 1.6 - - 1 1.15
Married 58 95.1 11 42.3 69 79.31
Widowed 2 3.3 15 57.7 17 19.54
Divorced - - -
Table 269: Number and Relative Proportion of Oesophagus cancer by religion
Religion Female (n=61) Female(n=26) Total(n=87) # % # % # %
Hindu 46 75.4 20 76.9 66 75.86
Muslim 10 16.4 5 19.2 15 17.24
Christian 5 8.2 1 3.8 6 6.89
Unknown - - - -
MCC Annual Report – HBCR 2011
249
Table 270: Number and Relative Proportion of Oesophagus cancer by education
Education Male (n=61) Female(n=26) Total(n=87) # % # % # %
Primary 31 50.8 12 46.2 43 49.43
Secondary 13 21.3 2 7.7 15 17.24
Illiterate 7 11.5 10 38.5 17 19.54
Literate 4 6.6 2 7.7 6 6.89
College 4 6.6 - - 4 4.59
Others 2 3.3 - - 2 2.29
Unknown - - - - - -
Table 271: Number and Relative Proportion of Oesophagus cancer by mother tongue
Mother Tongue Male (n=61) Female(n=26) Total(n=87)
# % # % # %
Malayalam 61 100 26 100 87 100
Kannada - - - - --
MCC Annual Report – HBCR 2011
250
X. NHL
Total Number(ICD10:C82-85,C-96):86 (45.35% females and 54.65% males)
NHL Cancer in females ranks 10TH among all the cancers. 9th leading cancer among males and 8th position in females.
Male to Female ratio:1.21:1
Peak age group: >75(19.15%) in males & 55-59&>75(20.51%) in Females
Average age at diagnosis :59.01 years.
Method of Diagnosis: Microscopic: 100% in Males & 100% in Females
Detailed Microscopic Diagnosis: Primary Histology: 97.9% in males & 100% in Females
Broad Treatment Group: Prior & treatment at RI– 14.9 % in males & 10.3% in Females Treatment only at RI - 42.6% in males & 48.7 % in Females
Clinical Extent of Disease Prior + treatment at RI – Males : Regional(42.9%) Distant (14.3%), others (42.9%) Females : Regional (75%), others (25%) Treatment only at RI : Males : regional (80%) and distant (20%) Females : regional(63.2%), distant (31.6%)
Type of Treatment: Prior + treatment at RI: Males : R(28.6%), C(42.9%) , R+C(28.6%) Females : C-(100%) Treatment only at RI Males : S(5%), R(5%), C(70%), R+C(15%) Females : C-(68.4%), R+C –( 26.3%)
Specific Treatment Prior + treatment at RI Males : Any R(44.4%), & Any C (55.6%) Females: Any C (100%) Treatment Only at RI Males : Any S(8.0%), Any R(20.0%), & Any C (72%) Females : Any S(3.8%), Any R(23.1%),& Any C (73.1%)
Treatment Status (Excluding cancer previously treated): Males : Received (46.9%) and not received (37.5%) Incomplete(15.6%) Females : Received (64.2%) Not Received (23.1%) and incomplete (3.8%).
Intent to treat: Males : Radical (65%) and Palliative (35%) Females : Radical (57.7%) and Palliative (42.1%)
Marital status: Males : Married (93.6%) Females : Married(48.7%)
Religion: Males : Hindu(68.1%) Females : Hindu(64.1%)
Education : Males : Primary(42.6%) Females : Primary(30.8%)
Mother Tongue: Malayalam 100% in males & females.
MCC Annual Report – HBCR 2011
251
Table 272: Number and Relative Proportion of NHLcancer by five year age group
Age group
male (n=47) Female(n=39) Total(n=86)
# % # % # %
Oct-14 1 2.13 - - 1 1.16
15-19 - - - - - -
20-24 - - 1 2.56 1 1.16
25-29 - - 1 2.56 1 1.16
30-34 3 6.38 - - 3 3.49
35-39 2 4.26 1 2.56 3 3.49
40-44 5 10.64 2 5.13 7 8.14
45-49 3 6.38 1 2.56 4 4.65
50-54 7 14.89 2 5.13 9 10.47
55-59 6 12.77 8 20.51 14 16.28
60-64 8 17.02 6 15.38 14 16.28
65-69 2 4.26 3 7.69 5 5.81
70-74 1 2.13 6 15.38 7 8.14
>75 9 19.15 8 20.51 17 19.76
Unknown - - - - - -
Table 273: Number and Relative Proportion of NHLcancer by method of diagnosis
Method of Diagnosis
Male(n=47) Female(n=39) Total(n=86)
# % # % # %
Microscopic 47 100 39 100 86 100
X-ray/Imaging - - - - - -
Clinical - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 274: Number and Relative Proportion of NHLcancer by detailed microscopic
diagnosis
Microscopic Diagnosis
Males (n=47) Females(n=39) Total(n=86)
# % # % # %
Primary Histology 46 97.9 39 100 85 98.84 Secondary Histology 1 2.1 - - 1 1.16
Cytology - - - - - -
Blood Film - - - - - -
Bone Marrow - - - - - -
Others - - - - - -
MCC Annual Report – HBCR 2011
252
MCC Annual Report – HBCR 2011
253
Table 275: Number (#) and relative proportion(%) of NHL by histology
Type of Histology Male(n=47) Female(n=39) Total(n=86)
# % # % # %
NHL 19 40.43 9 23.08 28 32.56
Diffuse Large B Cell Lymphoma 13 27.66 18 46.15 31 36.05
B-Cell Lymphoma 5 10.64 3 7.69 8 9.30
Follicular Lymphoma 4 8.51 4 10.26 8 9.30
T Cell Lymphoma 3 6.38 0 0 3 3.49
Anaplastic Large Cell Lymphoma 1 2.13 0 0 1 1.16
Marginal Lymphoma 1 2.13 0 0 1 1.16
Plasmablastic Lymphoma 1 2.13 0 0 1 1.16
Lymphoma 0 0 1 2.56 1 1.16
Mycosis Fungoides 0 0 1 2.56 1 1.16
Nhl Burkitts Lymphoma 0 0 1 2.56 1 1.16
Precursor B Cell Lymphoblastic Leukemia 0 0 2 5.13 2 2.33
Clinical Information
Table 276: Number and Relative Proportion of NHLcancer by Broad Treatment Group
Broad Treatment Group
Males (n=47) Female (n=39) Total(n=86)
# % # % # %
Prior Trmt only 8 17 9 23.1 17 19.77
Prior & Trmt at RI 7 14.9 4 10.3 11 12.79
Trmt only at RI 20 42.6 19 48.7 39 45.35
No Treatment 12 25.5 7 17.9 19 22.09
Table 277: Number and Relative Proportion of NHLcancer by Clinical Extent of Disease i. Prior Treatment only
Clinical extent
Male(n=8) Female(n=9) Total(n=17)
# % # % # %
Localised - - - - - -
Regional 2 25 5 55.6 7 41.18
Distant 2 25 2 22.2 4 23.53
Others 4 50 2 22.2 6 35.29
Unknown - - - - - -
MCC Annual Report – HBCR 2011
254
Table 278: ii. Treatment Only at RI
Clinical Extent
Male(n=20) Female(n=19) Total(n=39)
# % # % # %
Localised - - - - - -
Regional 16 80 12 63.2 28 71.79
Distant 4 20 6 31.6 10 25.64
Others - - 1 5.3 1 2.56
Unknown - - - - - -
Table 279: iii. Prior + Treatment at RI
Clinical extent
Male(n=7) Female(n=4) Total(n=11)
# % # % # %
Localised - - - - - -
Regional 3 42.9 3 75 6 54.55
Distant 1 14.3 - - 1 9.09
Others 3 42.9 1 25 4 36.36
Unknown - - - - - - Table 280: iv. No Treatment
Clinical extent
Male(n=12) Female(n=7) Total(n=19)
# % # % # %
Localised 1 8.3 - - 1 5.26
Regional 6 50 4 57.1 10 52.63
Distant 3 25 1 14.3 4 21.05
Others 2 16.7 2 28.6 4 21.05
Unknown - - - - - -
Table 281: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI, No Treatment
Clinical extent Males (n=47) Females(n=39) Total(n=86)
# % # % # %
Localised 1 2.1 - - 1 1.16
Regional 27 57.4 24 61.5 51 59.3
Distant 10 21.3 9 23.1 19 22.09
Others 9 19.1 6 15.4 15 17.44
Unknown - - - - - -
MCC Annual Report – HBCR 2011
255
Table 282: Number and Relative Proportion of NHLcancer by Type of treatment i. Prior Treatment only, No Treatment
Type of Treatment
Males (n=8) Females (n=9) Total(n=17) # % # % # %
Surgery - - - - - -
R-therapy 1 12.5 1 11.1 2 11.76
C-Therapy 6 75 8 88.9 14 82.35
S+R - - - - - -
S+C 1 12.5 - - 1 5.88
R+C - - - - - -
S+R+C - - - - - -
Others - - - - - -
Unknown - - - - - - Table 283: ii. Treatment Only at RI, No Treatment
Type of Treatment
Male (n=20) Female (n=19) Total(n=39)
# % # % # %
Surgery 1 5 - - 1 2.56
R-therapy 1 5 - - 1 2.56
C-Therapy 14 70 13 68.4 27 69.23
S+R - - - - - -
S+C - - - - - -
R+C 3 15 5 26.3 8 20.51
S+R+C 1 0 1 0 2 5.13
Others - - - - - -
Unknown - - - - -
Table 284: iii. Prior + Treatment at RI (Prior Treatment), No Treatment:
Type of Treatment
Male (n=7) Female (n=4) Total(n=11)
# % # % # %
Surgery 1 14.3 - - 1 9.09
R-therapy - - - - - -
C-Therapy 6 85.7 4 100 10 90.91
S+R - - - - - -
S+C - - - - - -
R+C - - - - - -
S+R+C - - - - - -
Others - - - - - -
Unknown - - - -
MCC Annual Report – HBCR 2011
256
Table 285: iv. Prior + Treatment at RI (RI Treatment), No Treatment:
Type of Treatment
Male (n=7) Female (n=4) Total(n=11)
# % # % # %
Surgery - - - - - -
R-therapy 2 28.6 - - 2 18.18
C-Therapy 3 42.9 4 100 7 63.64
S+R - - - - - -
S+C - - - - - -
R+C 2 28.6 - - 2 18.18
S+R+C - - - - - -
Others - - - - - -
Unknown - - - - - - Table 286: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Type of treatment
Male (n=35) Female (n=32) Total(n=67)
# % # % # %
Surgery 2 5.7 - - 2 2.99
R-therapy 2 5.7 1 3.1 3 4.48
C-Therapy 26 74.3 25 78.1 51 76.12
S+R - - - - - -
S+C 1 2.9 - - 1 1.49
R+C 3 8.6 5 15.6 8 11.94
S+R+C 1 0 1 0 2 2.99
Others - - - - - -
Unknown - - - - - -
Table 287: vi. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt), No Treatment:
Type of Treatment
Males (n=35) Females (n=32) Total(n=67) # % # % # %
Surgery 1 2.9 - - 1 1.49
R-therapy 4 11.4 1 3.1 5 7.46
C-Therapy 23 65.7 25 78.1 48 71.64
S+R - - - - - -
S+C 1 2.9 - - 1 1.49
R+C 5 14.3 5 15.6 10 14.93
S+R+C 1 0 1 0 2 2.99
Others - - - - - -
Unknown - - - - - -
MCC Annual Report – HBCR 2011
257
Table 288: Number and Relative Proportion of NHLcancer by Specific Treatment i. Prior Treatment Only, No Treatment
Specific Treatment
Male (n=9) Females(n=9) Total(n=18)
# % # % # %
Any S 1 11.1 - - 1 5.56
Any R 1 11.1 1 11.1 2 11.11
Any C 7 77.8 8 88.9 15 83.33
Any H - - - - - -
Others - - - - - -
Unknown - - - - - - Table 289: ii. Treatment Only at RI, No Treatment
Specific Treatment
Male (n=25) Female (n=26) Total(n=51)
# % # % # %
Any S 2 8 1 3.8 3 5.88
Any R 5 20 6 23.1 11 21.57
Any C 18 72 19 73.1 37 72.55
Any H - - - - - -
Others - - - - - -
Unknown - - - - - - Table 290: iii. Prior + Treatment at RI (Prior Tmt), , No Treatment
Specific Treatment
male (n=7) Female (n=4) Total(n=11) # % # % # %
Any S 1 14.3 - - 1 9.09
Any R - - - - - -
Any C 6 85.7 4 100 10 90.91
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 291: iv. Prior + Treatment at RI (RI Tmt), , No Treatment
Specific Treatment
Male (n=9) Female(n=4) Total(n=13)
# % # % # %
Any S - - - - - -
Any R 4 44.4 - - 4 30.77
Any C 5 55.6 4 100 9 69.23
Any H - - - - - -
Others - - - - - -
MCC Annual Report – HBCR 2011
258
Unknown - - - - - -
Table 292: v. Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(Prior Tmt), No Treatment:
Specific Treatment
Male (n=41) Female (n=39) Total(n=80) # % # % # %
Any S 4 9.8 1 2.6 5 6.25
Any R 6 14.6 7 17.9 13 16.25
Any C 31 75.6 31 79.5 62 77.5
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 293: Prior Treatment only, Treatment Only at RI, Prior + Treatment at RI(RI Tmt),, No Treatment:
Specific Treatment
Male (n=43) Female (n=39) Total(n=82)
# % # % # %
Any S 3 7 1 2.6 4 4.88
Any R 10 23.3 7 17.9 17 20.73
Any C 30 69.8 31 79.5 61 74.39
Any H - - - - - -
Others - - - - - -
Unknown - - - - - -
Table 294: Number and Relative Proportion of NHLCancer by Treatment Status (Excluding the Cancers Previously Treated)
Treatment Status Males (n=32) Females(n=26) Total(n=58) # % # % # %
Received 15 46.9 18 69.2 33 56.89
Not Received 12 37.5 6 23.1 18 31.03
Not Accepted - - - - - -
Incomplete 5 15.6 1 3.8 6 10.34
Unknown - - 1 3.8 1 1.72 Table 295: Number and Relative Proportion of NHLcancer by Intention to Treat (Excluding the Cancers Previously Treated)
Intention to Treat Male (n=20) Female (n=19) Total ( n=39)
# % # % # %
Radical 13 65 11 57.9 24 61.54
Palliative 7 35 8 42.1 15 38.46
Pain Relief Only - - - - - -
Symptomatic - - - - - -
MCC Annual Report – HBCR 2011
259
Unknown - - - - - -
DEMOGRAPHIC PARAMETERS
Table 296: Number and Relative Proportion of NHL cancer by marital status
Marital Status
Males (n=47) Female(n=39) Total(86)
# % # % # %
Unmarried 1 2.1 3 7.7 4 4.65
Married 44 93.6 19 48.7 63 73.26
Widowed 2 4.3 17 43.6 19 22.09
Divorced
Table 297: Number and Relative Proportion of NHL cancer by religion
Religion Males (n=47) Females(n=39) Total(n=86) # % # % # %
Hindu 32 68.1 25 64.1 57 66.28
Muslim 10 21.3 10 25.6 20 23.26
Christian 5 10.6 4 10.3 9 10.47
Unknown
Table 298: Number and Relative Proportion of NHLcancer by education
Education Male (n=47) Female(n=39) Total(n=86)
# % # % # %
Primary 20 42.6 12 30.8 32 37.21
Secondary 16 34 12 30.8 28 32.56
Illiterate 2 4.3 8 20.5 10 11.63
Literate 2 4.3 2 5.1 4 4.65
College 4 8.5 2 5.1 6 6.98
Others 3 6.4 3 7.7 6 6.98
Unknown
Table 299: Number and Relative Proportion of NHLcancer by mother tongue
Mother Tongue Male (n=47) Female(n=39) Total(n=86) # % # % # %
Malayalam 47 100 39 100 86 100
Kannada
MCC Annual Report – HBCR 2011
260
Table 300: CHILDHOOD CANCERS
HospNo Dt of Reg Age Primary Site Primary Histology System
1 110031 05.01.2011 18 Femur Lower 1/3rd Osteogenic Sarcoma Bone
2 110081 12.01.2011 2 Retina Retinioblastoma Eye
3 110092 13.01.2011 3 Cerebellum Desmoplastic Medulloblastoma Brain
4 110102 17.01.2011 16 Femur Rt Ewing Sarcoma Conn. & Soft Tissue
5 110147 25.01.2011 17 Pelvis Ewing Sarcoma Bone
6 110152 25.01.2011 16 Tibia Upper 3rd Osteogenic Sarcoma Bone
7 110215 04.02.2011 17 Ovary Dysgerminoma Ovary
8 110250 08.02.2011 14 Brain (Paraganglia) Neoplasm, Malignant High Grade Conn. & Soft Tissue
9 110337 22.02.2011 15 Bone Marrow Acute Myeloid Leukemia Hematopoietic And Reticuloendothelial Systems
10 110388 28.02.2011 14 Tibia Osteosarcoma Bone
11 110512 18.03.2011 13 Eye Lt Conjunctiva Squamous Cell Carcinoma W.D Eye
12 110535 22.03.2011 14 Anterior Mediastinum T‐Cell Lymphoblastic Lymphoma Thoracic Organs
13 110555 24.03.2011 10 Blood Acute Lymphocytic Leukemia Hematopoietic And Reticuloendothelial Systems
14 110609 31.03.2011 12 Primary Unknown Unknown Primary Unknown
15 110808 28.04.2011 13 Scapula(Lt) Synovial Sarcoma Conn. & Soft Tissue
16 111101 07.06.2011 14 Femur Osteosarcoma High Grade Bone
17 111277 01.07.2011 15 Rectum Mucinous Adenocarcinoma M D Rectum
18 111366 13.07.2011 10 Tibia Osteosarcoma Chondroblastic Variant Bone
MCC Annual Report – HBCR 2011
261
19 111385 18.07.2011 15 Femur Osteosarcoma Bone
20 111401 19.07.2011 11 Cerebellum Medulloblastoma Brain
21 111421 20.07.2011 12 Fibula Osteoblastic Osteosarcoma Bone
22 111643 22.08.2011 18 Thigh Dermatofibrosarcoma Protuberans Skin
23 111770 24.09.2011 3 Spine Ewing Sarcoma Bone
24 111944 08.10.2011 16 Blood Acute Lymphatic Leukemia Hematopoietic And Reticuloendothelial Systems
25 111949 10.10.2011 15 Femur Osteosarcoma High Grade Bone 26 112141 02.11.2011 14 Thigh Synovial Sarcoma Conn. & Soft Tissue 27 112161 08.11.2011 16 Tibia Osteofibrosarcoma High Grade Bone
28 112163 08.11.2011 9 Blood Acute Lymphatic Leukemia Tcell Hematopoietic And Reticuloendothelial Systems
29 112294 23.11.2011 18 Blood Acute Lymphoblastic Leukemia Hematopoietic And Reticuloendothelial Systems
30 112345 29.11.2011 16 Brain Glioblastoma Gr.IV Brain 31 112351 30.11.2011 8 Brain Stem Glioma Brain 32 112418 08.12.2011 13 Palate Mucoepidermoid Carcinoma Lowgrade Mouth
33 112585 05.01.2012 Femur Lower 1/3rd Osteogenic Sarcoma Bone
MCC Annual Report – HBCR 2011
262
Table 301: Number(#) and Proportion(%) in Childhood Cancers
SlNo System # % 1 Bone 12 36.36
2 Brain 4 12.12 3 Connective & Soft Tissue 4 12.12 4 Eye 2 6.06 5 Hematopoietic And
Reticuloendothelial Systems 5 15.15
6 Mouth 1 3.03 7 Ovary 1 3.03 8 Primary Unknown 1 3.03 9 Rectum 1 3.03 10 Skin 1 3.03 11 Thoracic Organs 1 3.03
Total
Table 302 : Number(#) and Proportion(%) of Scheduled Tribe Patients
SlNo System Primary Site # %
1 BREAST 3 13.04 2
HEAD & NECK
a) Buccal mucosa (8) b) Oropharynx (1) c) Fom (2) d) Hypopharynx (1) e) Tongue (2) f) Parotid gland (1)
15 65.22
3 LYMPHOMA g) LN Axilla(1) 1 4.35 4 LUNG 1 4.35 5 BONE Femur(1) 1 4.35 6 FEMALE GENITAL Ovary(1) 1 4.35 7 GASTRO-
INTESTINAL Stomach(3) Transverse Colon(1) 4 17.39
MCC Annual Report – HBCR 2011
263
MCC Annual Report – HBCR 2011
264
Table 303 : SCHEDULED TRIBE PATIENTS
Sl.No
Hosp No
HBCRNo Age Sex Family Hist.
Habits Diag.Dt Seq Lat PST PHM Regdt Lastcondt Living Status
Rad/ Pal/
notreat
Community Colony District
1 110031 1100032
18 M Nil Nil 01.01.2011 0 2 FEMUR OSTEOGENIC
SARCOMA 05.01.2011 05.12.2011 L Ra
Malavetuvan, Nattakallu, Kasargod
2 110128 1100131
65 M Nil A/S/
P 17.01.2011 0 0 L N AXILLA NHL DLBCL 21.01.2011 18.08.2011 L Ra
Kurichyan, Thalassery Kannur
3 110281 1100287
80 F Nil U 22.09.2010 0 1 BREAST IDC 14.02.2011 23.05.2011 U Pa Mavilan, Ajanur, Kasargod
4 110365 1100370
22 F Nil P 24.02.2011 0 0 TONGUE UNKNOWN 24.02.2011 14.03.2011 E N Paniyan, Vadakkinillam, Kannur
5 110387 1100391
51 M Moth
er A/P/
S 23.02.2011 0 1 LUNG NSCLC P.D 28.02.2011 13.04.2011 E Pa
Kurichyan, Mananthavady, Waynad
6 110418 1100423
72 F Nil P 03.03.2011 0 0 BUCCAL
MUCOSA SCC 04.03.2011 21.03.2012 L Pa
Kurichyan Kannavam Kannur
7 110664 1100662
40 M Nil C/A C/S O/P
06.04.2011 0 0 FOM SCC M.D 07.04.2011 18.04.2011 U Ra Kurichyan, Kannavam Kannur
8 110781 1100780
60 F Nil C/P A
20.04.2011 0 0 BUCCAL
MUCOSA SCC W.D 25.04.2011 19.03.2012 L Ra
Mavilan Perigaya Kasargod
9 110879 1100876
60 F Nil Nil 01.01.2007 0 0 STOMACH ADENOCARCINOMA SIGNET RING CELL CA.
07.05.2011 15.05.2011 U Pa Kurichyan Periya, Waynad
10 111014 1111007
61 F Nil C/P 23.05.2011 0 0 TONGUE SCC W.D 26.05.2011 20.07.2011 U Pa Paniyan, Kottiyur,
MCC Annual Report – HBCR 2011
265
Kannur
11 111060 1101051
80 F Nil Nil 25.09.2010 1 0 BREAST IDC 02.06.2011 21.03.2012 F Pa
Karimbalan‐Hindu, Payyavoor, Kannur
ST Patients 2011
Slno
Hosp No
HBCR No
Age Sex Family Hist.
HabitsDiag.
Dt Seq Lat PST PHM Regdt Lastcondt
Living Status
Rad /pal/
notreat
Community Colony District
12 111257 1101248 50 F Nil Nil 18.06.2011 0 0 BUCCAL
MUCOSA METS SCC 28.06.2011 23.09.2011 U Pa
Paniyan, Kotukappara, Kannur
13 111271 1101262 44 F Nil Nil 30.06.2011 0 0 BUCCAL
MUCOSA SCC 30.06.2011 11.11.2011 U Pa
Paniyan, Kelakam, Kannur
14 111350 1101343 69 F Nil C/P 01.07.2011 0 0 BUCCAL
MUCOSA SCC W.D 11.07.2011 25.01.2012 U Pa
Mavilan, West‐Eleri Thottiyil, Kasargod
15 111379 1101371 45 M Nil P 02.07.2011 0 0 FOM SCC M.D 16.07.2011 28.05.2012 L Ra Mavilan, Kodombelur, Kasargod
16 111516 1101504 55 F Nil P 12.12.2007 0 0 OROPHARY
NX SCC P.D 02.08.2011 16.07.2011 U N
Mavilan Periya Kasargod
17 111559 1101548 48 F Daughter Nil 20.07.2011 0 B/L OVARY PAPILLARY
SEROUS CYST ADENOCA.
09.08.2011 18.08.2012 F Ra Kuruman, Krishnagiri Wynad
18 111815 1101804 47 F Nil Nil 17.09.2011 0 1 BREAST IDC GR.II 22.09.2011 01.09.2012 L Ra Hindu Paniyan, Kelakam, Kannur
MCC Annual Report – HBCR 2011
266
19 111923 1101908 55 M Nil E/S 05.10.2011 0 0 STOMACH ADENOCA. 05.10.2011 23.10.2011 U Pa Karimbalan, Allakode Kannur
20 112080 1102065 58 M Nil C/S P
21.10.2011 0 0 BUCCAL
MUCOSA SCC 26.10.2011 27.08.2012 L Pa
Mavilan, Thaliparamba Kannur
21 112146 1102131 27 F Nil Nil 01.01.1993 0 2 PAROTID GLAND
ACINIC.CELL CA.
03.11.2011 26.09.2012 L Ra Mavilan Bandaduka Kasargod
ST Patients 2011
Slno
Hosp No
HBCR No
Age Sex
Family Hist.
Habits Diag.Dt Seq Lat PST PHM Regdt Lastcondt Living Status
Rad/ Pal/
notreat
Community Colony District
22 112281 1102269 44 M Nil S/A 11.11.2011 0 0 STOMACH SIGMET RING
CELL ADENOCA.
22.11.2011 04.05.2012 L Pa Mavilan, Belur, Kasargod
23 112401 1102630 22 F Nil Nil 01.04.2010 0 0 TRANSVERS
E COLON ADENOCA. 6.12.2011 24.08.2012 L Pa
Malavetuvan, Kundumkuzha, Kasargod
24 112494 1102542 58 F GF & F P 01.12.2011 0 0 BUCCAL
MUCOSA SCC W.D 16.12.2011 10.09.2012 L Ra
Kurichan, Kanichar, Kannur
25 112613 1102632 50 F Nil C/P 13.11.2011 0 0 BUCCAL
MUCOSA SCC W.D 28.12.2011 21.05.2012 L Pa
Paniyan, Aralam, Kannur
26 111985 1101971 42 M Nil S/A 27.09.2011 0 0 HYPOPHARY
NX SCC W.D 13.10.2011 26.10.2011 U Pa
Hindu‐Paniyan, Peruva Kannur
MCC Annual Report – HBCR 2011
267
MCC Annual Report – HBCR 2011
268
MULTIPLE CANCERS
MCC Annual Report – HBCR 2011
269
MCC Annual Report – HBCR 2011
270
MCC Annual Report – HBCR 2011
271
Table 304: Two Primary - Metachronous (N=43)
Sl. No
Hosp No
HBCRNO Age Sex Family Hist.
Habits Date of
diagnosis Seq Lat Primary Site Morphology Regd dt lastcont
Living Status
Treatment Ra/Pa/Sy/N
1 110021 1100021 49 M NIL A/S/P 4.12.2009 1 0 HYPOPHARYNX UNKNOWN 04.01.2011 27.04.2011 E N 1100022 51 11.01.2011 2 0 NASOPHARYNX SCC, M.D
2 110044 1100044 36 F NIL NIL 01.01.1996 1 0 CERVIX ADENOCA. 08.01.2011 8.12.2011 L Ra 1100045 50 29.12.2010 2 0 COLON ADENOCA.
3 110054 1100055 70 M NIL NIL 01.01.2006 1 0 PROSTATE UNKNOWN 10.01.2011 7.05.2011 E Pa 1100056 75 01.01.2011 2 1 LUNG NSCC.
4 110071 1100071 35 F NIL NIL 01.01.2006 1 UK BREAST IDC 11.01.2011 9.03.2011 E Pa 1100072 40 01.01.2011 2 B/L OVARY UNKNOWN
5 110075 1100076 72 M NIL A/S
07.10.2010 1 0 STOMACH ADENOCA. P.D 12.01.2011 13.01.2011 U Sy 1100077 72 07.10.2010 2 0 RECTUM ADENOCA.
6 110097 1100099 62 F NIL NIL 07.01.2011 1 0 ENDOMETRIUM ENDOMETROID ADENOCA.W.D 15.01.2011 5.01.2012 L Ra
1100100 62 27.07.2011 2 0 BONE MARROW
MULTIPLE MYELOMA
7 110224 1100228 49 M NIL A/S 01.03.2008 1 0 BOT UNKNOWN 05.02.2011 21.02.2011 U N 1100229 52 27.12.2011 2 2 LUNG SCC MD
8 110358 1100361 32 F Sister‐ Breast NIL
26.09.2006 1 2 BREAST DUCTAL 24.02.2011 17.01.2012 L Ra
1100362 37 16.02.2011 2 1 BREAST MEDULLARY 9 110363 1100367 67 M NIL NIL 01.01.2003 1 0 STOMACH UNKNOWN 24.02.2011 14.03.2011 U U 1100368 75 01.01.2003 2 U LUNG MALIGNANT
10 110408 1100412 73 F NIL P 01.01.2006 1 NIL BUCCAL MUCOSA (Lt) UNKNOWN 03.03.2011 3.03.2011 U U
1100413 80 20.01.2011 2 NIL BUCCAL MUCOSA (Rt) UNKNOWN
11 110600
1100596 80 F NIL NIL 25.03.2011 1 0 EXTERNAL NOSE
SCC M.D 30.03.2011 07.10.2011 U Ra
1100596 80 27.09.2011 2 0 RECTUM ADENOCA. M.D
12 110748 1100747 26 F NIL NIL 23.06.2009 1 0 THYROID PAPILLARY CA. 21.11.2011 21.11.2011 U U
1100747 27 F 22.11.2010 2 U OVARY SEROUS PAPILLARY CA.
MCC Annual Report – HBCR 2011
272
Two Primary Cases ‐ 2011
Sl. No
Hosp No
HBCRNO Age Sex Family Hist.
Habits Diag.Dt Seq Lat Primary Site Morphology Regd dt lastcont LivingStatus
Treatment R/P/Sy/NoTr
13 110798 1100795 52 M NIL S/A 25.02.2010 1 2 SKIN FOOT SCC WD 27.04.2011 08.05.2011 U Pa
1100795 53 27.4.2010 2 0 PRIMARY UNKNOWN ADENOCA. P.D
14 110850 1100847 45 F NIL NIL 01.01.2001 1 2 BREAST UNKNOWN 04.05.2011 05.12.2011 U Pa
1100848 55 30.04.2011 2 2 LUNG SCC
15 110869 1100865 65 M NIL Ex/A
P 01.01.2001 1 0 BUCCAL MUCOSA UNKNOWN 06.05.2011 21.05.2011 U Ra
1100865 75 01.03.2011 2 0 TONGUE SCC W D
16 110928 1100923 55 M NIL S 01.01.1995 1 0 LN HODGKIN LYMPHOMA 14.05.2011 31.05.2011 U Pa
1100923 61 06.05.2011 2 0 DESCENDING COLON ADENOCA. W.D
17 111083 1101073 73 M NIL Ex/CS 01.01.2005 1 0 OROPHARYNX SCC W D 04.06.2011 04.06.2011 U Pa
1101073 75 04.01.2011 2 1 LUNG P.D CA.
18 111098 1101089 60 M NIL NIL 26.03.2002 1 0 COLON UNKNOWN 07.06.2011 29.09.2011 U Pa
1101089 68 08.02.2011 2 2 LUNG ADENOCA.
19 111137 1101129 56 F Aunt NIL 01.05.2007 1 2 BREAST UNKNOWN 13.06.2011 13.6.2011 U U
1101129 51 10.06.2011 2 0 BLOOD A M L
20 111239 1101230 67 M Brother NIL 29.01.2011 1 0 BLADDER PAPILLARY UROTHELIAL CA. 27.06.2011 29.11.2011 U Pa
1101230 67 22.06.2011 2 2 LUNG SCC
21 111267 1101258 65 M
Brother‐Stoma
ch NIL 20.06.2011 1 0 ASCENDING COLON ADENOCA. M.D 30.06.2011 17.05.2012 L Pa
1101258 65 22.11.2011 2 1 EYEBROW (SKIN) SCC WD
22 111290 1101281 82 M NIL S/A 01.01.2002 1 0 TONGUE UNKNOWN 04.07.2011 12.08.2011 U Pa
1101281 90 04.07.2011 2 0 HYPOPHARYNX SCC M D
23 111404 1101396 73 M NIL Ex/S 26.03.2011 1 0 RECTUM ADENOCA. W D 19.07.2011 14.6.2012 L Ra
1101396 73 01.08.2011 2 0 CLN CLASSICAL HL
MCC Annual Report – HBCR 2011
273
Two Primary Cases ‐ 2011
Sl. No Hosp No HBCRNO Age Sex Family Hist. Habits Diag.Dt Seq Lat Primary Site Morphology Regd dt lastcont Living Status
Treatment R/P/NoTr
24 111522 1101510 68 F NIL C/P 02.08.2011 1 0 TONGUE (ANTERIOR‐ 2/3 rd) SCC M.D 03.08.2011 16.08.2012 L Pa
1101510 69 09.05.2012 2 0 LOWER ALVEOLUS SCC W.D
25 111525 1101514 59 M NIL NIL 01.10.2010 1 0 OESOPHAGUS SCC 04.08.2011 11.10.2011 E Pa
1101514 60 03.08.2011 2 0 LOWER ALVEOLUS SCC M.D
26 111548 1101536 42 F Sister –Cervix NIL 14.08.2007 1 0 BREAST UNKNOWN 08.08.2011 17.08.2011 U Sy
1101536 46 28.12.2010 2 0 COMMON HEPATIC DUCT CHOLANGIOCA.
27 111616 1101604 67 M Sister‐ Lung NIL 30.03.2005 1 1 PAROTID
MUCOEPIDERMOID CA. 17.08.2011 17.08.2011 U Pa
1101604 72 Mother
Oesophagus NIL 08.07.2011 2 2 LUNG ADENOCA.
28 111650 1101638 50 M Father‐
Oesophagus S/P 22.02.2007 1 0 THYROID PAPILLARY CA. 23.08.2011 15.09.2011 U Pa
1101638 55 05.08.2011 2 1 LUNG SCC P.D
29 111757 1101744 62 F Brother‐ BM NIL 01.01.1998 1 0 STOMACH ADENOCA. 13.09.2011 21.08.2012 L Pa
1101744 75 05.09.2011 2 0 CERVIX LCNK
30 111772 1101760 47 F Mother NIL 10.05.2006 1 0 TONGUE SCC M.D 14.09.2011 06.09.2012 L Ra
1101760 53 30.06.2011 2 0 TONGUE SCC W.D
31 111783 1101772 58 M NIL NIL 19.12.2008 1 0 BM UNKNOWN 16.09.2011 29.09.2011 U Pa
1101772 61 27.09.2011 2 1 LUNG UNKNOWN
32 111893 1101880 46 M NIL C/S E/A 29.08.1989 1 0 OROPHARYNX SCC 01.10.2011 28.10.2011 U Ra
1101880 68 01.10.2011 2 0 TONGUE UNKNOWN
33 111924 1101909 40 F NIL NIL 01.01.2001 1 2 BREAST MEDULLARY CA. 06.10.2011 25.09.2012 L N
1101909 50 04.05.2010 2 B/L OVARY
PAPILLARY SEROUS ADENOCA. ‐ HIGHGRADE
MCC Annual Report – HBCR 2011
274
Two Primary Cases ‐ 2011
Sl.No Hosp No HBCRNO Age Sex Family Hist. Habits Diag.Dt Seq Lat Primary Site Morphology Regd dt lastcont Living Status
Treatment Ra/Pa/NoTr
34 111991 1101977 73 F NIL NIL 18.12.2010 1 0 VALECULLA UNKNOWN 13.10.2011 14.10.2011 E N
1101977 74 13.10.2011 2 0 LYMPH NODE DLBCL
35 112007 1101994 69 M NIL NIL 18.02.2010 1 0 BLOOD APML 15.10.2011 20.10.2011 U N
1101994 70 29.09.2011 2 0 STOMACH CA.
36 112219 1102205 46 F NIL NIL 24.04.1996 1 0 RECTUM UNKNOWN 16.11.2011 8.09.2012 L Ra
1102205 61 16.11.2011 2 0 ENDOMETRIUM ADENOCA. GR.II
37 112284 1102272 66 M NIL A/S 26.10.2007 1 0 RMT UNKNOWN 22.11.2011 22.11.2011 U U
1102272 70 25.10.2010 2 0 FOM UNKNOWN
38 112300 1102289 56 F NIL E/P 27.11.2003 1 0 NASAL CAVITY ADENOID CYSTIC CA 23.11.2011 18.10.2012 L Pa
1102289 64 01.01.2009 2 0 TONGUE SCC W.D
39 112314 1102304 66 M NIL C/S C/P 25.07.2005 1 0 UPPER LIP VERRUCOUS CA. 25.11.2011 24.09.2012 L Pa
1102304 72 09.11.2011 2 0 HARD PALATE SCC W.D
40 112344 1102332 48 M Brother Larynx C/S 12.01.2008 1 0 LARYNX SCC M.D 29.11.2011 12.01.2012 U Pa
1102332 51 Wife‐
Ca. 01.01.2011 2 2 LUNG SCC W.D
41 112400 1102385 48 M NIL E/S 01.01.1982 1 0 LARYNX UNKNOWN 06.12.2011 06.12.2011 U Ra
1102385 78 09.11.2011 2 0 STOMACH ADENOCA.
42 112415 1102399 65 M NIL NIL 18.06.2001 1 0 LARYNX SCC W.D 08.12.2011 12.01.2012 U Pa
1102399 75 08.06.2011 2 0 COLON UNKNOWN
43 112436 1102419 66 F Brother C/P 01.01.1980 1 1 BREAST UNKNOWN 10.12.2011 31.05.2012 U Pa
1102419 87 10.12.2012 2 0 LOWER ALVEOLUS UNKNOWN
MCC Annual Report – HBCR 2011
275
Table 305: 2 Primary Cases 2011 – Synchronous Carcinoma (N=12)
Hosp.No HBCRNO Age Sex Family Hist. Habits Diag.Dt Seq Lat Primary Site Morphology Regd dt lastcont
Living Status
Treatment R/P/NoTr
1 110135 1100138 60 M NIL A/S 14.01.2011 1 0 OESOPHAGUS SCC P.D 22.01.2011 28.10.2011 L Ra
1100139 60 2 0 OROPHARYNX SCC M.D
2 110204 1100207 65 F NIL P 08.01.2011 1 0 B-M(RT) VERRUCUOS CA. 02.02.2011 03.02.2011 U Pa
1100208 65 2 0 LOWER ALVEOLUS SCC
3 110255 1100260 53 F NIL NIL 07.02.2011 1 1 BREAST IDC 09.02.2011 17.01.2012 L Pa
1100261 53 2 2 BREAST IDC
4 110615 1100612 70 F Mother/Sister
Stomach P/S 29.03.2011 1 0 ASCENDING COLON ADENOCA. M.D 01.04.2011 26.04.2011 L Pa
1100612 70 Brother
carcinoma 2 0 RECTO-SIGMOID JUNCTION MUCINOUS CARCINOMA
5 110989 1100982 62 F Sister Breast NIL 25.04.2011 1 1 FOOT SKIN MALIGNANT MELANOMA 24.05.2011 08.06.2012 L Pa
1100982 62 06.07.2011 2 1 BREAST IDC GR III
6 111222 1101212 56 F NIL NIL 18.06.2011 1 0 ENDOMETRIUM ENDOMETROID CA 24.06.2011 03.07.2012 L Ra
1101212 56 2 1 OVARY ADENOCA. M.D
7 111319 1101311 67 F NIL NIL 05.07.2011 1 1 BREAST IDC 07.07.2011 11.06.2012 L Pa
1101311 67 2 2 BREAST IDC
8 111895 1101883 47 F Father NIL 13.02.2009 1 0 ASCENDING COLON ADENOCA. M.D 01.10.2011 02.12.2011 U Pa
1101883 47 2 B/L OVARY PAPILLARY ADENOCA.
9 111926 1101912 42 F Cousin Sister -
Breast NIL 24.09.2011 1 2 BREAST IDC 06.10.2011 30.06.2012 L Ra
1101912 42 Cousin Sister -
Abdomin 2 B/L OVARY PAPILLARY SEROUS CARCINOMA
10 112412 1102395 30 F NIL NIL 05.12.2011 1 1 BREAST IDC GR.II 08.12.2011 29.12.2011 U Pa
1102395 30 2 2 BREAST IDC GR.II
11 112437 1102421 60 M NIL C/S 07.12.2011 1 0 OESOPHAGUS SCC MD 10.12.2011 04.01.2012 U Sy
1102421 60 2 0 STOMACH ADENOCA. P.D
12 112624 1102616 47 F 01.01.2008 1 1 BREAST IDC GR.III 30.12.2011 27.08.2012 L Ra
1102616 47 2 2 BREAST IDC GR.III
MCC Annual Report – HBCR 2011
276
Table 306: Three Primary Cases
Sl. No Hosp.No Age Sex FamilyHist Habits Diag.Dt Seq Lat Primary Site Morphology Regd dt lastcont
LivingStatus
Treatment Ra/Pa/Sy//N
1 1100643 55 F NIL P 01/01/1996 1 0 (RT) BUCCAL MUCOSA UK 05/04/11 23/04/11 L Pa
63 16/12/2004 2 0 LIP (UPPER) SCC W.D Pa
70
02/04/2011 3 0 BUCCAL
MUCOSA SCC M.D
Pa
2 112496 56 M NIL E/S 26/04/1999 1 0 FOM UK 16/12/11 01/12/11 U Pa
68 06/12/2011 2 0 OESOPHAGUS SCC M.D Pa
68
10/01/2012 3 0 BLADDER
UROTHELIAL CA. LOW GRADE
Pa
MCC Annual Report – HBCR 2011
277
NON MALIGNANT TUMORS
MCC Annual Report – HBCR 2011
278
MCC Annual Report – HBCR 2011
279
Table 307: Distribution of Non Malignant Tumours
Table 308: Details of Benign Tumors (N=25)
BENIGN
Slno Hosp.No Age of diag. Sex Family
hist Habits Anatomical site Morphology date of reg date of last cont
1 110033 24 M NIL NIL Testis(rt) Inflammatory 06/01/2011 20/01/2011
2 110138 13 M NIL NIL Humerus Osteochondromatosis 24/01/2011 12/12/2011
3 110286 35 F NIL NIL Anterior abdominal wall Desmoid tumour-benign 14/02/2011 14/02/2011
4 110347 29 F NIL NIL Pituitary gland Adenoma 23/02/2011 28/02/2011
5 110348 42 F NIL NIL Liver Adenoma 18/02/2011 23/01/2012
6 110382 38 M NIL O/A S
Lt. Arm(soft tissue) Neurofibroma 26/02/2011 18/04/2011
7 110482 14 F NIL NIL Popliteal fossa Fibromatosis 15/03/2011 20/01/2011
8 110486 53 M NIL A Liver Hydatid cyst 15/03/2011 26/03/2011
Type Total(66) % Non‐Neoplastic 20 30.30 Benign 25 37.88 Pre‐NeoPlastic Tumours(Mild/Mod./Insitu) 9 13.64 Borderline/Uncertian(Evaluation Incomplete) 6 9.09 Borderline/Uncertian(Evaluation Complete) 6 9.09
MCC Annual Report – HBCR 2011
280
C/S
9 110524 57 M NIL NIL Pituitary gland Papillary adenoma 21/03/2011 16/06/2011
10 110623 75 M NIL P Prostate Benign adenomyomatosis hyperplasia 01/04/2011 12/05/2011
11 110658 57 F NIL NIL Frontal lobe(brain) Meningioma 06/04/2011 0604/2011
12 110753 21 M NIL NIL Salivary gland Pleomorphic adenoma 22/04/2011 08/06/2011
13 110860 49 F NIL NIL Thyroid Follicular adenoma 05/05/2011 21/03/2012
14 111004 30 F NIL NIL Breast Fibro adenoma 25/05/2011 05/07/2011
15 111038 74 M SON-B.M S Parotid(rt) Warthin’s tumour 30/05/2011 30/05/2011
16 111157 19 F NIL NIL Retroperitoneum Ancient schwannoma 16/06/2011 08/05/2012
17 111206 42 F NIL NIL Breast(b/l) Benign cystic desease 22/06/2011 28/05/2012
18 111486 51 F NIL NIL Ring finger Benign tumour of nerve sheath origin
04/07/2011 10/08/2011
19 111904 68 F NIL NIL Sub. Cut. Swelling. Axilla Schwannoma 03/10/2011 03/10/2011
20 111906 16 F NIL NIL D8 spine Aneurysmal bone cyst 03/10/2011 23/07/2012
21 112111 22 M NIL NIL Bone skull Osteochondroma 29/10/2011 29/10/2011
22 112327 17 F NIL NIL Leg(rt) Neurofibroma 28/11/2011 09/04/2012
23 112379 35 F NIL NIL Pituitary gland Adenoma 02/12/2011 02/12/2011
24 112526 35 F NIL NIL Thigh Benign fibrous histiocytoma 19/12/2011 29/08/2012
25 112579 53 F NIL NIL Breast Inflamation 24/12/2011 29/03/2012
MCC Annual Report – HBCR 2011
281
Table 309: Details of Non- neoplastic Tumors (N= 20 )
NON NEOPLASTIC
Slno Hosp.No age of diag. Sex Family hist Habits Anatomicalsite Morphology date of reg date of last
cont
1 110563 65 F NIL NIL Thyroid Hashimotto’s thyroiditis 25/3/2011 19/10/2011
2 110574 52 F NIL NIL Skin lt foot Lentigo simplex 28/3/2011 06/04/2011
3 110862 35 F NIL NIL Breast Mastitis with abscess 5/5/2011 16/05/2011
4 110915 70 F NIL NIL Tongue Intraepithelial hyperplasia 12/5/2011 06/07/2011
5 110941 75 F UNCLE'S SON C/P Skin of leg Seborrhoeic keratosis 16/5/2011 26/05/2011
6 111070 61 F NIL NIL Peritoneum Grannulomatous inflammation 3/6/2011 06/08/2011
7 111248 65 F NIL C/P Tongue Acanthotic squamous epithelium 28/6/2011 03/09/2011
8 111409 68 M NIL E/S Bladder Nonspecific cystitis 19/7/2011 02/08/2011
9 111661 60 F SI/M STOMACH NIL Liver Koch’s 26/8/2011 12/10/2011
10 111669 55 F NIL NIL Liver Abscess 29/8/2011 01/11/2011
11 111940 39 F NIL NIL Ovary(b/l) Endometriosis 14/10/2011 18/11/2011
12 112067 46 M NIL NIL Heel Pseudoepitheliomatous hyperplasia 24/10/2011 18/11/2011
13 112077 61 F AUNT-OVARY NIL Endometrium Simple hyperplasia 25/10/2011 25/6/2012
14 112454 69 F NIL NIL Ovary Thecoma 13/12/2011 8/5/2012
15 112460 28 M NIL NIL Thigh Pseudo-epitheliomatous hyperplasia 13/12/2011 27/3/2012
16 112469 49 F NIL NIL Bone marrow Cellular trilineage displasia 14/12/2011 02/02/2012
17 112528 83 F NIL NIL Endometrium Complex hyperplasia 19/12/2011 2/2/2012
18 112532 46 F NIL NIL Tongue Dysplastic squamous epithelium 19/12/2011 20/7/2012
19 112540 44 M NIL S Vocal cord Polyp 20/12/2011 21/12/2011
20 110807 75 F NIL C/P Thyroid Hashimoto’s thyroiditis 28/4/2011 5/5/2011
MCC Annual Report – HBCR 2011
282
Table 309: Details of Border Line/Uncertain(Evaluation Incomplete) (N=6)
BORDER LINE/UNCERTAIN(EVALUATION INCOMPLETE) SlNo Hosp.No AgeofDiag. Sex FamilyHist Habits AnatomicalSite Morphology Date of Reg Date of Last
Contact
1 110061 44 F Sister-Breast NIL Uterus Fibroid? Malignancy 11/01/2011 12/01/2011
2 110063 36 F NIL NIL Breast Atypical Cells 11/01/2011 11/01/2011
3 110427 50 F NIL NIL Blood ?Leukemia 06/03/2011 08/03/2011
4 110788 55 M NIL NIL
Brain ?TB ?METS 26/04/2011 26/04/2011
5 110836 86 M NIL NIL
Rectum TubuloVillous Adenoma WITH Cellular Atypia 02/05/2011 09/03/2011
6 111794 50 M NIL NIL
Blood Chronic Lymphoproliferative disorder 20/09/2011 11/11/2011
Table 310: Details of Border Line/Uncertain(Evaluation Complete) (N=6)
BORDER LINE/UNCERTAIN(EVALUATION COMPLETE) SlNo Hosp.No
Age of
Diag.
Sex
Family Hist Habits AnatomicalSite Morphology Date of Reg
Date of Last
Contact 1 110952 15 M NIL NIL Rt.Supraclavicular fossa Desmoid Fibrometosis 18/05/2011 29/05/12 2 111056 74 F NIL NIL Rt Loin Kaposiform Haemangio Endothelium 01/06/2011 16/06/11 3 111146 55 M NIL NIL Liver Amyloidosis 16/06/2011 29/07/11 4 111568 54 F NIL NIL Breast Phylloides tumour 10/08/2011 14/06/12 5 112121 80 F NIL NIL Bone Marrow Chronic Lymphoproliferative Disorder 31/10/2011 31/10/12 6 112332 55 F NIL NIL Ovary(Rt) Adult Granulosa cell tumour 28/11/2011 07/09/12
MCC Annual Report – HBCR 2011
283
Table 311: Details of Pre-neoplastic Tumors
PRE NEOPLASTIC TUMOUR MILD/MOD/INSITU(SEVERE)
Slno Hospno age of diag. Sex
Family hist Habits Anatomicalsite Morphology date of reg
date of last cont
1 110425 63 F NIL NIL BREAST(RT) DUCTAL CELL CARCINOMA INSITU 05/03/2011 06/03/2012
2 110542 56 M NIL CHRONIC
A/P/S FLOOR OF MOUTH SQUAMOUS CELL CARCINOMA INSITU 22/03/2011 22/03/2011
3 110571 87 M NIL CHRONIC PAN PROSTATE PIN 28/03/2011 20/04/2011
4 110929 40 F NIL NIL CERVIX CIN(SEVERE DYSPLASIA) 16/05/2011 15/02/2011
5 111372 45 M NIL C/S P BUCCAL MUCOSA CARCINOMA INSITU 14/07/2011 29/06/2011
6 111448 40 F NIL NIL BREAST(Lt) DUCTAL CARCINOMA INSITU 23/07/2011 11/08/2011
7 111456 63 F NIL NIL CERVIX CIN-III 25/07/2011 12/07/2012
8 111612 73 F NIL NIL RECTOSIGMOID JUNCTION
TUBULOVILLOUS ADENOMA- INSITU CARCINOMA 16/08/2011 16/08/2011
9 111621 62 M SISTER NIL URINARY BLADDER INTRAUROTHELIAL NEOPLASIA HIGH GRADE 19/08/2011 18/06/2012
Table 312: Details of benign
BENIGN
Slno Hosp.No ageof diag. Sex Family
hist Habits Anatomical site Morphology date of reg date of last cont
1 110033 24 M NIL NIL Testis(rt) Inflammatory 06/01/2011 20/01/2011
2 110138 13 M NIL NIL Humerus Osteochondromatosis 24/01/2011 12/12/2011
3 110286 35 F NIL NIL Anterior abdominal wall Desmoid tumour-benign 14/02/2011 14/02/2011
MCC Annual Report – HBCR 2011
284
4 110347 29 F NIL NIL Pituitary gland Adenoma 23/02/2011 28/02/2011
5 110348 42 F NIL NIL Liver Adenoma 18/02/2011 23/01/2012
6 110382 38 M NIL O/A S
Lt. Arm(soft tissue) Neurofibroma 26/02/2011 18/04/2011
7 110482 14 F NIL NIL Popliteal fossa Fibromatosis 15/03/2011 20/01/2011
8 110486 53 M NIL A
C/S Liver Hydatid cyst 15/03/2011 26/03/2011
9 110524 57 M NIL NIL Pituitary gland Papillary adenoma 21/03/2011 16/06/2011
10 110623 75 M NIL P Prostate Benign adenomyomatosis hyperplasia 01/04/2011 12/05/2011
11 110658 57 F NIL NIL Frontal lobe(brain) Meningioma 06/04/2011 0604/2011
12 110753 21 M NIL NIL Salivary gland Pleomorphic adenoma 22/04/2011 08/06/2011
13 110860 49 F NIL NIL Thyroid Follicular adenoma 05/05/2011 21/03/2012
14 111004 30 F NIL NIL Breast Fibro adenoma 25/05/2011 05/07/2011
15 111038 74 M SON-B.M S Parotid(rt) Warthin’s tumour 30/05/2011 30/05/2011
16 111157 19 F NIL NIL Retroperitoneum Ancient schwannoma 16/06/2011 08/05/2012
17 111206 42 F NIL NIL Breast(b/l) Benign cystic desease 22/06/2011 28/05/2012
18 111486 51 F NIL NIL Ring finger Benign tumour of nerve sheath origin 04/07/2011 10/08/2011
19 111904 68 F NIL NIL Sub. Cut. Swelling. Axilla Schwannoma 03/10/2011 03/10/2011
20 111906 16 F NIL NIL D8 spine Aneurysmal bone cyst 03/10/2011 23/07/2012
21 112111 22 M NIL NIL Bone skull Osteochondroma 29/10/2011 29/10/2011
22 112327 17 F NIL NIL Leg(rt) Neurofibroma 28/11/2011 09/04/2012
23 112379 35 F NIL NIL Pituitary gland Adenoma 02/12/2011 02/12/2011
24 112526 35 F NIL NIL Thigh Benign fibrous histiocytoma 19/12/2011 29/08/2012
25 112579 53 F NIL NIL Breast Inflamation 24/12/2011 29/03/2012
MCC Annual Report – HBCR 2011
285
ABBREVIATIONS
C/CT Chemotherapy
ICD International Classification of Disease
EQAS External Quality Assurance Scheme DistMets Distant Metastasis F Females HBCR Hospital Based Cancer Registry HL Hodgkin's lymphoma HPR Histo-Pathology Report ICMR Indian Council of Medical Research M Males MCC Malabar cancer Centre NCRP National Cancer Registry Programme NCCP National Cancer Control Programme NHL Non-Hodgkin's lymphoma R/RT Radiation RI Reporting Institution S Surgery TRC Tobacco Related Cancers # Number CNS Central Nervous System PNS Peripheral Nervous System ANS Autonomic Nervous System GIT Gaestro Intestinal System CLN Cervical Lymph Node LN Lymph Node SCLN Supraclavicular Lymph Node BM Buccal Muccosa RMT Retro Molar Trigone FOM Floor of Mouth GR Grade Rt - Right
Lt Left LCNK Large Cell Non- Keratinizing WD Well Differentiated PD Poorly Differentiated Seq Sequence Lat Laterality UK/U Unknown B/L Bi lateral SCC Squamous Cell Carcinoma IDC Infiltrating Duct Carcinoma NSCC Non- Small Cell Carcinoma Ca Carcinoma Ra Radical Pa Palliative Sy Symptomatic N No Treatment
MCC Annual Report – HBCR 2011
286
REFERENCES
1. Isabel dos Santos Silva (1999). Cancer Epidemiology: Principles and Methods,
IARC Publications, France.
2. Maclennan et al, (1978). Cancer Registration and its Techniques, IARC Scientific
Publications No. 21,France
3. Young, J.L. (1991). Hospital Based Cancer Registry In, Cancer Registration:
Principles and Methods, IARC Publications, France
MCC Annual Report – HBCR 2011
287
Printed at : C‐APT, Kozhikode. Ph : 0495